WO2008131501A2 - New anti-viral nucleoside analogs - Google Patents
New anti-viral nucleoside analogs Download PDFInfo
- Publication number
- WO2008131501A2 WO2008131501A2 PCT/BE2008/000032 BE2008000032W WO2008131501A2 WO 2008131501 A2 WO2008131501 A2 WO 2008131501A2 BE 2008000032 W BE2008000032 W BE 2008000032W WO 2008131501 A2 WO2008131501 A2 WO 2008131501A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- chloro
- purine
- hept
- hydrogen
- Prior art date
Links
- 239000002777 nucleoside Substances 0.000 title claims abstract description 133
- 150000003833 nucleoside derivatives Chemical class 0.000 title claims abstract description 130
- 230000000840 anti-viral effect Effects 0.000 title claims abstract description 18
- 238000000034 method Methods 0.000 claims abstract description 63
- 238000002360 preparation method Methods 0.000 claims abstract description 27
- 239000003814 drug Substances 0.000 claims abstract description 26
- 241000700605 Viruses Species 0.000 claims abstract description 21
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 17
- 241000709664 Picornaviridae Species 0.000 claims abstract description 16
- 229910052739 hydrogen Inorganic materials 0.000 claims description 282
- 125000000217 alkyl group Chemical group 0.000 claims description 218
- 229910052757 nitrogen Inorganic materials 0.000 claims description 180
- 229910052799 carbon Inorganic materials 0.000 claims description 179
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Substances OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 138
- -1 6-(dimethylamino)-9H-purin-9-yl Chemical group 0.000 claims description 133
- 239000001257 hydrogen Substances 0.000 claims description 131
- 150000001875 compounds Chemical class 0.000 claims description 120
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 101
- 125000003118 aryl group Chemical group 0.000 claims description 87
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 81
- 229910052736 halogen Inorganic materials 0.000 claims description 76
- 150000002367 halogens Chemical class 0.000 claims description 76
- 125000005842 heteroatom Chemical group 0.000 claims description 49
- 239000004480 active ingredient Substances 0.000 claims description 41
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Chemical class N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims description 37
- 150000003839 salts Chemical class 0.000 claims description 35
- 125000002947 alkylene group Chemical group 0.000 claims description 34
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 34
- 238000011282 treatment Methods 0.000 claims description 34
- 229910052717 sulfur Inorganic materials 0.000 claims description 31
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 31
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 30
- 229910019142 PO4 Inorganic materials 0.000 claims description 29
- 239000004593 Epoxy Substances 0.000 claims description 28
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 27
- 239000010452 phosphate Substances 0.000 claims description 27
- 208000036142 Viral infection Diseases 0.000 claims description 25
- 229910052760 oxygen Inorganic materials 0.000 claims description 25
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 claims description 25
- 230000009385 viral infection Effects 0.000 claims description 25
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 24
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 21
- 241001465754 Metazoa Species 0.000 claims description 21
- 238000006243 chemical reaction Methods 0.000 claims description 20
- 229940002612 prodrug Drugs 0.000 claims description 19
- 239000000651 prodrug Substances 0.000 claims description 19
- 241000124008 Mammalia Species 0.000 claims description 16
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 16
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 16
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 15
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 15
- 239000002253 acid Substances 0.000 claims description 14
- ZQTYQMYDIHMKQB-UHFFFAOYSA-N exo-norborneol Chemical compound C1CC2C(O)CC1C2 ZQTYQMYDIHMKQB-UHFFFAOYSA-N 0.000 claims description 14
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 14
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 claims description 14
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 14
- 230000002265 prevention Effects 0.000 claims description 14
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 13
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 13
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 12
- MKOSBHNWXFSHSW-UHFFFAOYSA-N bicyclo[2.2.1]hept-2-en-5-ol Chemical compound C1C2C(O)CC1C=C2 MKOSBHNWXFSHSW-UHFFFAOYSA-N 0.000 claims description 11
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 11
- NGDNVOAEIVQRFH-UHFFFAOYSA-N 2-nonanol Chemical compound CCCCCCCC(C)O NGDNVOAEIVQRFH-UHFFFAOYSA-N 0.000 claims description 10
- 150000003230 pyrimidines Chemical class 0.000 claims description 10
- 241000282414 Homo sapiens Species 0.000 claims description 9
- 239000003937 drug carrier Substances 0.000 claims description 9
- 230000008878 coupling Effects 0.000 claims description 7
- 238000010168 coupling process Methods 0.000 claims description 7
- 238000005859 coupling reaction Methods 0.000 claims description 7
- 229940095102 methyl benzoate Drugs 0.000 claims description 7
- 229960000643 adenine Drugs 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 claims description 6
- 238000006798 ring closing metathesis reaction Methods 0.000 claims description 6
- 238000006751 Mitsunobu reaction Methods 0.000 claims description 5
- 239000012453 solvate Substances 0.000 claims description 5
- 230000002378 acidificating effect Effects 0.000 claims description 4
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 claims description 4
- 241001493065 dsRNA viruses Species 0.000 claims description 4
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims description 4
- LHGMCUVJFRBVBH-UHFFFAOYSA-N 4-chloropyrimidin-5-amine Chemical class NC1=CN=CN=C1Cl LHGMCUVJFRBVBH-UHFFFAOYSA-N 0.000 claims description 3
- 150000005008 5-aminopyrimidines Chemical class 0.000 claims description 3
- DSHXMENPUICESR-UHFFFAOYSA-N [5-(hydroxymethyl)-5-bicyclo[2.2.1]hept-2-enyl]methanol Chemical compound C1C2C(CO)(CO)CC1C=C2 DSHXMENPUICESR-UHFFFAOYSA-N 0.000 claims description 3
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 3
- HNMVZUWXQLASRL-UHFFFAOYSA-N bicyclo[2.2.1]heptane-2,3-diol Chemical compound C1CC2C(O)C(O)C1C2 HNMVZUWXQLASRL-UHFFFAOYSA-N 0.000 claims description 3
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 3
- 230000009466 transformation Effects 0.000 claims description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 224
- 239000000460 chlorine Substances 0.000 description 151
- 239000000203 mixture Substances 0.000 description 137
- 229910052801 chlorine Inorganic materials 0.000 description 123
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 85
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 72
- 238000005160 1H NMR spectroscopy Methods 0.000 description 69
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 69
- 239000000243 solution Substances 0.000 description 67
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 52
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 49
- 239000000741 silica gel Substances 0.000 description 46
- 229910002027 silica gel Inorganic materials 0.000 description 46
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 45
- 230000015572 biosynthetic process Effects 0.000 description 43
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 42
- 238000003786 synthesis reaction Methods 0.000 description 38
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 33
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 33
- 238000009472 formulation Methods 0.000 description 30
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 29
- 235000019439 ethyl acetate Nutrition 0.000 description 29
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 28
- 235000019441 ethanol Nutrition 0.000 description 28
- 239000011541 reaction mixture Substances 0.000 description 28
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 26
- 229940093499 ethyl acetate Drugs 0.000 description 26
- 239000000047 product Substances 0.000 description 25
- OAMZXMDZZWGPMH-UHFFFAOYSA-N ethyl acetate;toluene Chemical compound CCOC(C)=O.CC1=CC=CC=C1 OAMZXMDZZWGPMH-UHFFFAOYSA-N 0.000 description 24
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 22
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 22
- 239000000543 intermediate Substances 0.000 description 22
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 21
- 235000021317 phosphate Nutrition 0.000 description 20
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 19
- 150000001412 amines Chemical group 0.000 description 19
- 125000004432 carbon atom Chemical group C* 0.000 description 19
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 17
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 16
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 16
- 125000001424 substituent group Chemical group 0.000 description 16
- 238000004587 chromatography analysis Methods 0.000 description 15
- ZKBQDFAWXLTYKS-UHFFFAOYSA-N 6-Chloro-1H-purine Chemical compound ClC1=NC=NC2=C1NC=N2 ZKBQDFAWXLTYKS-UHFFFAOYSA-N 0.000 description 14
- 125000000623 heterocyclic group Chemical group 0.000 description 14
- 239000012074 organic phase Substances 0.000 description 14
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 14
- 125000003342 alkenyl group Chemical group 0.000 description 13
- 238000002425 crystallisation Methods 0.000 description 13
- 230000008025 crystallization Effects 0.000 description 13
- 229920006395 saturated elastomer Polymers 0.000 description 13
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 12
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 12
- 239000000706 filtrate Substances 0.000 description 12
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 12
- 239000007788 liquid Substances 0.000 description 12
- 239000007787 solid Substances 0.000 description 12
- 241000709661 Enterovirus Species 0.000 description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 11
- 239000002585 base Substances 0.000 description 11
- 238000001816 cooling Methods 0.000 description 11
- 125000000304 alkynyl group Chemical group 0.000 description 10
- 150000002148 esters Chemical class 0.000 description 10
- 239000004615 ingredient Substances 0.000 description 10
- 239000003921 oil Substances 0.000 description 10
- 239000012044 organic layer Substances 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- 239000000725 suspension Substances 0.000 description 10
- NIGDWBHWHVHOAD-UHFFFAOYSA-N 4,6-dichloropyrimidin-5-amine Chemical compound NC1=C(Cl)N=CN=C1Cl NIGDWBHWHVHOAD-UHFFFAOYSA-N 0.000 description 9
- 241000282412 Homo Species 0.000 description 9
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 9
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical group CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 9
- 239000003443 antiviral agent Substances 0.000 description 9
- ALDZLCMPPVNMIO-UHFFFAOYSA-N ethanol ethyl acetate propan-2-one hydrate Chemical compound O.CCO.CC(C)=O.CCOC(C)=O ALDZLCMPPVNMIO-UHFFFAOYSA-N 0.000 description 9
- 229910052731 fluorine Inorganic materials 0.000 description 9
- 235000019198 oils Nutrition 0.000 description 9
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 9
- 238000000926 separation method Methods 0.000 description 9
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 9
- 235000017557 sodium bicarbonate Nutrition 0.000 description 9
- GKASDNZWUGIAMG-UHFFFAOYSA-N triethyl orthoformate Chemical compound CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- 239000012300 argon atmosphere Substances 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 239000003995 emulsifying agent Substances 0.000 description 8
- 125000004005 formimidoyl group Chemical group [H]\N=C(/[H])* 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 8
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 7
- 239000000969 carrier Substances 0.000 description 7
- WBLIXGSTEMXDSM-UHFFFAOYSA-N chloromethane Chemical compound Cl[CH2] WBLIXGSTEMXDSM-UHFFFAOYSA-N 0.000 description 7
- 239000006071 cream Substances 0.000 description 7
- 125000000753 cycloalkyl group Chemical group 0.000 description 7
- 229910052740 iodine Inorganic materials 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- 239000004094 surface-active agent Substances 0.000 description 7
- 230000002195 synergetic effect Effects 0.000 description 7
- RMFWVOLULURGJI-UHFFFAOYSA-N 2,6-dichloro-7h-purine Chemical compound ClC1=NC(Cl)=C2NC=NC2=N1 RMFWVOLULURGJI-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 6
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 6
- 229930010555 Inosine Natural products 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 229910052786 argon Inorganic materials 0.000 description 6
- 239000003054 catalyst Substances 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Chemical compound CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 6
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 description 6
- 229960003786 inosine Drugs 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- URMYFQFQMJBCNT-UHFFFAOYSA-N nonan-2-ol Chemical compound CCCCCCCC(C)O.CCCCCCCC(C)O URMYFQFQMJBCNT-UHFFFAOYSA-N 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 229910052698 phosphorus Inorganic materials 0.000 description 6
- 229910052708 sodium Inorganic materials 0.000 description 6
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 229940075420 xanthine Drugs 0.000 description 6
- RYYIULNRIVUMTQ-UHFFFAOYSA-N 6-chloroguanine Chemical compound NC1=NC(Cl)=C2N=CNC2=N1 RYYIULNRIVUMTQ-UHFFFAOYSA-N 0.000 description 5
- MSSXOMSJDRHRMC-UHFFFAOYSA-N 9H-purine-2,6-diamine Chemical compound NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 description 5
- 241000991587 Enterovirus C Species 0.000 description 5
- 230000005526 G1 to G0 transition Effects 0.000 description 5
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 5
- 208000005155 Picornaviridae Infections Diseases 0.000 description 5
- 208000025935 Picornaviridae infectious disease Diseases 0.000 description 5
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 239000012298 atmosphere Substances 0.000 description 5
- 125000004429 atom Chemical group 0.000 description 5
- 150000001721 carbon Chemical group 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000013270 controlled release Methods 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- 239000003925 fat Substances 0.000 description 5
- 235000019197 fats Nutrition 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 150000002430 hydrocarbons Chemical group 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
- 150000003254 radicals Chemical class 0.000 description 5
- 239000012312 sodium hydride Substances 0.000 description 5
- 229910000104 sodium hydride Inorganic materials 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- PRNYETMUCSLSEP-GMTAPVOTSA-N 6-chloro-9-[[(1r,4s,5r)-6,6-dimethyl-4-bicyclo[3.1.1]heptanyl]methyl]purine Chemical compound C1=NC2=C(Cl)N=CN=C2N1C[C@@H](CC1)[C@H]2C[C@@H]1C2(C)C PRNYETMUCSLSEP-GMTAPVOTSA-N 0.000 description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 125000005041 acyloxyalkyl group Chemical group 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 239000012267 brine Substances 0.000 description 4
- 229940125904 compound 1 Drugs 0.000 description 4
- 125000000392 cycloalkenyl group Chemical group 0.000 description 4
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000002480 mineral oil Substances 0.000 description 4
- 239000002736 nonionic surfactant Substances 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 125000004430 oxygen atom Chemical group O* 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- 239000012047 saturated solution Substances 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 4
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 3
- ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-dimethylbutane Chemical group CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 description 3
- 150000005019 2-aminopurines Chemical class 0.000 description 3
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 3
- IGFHQQFPSIBGKE-UHFFFAOYSA-N 4-nonylphenol Chemical compound CCCCCCCCCC1=CC=C(O)C=C1 IGFHQQFPSIBGKE-UHFFFAOYSA-N 0.000 description 3
- DRWRVXAXXGJZIO-UHFFFAOYSA-N 5-bicyclo[2.2.1]hept-2-enyl acetate Chemical compound C1C2C(OC(=O)C)CC1C=C2 DRWRVXAXXGJZIO-UHFFFAOYSA-N 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 3
- 229930024421 Adenine Natural products 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- MTVBGMXBMXTJTR-UHFFFAOYSA-N C(C)(=O)OCC.C1(=CC=CC=C1)C.CC(=O)C.C(C)O Chemical compound C(C)(=O)OCC.C1(=CC=CC=C1)C.CC(=O)C.C(C)O MTVBGMXBMXTJTR-UHFFFAOYSA-N 0.000 description 3
- 241000709715 Hepatovirus Species 0.000 description 3
- 241000709721 Hepatovirus A Species 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical group O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 125000002252 acyl group Chemical group 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 3
- 150000003863 ammonium salts Chemical class 0.000 description 3
- VYPKVJUNYSEWKB-UHFFFAOYSA-N benzyl n-diazocarbamate Chemical compound [N-]=[N+]=NC(=O)OCC1=CC=CC=C1 VYPKVJUNYSEWKB-UHFFFAOYSA-N 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 239000003610 charcoal Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 229940125877 compound 31 Drugs 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 125000006125 ethylsulfonyl group Chemical group 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 235000010446 mineral oil Nutrition 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 229940124531 pharmaceutical excipient Drugs 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 3
- 235000015497 potassium bicarbonate Nutrition 0.000 description 3
- 239000011736 potassium bicarbonate Substances 0.000 description 3
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 3
- 229940086066 potassium hydrogencarbonate Drugs 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- 235000013772 propylene glycol Nutrition 0.000 description 3
- 229960004063 propylene glycol Drugs 0.000 description 3
- 230000005588 protonation Effects 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 239000012279 sodium borohydride Substances 0.000 description 3
- 229910000033 sodium borohydride Inorganic materials 0.000 description 3
- 235000019345 sodium thiosulphate Nutrition 0.000 description 3
- 239000012258 stirred mixture Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000029812 viral genome replication Effects 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- YTWCODZNNZBQFV-KBXCAEBGSA-N (1R,2R)-2-[[4-(2-fluoro-5-propan-2-yloxyphenyl)phenoxy]methyl]cyclopropane-1-carboxylic acid Chemical compound FC1=C(C=C(C=C1)OC(C)C)C1=CC=C(C=C1)OC[C@H]1[C@@H](C1)C(=O)O YTWCODZNNZBQFV-KBXCAEBGSA-N 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- MCTWTZJPVLRJOU-UHFFFAOYSA-N 1-methyl-1H-imidazole Chemical compound CN1C=CN=C1 MCTWTZJPVLRJOU-UHFFFAOYSA-N 0.000 description 2
- JBMBVWROWJGFMG-UHFFFAOYSA-N 2-chloro-7h-purine Chemical class ClC1=NC=C2NC=NC2=N1 JBMBVWROWJGFMG-UHFFFAOYSA-N 0.000 description 2
- NXSCCFXPCOMUCV-UHFFFAOYSA-N 2-iodo-7h-purine Chemical class IC1=NC=C2NC=NC2=N1 NXSCCFXPCOMUCV-UHFFFAOYSA-N 0.000 description 2
- BVGDAZBTIVRTGO-UONOGXRCSA-N 3-[(1r)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[4-methoxy-6-[(2s)-2-methylpiperazin-1-yl]pyridin-3-yl]pyridin-2-amine Chemical compound C1([C@@H](C)OC=2C(N)=NC=C(C=2)C2=CN=C(C=C2OC)N2[C@H](CNCC2)C)=C(Cl)C=CC(F)=C1Cl BVGDAZBTIVRTGO-UONOGXRCSA-N 0.000 description 2
- PNWOYKVCNDZOLS-UHFFFAOYSA-N 6-amino-5-chloro-1h-pyrimidin-2-one Chemical compound NC=1NC(=O)N=CC=1Cl PNWOYKVCNDZOLS-UHFFFAOYSA-N 0.000 description 2
- PEHVGBZKEYRQSX-UHFFFAOYSA-N 7-deaza-adenine Chemical compound NC1=NC=NC2=C1C=CN2 PEHVGBZKEYRQSX-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- 241000272525 Anas platyrhynchos Species 0.000 description 2
- 241000710189 Aphthovirus Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 101150034980 BRDT gene Proteins 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- 241000710190 Cardiovirus Species 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000710188 Encephalomyocarditis virus Species 0.000 description 2
- 241000988559 Enterovirus A Species 0.000 description 2
- 241000988556 Enterovirus B Species 0.000 description 2
- 241000991586 Enterovirus D Species 0.000 description 2
- 241000709691 Enterovirus E Species 0.000 description 2
- 241001468007 Erbovirus Species 0.000 description 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 2
- 239000005977 Ethylene Substances 0.000 description 2
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 2
- 241001468006 Kobuvirus Species 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- LFTLOKWAGJYHHR-UHFFFAOYSA-N N-methylmorpholine N-oxide Chemical compound CN1(=O)CCOCC1 LFTLOKWAGJYHHR-UHFFFAOYSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 108091092724 Noncoding DNA Proteins 0.000 description 2
- 241000991583 Parechovirus Species 0.000 description 2
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 101710172711 Structural protein Proteins 0.000 description 2
- 241000249096 Teschovirus Species 0.000 description 2
- 241001196954 Theilovirus Species 0.000 description 2
- 241001223089 Tremovirus A Species 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 125000005907 alkyl ester group Chemical group 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 150000001450 anions Chemical group 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 125000005018 aryl alkenyl group Chemical group 0.000 description 2
- 125000003785 benzimidazolyl group Chemical class N1=C(NC2=C1C=CC=C2)* 0.000 description 2
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 239000013553 cell monolayer Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 229940104302 cytosine Drugs 0.000 description 2
- 230000001085 cytostatic effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 229940039227 diagnostic agent Drugs 0.000 description 2
- 239000000032 diagnostic agent Substances 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 238000000132 electrospray ionisation Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical class CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 2
- HZAHPOBLARATTK-UHFFFAOYSA-N ethyl n-diazocarbamate Chemical compound CCOC(=O)N=[N+]=[N-] HZAHPOBLARATTK-UHFFFAOYSA-N 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 150000002191 fatty alcohols Chemical class 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- VUWZPRWSIVNGKG-UHFFFAOYSA-N fluoromethane Chemical compound F[CH2] VUWZPRWSIVNGKG-UHFFFAOYSA-N 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 238000001640 fractional crystallisation Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- RCBVKBFIWMOMHF-UHFFFAOYSA-L hydroxy-(hydroxy(dioxo)chromio)oxy-dioxochromium;pyridine Chemical compound C1=CC=NC=C1.C1=CC=NC=C1.O[Cr](=O)(=O)O[Cr](O)(=O)=O RCBVKBFIWMOMHF-UHFFFAOYSA-L 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 125000005647 linker group Chemical group 0.000 description 2
- 239000012280 lithium aluminium hydride Substances 0.000 description 2
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical compound [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 2
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 125000003835 nucleoside group Chemical group 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000003883 ointment base Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- 239000012285 osmium tetroxide Substances 0.000 description 2
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 2
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 2
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 2
- 150000003212 purines Chemical class 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 229930195734 saturated hydrocarbon Natural products 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 239000008259 solid foam Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-N sulfonic acid Chemical compound OS(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-N 0.000 description 2
- 150000003460 sulfonic acids Chemical class 0.000 description 2
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 2
- 238000003419 tautomerization reaction Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- 229940113082 thymine Drugs 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 210000003501 vero cell Anatomy 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 1
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 1
- CAYQIZIAYYNFCS-UHFFFAOYSA-N (4-chlorophenyl)boronic acid Chemical compound OB(O)C1=CC=C(Cl)C=C1 CAYQIZIAYYNFCS-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- IFSYJVQRVQMRKN-ONEGZZNKSA-N (E)-hept-5-en-2-ol Chemical compound C\C=C\CCC(C)O IFSYJVQRVQMRKN-ONEGZZNKSA-N 0.000 description 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- LLNAMUJRIZIXHF-CLFYSBASSA-N (z)-2-methyl-3-phenylprop-2-en-1-ol Chemical compound OCC(/C)=C\C1=CC=CC=C1 LLNAMUJRIZIXHF-CLFYSBASSA-N 0.000 description 1
- 0 *c1nc2c(*)nc(*)nc2[n]1C1C2OCC3(CO)C2CC1C3 Chemical compound *c1nc2c(*)nc(*)nc2[n]1C1C2OCC3(CO)C2CC1C3 0.000 description 1
- GGMQZPIDPNAGFP-UHFFFAOYSA-N 1,1-dibromo-1,2,2,2-tetrachloroethane Chemical compound ClC(Cl)(Cl)C(Cl)(Br)Br GGMQZPIDPNAGFP-UHFFFAOYSA-N 0.000 description 1
- QMMJWQMCMRUYTG-UHFFFAOYSA-N 1,2,4,5-tetrachloro-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=C(Cl)C(Cl)=CC(Cl)=C1Cl QMMJWQMCMRUYTG-UHFFFAOYSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- JIHQDMXYYFUGFV-UHFFFAOYSA-N 1,3,5-triazine Chemical class C1=NC=NC=N1 JIHQDMXYYFUGFV-UHFFFAOYSA-N 0.000 description 1
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical class C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 1
- LDMOEFOXLIZJOW-UHFFFAOYSA-N 1-dodecanesulfonic acid Chemical compound CCCCCCCCCCCCS(O)(=O)=O LDMOEFOXLIZJOW-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- LGEZTMRIZWCDLW-UHFFFAOYSA-N 14-methylpentadecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC(C)C LGEZTMRIZWCDLW-UHFFFAOYSA-N 0.000 description 1
- BAUMIJOSOBJQDK-UTLUCORTSA-N 2,6-dichloro-9-[[(1S,2S,5S)-6,6-dimethyl-2-bicyclo[3.1.1]heptanyl]methyl]purine Chemical compound ClC1=NC(=C2N=CN(C2=N1)C[C@@H]1[C@H]2C([C@@H](CC1)C2)(C)C)Cl BAUMIJOSOBJQDK-UTLUCORTSA-N 0.000 description 1
- JDSQBDGCMUXRBM-UHFFFAOYSA-N 2-[2-(2-butoxypropoxy)propoxy]propan-1-ol Chemical group CCCCOC(C)COC(C)COC(C)CO JDSQBDGCMUXRBM-UHFFFAOYSA-N 0.000 description 1
- JNONGIUWXHOEEN-UHFFFAOYSA-N 2-[bromomethyl(propan-2-yloxy)phosphoryl]oxypropane Chemical compound CC(C)OP(=O)(CBr)OC(C)C JNONGIUWXHOEEN-UHFFFAOYSA-N 0.000 description 1
- MWBWWFOAEOYUST-UHFFFAOYSA-N 2-aminopurine Chemical compound NC1=NC=C2N=CNC2=N1 MWBWWFOAEOYUST-UHFFFAOYSA-N 0.000 description 1
- CFWRDBDJAOHXSH-SECBINFHSA-N 2-azaniumylethyl [(2r)-2,3-diacetyloxypropyl] phosphate Chemical compound CC(=O)OC[C@@H](OC(C)=O)COP(O)(=O)OCCN CFWRDBDJAOHXSH-SECBINFHSA-N 0.000 description 1
- ICHLNDWMYWZUTG-UHFFFAOYSA-N 2-azido-7h-purine Chemical compound [N-]=[N+]=NC1=NC=C2NC=NC2=N1 ICHLNDWMYWZUTG-UHFFFAOYSA-N 0.000 description 1
- WBIQQQGBSDOWNP-UHFFFAOYSA-N 2-dodecylbenzenesulfonic acid Chemical class CCCCCCCCCCCCC1=CC=CC=C1S(O)(=O)=O WBIQQQGBSDOWNP-UHFFFAOYSA-N 0.000 description 1
- SFAAOBGYWOUHLU-UHFFFAOYSA-N 2-ethylhexyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(CC)CCCC SFAAOBGYWOUHLU-UHFFFAOYSA-N 0.000 description 1
- 125000004847 2-fluorobenzyl group Chemical group [H]C1=C([H])C(F)=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000004398 2-methyl-2-butyl group Chemical group CC(C)(CC)* 0.000 description 1
- 125000004918 2-methyl-2-pentyl group Chemical group CC(C)(CCC)* 0.000 description 1
- 125000004922 2-methyl-3-pentyl group Chemical group CC(C)C(CC)* 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- GEVCSRLIETZLTD-UHFFFAOYSA-N 2-methylsulfanyl-7h-purine Chemical compound CSC1=NC=C2NC=NC2=N1 GEVCSRLIETZLTD-UHFFFAOYSA-N 0.000 description 1
- WVKPYYLOFMTDHB-UHFFFAOYSA-N 2-norbornyl radical Chemical group C1CC2[CH]CC1C2 WVKPYYLOFMTDHB-UHFFFAOYSA-N 0.000 description 1
- KRTGJZMJJVEKRX-UHFFFAOYSA-N 2-phenylethan-1-yl Chemical group [CH2]CC1=CC=CC=C1 KRTGJZMJJVEKRX-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- GIIGHSIIKVOWKZ-UHFFFAOYSA-N 2h-triazolo[4,5-d]pyrimidine Chemical class N1=CN=CC2=NNN=C21 GIIGHSIIKVOWKZ-UHFFFAOYSA-N 0.000 description 1
- 125000006512 3,4-dichlorobenzyl group Chemical group [H]C1=C(Cl)C(Cl)=C([H])C(=C1[H])C([H])([H])* 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000006180 3-methyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C(=C1[H])C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004917 3-methyl-2-butyl group Chemical group CC(C(C)*)C 0.000 description 1
- 125000004919 3-methyl-2-pentyl group Chemical group CC(C(C)*)CC 0.000 description 1
- 125000004921 3-methyl-3-pentyl group Chemical group CC(CC)(CC)* 0.000 description 1
- 238000004679 31P NMR spectroscopy Methods 0.000 description 1
- XJPZKYIHCLDXST-UHFFFAOYSA-N 4,6-dichloropyrimidine Chemical compound ClC1=CC(Cl)=NC=N1 XJPZKYIHCLDXST-UHFFFAOYSA-N 0.000 description 1
- ZXWGHENZKVQKPX-UHFFFAOYSA-N 4,6-dichloropyrimidine-2,5-diamine Chemical compound NC1=NC(Cl)=C(N)C(Cl)=N1 ZXWGHENZKVQKPX-UHFFFAOYSA-N 0.000 description 1
- WWPHYSRKWSMOLO-UHFFFAOYSA-N 4-(hydroxymethyl)bicyclo[2.2.1]hept-2-en-5-ol Chemical compound C1C2CC(O)C1(CO)C=C2 WWPHYSRKWSMOLO-UHFFFAOYSA-N 0.000 description 1
- 125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 description 1
- 125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- 125000006181 4-methyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004920 4-methyl-2-pentyl group Chemical group CC(CC(C)*)C 0.000 description 1
- RZEXJHGIEXQMTI-UHFFFAOYSA-N 5-(methoxymethyl)-1h-pyrimidine-2,4-dione Chemical compound COCC1=CNC(=O)NC1=O RZEXJHGIEXQMTI-UHFFFAOYSA-N 0.000 description 1
- LMNPKIOZMGYQIU-UHFFFAOYSA-N 5-(trifluoromethyl)-1h-pyrimidine-2,4-dione Chemical compound FC(F)(F)C1=CNC(=O)NC1=O LMNPKIOZMGYQIU-UHFFFAOYSA-N 0.000 description 1
- BLXGZIDBSXVMLU-OWOJBTEDSA-N 5-[(e)-2-bromoethenyl]-1h-pyrimidine-2,4-dione Chemical compound Br\C=C\C1=CNC(=O)NC1=O BLXGZIDBSXVMLU-OWOJBTEDSA-N 0.000 description 1
- SVXNJCYYMRMXNM-UHFFFAOYSA-N 5-amino-2h-1,2,4-triazin-3-one Chemical compound NC=1C=NNC(=O)N=1 SVXNJCYYMRMXNM-UHFFFAOYSA-N 0.000 description 1
- MFEFTTYGMZOIKO-UHFFFAOYSA-N 5-azacytosine Chemical compound NC1=NC=NC(=O)N1 MFEFTTYGMZOIKO-UHFFFAOYSA-N 0.000 description 1
- LQLQRFGHAALLLE-UHFFFAOYSA-N 5-bromouracil Chemical compound BrC1=CNC(=O)NC1=O LQLQRFGHAALLLE-UHFFFAOYSA-N 0.000 description 1
- ZFTBZKVVGZNMJR-UHFFFAOYSA-N 5-chlorouracil Chemical compound ClC1=CNC(=O)NC1=O ZFTBZKVVGZNMJR-UHFFFAOYSA-N 0.000 description 1
- 125000006043 5-hexenyl group Chemical group 0.000 description 1
- KSNXJLQDQOIRIP-UHFFFAOYSA-N 5-iodouracil Chemical compound IC1=CNC(=O)NC1=O KSNXJLQDQOIRIP-UHFFFAOYSA-N 0.000 description 1
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 1
- UJBCLAXPPIDQEE-UHFFFAOYSA-N 5-prop-1-ynyl-1h-pyrimidine-2,4-dione Chemical compound CC#CC1=CNC(=O)NC1=O UJBCLAXPPIDQEE-UHFFFAOYSA-N 0.000 description 1
- QFVKLKDEXOWFSL-UHFFFAOYSA-N 6-amino-5-bromo-1h-pyrimidin-2-one Chemical compound NC=1NC(=O)N=CC=1Br QFVKLKDEXOWFSL-UHFFFAOYSA-N 0.000 description 1
- UFVWJVAMULFOMC-UHFFFAOYSA-N 6-amino-5-iodo-1h-pyrimidin-2-one Chemical compound NC=1NC(=O)N=CC=1I UFVWJVAMULFOMC-UHFFFAOYSA-N 0.000 description 1
- UBACCXSBTPBSQK-IQJOONFLSA-N 6-chloro-9-[(1s,2r,4r)-3,3-dimethyl-2-bicyclo[2.2.1]heptanyl]purine Chemical compound C1=NC2=C(Cl)N=CN=C2N1[C@@H]1[C@H](C2)CC[C@H]2C1(C)C UBACCXSBTPBSQK-IQJOONFLSA-N 0.000 description 1
- YROJDNYMZYVKSA-QWRGUYRKSA-N 6-chloro-9-[[(1s,5r)-6,6-dimethyl-4-bicyclo[3.1.1]hept-3-enyl]methyl]purine Chemical compound C1=NC2=C(Cl)N=CN=C2N1CC1=CC[C@@H]2C(C)(C)[C@H]1C2 YROJDNYMZYVKSA-QWRGUYRKSA-N 0.000 description 1
- NIBFSSALYRLHPY-UHFFFAOYSA-N 6-iodo-7h-purine Chemical compound IC1=NC=NC2=C1NC=N2 NIBFSSALYRLHPY-UHFFFAOYSA-N 0.000 description 1
- LOSIULRWFAEMFL-UHFFFAOYSA-N 7-deazaguanine Chemical compound O=C1NC(N)=NC2=C1CC=N2 LOSIULRWFAEMFL-UHFFFAOYSA-N 0.000 description 1
- VKKXEIQIGGPMHT-UHFFFAOYSA-N 7h-purine-2,8-diamine Chemical compound NC1=NC=C2NC(N)=NC2=N1 VKKXEIQIGGPMHT-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000006740 Aseptic Meningitis Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 108091032955 Bacterial small RNA Proteins 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 239000004358 Butane-1, 3-diol Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- 241000709687 Coxsackievirus Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 241000725619 Dengue virus Species 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241001466953 Echovirus Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical class C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 241000710831 Flavivirus Species 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 208000037319 Hepatitis infectious Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 206010027201 Meningitis aseptic Diseases 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- QMGVPVSNSZLJIA-UHFFFAOYSA-N Nux Vomica Natural products C1C2C3C4N(C=5C6=CC=CC=5)C(=O)CC3OCC=C2CN2C1C46CC2 QMGVPVSNSZLJIA-UHFFFAOYSA-N 0.000 description 1
- FSVHRKAYSADSKV-UHFFFAOYSA-N OCC(C(C1)C2NC(OCc3ccccc3)=O)C3C1C2OC3 Chemical compound OCC(C(C1)C2NC(OCc3ccccc3)=O)C3C1C2OC3 FSVHRKAYSADSKV-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 241001144416 Picornavirales Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 108010076039 Polyproteins Proteins 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- 102000002067 Protein Subunits Human genes 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 206010061494 Rhinovirus infection Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 241000710772 Yellow fever virus Species 0.000 description 1
- SYJBFPCQIJQYNV-CIUDSAMLSA-N [(1s,4r,5s)-6,6-dimethyl-4-bicyclo[3.1.1]heptanyl]methanamine Chemical compound C1[C@@H]2C(C)(C)[C@H]1CC[C@H]2CN SYJBFPCQIJQYNV-CIUDSAMLSA-N 0.000 description 1
- IGHHPVIMEQGKNE-UHFFFAOYSA-N [3-(hydroxymethyl)-2-bicyclo[2.2.1]hept-5-enyl]methanol Chemical compound C1C2C=CC1C(CO)C2CO IGHHPVIMEQGKNE-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910001413 alkali metal ion Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910001420 alkaline earth metal ion Inorganic materials 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000005082 alkoxyalkenyl group Chemical group 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000013011 aqueous formulation Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000003435 aroyl group Chemical group 0.000 description 1
- 125000004659 aryl alkyl thio group Chemical group 0.000 description 1
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 1
- 125000005015 aryl alkynyl group Chemical group 0.000 description 1
- 125000005129 aryl carbonyl group Chemical group 0.000 description 1
- 150000005840 aryl radicals Chemical class 0.000 description 1
- 125000005110 aryl thio group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- CBHOOMGKXCMKIR-UHFFFAOYSA-N azane;methanol Chemical compound N.OC CBHOOMGKXCMKIR-UHFFFAOYSA-N 0.000 description 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- PUJDIJCNWFYVJX-UHFFFAOYSA-N benzyl carbamate Chemical compound NC(=O)OCC1=CC=CC=C1 PUJDIJCNWFYVJX-UHFFFAOYSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- IYYIVELXUANFED-UHFFFAOYSA-N bromo(trimethyl)silane Chemical compound C[Si](C)(C)Br IYYIVELXUANFED-UHFFFAOYSA-N 0.000 description 1
- RRKTZKIUPZVBMF-IBTVXLQLSA-N brucine Chemical compound O([C@@H]1[C@H]([C@H]2C3)[C@@H]4N(C(C1)=O)C=1C=C(C(=CC=11)OC)OC)CC=C2CN2[C@@H]3[C@]41CC2 RRKTZKIUPZVBMF-IBTVXLQLSA-N 0.000 description 1
- RRKTZKIUPZVBMF-UHFFFAOYSA-N brucine Natural products C1=2C=C(OC)C(OC)=CC=2N(C(C2)=O)C3C(C4C5)C2OCC=C4CN2C5C31CC2 RRKTZKIUPZVBMF-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001722 carbon compounds Chemical class 0.000 description 1
- 125000005587 carbonate group Chemical group 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000013626 chemical specie Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- QSKWJTXWJJOJFP-UHFFFAOYSA-N chloroform;ethoxyethane Chemical compound ClC(Cl)Cl.CCOCC QSKWJTXWJJOJFP-UHFFFAOYSA-N 0.000 description 1
- SKCNIGRBPJIUBQ-UHFFFAOYSA-N chloroform;ethyl acetate Chemical compound ClC(Cl)Cl.CCOC(C)=O SKCNIGRBPJIUBQ-UHFFFAOYSA-N 0.000 description 1
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229940125807 compound 37 Drugs 0.000 description 1
- 229940126540 compound 41 Drugs 0.000 description 1
- 229940125936 compound 42 Drugs 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000007859 condensation product Substances 0.000 description 1
- 238000004320 controlled atmosphere Methods 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 125000000000 cycloalkoxy group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- SASYSVUEVMOWPL-NXVVXOECSA-N decyl oleate Chemical compound CCCCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC SASYSVUEVMOWPL-NXVVXOECSA-N 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 231100000223 dermal penetration Toxicity 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- MHDVGSVTJDSBDK-UHFFFAOYSA-N dibenzyl ether Chemical compound C=1C=CC=CC=1COCC1=CC=CC=C1 MHDVGSVTJDSBDK-UHFFFAOYSA-N 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical group OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- SIPUZPBQZHNSDW-UHFFFAOYSA-N diisobutylaluminium hydride Substances CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000008387 emulsifying waxe Substances 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- JOZGNYDSEBIJDH-UHFFFAOYSA-N eniluracil Chemical compound O=C1NC=C(C#C)C(=O)N1 JOZGNYDSEBIJDH-UHFFFAOYSA-N 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- PSLIMVZEAPALCD-UHFFFAOYSA-N ethanol;ethoxyethane Chemical compound CCO.CCOCC PSLIMVZEAPALCD-UHFFFAOYSA-N 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- DLLJVQNYBYOKGS-UHFFFAOYSA-N ethoxyethane;pentane Chemical compound CCCCC.CCOCC DLLJVQNYBYOKGS-UHFFFAOYSA-N 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- 229940093476 ethylene glycol Drugs 0.000 description 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 description 1
- 229960004413 flucytosine Drugs 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- BNSYGCKJOAPBCM-UHFFFAOYSA-N heptan-2-ol Chemical compound [CH2]C(O)CCCCC BNSYGCKJOAPBCM-UHFFFAOYSA-N 0.000 description 1
- 125000005343 heterocyclic alkyl group Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- 239000008309 hydrophilic cream Substances 0.000 description 1
- 229920013821 hydroxy alkyl cellulose Polymers 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 125000002249 indol-2-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([*])=C([H])C2=C1[H] 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229940078545 isocetyl stearate Drugs 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 125000002463 lignoceryl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- RENRQMCACQEWFC-UGKGYDQZSA-N lnp023 Chemical compound C1([C@H]2N(CC=3C=4C=CNC=4C(C)=CC=3OC)CC[C@@H](C2)OCC)=CC=C(C(O)=O)C=C1 RENRQMCACQEWFC-UGKGYDQZSA-N 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 150000002736 metal compounds Chemical class 0.000 description 1
- 229910000000 metal hydroxide Inorganic materials 0.000 description 1
- 150000004692 metal hydroxides Chemical class 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- JNMIXMFEVJHFNY-UHFFFAOYSA-M methyl(triphenyl)phosphanium;iodide Chemical compound [I-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(C)C1=CC=CC=C1 JNMIXMFEVJHFNY-UHFFFAOYSA-M 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 208000030194 mouth disease Diseases 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 238000003541 multi-stage reaction Methods 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- IDWFNRUQYRSLPH-OVCLIPMQSA-N n-[(e)-(2-fluorophenyl)methylideneamino]-4,6-dimethylpyrimidin-2-amine Chemical compound CC1=CC(C)=NC(N\N=C\C=2C(=CC=CC=2)F)=N1 IDWFNRUQYRSLPH-OVCLIPMQSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 1
- 244000309711 non-enveloped viruses Species 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- UYDLBVPAAFVANX-UHFFFAOYSA-N octylphenoxy polyethoxyethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCOCCOCCOCCO)C=C1 UYDLBVPAAFVANX-UHFFFAOYSA-N 0.000 description 1
- 150000002888 oleic acid derivatives Chemical class 0.000 description 1
- 125000001117 oleyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- KJLARRXJXZWUGO-UHFFFAOYSA-N oxocarbamic acid Chemical compound OC(=O)N=O KJLARRXJXZWUGO-UHFFFAOYSA-N 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 125000005489 p-toluenesulfonic acid group Chemical class 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 201000006995 paralytic poliomyelitis Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000004965 peroxy acids Chemical class 0.000 description 1
- 239000008251 pharmaceutical emulsion Substances 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- PWXJULSLLONQHY-UHFFFAOYSA-N phenylcarbamic acid Chemical class OC(=O)NC1=CC=CC=C1 PWXJULSLLONQHY-UHFFFAOYSA-N 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- 108700010786 picornaviridae proteins Proteins 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 229920001483 poly(ethyl methacrylate) polymer Polymers 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000151 polyglycol Polymers 0.000 description 1
- 239000010695 polyglycol Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Chemical group 0.000 description 1
- OVARTBFNCCXQKS-UHFFFAOYSA-N propan-2-one;hydrate Chemical compound O.CC(C)=O OVARTBFNCCXQKS-UHFFFAOYSA-N 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 239000011253 protective coating Substances 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 125000005504 styryl group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 108020001572 subunits Proteins 0.000 description 1
- 229960005137 succinic acid Drugs 0.000 description 1
- 235000011044 succinic acid Nutrition 0.000 description 1
- 150000003444 succinic acids Chemical class 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid group Chemical class S(N)(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000004001 thioalkyl group Chemical group 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 125000004055 thiomethyl group Chemical group [H]SC([H])([H])* 0.000 description 1
- 229940100611 topical cream Drugs 0.000 description 1
- 229940100615 topical ointment Drugs 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000440 toxicity profile Toxicity 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 1
- MWKJTNBSKNUMFN-UHFFFAOYSA-N trifluoromethyltrimethylsilane Chemical compound C[Si](C)(C)C(F)(F)F MWKJTNBSKNUMFN-UHFFFAOYSA-N 0.000 description 1
- PYOKUURKVVELLB-UHFFFAOYSA-N trimethyl orthoformate Chemical group COC(OC)OC PYOKUURKVVELLB-UHFFFAOYSA-N 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-I triphosphate(5-) Chemical compound [O-]P([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O UNXRWKVEANCORM-UHFFFAOYSA-I 0.000 description 1
- 238000007039 two-step reaction Methods 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229940051021 yellow-fever virus Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/28—Oxygen atom
- C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/36—Sulfur atom
- C07D473/38—Sulfur atom attached in position 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
Definitions
- the present invention relates to a series of novel nucleoside analogs which have been shown to possess antiviral activity, in particular against viruses of the family of the Picornaviridae.
- the invention therefore relates to the new nucleoside analogs, methods for their preparation, pharmaceutical compositions comprising them and to the nucleoside analogs for use as a medicament, more in particular antiviral medicament.
- Picornaviridae are small, non-enveloped viruses containing a single-stranded (+)-sense RNA genome of 7.5kb, which is covalently linked to a small viral protein (VPg) at its 5' end and polyadenylated at its 3' end.
- the genomic RNA has a long, highly structured 5' noncoding region that contains the internal ribosome entry site (IRES) necessary for translation initiation, and a shorter 3' noncoding region preceding the poly(A) tract, which are both thought to be involved in RNAreplication and translation.
- the coding region encodes a single polyprotein that will eventually be cleaved to generate 4 structural and 7 non-structural proteins.
- the icosahedral capsid of the virus is formed by 60 protomers, each one assembled by the 4 structural proteins, designated VP 1-4.
- the non-structural region comprises two proteases, the viral RNA-dependent RNA polymerase (RdRp) and 4 other mature proteins that, either cleaved or as a precursor, are involved in viral replication.
- RdRp viral RNA-dependent RNA polymerase
- Picornaviruses are a family of small RNA viruses comprising some important pathogens of humans and animals. Transmission usually occurs mechanically. There are ten genera, being Aphthovirus (Foot-and-Mouth Disease Virus), Cardiovirus (Encephalomyocarditis virus + and Theilovirus), Enterovirus (Human Enterovirus A, B, C and D, Bovine Enterovirus, Porcine Enterovirus and Poliovirus), Erbovirus, Duck Hepatitis virus, Hepatovirus (Avian Encephalomyelitis Virus, Hepatitis A virus +), Kobuvirus, Parecho virus, Rhino virus and Tescho virus.
- Aphthovirus Feot-and-Mouth Disease Virus
- Cardiovirus Engelphalomyocarditis virus + and Theilovirus
- Enterovirus Human Enterovirus A, B, C and D, Bovine Enterovirus, Porcine Enterovirus and Poliovirus
- Erbovirus Erbovirus
- entero- and rhinoviruses are implicated in a wide range of infections in humans (and animals).
- enteroviruses include coxsackieviruses, which are reported to be associated with the development of myocarditis, pancreatitis, meningitis and encephalitis.
- Other important prototypes amongst the enteroviruses are poliovirus, which can lead to paralytic poliomyelitis, and echovirus, causing aseptic meningitis or encephalomyelitis.
- Rhinoviruses are the most important etiological factor associated with the common cold, and although often mild and self-limiting, rhinovirus infections have an enormous socio-economical impact.
- hepatovirus belongs the hepatitis A virus, a virus that is causing infectious hepatitis in man.
- the aphtovirus, food and mouth disease virus and the enterovirus swine vesicular virus are important patogens in life stock.
- a goal of the present invention is to satisfy this urgent need by identifying efficient and non-harmful pharmaceutically active ingredients and combination of ingredients for the treatment of Picornaviridae infections in animals and in humans.
- the present invention relates to new nucleoside analogs and to their use as anti-viral agents.
- the prior art namely by Hrebabecky H. in Collection of Czechoslovak Chemical Communications 2005, 70(1), p 103-123, describes nucleoside analogs being 9-(6- substituted or 6,8-disubstituted or 2,6-disubstituted -9H-purin-9-yl)-5-oxa- tricyclo[4.2.1.0 3 ' 7 ]nonane-3-methanols such as the 6-amino-9 ⁇ -purin-9-yl; the 2,6- diamino-9H-purin-9-yl; 6-(dimethylamino)-9H-purin-9-yl; 6-cyclopropylamino-9H- purin-9-yl; the 6-amino-8-methyl-9H-purin-9-yl derivatives of 5-oxa- tricyclo[4.2.1.0 3 ' 7 ]nonane-3-m
- 6-chloro-8-methyl-9H-purin-9-yl; 6- chloro-9H-purin-9-yl and 2-amino-6-chloro-9H-purin-9-yl derivative of 5-oxa- tricyclo[4.2.1.0 3 ' 7 ]nonane-3-methanol are described.
- the prior art also describes the compounds 9-[(2-amino-6-chloropyrimidin-4-yl)amino]- 5-oxatricyclo[4.2.1.0 3 ' 7 ]nonane-3-methanol, 9-[(5-amino-6-chloropyrimidin-4- yl)amino]-5-oxatricyclo[4.2.1.0 3 ' 7 ]nonane-3-methanol, 9-[(2-amino-6-chloro-5-[(4- chlorophenyl)azo]pyrimidin-4-yl]-amino)-5-oxatricyclo[4.2.1.0 3 ' 7 ]nonane-3-methanol and 9-[(2,5-diamino-6-chloro-pyrimidin-4-yl]-amino)- 5-oxatricyclo[4.2.1.0 3 ' 7 ]nonane-3-methanol.
- new anti-viral, more in particular anti-Picornaviridae nucleoside analogs are provided.
- the nucleoside analogs have a substituted or unsubstituted bridged carbocycle and it has been shown that they possess anti-viral activity, more specifically against Picornaviridae.
- the present invention demonstrates that the nucleoside analogs inhibit the replication of Picornaviridae. Therefore, these nucleoside analogs constitute a new potent class of anti-viral agents that can be used in the treatment and prevention of viral infections in animals, mammals and humans, more specifically for the treatment and prevention of Picornaviridae.
- the present invention provides novel nucleoside analogs which have virus replication inhibiting properties.
- the invention also provides methods for preparation of all such nucleoside analogs and provides pharmaceutical compositions comprising the nucleoside analogs.
- the invention further relates to the novel nucleoside analogs for use as a medicament and for the prevention and/or treatment of viral infections in subjects (including animals, mammals and humans).
- the invention also relates to the use of the nucleoside analogs in the manufacture of a medicament for the prevention or treatment of subjects suffering from Picornaviridae infection, as well as for treatment of other viral infections of subjects suffering from such infections.
- the invention also provides methods of treatment or prevention of a viral infection in a subject, inlcuding animals, mammals and humans.
- nucleoside analogs having a structure according to the formula (A'):
- - B is selected from an unsubstituted or substituted pyrimidine or purine heterocycle; whereby the purine heterocycle is not substituted with -CF 3 in its 2-position;
- - W is selected from (-CH 2 -) n , wherein n is selected from 0 or 1;
- - X is not present (thereby forming a bond between carbon (2) and carbon (3)) or is selected from -CR 6 R 6 - or -CR 7 R 7' -C R 8 R 8' -;
- each of R 1 and R 4 is independently selected from hydrogen; alkyl; -OH; phosphate; phosphate-alkylene; phosphonate; or phosphonate-alkylene; wherein said alkyl or alkylene can independently be substituted with one or more -OH, aryl or halogen; and wherein said alkyl or alkylene can contain a heteroatom in or at the end of the alkyl chain, said heteroatom selected from O, S and N; and thereby the term phosphate- alkylene includes phosphate-alkoxy and the term phosphonate-alkylene includes phosphonalkyloxy (such as phosphonylmethyl ether)
- each of R 2 and R 3 is independently selected from hydrogen; alkyl; -OH; phosphate; phosphate-alkylene; phosphonate; or phosphonate-alkylene- (such as phosphonylmethyl ether); or when taken together with R 6 , R 6 , R 7 or R 7 forms a double bond or -O- (thereby forming an epoxy); wherein said alkyl or alkylene can independently be substituted with one or more -OH; aryl; -OOC-aryl; or halogen; and wherein said alkyl or alkylene can contain a heteroatom in or at the end of the alkyl chain, said heteroatom selected from O, S and N;
- R 16 , R 17 , R 18 and R 19 is independently selected from hydrogen; F; Cl; Br or alkyl;
- R 5 is hydrogen or when taken together with R 9 , R 9 , R 1 ' or R 11 forms a double bond;
- each of R 6 and R 6 is independently selected from hydrogen; alkyl; or -OH; or taken together with R 9 , R 9' , R 10 , R 10' , R 11 or R H> is -CH 2 -O- or -O-CH 2 - thereby forming a 5- membered ring; or when taken together with one of R 2 or R 3 forms a double bond or -O- (thereby forming an epoxy); wherein said alkyl can be substituted with one or more -OH; aryl; or halogen;
- each of R 7 and R 7 is independently selected from hydrogen; alkyl; or -OH; or when taken together with one of R 2 or R 3 forms a double bond or -O- (thereby forming an epoxy); or when taken together with R 9 , R 9' , R 10 , R 10' , R 11 or R 11' is -CH 2 -O- or -O- CH 2 - thereby forming a 5-membered ring; wherein said alkyl can be substituted with one or more -OH; aryl; or halogen;
- each of R and R is independently selected from hydrogen; alkyl; or -OH; or taken together with R 9 , R 9' , R 10 , R 10' , R 11 or R 11' is -CH 2 -O- or -O-CH 2 - thereby forming a 5- membered ring; wherein said alkyl can be substituted with one or more -OH; aryl; or halogen;
- each of R 9 and R 9 is independently selected from hydrogen; alkyl; or -OH; or taken together with R 6 , R 6' , R 7 , R 7> , R 8 or R 8' is -CH 2 -O- or -0-CH 2 - thereby forming a 5- membered ring; or when taken together with R 5 forms a double bond; wherein said alkyl can be substituted with one or more -OH; aryl; or halogen;
- each of R 10 and R 10 is independently selected from hydrogen; alkyl; or -OH; or taken together with R 6 , R 6' , R 7 , R 7' , R 8 or R 8' is -CH 2 -O- or -0-CH 2 - thereby forming a 5- membered ring; or when taken together with R 5 forms a double bond;
- each of R 11 and R 11 is independently selected from hydrogen; alkyl; or -OH; or when taken together with R 5 forms a double bond; or taken together with R 6 , R 6 , R 7 , R 7' , R 8 or R 8 is -CH 2 -O- or -0-CH 2 - thereby forming a 5-membered ring; wherein said alkyl can be substituted with one or more -OH; aryl; or halogen;
- each of R 6 and R 6 is independently selected from hydrogen; alkyl; or -OH; or taken together with R 9 , R 9' , R 10 , R 10' , R 11 or R 11' is -CH 2 -O- or -O-CH 2 - thereby forming a 5-membered ring; or when taken together with one of R 2 or R 3 forms a double bond or -O- (thereby forming an epoxy); wherein said alkyl can be substituted with one or more aryl; or halogen.
- a particular embodiment of this aspect relates to the nucleoside analogs according to formula (A):
- - B is selected from an unsubstituted or substituted pyrimidine or purine heterocycle
- - W is selected from (-CH 2 -) n , wherein n is selected from O or 1 ;
- - X is not present (thereby forming a bond between carbon (2) and carbon (3)) or is selected from -CR 6 R 6' - or -CR 7 R 7' -C R 8 R 8' -;
- - Y is not present (thereby forming a bond between carbon (2) and carbon (I)) or is selected from -CR 9 R 9' - or -CR 10 R 10' -C R 11 R 11' -;
- each of R 2 and R 3 is independently selected from hydrogen; alkyl; -OH; phosphate; phosphate-alkylene; phosphonate; or phosphonate-alkylene; or when taken together with R 6 , R 6 , R 7 or R 7 forms a double bond or -O- (thereby forming an epoxy); wherein said alkyl or alkylene can be substituted with one or more -OH; aryl; arylalkyl (such as trityl); -OOC-aryl; or halogen; and wherein said alkyl or alkylene can contain a heteroatom in or at the end of the alkyl chain, said heteroatom selected from O, S and N;
- R 16 , R 17 , R 18 and R 19 is independently selected from hydrogen; F; Cl; Br or alkyl; - R 5 is hydrogen or when taken together with R 9 , R 9 , R 11 or R 11 forms a double bond;
- each of R 6 and R 6 is independently selected from hydrogen; alkyl; or -OH; or taken together with R 9 , R 9' , R 10 or R 10' is -CH 2 -O- or -0-CH 2 - thereby forming a 5- membered ring; or when taken together with one of R or R forms a double bond or -O- (thereby forming an epoxy); wherein said alkyl can be substituted with one or more -OH; aryl; or halogen;
- each of R 7 and R 7 is independently selected from hydrogen; alkyl; or -OH; or when taken together with one of R 2 or R 3 forms a double bond or -O- (thereby forming an epoxy); wherein said alkyl can be substituted with one or more -OH; aryl; or halogen;
- each of R and R is independently selected from hydrogen; alkyl; or -OH; or taken together with R 9 , R 9' , R 10 or R 10' is -CH 2 -O- or -0-CH 2 - thereby forming a 5- membered ring; wherein said alkyl can be substituted with one or more -OH; aryl; or halogen;
- each of R and R 9 is independently selected from hydrogen; alkyl; or -OH; or taken together with R 6 , R 6' , R 8 or R 8' is -CH 2 -O- or -0-CH 2 - thereby forming a 5-membered ring; or when taken together with R 5 forms a double bond; wherein said alkyl can be substituted with one or more -OH; aryl; or halogen; - each of R 10 and R 10 is independently selected from hydrogen; alkyl; or -OH; or taken together with R 6 , R 6' , R 8 or R 8' is -CH 2 -O- or -0-CH 2 - thereby forming a 5-membered ring;
- each of R 11 and R 11 is independently selected from hydrogen; alkyl; or -OH; or when taken together with R 5 forms a double bond; wherein said alkyl can be substituted with one or more -OH; aryl; or halogen;
- each of R 12 , R 12' , R 13 , R 13' , R 14 R 14' , R 15 , R 15' is independently selected from hydrogen or alkyl; wherein said alkyl can be substituted with one or more -OH; aryl; or halogen;
- 6-amino-9 ⁇ -purin-9-yl 6-(dimethylamino)-9H-purin-9-yl; 6- cyclopropylamino-9H-purin-9-yl; the 2,6-diamino-9H-purin-9-yl; the 6-amino-8-methyl- 9H-purin-9-yl; the 6-chloro-8-methyl-9H-purin-9-yl; the 6-chloro-9H-purin-9-yl or the 2-amino-6-chloro-9H-purin-9-yl derivative of 5-oxa-tricyclo[4.2.1.0 3 ' 7 ]nonane-3- methanol.
- B is selected from an unsubstituted or substituted pyrimidine or purine heterocycle
- this also includes the analogs and derivatives such as the aza and deaza analogs and substituted derivatives.
- the nucleoside analogs are not 9-(6-substituted or 6,8- disubstituted or 2,6-disubstituted -9H-purin-9-yl)-5-oxa-tricyclo[4.2.1.0 3 ' 7 ]nonane-3- methanol (according to Formula N), more in particular are not the 6-amino-9 ⁇ -purin-9- yl; 6-(dimethylamino)-9H-purin-9-yl; 6-cyclopropylamino-9H-purin-9-yl; the 2,6- diamino-9H-purin-9-yl; the 6-amino-8-methyl-9H-purin-9-yl; the 6-chloro-8-methyl-9H- purin-9-yl; the 6-chloro-9H-purin-9-yl or the 2-amino-6-chloro-9H-purin-9-yl derivative of 5-oxa-tricyclo[4.2.1.0 3 '
- Sub refers to hydrogen or a substituent, in a particular embodiment selected from -N(CH 3 ) 2 ; -NH(cyclopropyl); halogen (more in particular Cl); alkyl (more in particular methyl); or amino.
- nucleoside analogs according to formula A' such as the nucleosides according to formulae (A-2), (A-3) including (A-3a) and (A-3b), (A-4), (A-5) or (A-6).
- nucleoside analogs of the present invention are according to formula (A-2), wherein Y is -CR 9 R 9' - and X is -CR 6 R 6' -:
- R 5 is hydrogen or when taken together with one of R 9 or R 9 forms a double bond; - each of R 6 and R 6 is independently selected from hydrogen; alkyl; or -OH; or taken together with one of R 9 or R 9 is -CH 2 -O- or -0-CH 2 - thereby forming a 5-membered ring; or when taken together with one of R 2 or R 3 forms a double bond or -O- (thereby forming an epoxy); wherein said alkyl can be substituted with one or more -OH; aryl; or halogen; - each of R 9 and R 9 is independently selected from hydrogen; alkyl; or -OH; or taken together with one of R 6 or R 6 is -CH 2 -O- or -0-CH 2 - thereby forming a 5-membered ring; or when taken together with R 5 forms a double bond; wherein said alkyl can be substituted with one or more -OH; aryl; or halogen.
- - Z is selected from -CR 12 R 12' -;
- R 4 is selected from hydrogen or alkyl; - each of R 12 and R 12 is independently selected from hydrogen or alkyl;
- each of R 2 and R 3 is independently selected from hydrogen; alkyl; -OH; phosphate; phosphate-alkylene; phosphonate; or phosphonate-alkylene; or when taken together with one of R 6 or R 6 forms a double bond or -O- (thereby forming an epoxy); wherein said alkyl or alkylene can be substituted with one or more -OH; aryl; -OOC-aryl; or halogen; and wherein said alkyl or alkylene can contain a heteroatom in or at the end of the alkyl chain, said heteroatom selected from O, S and N; or R or R when taken together with R 6 or R 6' is -CH 2 -CH 2 -CH 2 -; -CH 2 -CH 2 -CH 2 -CH 2 - or -CHR 1 ⁇ CHR 17 -CHR" 8 ⁇ CHR 19 -, wherein each of R 16 , R 17 , R 18 and R 19 is independently selected from hydrogen; F
- R 5 is hydrogen or when taken together with one of R 9 or R 9 forms a double bond
- each of R 6 and R 6 is independently selected from hydrogen; alkyl; or -OH; or when taken together with one of R 2 or R 3 forms a double bond or -O- (thereby forming an epoxy); wherein said alkyl can be substituted with one or more -OH; aryl; or halogen;
- each of R 9 and R 9 is independently selected from hydrogen; alkyl; or -OH; or when taken together with R 5 forms a double bond; wherein said alkyl can be substituted with one or more -OH; aryl; or halogen.
- nucleoside analogs according to formula (A-3a) or (A- 3b), wherein R 6 and R 9 are taken together to form -0-CH 2 - or -CH 2 -O-:
- each of R 2 and R 3 is independently selected from hydrogen; alkyl; -OH; phosphate; phosphate-alkylene; phosphonate; or phosphonate-alkylene; or when taken together with one of R 6 or R 6 forms a double bond or -O- (thereby forming an epoxy); wherein said alkyl or alkylene can be substituted with one or more -OH; aryl; -OOC-aryl; or halogen; and wherein said alkyl or alkylene can contain a heteroatom in or at the end of the alkyl chain, said heteroatom selected from O, S and N; - R 5 is hydrogen or when taken together with one of R 9 or R 9 forms a double bond; - R 6 is selected from hydrogen; alkyl; or -OH; or when taken together with one of R 2 or R 3 forms a double bond or -O- (thereby forming an epoxy); wherein said alkyl can be substituted with one or more -OH; aryl; or halogen
- R 9 is selected from hydrogen; alkyl; or -OH; or when taken together with R 5 forms a double bond; wherein said alkyl can be substituted with one or more -OH; aryl; or halogen.
- - Z is selected from -CH 2 -; -0-; or -CH 2 -CH 2 -; - each of R 1 , R 4 , R 5 , R 6 and R 9 are hydrogen;
- each of R 2 and R 3 is independently selected from hydrogen; -OH; -OCH 3 ; phosphonylmethylether; benzyloxymethyl; methoxymethyl and chloromethyl.
- nucleoside analogs are according to formula (A-4), claim 1, wherein Y is not present and thereby the nucleoside analogs are according to the formula IV,
- each of R 6 and R 6 is independently selected from hydrogen; alkyl; or -OH; or when taken together with R 2 or R 3 forms a double bond or -O- (thereby forming an epoxy); wherein said alkyl can be substituted with one or more -OH; aryl; or halogen.
- R 1 , R 4 and R 5 are hydrogen
- Another particular embodiment relates to nucleoside analogs according to formula (A-5), wherein Y is -CR 10 R 1 ⁇ -CR 11 R 11' - and X is not present
- each of R 2 and R 3 is independently selected from hydrogen; alkyl; -OH; phosphate; phosphate-alkylene; phosphonate; or phosphonate-alkylene; wherein said alkyl or alkylene can be substituted with one or more -OH; aryl; -OOC-aryl; or halogen; and wherein said alkyl or alkylene can contain a heteroatom in or at the end of the alkyl chain, said heteroatom selected from O, S and N;
- R 5 is hydrogen or when taken together with R 11 or R 11 forms a double bond
- each of R 10 and R 10 is independently selected from hydrogen; alkyl; or -OH;
- each of R 11 and R 11 is independently selected from hydrogen; alkyl; or -OH; or when taken together with R 5 forms a double bond; wherein said alkyl can be substituted with one or more -OH; aryl; or halogen.
- nucleoside analogs can be according to formula (A-6), wherein
- the dotted line represents a double line which can be present or not present
- each of R 2 , R 3 , R 12 and R 12 is independently selected from hydrogen or alkyl (more in particular methyl).
- the purine and pyrimidine heterocycles of B are coupled directly to carbon (1) (if W is not present) or are coupled to W as following: - for purines via their N 9 or N 7 , preferabky via N 9 ; and
- N 3 or N 1 for pyrimidines via their N 3 or N 1 , preferably via N 3 .
- the purine heterocycles of B are coupled directly to carbon (1) (if W is not present) or are coupled to W via their N 9 or N 7 , preferably via N 9 .
- R 2 is hydrogen, while R 3 is selected from hydrogen; alkyl; -OH; phosphate; phosphate- alkylene; phosphonate; or phosphonate-alkylene- (such as phosphonylmethyl ether); or when taken together with R 6 , R 6 , R 7 or R 7 forms a double bond or -O- (thereby forming an epoxy); wherein said alkyl or alkylene can be substituted with one or more -OH; aryl; -OOC-aryl; halogen; phosphate; phosphate-alkylene; phosphonate; or phosphonate- alkylene- (such as phosphonylmethyl ether); and wherein said alkyl or alkylene can contain a heteroatom in or at the end of the alkyl chain, said heteroatom selected from O, S and N.
- each of R 1 and R 4 is independently selected from hydrogen; alkyl; or -OH; wherein said alkyl can be substituted with -OH, aryl, or halogen; and wherein said alkyl can contain a heteroatom in or at the end of the alkyl chain, said heteroatom selected from O, S and N.
- nucleoside analogs are of general formulae (A-2), (A3-a), (A3-b), (A-4), (A-5) and (A-6);
- - W is selected from (-CH 2 -) n , wherein n is selected from O or 1 ;
- - X is not present (thereby forming a bond between carbon (2) and carbon (3)) or is selected from -CR 6 R 6' - or -CR 7 R 7' -C R 8 R 8' -;
- R 5 is hydrogen or when taken together with R 9 , R 9 , R 11 or R 11 forms a double bond
- - each of R 6 and R 6 is independently selected from hydrogen; alkyl; or -OH; or taken together with R 9 , R 9' , R 10 or R 10' is -CH 2 -O- or -O-CH 2 - thereby forming a 5- membered ring; or when taken together with one of R 2 or R 3 forms a double bond or -O- (thereby forming an epoxy); wherein said alkyl can be substituted with one or more -OH; aryl; or halogen; - each of R 7 and R 7 is independently selected from hydrogen; alkyl; or -OH; or when taken together with one of R 2 or R 3 forms a double bond or -O- (thereby forming an epoxy); wherein said alkyl can be substituted with one or more -OH; aryl; or halogen;
- each of R 8 and R 8 is independently selected from hydrogen; alkyl; or -OH; or taken together with R 9 , R 9' , R 10 or R 10' is -CH 2 -O- or -0-CH 2 - thereby forming a 5- membered ring; wherein said alkyl can be substituted with one or more -OH; aryl; or halogen;
- each of R 9 and R 9 is independently selected from hydrogen; alkyl; or -OH; or taken together with R 6 , R 6> , R 8 or R 8' is -CH 2 -O- or -0-CH 2 - thereby forming a 5-membered ring; or when taken together with R 5 forms a double bond; wherein said alkyl can be substituted with one or more -OH; aryl; or halogen;
- each of R 10 and R 10 is independently selected from hydrogen; alkyl; or -OH; or taken together with R 6 , R 6' , R 8 or R 8' is -CH 2 -O- or -0-CH 2 - thereby forming a 5-membered ring;
- each of R 1 ' and R 11 is independently selected from hydrogen; alkyl; or -OH; or when taken together with R 5 forms a double bond; wherein said alkyl can be substituted with one or more -OH; aryl; or halogen;
- each of R 12 , R 12> , R 13 , R 13' , R 14 R 14' , R 15 , R 15' is independently selected from hydrogen or alkyl; wherein said alkyl can be substituted with one or more -OH; aryl; or halogen;
- nucleoside analog is not a 9-(6-substituted or 6,8-disubstituted or 2,6- disubstituted -9H-purin-9-yl)-5-oxa-tricyclo[4.2.1.0 3 ' 7 ]nonane-3-methanol;
- R 22 is selected from hydrogen; F; Cl; Br; I; -COOH; -COO-CH 3 ; -COO-C 2 H 5 ; -COO- CH(CH 3 ) 2 ; -COO-C(CH 3 ) 3 ; n-butyl; isobutyl; n-pentyl; sec-pentyl; -CH 2 -OH; -CH 2 -CH 2 - OH; -CH 3 ; -C 2 H 5 ; -CH 2 -CH 2 -CH 3 ; n-butyl; isobutyl; n-pentyl; sec-pentyl; -CH(CH 3 ) 2 and -C(CH 3 ) 3 .
- the nucleoside analogs of the present invention are selected from the list of compounds in table 1 (encoded from compound number 1 to 86).
- nucleoside analogs are selected from the list of:
- the invention relates to the nucleoside analogs as described herein for use as a medicament, more in particular for use as an antiviral medicament and for the use in the prevention or treatment of a viral infection in a subject (animal, mammal or human).
- the present invention also relates to the use of the nucleoside analogs of the formulae (including but not limited to A', A, A-2, A-3a, A-3b, A-4, A-5 and A-6) and claims herein as antiviral compounds, more particularly as compounds active against Picornaviridae.
- the invention also relates to the use of nucleoside analogs of the formulae and claims herein for the manufacture of a medicament or as a pharmaceutically active ingredient, especially as a virus replication inhibitor, for instance for the manufacture of a medicament or pharmaceutical composition having antiviral activity for the prevention and/or treatment of viral infections in humans, mammals and animals in general.
- the present invention further relates to a method of prevention or treatment of a viral infection, preferably a Picornaviridae infection in an animal, including mammals, including a human, comprising administering to the animal in need of such treatment a therapeutically effective amount of a nucleoside analog of formulae and claims herein as an active ingredient, preferably in admixture with at least a pharmaceutically acceptable carrier.
- a viral infection preferably a Picornaviridae infection in an animal, including mammals, including a human
- Another aspect of the invention further relates to methods for the preparation of compounds of formulae and claims herein.
- the intermediates (amines and hydroxy bearing derivatives as specified in the examples) used in the preparation methods described herein are aspects of the present invention.
- One embodiment relates to a method for the preparation of the nucleoside analogs of the invention, said method comprising the steps of coupling a substituted or unsubstituted pyrimidine or purine heterocycle, preferably a substituted or unsubstituted purine heterocycle, to compounds of the formula (A-7), in particular via the Mitsunobu-reaction:
- Another particular embodiment relates to a method for the preparation of the nucleoside analogs of the invention, said method comprising the steps of coupling a substituted or unsubstituted pyrimidine or purine heterocycle, preferably a substituted pyrimidine heterocycle, to compounds of the formula (A-8),
- compositions comprising the nucleoside analogs of the invention according to formulae and claims herein in admixture with at least a pharmaceutically acceptable carrier, the active ingredient preferably being in a concentration range of about 0.1 to 100% by weight, and to the use of these derivatives namely as drugs useful for the treatment of subjects suffering from a viral infection, in particular a Picornaviridae infection.
- the invention further relates to the use of a composition
- a composition comprising (a) one or more derivatives of formulae and claims herein, and (b) one or more viral inhibitors as biologically active agents in respective proportions such as to provide a synergistic effect against a viral infection in a mammal, for instance in the form of a combined preparation for simultaneous, separate or sequential use in viral infection therapy.
- the viral enzyme inhibitors used as a therapeutically active ingredients (b) may belong to categories already known in the art.
- alkylene refers to a saturated, branched or straight chain hydrocarbon radical of Cj -18 carbon atoms, and having two monovalent radical centers derived by the removal of two hydrogen atoms from the same or two different carbon atoms of a parent alkane.
- Typical alkylene radicals include, but are not limited to: methylene (-CH2-) 1,2-ethyl (-CH2CH2-), 1,3-propyl (-CH2CH2CH2-), 1,4-butyl (- CH2CH2CH2CH2-), and the like.
- alkyl can contain a heteroatom in or at the end of the alkyl chain, said heteroatom selected from O, S and N", than any carbon atom of the alkyl can be exchanged for a heteroatom selected from O, S and N when chemically feasible. Examples are CH 3 -CH 2 -O-; CH 3 -O-CH 2 - and CH 3 -CH 2 -CH 2 -NH-CH 2 -.
- alkylene whereby the term “phosphonate-alkylene can contain a heteroatom in or at the end of the alkyl chain, said heteroatom selected from O, S and N” also includes phosphonalkyloxy such as phosphonylmethyl ether.
- phosphonalkyloxy refers to a phosphonate coupled via an alkylgroup (such as defined herein after) to an oxygen atom which itself can be coupled to another molecule or group.
- cycloalkyl means a monocyclic saturated hydrocarbon monovalent radical having from 3 to 10 carbon atoms, such as for instance cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl and the like, or a C 7-10 polycyclic saturated hydrocarbon monovalent radical having from 7 to 10 carbon atoms such as, for instance, norbornyl, fenchyl, trimethyltricycloheptyl or adamantyl.
- alkenyl and cycloalkenyl as used herein is C2-C18 normal, preferably primary, secondary or tertiary and respectively C3-10 cyclic hydrocarbon with at least one site (usually 1 to 3, preferably 1) of unsaturation, i.e. a carbon-carbon, sp2 double bond.
- sites usually 1 to 3, preferably 1 of unsaturation, i.e. a carbon-carbon, sp2 double bond.
- the double bond may be in the cis or trans configuration.
- aryl as used herein means a aromatic hydrocarbon radical of 6-20 carbon atoms derived by the removal of hydrogen from a carbon atom of a parent aromatic ring system.
- Typical aryl groups include, but are not limited to 1 ring, or 2 or 3 rings fused together, radicals derived from benzene, naphthalene, anthracene, biphenyl, and the like.
- Arylalkyl refers to an alkyl radical in which one of the hydrogen atoms bonded to a carbon atom, typically a terminal or sp3 carbon atom, is replaced with an aryl radical.
- Typical arylalkyl groups include, but are not limited to, benzyl, 2- phenylethan-1-yl, 2-phenylethen-l-yl, naphthyhnethyl, 2-naphthylethan-l-yl, 2- naphthylethen-1-yl, naphthobenzyl, 2-naphthophenylethan-l-yl and the like.
- the arylalkyl group comprises 6 to 20 carbon atoms, preferably 7 to 20 carbon atom, e.g. the alkyl moiety, including alkanyl, alkenyl or alkynyl groups, of the arylalkyl group is 1 to 6 carbon atoms and the aryl moiety is 5 to 14 carbon atoms, preferably 6 to 14 carbon atoms.
- arylalkyl radical may itself be substituted such as but not limited to 4- chlorobenzyl, 4-fluorobenzyl, 2-fluorobenzyl, 3,4-dichlorobenzyl, 2,6-dichlorobenzyl, 3- methylbenzyl, 4-methylbenzyl, 4-ter-butylbenzyl, l-amino-2-phenylethyl and l-amino-2- [4-hydroxy-phenyl]ethyl.
- purine and pyrimidine heterocycles include, but are not limited to, adenine, thymine, cytosine, uracyl, guanine and (2,6-)diaminopurine such as may be found in naturally-occurring nucleosides.
- the term also includes analogs and derivatives thereof.
- An analog thereof is a heterocycle which mimics such naturally-occurring bases in such a way that its structure (the kinds of atoms present and their arrangement) is similar to the above-listed naturally-occurring heterocycles but is modified by either having additional functional properties with respect to the naturally-occurring bases or lacking certain functional properties of the naturally- occurring bases.
- Such analogues include, but are not limited to, those derived by replacement of a -CH- moiety by a nitrogen atom ("aza-analogs” e.g. 5-azapyrimidines such as 5-azacytosine) or vice-versa ("deaza-analogs” e.g. 7-deazapurines, such as 7- deaza-adenine or 7-deazaguanine) or both (e.g. 7-deaza, 8-azapurines).
- the purine and pyrimidine heterocycles can be unsubstituted or substituted and in the last instance can be refered to as a "derivative" of naturally-occurring heterocycles (bases), or analogs thereof.
- purine or pyrimidine heterocycles, analogs and derivatives thereof are well known to those skilled in the art.
- Specific embodiments of purine and pyrimidine heterocycles B suitable for inclusion into the nucleoside analogs of the present invention include, but are not limited to, hypoxanthine, guanine, adenine, cytosine, inosine, thymine, uracil, xanthine, 8-aza derivatives of 2-aminopurine, 2,6-diaminopurine, 6-chloro-purine, 2,6-dichloro-purine, 2-amino-6-chloropurine, hypoxanthine, inosine and xanthine; 7-deaza-8-aza derivatives of adenine, guanine, 2-aminopurine, 2,6-diaminopurine, 6-chloro-purine, 2,6-dichloro- purine, 2-amino-6-chloropurine, hypoxanthin
- B is a 9- purinyl residue selected from guanyl, 3-deazaguanyl, 1-deazaguanyl, 8-azaguanyl, 7- deazaguanyl, adenyl, 3-deazaadenyl, 1-dezazadenyl, 8-azaadenyl, 7-deazaadenyl, 2,6- diaminopurinyl, 2-aminopurinyl, 6-chloro-2-aminopurinyl and 6-thio-2-aminopurinyl.
- the purine heterocycle is according to formula (P-I),
- each of R 20 and R 21 are independently selected from hydrogen; halogen; -NH 2 ; - N 3 ; -OH; -O-alkyl (such as -OCH 3 ); -SH; -S-alkyl (such as -SCH 3 ); -CF 3 ; -NO 2 ; -COOH; -COO-alkyl; -S0 2 alkyl; aryl; or alkyl; wherein each of said alkyl and aryl can again be substituted with hydroxy, amino, halogen or -SH;
- R 22 is selected from hydrogen; halogen; -NH 2 ; -OH; -O-alkyl (such as -OCH 3 ); -SH; -S-alkyl (such as -SCH 3 ); -N 3 ; -NO 2 ; -COOH; -COO-alkyl; -S0 2 alkyl; aryl; or alkyl; wherein each of said alkyl and aryl can again be substituted with hydroxy, amino or -SH
- the purine heterocycle is according to formula (P-I), wherein
- each of R 20 and R 21 are independently selected from hydrogen; F; Cl; Br; I; -N 3 ; -NH 2 ; - OH; -0-CH 3 ; -0-C 2 H 5 ; -0-CH 2 -CH 2 -CH 3 ; -O-CH(CH 3 ) 2 ; -O-C(CH 3 ) 3 ; -SH; -S-CH 3 ; -S-
- the purine heterocycle is according to formula (P-I), wherein
- R 20 is selected from hydrogen; F; Cl; Br; I; -N 3 ; -NH 2 ; -OH; -0-CH 3 ; -0-C 2 H 5 ; -0-CH 2 - CH 2 -CH 3 ; -O-CH(CH 3 ) 2 ; -O-C(CH 3 ) 3 ; -SH; -S-CH 3 ; -S-C 2 H 5 ; -S-CH 2 -CH 2 -CH 3 ; -S-
- R 21 is selected from hydrogen; F; Cl; Br; I; -0-CH 3 ; -0-C 2 H 5 ; -0-CH 2 -CH 2 -CH 3 ; -O- CH(CH 3 ) 2 ; -O-C(CH 3 ) 3 ; -CH 3 ; -C 2 H 5 ; -CH 2 -CH 2 -CH 3 ; -CH(CH 3 ) 2 ; -C(CH 3 ) 3 ; n-butyl; isobutyl; n-pentyl and sec-pentyl;
- R 22 is selected from hydrogen; F; Cl; Br; I; -COOH; -COO-CH 3 ; -COO-C 2 H 5 ; -COO- CH(CH 3 ) 2 ; -COO-C(CH 3 ) 3 ; n-butyl; isobutyl; n-pentyl; sec-pentyl; -CH 2 -OH; -CH 2 -CH 2 - OH; -CH 3 ; -C 2 H 5 ; -CH 2 -CH 2 -CH 3 ; n-butyl; isobutyl; n-pentyl; sec-pentyl; -CH(CH 3 ) 2 and -C(CH 3 ) 3 .
- arylalkyl refers to an aliphatic saturated or ethylenically unsaturated hydrocarbon monovalent group (preferably a C 1-I8 alkyl or C 2-18 alkenyl such as defined above) onto which an aryl or heterocyclic group (such as defined herein) is already bonded, and wherein the said aliphatic group and/or the said aryl or heterocyclic group may be optionally substituted with one or more substituents independently selected from the group consisting of halogen, amino, hydroxyl, sulfhydryl, Ci -7 alkyl, trifluoromethyl and nitro, such as but not limited to l-amino-2-[indol-2-yl]ethyl, styryl, pyridylmethyl (including all isomers thereof), pyr
- halogen means any atom selected from the group consisting of fluorine (F), chlorine (Cl), bromine (Br) and iodine
- Substituents optionally are designated with or without bonds. Regardless of bond indications, if a substituent is polyvalent (based on its position in the structure referred to), then any and all possible orientations of the substituent are intended.
- the present invention relates to a series of novel nucleoside analogs which have been shown to possess antiviral activity, in particular against viruses of the family of the Picornaviridae.
- the invention therefore relates to the new nucleoside analogs, methods for their preparation, pharmaceutical compositions comprising them, the use of the nucleoside analogs for the preparation of a medicament and to the nucleoside analogs for use as a medicament, more in particular as antiviral medicament.
- the compounds of the invention are employed for the treatment or prophylaxis of viral infections, more particularly Picornaviridae infections.
- the present invention further relates to a method for preventing or treating a viral infections in a subject or patient by administering to the patient in need thereof a therapeutically effective amount of the nucleoside analogs of the present invention.
- the therapeutically effective amount of the preparation of the compound(s), especially for the treatment of viral infections in humans and other mammals preferably is Picornaviridae protein/enzyme inhibiting amount. More preferably, it is a Picornaviridae replication inhibiting amount or a Picornaviridae enzyme inhibiting amount of the nucleoside analogs of the formulae as defined herein.
- the effective amount may be divided into several sub- units per day or may be administered at more than one day intervals.
- ED x is the dose of the first or respectively second drug used alone (Ia, 2a), or in combination with the second or respectively first drug (Ic, 2c), which is needed to produce a given effect.
- the combination When the minimum FIC index corresponding to the FIC of combined compounds (e.g., FIC x + FIC y ) is equal to 1.0, the combination is said to be additive; when it is between 1.0 and 0.5, the combination is defined as subsynergistic, and when it is lower than 0.5, the combination is defined as synergistic. When the minimum FIC index is between 1.0 and 2.0, the combination is defined as subantagonistic and, when it is higher than 2.0, the combination is defined as antagonistic. This principle may be applied to a combination of different antiviral drugs of the invention or to a combination of the antiviral drugs of the invention with other drugs that exhibit anti-Picornaviridae activity.
- nucleoside analogs of the present invention (d) at least one of the nucleoside analogs of the present invention, and (e) optionally one or more pharmaceutical excipients or pharmaceutically acceptable carriers, for simultaneous, separate or sequential use in the treatment or prevention of a viral infection.
- the pharmaceutical composition or combined preparation with synergistic activity against viral infection may contain nucleoside analogs of the present invention, compounds according to the formulae of the application, over a broad content range depending on the contemplated use and the expected effect of the preparation.
- the content of the nucleoside analogs of the present invention of the combined preparation is within the range of 0.1 to 99.9% by weight, preferably from 1 to 99% by weight, more preferably from 5 to 95% by weight.
- the nucleoside analogs of the invention can be used for the treatment or prevention of Aphthovirus (Foot-and-Mouth Disease Virus), Cardiovirus (Encephalomyocarditis virus + and Theilovirus), Enterovirus (Human Enterovirus A, B, C and D, Bovine Enterovirus, Porcine Enterovirus and Poliovirus), Erbovirus, Duck Hepatitis virus, Hepato virus (Avian Encephalomyelitis Virus, Hepatitis A virus +), Kobuvirus, Parechovirus, Rhinovirus or Teschovirus.
- Aphthovirus Feot-and-Mouth Disease Virus
- Cardiovirus Encephalomyocarditis virus + and Theilovirus
- Enterovirus Human Enterovirus A, B, C and D, Bovine Enterovirus, Porcine Enterovirus and Poliovirus
- Erbovirus Erbovirus
- Duck Hepatitis virus Hepato virus (Avian Encephalomyelitis
- the invention also relates to the nucleoside analogs of the invention, according to the formulae of the application being used for inhibition of the proliferation of other viruses than Picornaviridae, particularly for the inhibition of other RNA- viruses, including ds and ss RNA viruses and thereby including negative strand and positive strand viruses.
- the present invention further provides veterinary compositions comprising at least one active ingredient as above defined together with a veterinary carrier therefore.
- Veterinary carriers are materials useful for the purpose of administering the composition and may be solid, liquid or gaseous materials which are otherwise inert or acceptable in the veterinary art and are compatible with the active ingredient. These veterinary compositions may be administered orally, parenterally or by any other desired route.
- the invention relates to the compounds according to the formulae of the application being useful as agents having biological activity (particularly antiviral activity) or as diagnostic agents.
- Any of the uses mentioned with respect to the present invention may be restricted to a non-medical use, a non-therapeutic use, a non-diagnostic use, or exclusively an in vitro use, or a use related to cells remote from an animal.
- the compounds of the invention optionally are bonded covalently to an insoluble matrix and used for affinity chromatography (separations, depending on the nature of the groups of the compounds, for example compounds with aryl are useful in hydrophobic affinity separations.
- the compounds of the invention may exist in many different protonation states, depending on, among other things, the pH of their environment. While the structural formulae provided herein depict the compounds in only one of several possible protonation states, it will be understood that these structures are illustrative only, and that the invention is not limited to any particular protonation state, any and all protonated forms of the compounds are intended to fall within the scope of the invention.
- the term "pharmaceutically acceptable salts" as used herein means the therapeutically active non-toxic salt forms which the compounds according to the formulae of the application are able to form. Therefore, the compounds of this invention optionally comprise salts of the compounds herein, especially pharmaceutically acceptable non- toxic salts containing, for example, Na+, Li+, K+, Ca+2 and Mg+2. Such salts may include those derived by combination of appropriate cations such as alkali and alkaline earth metal ions or ammonium and quaternary amino ions with an acid anion moiety, typically a carboxylic acid.
- the compounds of the invention may bear multiple positive or negative charges. The net charge of the compounds of the invention may be either positive or negative.
- any associated counterions are typically dictated by the synthesis and/or isolation methods by which the compounds are obtained.
- Typical counterions include, but are not limited to ammonium, sodium, potassium, lithium, halides, acetate, trifluoroacetate, etc., and mixtures thereof. It will be understood that the identity of any associated counter ion is not a critical feature of the invention, and that the invention encompasses the compounds in association with any type of counter ion.
- the invention is intended to encompass not only forms of the compounds that are in association with counterions (e.g., dry salts), but also forms that are not in association with counterions (e.g., aqueous or organic solutions).
- Metal salts typically are prepared by reacting the metal hydroxide with a compound of this invention.
- metal salts which are prepared in this way are salts containing Li+, Na+, and K+. A less soluble metal salt can be precipitated from the solution of a more soluble salt by addition of the suitable metal compound.
- salts may be formed from acid addition of certain organic and inorganic acids to basic centers, typically amines, or to acidic groups. Examples of such appropriate acids include, for instance, inorganic acids such as hydrohalic acids, e.g.
- hydrochloric or hydrobromic acid sulfuric acid, nitric acid, phosphoric acid and the like; or organic acids such as, for example, acetic, propanoic, hydroxyacetic, 2-hydroxypropanoic, 2- oxopropanoic, lactic, pyruvic, oxalic (i.e. ethanedioic), malonic, succinic (i.e. butanedioic acid), maleic, fumaric, malic, tartaric, citric, methanesulfonic, ethanesulfonic, benzenesulfonic, p-toluenesulfonic, cyclohexanesulfamic, salicylic (i.e.
- compositions herein comprise compounds of the invention in their unionized, as well as zwitterionic form, and combinations with stoichiometric amounts of water as in hydrates.
- the salts of the parental compounds with one or more amino acids are included within the scope of this invention.
- the amino acid typically is one bearing a side chain with a basic or acidic group, e.g., lysine, arginine or glutamic acid, or a neutral group such as glycine, serine, threonine, alanine, isoleucine, or leucine.
- Physiologically acceptable salts of a compound containing a hydroxy group include the anion of said compound in combination with a suitable cation such as Na+ and NX 4 + (wherein X typically is independently selected from H or a C 1 -C 4 alkyl group).
- a suitable cation such as Na+ and NX 4 + (wherein X typically is independently selected from H or a C 1 -C 4 alkyl group).
- salts of acids or bases which are not physiologically acceptable may also find use, for example, in the preparation or purification of a physiologically acceptable compound. All salts, whether or not derived form a physiologically acceptable acid or base, are within the scope of the present invention.
- nucleoside analogs of the present invention can have different isomeric forms and during the synthesis as provided herein normally one isomeric form is prepared (except for some isomeric impurities). All the atoms in the nucleoside analogs of the present invention can be in the R or S form. For some specific nucleoside analogs of the present invention, the isomeric configuration is given herein. hi a particular embodiment of the different aspects of the invention, the nucleoside analogs of the invention are according to one of the formulae A-IO to A-23 hereunder:
- enantiomer means each individual optically active form of a compound of the invention, having an optical purity or enantiomeric excess (as determined by methods standard in the art) of at least 80% (i.e. at least 90% of one enantiomer and at most 10% of the other enantiomer), preferably at least 90% and more preferably at least 98%.
- stereogenic centers may have either the R- or S-configuration, and multiple bonds may have either cis- or trans-configuration.
- stereoisomers Separation of stereoisomers is accomplished by standard methods known to those skilled in the art.
- One enantiomer of a compound of the invention can be separated substantially free of its opposing enantiomer by a method such as formation of diastereomers using optically active resolving agents ("Stereochemistry of Carbon Compounds,” (1962) by E. L. Eliel, McGraw Hill; Lochmuller, C. H., (1975) J. Chromatogr., 113:(3) 283-302).
- diastereomeric salts can be formed by reaction of enantiomerically pure chiral bases such as brucine, quinine, ephedrine, strychnine, a- methyl-b-phenylethylamine (amphetamine), and the like with asymmetric compounds bearing acidic functionality, such as carboxylic acid and sulfonic acid.
- the diastereomeric salts may be induced to separate by fractional crystallization or ionic chromatography.
- addition of chiral carboxylic or sulfonic acids such as camphorsulfonic acid, tartaric acid, mandelic acid, or lactic acid can result in formation of the diastereomeric salts.
- the substrate to be resolved may be reacted with one enantiomer of a chiral compound to form a diastereomeric pair
- a diastereomeric pair Eliel, E. and Wilen, S. (1994) Stereochemistry of Organic Compounds, John Wiley & Sons, Inc., p. 322).
- Diastereomeric compounds can be formed by reacting asymmetric compounds with enantiomerically pure chiral derivatizing reagents, such as menthyl derivatives, followed by separation of the diastereomers and hydrolysis to yield the free, enantiomerically enriched compounds of the invention.
- Tautomers are organic compounds that are interconvertible by a chemical reaction called tautomerization. As most commonly encountered, this reaction results in the formal migration of a hydrogen atom or proton, accompanied by a switch of a single bond and adjacent double bond. In solutions where tautomerization is possible, a chemical equilibrium of the tautomers will be reached. The exact ratio of the tautomers depends on everal factors, including temperature, solvent, and pH. For example, the compound 9-(l- benzyl)-l,9-dihydro-6H-purin-6-one is a tautomer of 9-(l-benzyl)-6-hydroxy-9 ⁇ -purine.
- the term "pharmaceutically acceptable carrier” as used herein means any material or substance with which the active ingredient is formulated in order to facilitate its application or dissemination to the locus to be treated, for instance by dissolving, dispersing or diffusing the said composition, and/or to facilitate its storage, transport or handling without impairing its effectiveness.
- the pharmaceutically acceptable carrier may be a solid or a liquid or a gas which has been compressed to form a liquid, i.e. the compositions of this invention can suitably be used as concentrates, emulsions, solutions, granulates, dusts, sprays, aerosols, suspensions, ointments, creams, tablets, pellets or powders.
- Suitable pharmaceutical carriers for use in the said pharmaceutical compositions and their formulation are well known to those skilled in the art, and there is no particular restriction to their selection within the present invention. They may also include additives such as wetting agents, dispersing agents, stickers, adhesives, emulsifying agents, solvents, coatings, antibacterial and antifungal agents (for example phenol, sorbic acid, chlorobutanol), isotonic agents (such as sugars or sodium chloride) and the like, provided the same are consistent with pharmaceutical practice, i.e. carriers and additives which do not create permanent damage to mammals.
- additives such as wetting agents, dispersing agents, stickers, adhesives, emulsifying agents, solvents, coatings, antibacterial and antifungal agents (for example phenol, sorbic acid, chlorobutanol), isotonic agents (such as sugars or sodium chloride) and the like, provided the same are consistent with pharmaceutical practice, i.e. carriers and additives which do not create permanent damage to mammals.
- compositions of the present invention may be prepared in any known manner, for instance by homogeneously mixing, coating and/or grinding the active ingredients, in a one-step or multi-steps procedure, with the selected carrier material and, where appropriate, the other additives such as surface-active agents may also be prepared by inicronisation, for instance in view to obtain them in the form of microspheres usually having a diameter of about 1 to 10 gm, namely for the manufacture of microcapsules for controlled or sustained release of the active ingredients.
- Synthetic surfactants include sodium or calcium salts of polyacrylic acids; fatty sulphonates and sulphates; sulphonated benzimidazole derivatives and alkylarylsulphonates.
- Fatty sulphonates or sulphates are usually in the form of alkaline or alkaline-earth metal salts, unsubstituted ammonium salts or ammonium salts substituted with an alkyl or acyl radical having from 8 to 22 carbon atoms, e.g.
- phosphatidylethanolamine phosphatidylserine, phosphatidylglycerine, lysolecithin, cardiolipin, dioctanylphosphatidyl-choline, dipalmitoylphoshatidyl -choline and their mixtures.
- Suitable non-ionic surfactants include polyethoxylated and polypropoxylated derivatives of alkylphenols, fatty alcohols, fatty acids, aliphatic amines or amides containing at least 12 carbon atoms in the molecule, alkylarenesulphonates and dialkylsulphosuccinates, such as polyglycol ether derivatives of aliphatic and cycloaliphatic alcohols, saturated and unsaturated fatty acids and alkylphenols, said derivatives preferably containing 3 to 10 glycol ether groups and 8 to 20 carbon atoms in the (aliphatic) hydrocarbon moiety and 6 to 18 carbon atoms in the alkyl moiety of the alkylphenol.
- non- ionic surfactants are water-soluble adducts of polyethylene oxide with poylypropylene glycol, ethylenediaminopolypropylene glycol containing 1 to 10 carbon atoms in the alkyl chain, which adducts contain 20 to 250 ethyleneglycol ether groups and/or 10 to 100 propyleneglycol ether groups.
- Such compounds usually contain from 1 to 5 ethyleneglycol units per propyleneglycol unit.
- non-ionic surfactants are nonylphenol -polyethoxyethanol, castor oil polyglycolic ethers, polypropylene/polyethylene oxide adducts, tributylphenoxypolyethoxyethanol, polyethyleneglycol and octylphenoxypolyethoxyethanol.
- Fatty acid esters of polyethylene sorbitan such as polyoxyethylene sorbitan trioleate
- glycerol glycerol
- sorbitan sucrose and pentaerythritol are also suitable non-ionic surfactants.
- Suitable cationic surfactants include quaternary ammonium salts, particularly halides, having 4 hydrocarbon radicals optionally substituted with halo, phenyl, substituted phenyl or hydroxy; for instance quaternary ammonium salts containing as N-substituent at least one C8C22 alkyl radical (e.g. cetyl, lauryl, palmityl, myristyl, oleyl and the like) and, as further substituents, unsubstituted or halogenated lower alkyl, benzyl and/or hydroxy-lower alkyl radicals.
- C8C22 alkyl radical e.g. cetyl, lauryl, palmityl, myristyl, oleyl and the like
- Compounds of the invention and their physiologically acceptable salts may be administered by any route appropriate to the condition to be treated, suitable routes including oral, rectal, nasal, topical (including ocular, buccal and sublingual), vaginal and parenteral (including subcutaneous, intramuscular, intravenous, intradermal, intrathecal and epidural).
- suitable routes including oral, rectal, nasal, topical (including ocular, buccal and sublingual), vaginal and parenteral (including subcutaneous, intramuscular, intravenous, intradermal, intrathecal and epidural).
- the preferred route of administration may vary with for example the condition of the recipient.
- the formulations both for veterinary and for human use, of the present invention comprise at least one active ingredient, as above described, together with one or more pharmaceutically acceptable carriers therefore and optionally other therapeutic ingredients.
- the carrier(s) optimally are "acceptable” in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
- the formulations include those suitable for oral, rectal, nasal, topical (including buccal and sublingual), vaginal or parenteral (including subcutaneous, intramuscular, intravenous, intradermal, intrathecal and epidural) administration.
- the formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy.
- Such methods include the step of bringing into association the active ingredient with the carrier which constitutes one or more accessory ingredients, hi general the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.
- Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as solution or a suspension in an aqueous liquid or a non-aqueous liquid; or as an oil-in- water liquid emulsion or a water- in-oil liquid emulsion.
- the active ingredient may also be presented as a bolus, electuary or paste.
- the aqueous phase of the cream base may include, for example, at least 30% w/w of a polyhydric alcohol, i.e. an alcohol having two or more hydroxyl groups such as propylene glycol, butane 1,3-diol, mannitol, sorbitol, glycerol and polyethylene glycol (including PEG400) and mixtures thereof.
- the topical formulations may desirably include a compound which enhances absorption or penetration of the active ingredient through the skin or other affected areas. Examples of such dermal penetration enhancers include dimethylsulfoxide and related analogs.
- the oily phase of the emulsions of this invention may be constituted from known ingredients in a known manner. While the phase may comprise merely an emulsifier (otherwise known as an emulgent), it desirably comprises a mixture of at least one emulsifier with a fat or an oil or with both a fat and an oil. Optionally, a hydrophilic emulsifier is included together with a lipophilic emulsifier which acts as a stabilizer. It is also preferred to include both an oil and a fat.
- the emulsifier(s) with or without stabilizer(s) make up the so-called emulsifying wax
- the wax together with the oil and fat make up the so-called emulsifying ointment base which forms the oily dispersed phase of the cream formulations.
- Formulations suitable for topical administration to the eye also include eye drops wherein the active ingredient is dissolved or suspended in a suitable carrier, especially an aqueous solvent for the active ingredient.
- the active ingredient is optionally present in such formulations in a concentration of 0.5 to 20%, advantageously 0.5 to 10% particularly about 1.5% w/w.
- Formulations suitable for topical administration in the mouth include lozenges comprising the active ingredient in a flavored basis, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert basis such as gelatin and glycerin, or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.
- Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents.
- the formulations may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use.
- Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.
- Control release compositions may thus be achieved by selecting appropriate polymer carriers such as for example polyesters, polyamino acids, polyvinyl pyrrolidone, ethylene-vinyl acetate copolymers, methylcellulose, carboxymethylcellulose, protamine sulfate and the like.
- the rate of drug release and duration of action may also be controlled by incorporating the active ingredient into particles, e.g. microcapsules, of a polymeric substance such as hydrogels, polylactic acid, hydroxymethylcellulose, polyethyl methacrylate and the other above-described polymers.
- Such methods include colloid drug delivery systems like liposomes, microspheres, microemulsions, nanoparticles, nanocapsules and so on.
- the pharmaceutical composition may require protective coatings.
- Pharmaceutical forms suitable for injectionable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation thereof. Typical carriers for this purpose therefore include biocompatible aqueous buffers, ethanol, glycerol, propylene glycol, polyethylene glycol and the like and mixtures thereof.
- the corresponding composition may also be in the form of a medical kit or package containing the two ingredients in separate but adjacent repositories or compartments, hi the latter context, each active ingredient may therefore be formulated in a way suitable for an administration route different from that of the other ingredient, e.g. one of them may be in the form of an oral or parenteral formulation whereas the other is in the form of an ampoule for intravenous injection or an aerosol.
- nucleoside analogs of the present invention Another embodiment of this invention relates to various precursor or " pro-drug " forms of the nucleoside analogs of the present invention. It may be desirable to formulate the nucleoside analogs of the present invention in the form of a chemical species which itself is not significantly biologically-active, but which when delivered to the animal or human will undergo a chemical reaction catalysed by the normal function of the body, inter alia, enzymes present in the stomach or in blood serum, said chemical reaction having the effect of releasing a nucleoside analog as defined herein.
- the term "pro-drug” thus relates to these species which are converted in vivo into the active pharmaceutical ingredient.
- the pro-drugs of the present invention can have any form suitable to the formulator, for example, esters are non-limiting common pro-drug forms.
- the pro-drug may necessarily exist in a form wherein a covalent bond is cleaved by the action of an enzyme present at the target locus.
- a C-C covalent bond may be selectively cleaved by one or more enzymes at said target locus and, therefore, a pro-drug in a form other than an easily hydrolysable precursor, inter alia an ester, an amide, and the like, may be used.
- the counterpart of the active pharmaceutical ingredient in the pro-drug can have different structures such as an amino acid or peptide structure, alkyl chains, sugar moieties and others as known in the art.
- the term "therapeutically suitable pro-drug” is defined herein as "a nucleoside analog modified in such a way as to be transformed in vivo to the therapeutically active form, whether by way of a single or by multiple biological transformations, when in contact with the tissues of the animal or human to which the pro-drug has been administered, and without undue toxicity, irritation, or allergic response, and achieving the intended therapeutic outcome ".
- the present invention relates to the phosphate or phosphonate prodrugs of the nucleoside analogs of the invention, thereby including but not limited to phosphate or phosphonate esters, amidates or esteramidates, wherein the phosphate or phosphonate can be mono- or disubstituted.
- esters comprise alkyl esters, alkenyl esters, alkynyl esters, alkoxyalkyl esters, alkoxyalkenyl esters such as octyl, tetracosyl, hexadecyloxypropyl, octadecyloxyethyl, oleyloxypropyl, tetradecyloxypropyl, octadecyloxypropyl, oleyloxyethyl, l-O-octadecyl-2-O-benzyl- glyceryl and the like as described in the prior art (i.e. Keith K.A. et al.
- each R 30 and R 31 are independently selected from the group consisting of hydrogen; (- PO 3 R 32 VPO 3 R 33 R 34 ; alkyl; alkenyl; alkynyl; cycloalkyl; cycloalkenyl; cycloalkynyl; aryl; arylalkyl; heterocyclic ring; heterocyclic ring-alkyl; acyloxyalkyl; acyloxyalkenyl; acyloxyalkynyl; acyloxyaryl; acyloxyarylalkyl; acyloxyarylalkenyl; acyloxyarylalkynyl; dialkylcarbonate; alkylarylcarbonate; alkylalkenylcarbonate; alkylalkynylcarbonate; alkenylarylcarbonate; alkynyl-arylcarbonate; alkenylalkynylcarbonate; dialkenylcarbonate; dialkynyl-carbonate; wherein said alkyl,
- R 32 , R 33 and R 34 are each independently selected from the group consisting of hydrogen; alkyl; alkenyl; alkynyl; cycloalkyl; cycloalkenyl; cycloalkynyl; aryl; arylalkyl; heterocyclic ring; heterocyclic ring-alkyl; acyloxyalkyl; wherein said alkyl, alkenyl and alkynyl can contain a heteroatom in or at the end of the hydrocarbon chain, said heteroatom being selected from the group consisting of oxygen, sulfur and nitrogen; and R 3 , R 33 and R 4 are further selected from substituents known for phosphonates described as anti-viral agents;
- prodrugs can also be in the form of amidates wherein in a particular embodiment the oxygen of each of OR 30 and OR 31 can be a nitrogen such as NHR 30 and NHR 31 .
- nucleoside analogs of the invention according to the formulae of the application can be prepared while using a series of chemical reactions known to those skilled in the art, altogether making up the process for preparing said compounds and exemplified further.
- the processes described further are only meant as examples and by no means are meant to limit the scope of the present invention.
- the compound of this invention can be prepared by the following general methods:
- the nucleoside analogs 35 and 36 can be prepared by the treatment of the benzoates 51 or 52 with a reducing agent such as lithium aluminium hydride or diisobutyl aluminium hydride in tetrahydrofurane at a temperature from -78 °C to 0 °C (Example 4).
- a reducing agent such as lithium aluminium hydride or diisobutyl aluminium hydride in tetrahydrofurane at a temperature from -78 °C to 0 °C (Example 4).
- nucleoside analogs with a structure in analogy with the nucleoside analog 23 can be prepared from the amine of the formula X and analoguous structures like compounds 25, 27 and 57 can for example be prepared with the starting materials XXII, XXIII or XXIV:
- ring-closure can be carried out in trimethyl or triethyl orthoformate in the presence of acid such as concentrated hydrochloric acid, sulfuric acid or trifluoroacetic acid. Chromatography or crystallization from aqueous ethanol or aqueous methanol can be used for isolation of thus obtained compounds from the reaction mixture.
- acid such as concentrated hydrochloric acid, sulfuric acid or trifluoroacetic acid.
- nucleoside analogs with a structure in analogy with the nucleoside analogs 1, 14, 16, 24, 26, 32, 58, 59, 60, 62, 63, 64, 65 and 66 can be prepared from the amines of the formula XI- XXXIII (and analoguous structures) by the same procedure as described for 23 followed by hydrolysis which can be performed in the mixture of tetrahydrofurane or dioxane and diluted mineral acid (e.g. hydrochloric acid, sulfuric acid).
- mineral acid e.g. hydrochloric acid, sulfuric acid
- reaction procedure 2 wherein Z 1 is a methylene, an ethylene group, an oxygen atom).
- the reaction procedure 2 can be effected by reacting XVI, XVII or XVIII with benzyl azidoformate in the presence of a small amount of an inert solvent such as toluene, dioxane at a temperature from around 68 °C to 110 °C. This is followed be hydrogenolysis of the obtained benzyloxycarbonylamine which can be performed in an organic solvent (e.g. methanol, ethanol) in the presence of palladium on carbon at room temperature.
- an organic solvent e.g. methanol, ethanol
- the unsaturated amine of the formula XIV can be obtained by multistep reaction procedure(l) (Example 7):
- the amine of the formula (XV) can be prepared from the unsaturated amine having the formula (XIV) by hydrogenation on palladium catalyst in an alcohol (e.g. methanol, ethanol).
- nucleoside analogs with a structure in analogy with the nucleoside analogs 2 and 20 can be prepared by the treatment of the compound 1 or 16 respectively, with methyl iodide in dimethylformamide.
- nucleoside analogs with a structure in analogy with the nucleoside analog 7 can be prepared by the treatment of the compound 1 with benzyl bromide and sodium hydride in dimethylformamide.
- nucleoside analogs with a structure in analogy with the nucleoside analog 6 can be prepared by the treatment of the compound 1 with phenyl- (methoxy-L-alaninyl)-phosphorochloridate in the presence of 1-methylimidazole in tetrahydrofurane.
- nucleoside analogs with a structure in analogy with the nucleoside analogs 8 can be prepared by by the treatment of the compound 1 with thionyl chloride in hexamethylphosphortriamide. With the same procedure, for example compounds 67 and 68 can be prepared from their hydroxy-comprising analogs.
- DAST diethylaminosulfur trifluoride
- Modifications like in compound 42 can be prepared by the treatment of the compound 31 with peracid (e.g. peracetic acid, m-chloroperbenzoic acid) in chlorinated solvent
- peracid e.g. peracetic acid, m-chloroperbenzoic acid
- dihydroxy-substituents like in compound 37 can be introduced starting from compound 31 by the treatment with osmium tetroxide and 4-methylmorpholine-4-oxide in a mixture of water and methanol.
- the compound above can be prepared by the treatment of the compound I with 4-chloro-7H-pyrrolo[2,3- cTjpyrimidine under conditions of the Mitsunobu reaction.
- the purine base of the nucleoside analoges can be modified using the known methods as shown for compound I in the Scheme 1.
- Scheme 1 Modification of a purine base of compounds of the invention.
- Table 1 Structures of example nucleoside analogs of the invention and their respective codes.
- Anti-Coxsackie virus assay Ninety-six-well cell culture plates can be seeded with Vero cells in DMEM medium containing 10 fetal calf serum (FCS) so that cells reache confluency 24 -48 hr later. Medium can then be removed and serial 5-fold dilutions of the test compounds can be added in a total volume of 100 ⁇ l, after which the virus inoculum (100 ⁇ l) can be added to each well. The virus inoculum used results normally in a 90 - 100 % destruction of the cell monolayer after 5 days incubation at 37°C. Uninfected cells and cells receiving virus without compound can be included in each asay plate.
- FCS fetal calf serum
- the 50% effective concentration (EC50) value can than be defined as the concentration of compound that protects 50% of the cell monolayer from virus-induced cytopathic effect.
- Cytostatic activity assays All assays are performed in 96-well microtiter plates. To each well are added 5 - 7.5 x 10 4 Vero cells and a given amount of the test compound. The cells are allowed to proliferate for 72 h at 37°C in a humidified CO 2 -controlled atmosphere. At the end of the incubation period the effect of the compounds on cell proliferation is measured using the MTS/PMS method (Promega). The CC 50 (50% cytostatic concentration) was defined as the concentration of the compound that reduced the number of cells by 50%.
- nucleoside analogs of the invention showed an EC50 of between 5 ⁇ M and 50 ⁇ M, while the CC50 was always higher than 200 ⁇ M.
- results of some nucleoside analogs in the anti-Coxsackie virus B3 (CBV) assay are shown in table 2.
- Pyrimidine intermediate was eluted with ethylacetate ⁇ ethylacetate - toluene - acetone - ethanol (17:4:3:1) and this intermediate was immediately used in the next step.
- Concentrated hydrochloric acid (1.5 ml) was added to a suspension of pyrimidine intermediate in triethyl ortho formate (100 ml) and T ⁇ F (20 ml) and the reaction mixture was vigorously stirred for 4 days at room temperature. Solution was evaporated and the residue was dissolved in mixture in a mixture of tetrahydrofuran (20 ml) and 0.5 M hydrochloric acid (20 ml) and stirred at room temperature for 4 hours.
- EXAMPLE 11 SYNTHESIS OF PHOSPHATE COMPRISING NUCLEOSIDE ANALOGS OF THE INVENTION SUCH AS 6
- EXAMPLE 15 Syntesis of 9-[(li?*,2i?*,4S*)-bicyclo[2.2.1]hept-2-yl]-6- (methylsulfanyl)-9H " -purine (39)
- EXAMPLE 16 Synthesis of 9-[(l/?*,2i?*,4S*)-bicyclo[2.2.1]hept-2-yl]-6- (methylsulfonyl)-9//-purine (45) S-methylthiopurine (39, 1.2 mmol) was dissolved in chloroform (20 ml). To this mixture was slowly added solution of m-chlorperbenzoic acid (1.46 g, 5.9 mmol, 65%) in chloroform (25 ml).
- the compound 17 (400 mg, 1.61 mmol) was added portionswise into a stirred 57% aqueous HI (5 ml) at 0 0 C and the resulting suspension was stirred at 0 °C for 2 h. Reaction mixture was poured onto water + ice (50 ml) and 35% aqueous NH 3 (15 ml) was added. To this mixture, ethylacetate (150 ml) was added. Organic phase was washed with saturated aqueous Na 2 S 2 O 3 (2 x 70 ml), and water (100 ml).
- EXAMPLE 22 Synthesis of 9-[(li?*,2 ⁇ *,45*)-bicyclo[2.2.1]hept-2-yl]-6-(4- chlorophenyl)-9H-purine (76) Toluene (12 ml) was added to an argon-purged flask containing 17 (300 mg, 1.21 mmol), K 2 CO 3 (242 mg, 1.82 mmol), 4-chlorphenylboronic acid (283 mg, 1.8 mmol) and Pd(PPh 3 ) 4 (71 mg, 0.07 mmol) and the mixture was stirred under argon at 100 0 C for 8 h.
- EXAMPLE 25 Synthesis of 9-[(li?*,2i?*,45*)-bicyclo[2.2.1]hept-2-yl]-6-methyl-9H- purine (79)
- a solution of 17 (360 mg, 1.44 mmol) in THF (15 ml) was added to a mixture of methyltriphenylphosphonium iodide (1.14 g, 3.17 mmol) and n-butyllithium (1.6 M in tetrahydrofuran, 1.9 ml). Reation mixture was refluxed under argon for 5 hours.
- Sodium carbonate (500 mg) in water (15 ml) was added and refluxing continued an additional 8 h.
- Trifluoroaceticacid anhydride (0.37 ml, 2.58 mmol) was added dropwise to a solution of 1 (400 mg, 1.6 mmol) and tetrabutylammonium nitrate (790 mg, 2.6 mmol) in dry CH 2 Cl 2 (5 ml) at 0 °C under a argon atmosphere. After stirring for 1 h the solution was poured into 75 ml of sat. aqueous NaHCO 3 -ice (1:1). The aqueous layer was extracted with 2 portions of 50 ml EtOAc-CHCl 3 (3:1). The collected organic layers were washed with water (100 ml) and dried over anhydrous sodium sulfate and evaporated.
- Ethyl chloroformate (0.5 ml, 5.3 mmol) was added to the lithiated intermediate (see Example27) and the mixture was stirred for 1 hour at -78 0 C and for 1 hour at -50 0 C. A saturated aqueous solution of NH 4 Cl (20 ml) was added. The mixture was allowed to warm to room temperature. Water (60 ml) was added to the mixture and the mixture was extracted with EtOAc (100 ml). The organic phase was washed with water (50 ml), dried over anhydrous sodium sulfate and evaporated.
- EXAMLE 34 Synthesis of (li?*,2i?*,3i?*,6i?*,75*,95*)-2-(2-amino-6-chloro-9H-purin- 9-yl)-4-oxatricyclo[4.2.1.0 3>7 ]nonane-9-methanol (9)
- EXAMPLE 35 Synthesis of 6-chloro-9-[(li?*,3 ⁇ *,6i?*,7i?*,9i?*)-4- oxatricyclo[4.2.1.0 3J ]non-9-yl]-9H-purine (5)
- EXAMPLE 36 SYNTHESIS OF ( ⁇ [(li?*,3S*,6S*,7#*)-2-(5-METHYL-2,4-DIOXO-3,4- DIHYDROPYRIMIDIN- 1 (2H)-YL)-4-OXATRICYCLO[4.2.1.0 3 ' 7 ]NON-9- YL]OXY ⁇ MET ⁇ YL)P ⁇ OSP ⁇ ONIC ACID (3)
- EXAMPLE 37 SYNTHESIS OF 4-[(li?*,2 ⁇ *,45*)-BICYCLO[2.2.1]HEPT-2- YLOXY]- 6-CHLOROPYRIMIDINE (81)
- EXAMPLE 38 SYNTHESIS OF 3-[(li?*,2i?*,4S*)-BICYCLO[2.2.1]HEPT-2-YL]-7- CHL0R0-3H-[ 1 ,2,3]TRIAZOLO[4,5-D]PYRIMIDINE (82)
- hydrochloric acid (1.4 ml) was added to a stirred mixture of this compound (226 mg, 0.8 mmol) and triethyl ortho formate (14 ml), the resulting solution was stored at room temperature for 3 days and then evaporated. The residue was dissolved in tetrahydrofuran (5 ml). To the stirred solution, 0.5 M hydrochloric acid (5 ml) was added, the mixture was stirred at room temperature for 4 h and then neutralized with solid sodium hydrogencarbonate. The organic layer was separated and the aqueous layer was extracted with tetrahydrofuran (4 x 8 ml). The combined organic phases were dried over anhydrous sodium sulfate and evaporated.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a series of novel nucleoside analogs which have been shown to possess antiviral activity, in particular against viruses of the family of the Picornaviridae. The invention therefore relates to the new nucleoside analogs, methods for their preparation, pharmaceutical compositions comprising them and to the nucleoside analogs for use as a medicament, more in particular antiviral medicament.
Description
NEW ANTI-VIRAL NUCLEOSIDE ANALOGS
FIELD OF THE INVENTION
The present invention relates to a series of novel nucleoside analogs which have been shown to possess antiviral activity, in particular against viruses of the family of the Picornaviridae. The invention therefore relates to the new nucleoside analogs, methods for their preparation, pharmaceutical compositions comprising them and to the nucleoside analogs for use as a medicament, more in particular antiviral medicament.
BACKGROUND OF THE INVENTION
Picornaviridae are small, non-enveloped viruses containing a single-stranded (+)-sense RNA genome of 7.5kb, which is covalently linked to a small viral protein (VPg) at its 5' end and polyadenylated at its 3' end. The genomic RNA has a long, highly structured 5' noncoding region that contains the internal ribosome entry site (IRES) necessary for translation initiation, and a shorter 3' noncoding region preceding the poly(A) tract, which are both thought to be involved in RNAreplication and translation. The coding region encodes a single polyprotein that will eventually be cleaved to generate 4 structural and 7 non-structural proteins. The icosahedral capsid of the virus is formed by 60 protomers, each one assembled by the 4 structural proteins, designated VP 1-4. The non-structural region comprises two proteases, the viral RNA-dependent RNA polymerase (RdRp) and 4 other mature proteins that, either cleaved or as a precursor, are involved in viral replication.
Picornaviruses are a family of small RNA viruses comprising some important pathogens of humans and animals. Transmission usually occurs mechanically. There are ten genera, being Aphthovirus (Foot-and-Mouth Disease Virus), Cardiovirus (Encephalomyocarditis virus + and Theilovirus), Enterovirus (Human Enterovirus A, B, C and D, Bovine Enterovirus, Porcine Enterovirus and Poliovirus), Erbovirus, Duck Hepatitis virus,
Hepatovirus (Avian Encephalomyelitis Virus, Hepatitis A virus +), Kobuvirus, Parecho virus, Rhino virus and Tescho virus.
Entero- and rhinoviruses are implicated in a wide range of infections in humans (and animals). Among the genus of enteroviruses are coxsackieviruses, which are reported to be associated with the development of myocarditis, pancreatitis, meningitis and encephalitis. Other important prototypes amongst the enteroviruses are poliovirus, which can lead to paralytic poliomyelitis, and echovirus, causing aseptic meningitis or encephalomyelitis. Rhinoviruses are the most important etiological factor associated with the common cold, and although often mild and self-limiting, rhinovirus infections have an enormous socio-economical impact. To the genus hepatovirus belongs the hepatitis A virus, a virus that is causing infectious hepatitis in man. The aphtovirus, food and mouth disease virus and the enterovirus swine vesicular virus are important patogens in life stock.
There is currently no approved antiviral therapy for the treatment of picornaviral infections in man or animals.
Therefore, there is still a stringent need in the art for potent inhibitors of Picornaviridae.
Therefore a goal of the present invention is to satisfy this urgent need by identifying efficient and non-harmful pharmaceutically active ingredients and combination of ingredients for the treatment of Picornaviridae infections in animals and in humans.
The present invention relates to new nucleoside analogs and to their use as anti-viral agents. The prior art, namely by Hrebabecky H. in Collection of Czechoslovak Chemical Communications 2005, 70(1), p 103-123, describes nucleoside analogs being 9-(6- substituted or 6,8-disubstituted or 2,6-disubstituted -9H-purin-9-yl)-5-oxa- tricyclo[4.2.1.03'7]nonane-3-methanols such as the 6-amino-9Η-purin-9-yl; the 2,6- diamino-9H-purin-9-yl; 6-(dimethylamino)-9H-purin-9-yl; 6-cyclopropylamino-9H- purin-9-yl; the 6-amino-8-methyl-9H-purin-9-yl derivatives of 5-oxa- tricyclo[4.2.1.03'7]nonane-3-methanols. Also the 6-chloro-8-methyl-9H-purin-9-yl; 6- chloro-9H-purin-9-yl and 2-amino-6-chloro-9H-purin-9-yl derivative of 5-oxa- tricyclo[4.2.1.03'7]nonane-3-methanol are described.
The prior art also describes the compounds 9-[(2-amino-6-chloropyrimidin-4-yl)amino]- 5-oxatricyclo[4.2.1.03'7]nonane-3-methanol, 9-[(5-amino-6-chloropyrimidin-4- yl)amino]-5-oxatricyclo[4.2.1.03'7]nonane-3-methanol, 9-[(2-amino-6-chloro-5-[(4- chlorophenyl)azo]pyrimidin-4-yl]-amino)-5-oxatricyclo[4.2.1.03'7]nonane-3-methanol and 9-[(2,5-diamino-6-chloro-pyrimidin-4-yl]-amino)- 5-oxatricyclo[4.2.1.03'7]nonane-3- methanol.
From these prior art 5-oxa-tricyclo[4.2.1.03'7]nonane-3-methanols no mention is made of any biological activity.
SUMMARY OF THE INVENTION
In the present invention, new anti-viral, more in particular anti-Picornaviridae nucleoside analogs are provided. The nucleoside analogs have a substituted or unsubstituted bridged carbocycle and it has been shown that they possess anti-viral activity, more specifically against Picornaviridae. The present invention demonstrates that the nucleoside analogs inhibit the replication of Picornaviridae. Therefore, these nucleoside analogs constitute a new potent class of anti-viral agents that can be used in the treatment and prevention of viral infections in animals, mammals and humans, more specifically for the treatment and prevention of Picornaviridae.
The present invention provides novel nucleoside analogs which have virus replication inhibiting properties. The invention also provides methods for preparation of all such nucleoside analogs and provides pharmaceutical compositions comprising the nucleoside analogs. The invention further relates to the novel nucleoside analogs for use as a medicament and for the prevention and/or treatment of viral infections in subjects (including animals, mammals and humans). The invention also relates to the use of the nucleoside analogs in the manufacture of a medicament for the prevention or treatment of subjects suffering from Picornaviridae infection, as well as for treatment of other viral infections of subjects suffering from such infections. The invention also provides
methods of treatment or prevention of a viral infection in a subject, inlcuding animals, mammals and humans.
One aspect of the present invention is the provision of novel nucleoside analogs, said nucleoside analog having a structure according to the formula (A'):
- B is selected from an unsubstituted or substituted pyrimidine or purine heterocycle; whereby the purine heterocycle is not substituted with -CF3 in its 2-position; - W is selected from (-CH2-)n, wherein n is selected from 0 or 1;
- X is not present (thereby forming a bond between carbon (2) and carbon (3)) or is selected from -CR6R6 - or -CR7R7'-C R8R8'-;
- Y is not present (thereby forming a bond between carbon (2) and carbon (I)) or is selected from -CR9R9'- or -CR10R10'-C R11R11'-; - Z is selected from -CR12R12'-; -CR13R13'-C R14R14'-; -CR15=CR15'-; -O-; and -S-;
- each of R1 and R4 is independently selected from hydrogen; alkyl; -OH; phosphate; phosphate-alkylene; phosphonate; or phosphonate-alkylene; wherein said alkyl or alkylene can independently be substituted with one or more -OH, aryl or halogen; and wherein said alkyl or alkylene can contain a heteroatom in or at the end of the alkyl chain, said heteroatom selected from O, S and N; and thereby the term phosphate- alkylene includes phosphate-alkoxy and the term phosphonate-alkylene includes phosphonalkyloxy (such as phosphonylmethyl ether)
- each of R2 and R3 is independently selected from hydrogen; alkyl; -OH; phosphate; phosphate-alkylene; phosphonate; or phosphonate-alkylene- (such as phosphonylmethyl ether); or when taken together with R6, R6 , R7 or R7 forms a double bond or -O- (thereby forming an epoxy); wherein said alkyl or alkylene can independently be
substituted with one or more -OH; aryl; -OOC-aryl; or halogen; and wherein said alkyl or alkylene can contain a heteroatom in or at the end of the alkyl chain, said heteroatom selected from O, S and N;
- or R2 or R3 when taken together with R6 or R6' is -CH2-CH2-CH2-; -CH2-CH2-CH2- CH2- or -CHR16=CHR17-CHR18=CHR19-, wherein each of R16, R17, R18 and R19 is independently selected from hydrogen; F; Cl; Br or alkyl;
- R5 is hydrogen or when taken together with R9, R9 , R1 ' or R11 forms a double bond;
- each of R6 and R6 is independently selected from hydrogen; alkyl; or -OH; or taken together with R9, R9', R10, R10', R11 or RH> is -CH2-O- or -O-CH2- thereby forming a 5- membered ring; or when taken together with one of R2 or R3 forms a double bond or -O- (thereby forming an epoxy); wherein said alkyl can be substituted with one or more -OH; aryl; or halogen;
- each of R7 and R7 is independently selected from hydrogen; alkyl; or -OH; or when taken together with one of R2 or R3 forms a double bond or -O- (thereby forming an epoxy); or when taken together with R9, R9', R10, R10', R11 or R11' is -CH2-O- or -O- CH2- thereby forming a 5-membered ring; wherein said alkyl can be substituted with one or more -OH; aryl; or halogen;
- each of R and R is independently selected from hydrogen; alkyl; or -OH; or taken together with R9, R9', R10, R10', R11 or R11' is -CH2-O- or -O-CH2- thereby forming a 5- membered ring; wherein said alkyl can be substituted with one or more -OH; aryl; or halogen;
- each of R9 and R9 is independently selected from hydrogen; alkyl; or -OH; or taken together with R6, R6', R7, R7>, R8 or R8' is -CH2-O- or -0-CH2- thereby forming a 5- membered ring; or when taken together with R5 forms a double bond; wherein said alkyl can be substituted with one or more -OH; aryl; or halogen;
- each of R10 and R10 is independently selected from hydrogen; alkyl; or -OH; or taken together with R6, R6', R7, R7', R8 or R8' is -CH2-O- or -0-CH2- thereby forming a 5- membered ring; or when taken together with R5 forms a double bond;
- each of R11 and R11 is independently selected from hydrogen; alkyl; or -OH; or when taken together with R5 forms a double bond; or taken together with R6, R6 , R7, R7', R8 or
R8 is -CH2-O- or -0-CH2- thereby forming a 5-membered ring; wherein said alkyl can be substituted with one or more -OH; aryl; or halogen;
- each of R12, R12', R13, R13', R14 R14', R15, R15> is independently selected from hydrogen or alkyl; wherein said alkyl can be substituted with one or more -OH; aryl; or halogen; - the selections for the X, Y and R-groups like -CR7R7'-C R8R8'-; -CH2-O- or -CH2- O- or -0-CH2- have to be placed in formula (I) from left to right; and isomers (in particular stereo-isomers or tautomers), solvates or pharmaceutically acceptable salts thereof or prodrugs thereof.
Preferably each of R6 and R6 is independently selected from hydrogen; alkyl; or -OH; or taken together with R9, R9', R10, R10', R11 or R11' is -CH2-O- or -O-CH2- thereby forming a 5-membered ring; or when taken together with one of R2 or R3 forms a double bond or -O- (thereby forming an epoxy); wherein said alkyl can be substituted with one or more aryl; or halogen.
A particular embodiment of this aspect relates to the nucleoside analogs according to formula (A):
- W is selected from (-CH2-)n, wherein n is selected from O or 1 ;
- X is not present (thereby forming a bond between carbon (2) and carbon (3)) or is selected from -CR6R6'- or -CR7R7'-C R8R8'-;
- Y is not present (thereby forming a bond between carbon (2) and carbon (I)) or is selected from -CR9R9'- or -CR10R10'-C R11R11'-;
- Z is selected from -CR12R12'-; -CR13R13'-C R14R14'-; -CR15=CR15'-; -0-; and -S-;
- each of R1 and R4 is independently selected from hydrogen; alkyl; -OH; phosphate; phosphate-alkylene; phosphonate; or phosphonate-alkylene; wherein said alkyl or alkylene can be substituted with one or more -OH, aryl, halogen; and wherein said alkyl or alkylene can contain a heteroatom in or at the end of the alkyl chain, said heteroatom selected from O, S and N;
- each of R2 and R3 is independently selected from hydrogen; alkyl; -OH; phosphate; phosphate-alkylene; phosphonate; or phosphonate-alkylene; or when taken together with R6, R6 , R7 or R7 forms a double bond or -O- (thereby forming an epoxy); wherein said alkyl or alkylene can be substituted with one or more -OH; aryl; arylalkyl (such as trityl); -OOC-aryl; or halogen; and wherein said alkyl or alkylene can contain a heteroatom in or at the end of the alkyl chain, said heteroatom selected from O, S and N;
- or R2 or R3 when taken together with R6 or R6' is -CH2-CH2-CH2-; -CH2-CH2-CH2- CH2- or -CHR16=CHR17-CHR18=CHR19-, wherein each of R16, R17, R18 and R19 is independently selected from hydrogen; F; Cl; Br or alkyl; - R5 is hydrogen or when taken together with R9, R9 , R11 or R11 forms a double bond;
- each of R6 and R6 is independently selected from hydrogen; alkyl; or -OH; or taken together with R9, R9', R10 or R10' is -CH2-O- or -0-CH2- thereby forming a 5- membered ring; or when taken together with one of R or R forms a double bond or -O- (thereby forming an epoxy); wherein said alkyl can be substituted with one or more -OH; aryl; or halogen;
- each of R7 and R7 is independently selected from hydrogen; alkyl; or -OH; or when taken together with one of R2 or R3 forms a double bond or -O- (thereby forming an epoxy); wherein said alkyl can be substituted with one or more -OH; aryl; or halogen;
- each of R and R is independently selected from hydrogen; alkyl; or -OH; or taken together with R9, R9', R10 or R10' is -CH2-O- or -0-CH2- thereby forming a 5- membered ring; wherein said alkyl can be substituted with one or more -OH; aryl; or halogen;
- each of R and R9 is independently selected from hydrogen; alkyl; or -OH; or taken together with R6, R6', R8 or R8' is -CH2-O- or -0-CH2- thereby forming a 5-membered ring; or when taken together with R5 forms a double bond; wherein said alkyl can be substituted with one or more -OH; aryl; or halogen;
- each of R10 and R10 is independently selected from hydrogen; alkyl; or -OH; or taken together with R6, R6', R8 or R8' is -CH2-O- or -0-CH2- thereby forming a 5-membered ring;
- each of R11 and R11 is independently selected from hydrogen; alkyl; or -OH; or when taken together with R5 forms a double bond; wherein said alkyl can be substituted with one or more -OH; aryl; or halogen;
- each of R12, R12', R13, R13', R14 R14', R15, R15' is independently selected from hydrogen or alkyl; wherein said alkyl can be substituted with one or more -OH; aryl; or halogen;
- the selections for the X, Y and R-groups like -CR7R7'-C R8R8'-; -CH2-O- or -CH2- O- or -0-CH2- have to be placed in formula I from left to right; and isomers (in particular stereo-isomers or tautomers), solvates or pharmaceutically acceptable salts thereof or prodrugs thereof; provided that the nucleoside analog is not a 9-(6-substituted or 6,8-disubstituted or 2,6- disubstituted -9H-purin-9-yl)-5-oxa-tricyclo[4.2.1.03'7]nonane-3-methanol,
more in particular is not the 6-amino-9Η-purin-9-yl; 6-(dimethylamino)-9H-purin-9-yl; 6- cyclopropylamino-9H-purin-9-yl; the 2,6-diamino-9H-purin-9-yl; the 6-amino-8-methyl- 9H-purin-9-yl; the 6-chloro-8-methyl-9H-purin-9-yl; the 6-chloro-9H-purin-9-yl or the 2-amino-6-chloro-9H-purin-9-yl derivative of 5-oxa-tricyclo[4.2.1.03'7]nonane-3- methanol.
When reference is made to "B is selected from an unsubstituted or substituted pyrimidine or purine heterocycle" this also includes the analogs and derivatives such as the aza and deaza analogs and substituted derivatives.
In a particular embodiment, the nucleoside analogs are not 9-(6-substituted or 6,8- disubstituted or 2,6-disubstituted -9H-purin-9-yl)-5-oxa-tricyclo[4.2.1.03'7]nonane-3- methanol (according to Formula N), more in particular are not the 6-amino-9Η-purin-9- yl; 6-(dimethylamino)-9H-purin-9-yl; 6-cyclopropylamino-9H-purin-9-yl; the 2,6- diamino-9H-purin-9-yl; the 6-amino-8-methyl-9H-purin-9-yl; the 6-chloro-8-methyl-9H-
purin-9-yl; the 6-chloro-9H-purin-9-yl or the 2-amino-6-chloro-9H-purin-9-yl derivative of 5-oxa-tricyclo[4.2.1.03'7]nonane-3-methanol.
(in formula (N), "Sub" refers to hydrogen or a substituent, in a particular embodiment selected from -N(CH3)2; -NH(cyclopropyl); halogen (more in particular Cl); alkyl (more in particular methyl); or amino.
Particular embodiments of this aspect are described in the claims and relate to subtypes of nucleoside analogs according to formula A' such as the nucleosides according to formulae (A-2), (A-3) including (A-3a) and (A-3b), (A-4), (A-5) or (A-6).
In a particular embodiment, the nucleoside analogs of the present invention are according to formula (A-2), wherein Y is -CR9R9'- and X is -CR6R6'-:
- each of B, W, Z, R1, R4, R12 and R12', is according to formula (A);
- each of R2 and R3 is independently selected from hydrogen; alkyl; -OH; phosphate; phosphate-alkylene; phosphonate; or phosphonate-alkylene; or when taken together with one of R6 or R6 forms a double bond or -O- (thereby forming an epoxy); wherein said alkyl or alkylene can be substituted with one or more -OH; aryl; -OOC-aryl; or halogen; and wherein said alkyl or alkylene can contain a heteroatom in or at the end of the alkyl chain, said heteroatom selected from O, S and N; or R2 or R3 when taken together with
R6 or R6' is -CH2-CH2-CH2-; -CH2-CH2-CH2-CH2- or -CHR16=CHR17-CHR18=CHR19-, wherein each of R16, R17, R18 and R19 is independently selected from hydrogen; F; Cl; Br or alkyl;
- R5 is hydrogen or when taken together with one of R9 or R9 forms a double bond; - each of R6 and R6 is independently selected from hydrogen; alkyl; or -OH; or taken together with one of R9 or R9 is -CH2-O- or -0-CH2- thereby forming a 5-membered ring; or when taken together with one of R2 or R3 forms a double bond or -O- (thereby forming an epoxy); wherein said alkyl can be substituted with one or more -OH; aryl; or halogen; - each of R9 and R9 is independently selected from hydrogen; alkyl; or -OH; or taken together with one of R6 or R6 is -CH2-O- or -0-CH2- thereby forming a 5-membered ring; or when taken together with R5 forms a double bond; wherein said alkyl can be substituted with one or more -OH; aryl; or halogen.
In a more particular embodiment of formula (A-2),
- W is not present whereby B is directly bonded to carbon (1) or is -CH2-;
- Z is selected from -CR12R12'-;
- R1 is hydrogen;
- R4 is selected from hydrogen or alkyl; - each of R12 and R12 is independently selected from hydrogen or alkyl;
- each of R2 and R3 is independently selected from hydrogen; alkyl; -OH; phosphate; phosphate-alkylene; phosphonate; or phosphonate-alkylene; or when taken together with one of R6 or R6 forms a double bond or -O- (thereby forming an epoxy); wherein said alkyl or alkylene can be substituted with one or more -OH; aryl; -OOC-aryl; or halogen; and wherein said alkyl or alkylene can contain a heteroatom in or at the end of the alkyl chain, said heteroatom selected from O, S and N; or R or R when taken together with R6 or R6' is -CH2-CH2-CH2-; -CH2-CH2-CH2-CH2- or -CHR1 ^CHR17-CHR" 8^CHR19-, wherein each of R16, R17, R18 and R19 is independently selected from hydrogen; F; Cl; Br or alkyl;
- R5 is hydrogen or when taken together with one of R9 or R9 forms a double bond;
- each of R6 and R6 is independently selected from hydrogen; alkyl; or -OH; or when taken together with one of R2 or R3 forms a double bond or -O- (thereby forming an epoxy); wherein said alkyl can be substituted with one or more -OH; aryl; or halogen;
- each of R9 and R9 is independently selected from hydrogen; alkyl; or -OH; or when taken together with R5 forms a double bond; wherein said alkyl can be substituted with one or more -OH; aryl; or halogen.
In yet another more particular embodiment of formula (A-2), - Z iS -CH2-; - each of R4, R2, R3, R5, R6, R6', R9 and R9' are hydrogen.
Another embodiment relates to nucleoside analogs according to formula (A-3a) or (A- 3b), wherein R6 and R9 are taken together to form -0-CH2- or -CH2-O-:
wherein
- each of B, W, Z, R1 and R4, is according to formula (A);
- each of R2 and R3 is independently selected from hydrogen; alkyl; -OH; phosphate; phosphate-alkylene; phosphonate; or phosphonate-alkylene; or when taken together with one of R6 or R6 forms a double bond or -O- (thereby forming an epoxy); wherein said alkyl or alkylene can be substituted with one or more -OH; aryl; -OOC-aryl; or halogen; and wherein said alkyl or alkylene can contain a heteroatom in or at the end of the alkyl chain, said heteroatom selected from O, S and N; - R5 is hydrogen or when taken together with one of R9 or R9 forms a double bond;
- R6 is selected from hydrogen; alkyl; or -OH; or when taken together with one of R2 or R3 forms a double bond or -O- (thereby forming an epoxy); wherein said alkyl can be substituted with one or more -OH; aryl; or halogen;
- R9 is selected from hydrogen; alkyl; or -OH; or when taken together with R5 forms a double bond; wherein said alkyl can be substituted with one or more -OH; aryl; or halogen.
hi a more particular embodiment of formula (A-3 a and b),
- Z is selected from -CH2-; -0-; or -CH2-CH2-; - each of R1 , R4, R5, R6 and R9 are hydrogen;
- each of R2 and R3 is independently selected from hydrogen; -OH; -OCH3; phosphonylmethylether; benzyloxymethyl; methoxymethyl and chloromethyl.
hi another embodiment, the nucleoside analogs are according to formula (A-4), claim 1, wherein Y is not present and thereby the nucleoside analogs are according to the formula IV,
- each of B, W, X, Z, R1, R2, R3 and R4, is according to formula (A); - R5 is hydrogen;
- each of R6 and R6 is independently selected from hydrogen; alkyl; or -OH; or when taken together with R2 or R3 forms a double bond or -O- (thereby forming an epoxy); wherein said alkyl can be substituted with one or more -OH; aryl; or halogen.
- Z is selected from -CH2-CH2-; or -CH2=CH2-;
- each of R1, R4 and R5 are hydrogen;
- each of R2 and R3 is independently selected from hydrogen; -OH; or -OCH3. phosphonylmethylether; benzyloxymethyl; methoxymethyl and chloromethyl.
Another particular embodiment relates to nucleoside analogs according to formula (A-5), wherein Y is -CR10R1^-CR11R11'- and X is not present
- each of B, W, Z, R1 and R4, is according to formula (A);
- each of R2 and R3 is independently selected from hydrogen; alkyl; -OH; phosphate; phosphate-alkylene; phosphonate; or phosphonate-alkylene; wherein said alkyl or alkylene can be substituted with one or more -OH; aryl; -OOC-aryl; or halogen; and wherein said alkyl or alkylene can contain a heteroatom in or at the end of the alkyl chain, said heteroatom selected from O, S and N;
- R5 is hydrogen or when taken together with R11 or R11 forms a double bond;
- each of R10 and R10 is independently selected from hydrogen; alkyl; or -OH;
- each of R11 and R11 is independently selected from hydrogen; alkyl; or -OH; or when taken together with R5 forms a double bond; wherein said alkyl can be substituted with one or more -OH; aryl; or halogen.
- the dotted line represents a double line which can be present or not present;
- each of R2, R3, R12 and R12 is independently selected from hydrogen or alkyl (more in particular methyl).
In a particular embodiment of the different formulae encoded A (A, A', A-2 to A- 23) of the invention, the purine and pyrimidine heterocycles of B are coupled directly to carbon (1) (if W is not present) or are coupled to W as following: - for purines via their N9 or N7, preferabky via N9; and
- for pyrimidines via their N3 or N1, preferably via N3.
In a more particular embodiment of the different formulae encoded A (A, A', A-2 to A- 23) of the invention, the purine heterocycles of B are coupled directly to carbon (1) (if W is not present) or are coupled to W via their N9 or N7, preferably via N9.
In another particular embodiment of the different formulae of the invention, R2 is hydrogen, while R3 is selected from hydrogen; alkyl; -OH; phosphate; phosphate- alkylene; phosphonate; or phosphonate-alkylene- (such as phosphonylmethyl ether); or when taken together with R6, R6 , R7 or R7 forms a double bond or -O- (thereby forming an epoxy); wherein said alkyl or alkylene can be substituted with one or more -OH; aryl; -OOC-aryl; halogen; phosphate; phosphate-alkylene; phosphonate; or phosphonate- alkylene- (such as phosphonylmethyl ether); and wherein said alkyl or alkylene can contain a heteroatom in or at the end of the alkyl chain, said heteroatom selected from O, S and N. In another particular embodiment of the different formulae of the invention, each of R1 and R4 is independently selected from hydrogen; alkyl; or -OH; wherein said alkyl
can be substituted with -OH, aryl, or halogen; and wherein said alkyl can contain a heteroatom in or at the end of the alkyl chain, said heteroatom selected from O, S and N.
In a further embodiment of the invention, the nucleoside analogs are of general formulae (A-2), (A3-a), (A3-b), (A-4), (A-5) and (A-6);
wherein
- W is selected from (-CH2-)n, wherein n is selected from O or 1 ;
- X is not present (thereby forming a bond between carbon (2) and carbon (3)) or is selected from -CR6R6'- or -CR7R7'-C R8R8'-;
- Z is selected from -CR12R12'-; -CR13R13'-C R14R14'-; -CR15=CR15'-; -O-; and -S-; - each of R1 and R4 is independently selected from hydrogen; alkyl; -OH; phosphate; phosphate-alkylene; phosphonate; or phosphonate-alkylene; wherein said alkyl or alkylene can be substituted with one or more -OH, aryl, halogen; and wherein said alkyl or alkylene can contain a heteroatom in or at the end of the alkyl chain, said heteroatom selected from O, S and N; - each of R2 and R3 is independently selected from hydrogen; alkyl; -OH; phosphate; phosphate-alkylene; phosphonate; or phosphonate-alkylene; or when taken together with R6, R6 , R7 or R7 forms a double bond or -O- (thereby forming an epoxy); wherein said alkyl or alkylene can be substituted with one or more -OH; aryl; arylalkyl (such as trityl); -OOC-aryl; or halogen; and wherein said alkyl or alkylene can contain a heteroatom in or at the end of the alkyl chain, said heteroatom selected from O, S and N;
- or R2 or R3 when taken together with R6 or R6' is -CH2-CH2-CH2-; -CH2-CH2-CH2- CH2- or -CHR16=CHR17-CHR18=CHR19-, wherein each of R16, R17, R18 and R19 is independently selected from hydrogen; F; Cl; Br or alkyl;
- R5 is hydrogen or when taken together with R9, R9 , R11 or R11 forms a double bond; - each of R6 and R6 is independently selected from hydrogen; alkyl; or -OH; or taken together with R9, R9', R10 or R10' is -CH2-O- or -O-CH2- thereby forming a 5- membered ring; or when taken together with one of R2 or R3 forms a double bond or -O- (thereby forming an epoxy); wherein said alkyl can be substituted with one or more -OH; aryl; or halogen; - each of R7 and R7 is independently selected from hydrogen; alkyl; or -OH; or when taken together with one of R2 or R3 forms a double bond or -O- (thereby forming an epoxy); wherein said alkyl can be substituted with one or more -OH; aryl; or halogen;
- each of R8 and R8 is independently selected from hydrogen; alkyl; or -OH; or taken together with R9, R9', R10 or R10' is -CH2-O- or -0-CH2- thereby forming a 5- membered ring; wherein said alkyl can be substituted with one or more -OH; aryl; or halogen;
- each of R9 and R9 is independently selected from hydrogen; alkyl; or -OH; or taken together with R6, R6>, R8 or R8' is -CH2-O- or -0-CH2- thereby forming a 5-membered ring; or when taken together with R5 forms a double bond; wherein said alkyl can be substituted with one or more -OH; aryl; or halogen;
- each of R10 and R10 is independently selected from hydrogen; alkyl; or -OH; or taken together with R6, R6', R8 or R8' is -CH2-O- or -0-CH2- thereby forming a 5-membered ring;
- each of R1 ' and R11 is independently selected from hydrogen; alkyl; or -OH; or when taken together with R5 forms a double bond; wherein said alkyl can be substituted with one or more -OH; aryl; or halogen;
- each of R12, R12>, R13, R13', R14 R14', R15, R15' is independently selected from hydrogen or alkyl; wherein said alkyl can be substituted with one or more -OH; aryl; or halogen;
- the selections for the X, Y and R-groups like -CR7R7'-C R8R8'-; -CH2-O- or -CH2- O- or -0-CH2- have to be placed in formula I from left to right;
and isomers (in particular stereo-isomers or tautomers), solvates or pharmaceutically acceptable salts thereof or prodrugs thereof;
provided that the nucleoside analog is not a 9-(6-substituted or 6,8-disubstituted or 2,6- disubstituted -9H-purin-9-yl)-5-oxa-tricyclo[4.2.1.03'7]nonane-3-methanol;
and wherein B is according to formula (P-I),
each of R20 and R21 are independently selected from hydrogen; F; Cl; Br; I; -N3; -NH2; - OH; -0-CH3; -0-C2H5; -0-CH2-CH2-CH3; -O-CH(CH3)2; -O-C(CH3)3; -SH; -S-CH3; -S- C2H5; -S-CH2-CH2-CH3; -S-CH(CH3)2; -S-C(CH3)3; -CF3; -NO2; -COOH; -COO-CH3; - COO-C2H5; -COO-CH(CH3)2; -COO-C(CH3)3; -SO2-CH3; -SO2-C2H5; -SO2-CH2-CH2- CH3; -SO2-CH(CH3)2; -SO2-C(CH3)3; -CH2F; -CHF2; -CH2Cl; -CHCl2; -CH2-OH; -CH2- CH2-OH; -CH3; -C2H5; -CH2-CH2-CH3; -CH(CH3)2; -C(CH3)3; n-butyl; isobutyl; n- pentyl; sec-pentyl; -(4-chloro)-phenyl; -(4-bromo)-phenyl and -{4-fluoro)-phenyl;
and R22 is selected from hydrogen; F; Cl; Br; I; -COOH; -COO-CH3; -COO-C2H5; -COO- CH(CH3)2; -COO-C(CH3)3; n-butyl; isobutyl; n-pentyl; sec-pentyl; -CH2-OH; -CH2-CH2- OH; -CH3; -C2H5; -CH2-CH2-CH3; n-butyl; isobutyl; n-pentyl; sec-pentyl; -CH(CH3)2 and -C(CH3)3.
In a particular embodiment, the nucleoside analogs of the present invention are selected from the list of compounds in table 1 (encoded from compound number 1 to 86).
Yet in a more particular embodiment, the nucleoside analogs are selected from the list of:
- 9-[(lR*,2R*,4S*)-bicyclo[2.2.1]hept-2-yl]-6-chloro-9H-purine; - 9-[(lR*,2R*,4S*)-bicyclo[2.2.1]hept-2-yl]-2,6-dichloro-9H-purine;
- 6-chloro-9-[(lS,2S,4S)-l,7,7-trimethylbicyclo[2.2.1]hept-2-yl]-9H-purine;
- 6-chloro-9- {[(1 S,2S,5S)-6,6-dimethylbicyclo[3.1.1 ]hept-2-yl]methyl} -9H-purine;
- 2,6-dichloro-9- {[(1 S,2S,5S)-6,6-dimethylbicyclo[3.1. l]hept-2-yl]methyl}-9H-purine;
- 6-chloro-9- { [( 1 R,5 S)-6,6-dimethylbicyclo[3.1.1 ]hept-2-en-2-yl]methyl} -9H-purine; - 6-chloro-9-[(l S,2R,4R)-3,3-dimethylbicyclo[2.2.1 ]heρt-2-yl]-9H-purine;
- 9-[(lR*,2S*,4R*)-bicyclo[2.2.1]hept-5-en-2-yl]-6-chloro-9H-purine;
[(li?*,2i?*,45'*,65*)-6-(6-chloro-9H-purin-9-yl)bicyclo[2.2.1]hept-2-yl]methyl benzoate;
[(l^*,25*,4i?*,55*)-5-(6-chloro-9H-purin-9-yl)bicyclo[2.2.1]hept-2-yl]methyl benzoate;
(li?*,2i?*,3Λ*,6JR*,75*,9i?*)-9-[(6-chloro-9H-purin-9-yl)methyl]-4-oxatricyclo [4.2.1.03>7]nonan-2-ol;
(IR *,2R *,3R *,6R *,7S*,9R *)-9-[(2,6-dichloro-9H-purin-9-yl)methyl]-4-oxatricyclo [4.2.1.03J]nonan-2-ol; - [(li?*,2i?*,45*,65*)-6-(6-chloro-9H-purin-9-yl)bicyclo[2.2.1]hept-2-yl]methanol; - [(li?*,25*,4/?*,55*)-5-(6-chloro-9H-purin-9-yl)bicyclo[2.2.1]hept-2-yl]methanol;
- 6-chloro-9-{[(lR,2S,5R)-6,6-dimethylbicyclo[3.1. l]hept-2-yl]methyl} -9Η-purine;
(lR*,2R*,3R*,6R*,7S*,9S*)-2-(6-chloro-9H-purin-9-yl)-4-oxatricyclo[4.2.1.03'7] nonane-9-methanol; - (lR*,2S*,4R*,7R*)-7-(6-chloro-9H-purin-9-yl)bicyclo[2.2. l]heptan-2-ol;
- (lR*,2S*,4S*,7R*)-7-(6-chloro-9H-purin-9-yl)bicyclo[2.2.1]hept-5-en-2-ol;
-6-chloro-9-[(li?*,2i?*,3i?*,6i?*75*,95*)-9-(methoxymethyl)-4- oxatricyclo[4.2.1.03'7]non-2-yl]-9H-purine;
- 6-chloro-9-[(lR*,2S*,4R*,7R*)-2-methoxybicyclo[2.2.1]hept-7-yl]-9Η-purine; - 9- {(lR*,2R*,3R*,6R*,7S*,9S*)-9-[(benzyloxy)methyl]-4-oxatricyclo[4.2.1.03'7]non-2- yl } -6-chloro-9H-purine;
(lR*,2R*,3R*,6R*,7S*,9S*)-2-(6-chloro-9H-purin-9-yl)-4-oxatricyclo[4.2.1.03'7] nonane-9-methyl [phenyl methoxy-L-alaninyl]-phosphate;
- 6-chloro-9-[(lR*,2R*,3R*,6R*,7S*,9S*)-9-(chloromethyl)- 4-oxatricyclo[4.2.1.03'7] non-2-yl] -9H-purine. - 6-chloro-9-[(li?*,2i?*,6i?*,7/?*,85*)-tricyclo[5.2.1.02'6]dec-8-yl]-9H-purine;- 6-chloro- 9-[(IR *,8i? *,9S*)-tricyclo[6.2.1.02'7]undeca-2,4,6-trien-9-yl]-9H-purine; - 6-chloro-9-[(li?*,25*,35*,65*,7i?*)-4-oxatricyclo[4.2.1.03>7]non-2-yl]-9H-purine;
- 9-[(7-syn)-bicyclo[2.2. l]hept-2-en-7-yl]-6-chloro-9Η-purine;
- 9-[(lR,4S)-bicyclo[2.2. l]hept-7-yl]-6-chloro-9H-purine; - [(Ii? *,2i? *,3R *,6R *,7S*, 10*5)-2-(6-chloro-9H-purin-9-yl)-4-oxatricyclo[4.3.1.03'7]dec- 10-yl]methanol;
- {(li? *,2R *,3S*,6S*,7S*,9S*)-2-(6-chloτo-9H-pυήn-9-yl)-4,8- dioxatricyclo[4.2.1.03'7]non-9-yl} methanol; - [(li?*,2i?*,4i?*,75*)-7-(6-chloro-9H-purin-9-yl)bicyclo[2.2.1]heρt-5-en-2-yl]methanol; - [(li?*,2i?*,45*,75'*)-7-(6-chloro-9H-purin-9-yl)bicyclo[2.2.1]hept-2-yl]methanol;
- [(li?*,25*,4i?*,75*)-7-(6-chloro-9H-purin-9-yl)bicyclo[2.2.1]hept-5-en-2-yl]methanol;
- (li?*,2,S*,45*,6/?*)-6-(6-chloro-9H-purin-9-yl)bicyclo[2.2.1]heptan-2-ol;
- (li?*,25*,4i?*,55*)-5-(6-chloro-9H-purin-9-yl)bicyclo[2.2.1]heptan-2-ol;
- (li?*,2/?*,45*,6i?*)-6-(6-chloro-9H-purin-9-yl)bicyclo[2.2.1]heptan-2-ol; - (li?*,2i?*,4i?*,55*)-5-(6-chloro-9H-purin-9-yl)bicyclo[2.2.1]heptan-2-ol;
- [(lΛ*,25*,35*,45*)-3-(6-chloro-9H-purin-9-yl)bicyclo[2.2.1]hept-5-en-2-yl]methanol;
- [(Ii? *,2i? *,3i? *,45*)-3-(6-chloro-9H-purin-9-yl)bicyclo[2.2.1 ]hept-5-en-2-yl]methanol; -6-chloro-9-[(li? *,2i? *,3i? *,6S*,7S*, 10^*)- 10-(chloromethyl)-4- oxatricyclo[4.3.1.03'7]dec-2-yl]-9H-purine; -6-chloro-9-[(li? *,2i? *,3S*,6S*,7S*,9R *)-9-(chloromethyl)-4,8- dioxatricyclo[4.2.1.03>7]non-2-yl]-9H-purine;
-6-chloro-9-[(li? *,2i? *,3i? *,6S*,7S*, 105*)- 10-(fluororomethyl)-4- oxatricyclo[4.3.1.03'7]dec-2-yl]-9H-purine;
-6-chloro-9-[(li? *,2i? *,3S*,6S*,7S*,9R *)-9-(fluoromethyl)-4,8- dioxatricyclo[4.2.1.03'7]non-2-yl]-9H-purine;
- 6-chloro-9-[(15*,25*,4i? *,6i? *)-6-fluorobicyclo[2.2.1 ]hept-2-yl]-9H-purine;
- 6-chloro-9-[(li?*,25*,4i?*,55*)-5-fluorobicyclo[2.2.1]hept-2-yl]-9H-purine;
- 9-[(IR *,2R *,45*)-bicyclo[2.2.1 ]hept-2-yl]-9H-purine-6-thiol; - 9-[(li?*,2i?*,45'*)-bicyclo[2.2.1]hept-2-yl]-6-(methylsulfanyl)-9H-purine;
- 9-[{\R *,2R *,4S*)-bicyclo[2.2.1 ]hept-2-yl]-6-(methylsulfonyl)-9H-purine; - 9-[(l/?*,2i?*,45*)-bicyclo[2.2.1]hept-2-yl]-9H-purine;
- 9-[(li?*,2Λ*,45*)-bicyclo[2.2.1]hept-2-yl]-6-iodo-9H-purine; - 6-azido-9-[(li?*,2i?*,4,S'*)-bicyclo[2.2.1]hept-2-yl]-9H-purine; - 9-[(lR*,2R*,4S*)-bicyclo[2.2.1]hept-2-yl]-9H-purin-6-amine; - 9-[(l/?*,2/?*,45*)-bicyclo[2.2.1]hept-2-yl]-6-fluoro-9H-purine; - 9-[{\R *,2R *,4S*)-bicyclo[2.2.1 ]hept-2-yl]-6-(4-chlorophenyl)-9H-purine; - 9-[(li?*,2i?*,45*)-bicyclo[2.2.1]hept-2-yl]-6-(trifluoromethyl)-9H-purine;
- 9-[(IR *,2R *,45*)-bicyclo[2.2.1 ]hept-2-yl]-6-methoxy-9H-purine;
- 9-[(IR *,2R *,45*)-bicyclo[2.2.1 ]hept-2-yl]-6-methyl-9H-purine;
- 9-[(lΛ *,2R *,4S*)-bicyclo[2.2.1 ]hept-2-yl]-6-chloro-2-nitro-9H-purine; - 9-[(li? *,2R *,4S*)-bicyclo[2.2.1 ]hept-2-yl]-8-bromo-6-chloro-9H-purine;
- 9-[(li? *,2R *,45*)-bicyclo[2.2.1 ]hept-2-yl]-6-chloro-8-iodo-9H-purine;
- ethyl 9-[(lΛ*,2i?*,45'*)-bicyclo[2.2.1]hept-2-yl]-6-chloro-9H-purine-8-carboxylate;
- {9-[(l/?*,2i?*,4,S*)-bicyclo[2.2.1]hept-2-yl]-6-chloro-9H-purin-8-yl} methanol; - 6-chloro-9-[(li?*,2i?*,4,S*,55*,65*)-3-oxatricyclo[3.2.1.02'4]oct-6-yl]-9H-purine; - (li?*,2i?*,35r*,45'*,55*)-5-(6-chloro-9H-purin-9-yl)bicyclo[2.2.1]heptane-2,3-diol;
- 7-[( Ii? *,2R *,45*)-bicyclo[2.2.1 ]hept-2-yl]-4-chloro-7H-pyrrolo[2,3- J]pyrimidine; -(li?*,2i?*,3i?*,6i?*,75*,95*)-2-(2-amino-6-chloro-9H-purin-9-yl)-4- oxatricyclo[4.2.1.03'7]nonane-9-methanol; and
- 6-chloro-9-[(li? *,3R *,6R *,1R *,9R *)-4-oxatricyclo[4.2.1.03'7]non-9-yl]-9H-purine - (lR*,2R*,3S*,4S*)-6-(chloromethyl)-3-(6-chloro-9Η-purin-9-yl)bicyclo[2.2.1]hept-5- en-2-ol;
- (li?*,2JR*,35*,45*)-3-(6-chloro-9H-purin-9-yl)-6-(hydroxymethyl)bicyclo[2.2.1]hept-5- en-2-ol;
- (li?*,2/?*,35*,45*)-3-(chloro-9H-purin-9-yl)-5-(hydroxymethyl)bicyclo[2.2.1]hept-5- en-2-ol and
- (li?*,4i?*,75*)-7-(6-Chloro-9H-purin-9-yl)bicyclo[2.2.1]hept-5-ene-2,2-dimethanol.
According to a second aspect, the invention relates to the nucleoside analogs as described herein for use as a medicament, more in particular for use as an antiviral medicament and for the use in the prevention or treatment of a viral infection in a subject (animal, mammal or human).
The present invention also relates to the use of the nucleoside analogs of the formulae (including but not limited to A', A, A-2, A-3a, A-3b, A-4, A-5 and A-6) and claims herein as antiviral compounds, more particularly as compounds active against Picornaviridae. The invention also relates to the use of nucleoside analogs of the formulae and claims herein for the manufacture of a medicament or as a pharmaceutically active ingredient, especially as a virus replication inhibitor, for instance for the manufacture of a medicament or pharmaceutical composition having antiviral activity for the prevention and/or treatment of viral infections in humans, mammals and animals in general. The present invention further relates to a method of prevention or treatment of a viral infection, preferably a Picornaviridae infection in an animal, including mammals, including a human, comprising administering to the animal in need of such treatment a therapeutically effective amount of a nucleoside analog of formulae and claims herein as an active ingredient, preferably in admixture with at least a pharmaceutically acceptable carrier.
Another aspect of the invention further relates to methods for the preparation of compounds of formulae and claims herein. Also the intermediates (amines and hydroxy bearing derivatives as specified in the examples) used in the preparation methods described herein are aspects of the present invention. One embodiment relates to a method for the preparation of the nucleoside analogs of the invention, said method comprising the steps of coupling a substituted or unsubstituted pyrimidine or purine heterocycle, preferably a substituted or unsubstituted purine heterocycle, to compounds of the formula (A-7), in particular via the Mitsunobu-reaction:
wherein each of W, X, Y, Z, R1, R2, R3, R4, R5, is according to formula (A).
Another particular embodiment relates to a method for the preparation of the nucleoside analogs of the invention, said method comprising the steps of coupling a substituted or unsubstituted pyrimidine or purine heterocycle, preferably a substituted pyrimidine heterocycle, to compounds of the formula (A-8),
wherein each of W, X, Z, Y, R1, R2, R3, R4, R5, ' is according to formula (A), said method comprising the steps of
- coupling a substituted 5-amino-pyrimidine, preferably a substituted 4-chloro-5-amino- pyrimidine, to the compounds of formula (A-8); and - performing a ring-closure in acid trialkyl orthoformate reaction conditions.
Yet another aspect of the present invention relates to pharmaceutical compositions comprising the nucleoside analogs of the invention according to formulae and claims herein in admixture with at least a pharmaceutically acceptable carrier, the active ingredient preferably being in a concentration range of about 0.1 to 100% by weight, and to the use of these derivatives namely as drugs useful for the treatment of subjects suffering from a viral infection, in particular a Picornaviridae infection.
The invention further relates to the use of a composition comprising (a) one or more derivatives of formulae and claims herein, and (b) one or more viral inhibitors as biologically active agents in respective proportions such as to provide a synergistic effect against a viral infection in a mammal, for instance in the form of a combined preparation for simultaneous, separate or sequential use in viral infection therapy. Within the framework of this embodiment of the invention, the viral enzyme inhibitors used as a therapeutically active ingredients (b) may belong to categories already known in the art.
The invention also relates to the nucleoside analogs of the invention according to formulae and claims herein being used for inhibition of the proliferation of other viruses than Picornaviridae, preferably the inhibition of viral activity of other RNA- viruses such as hepatitis B virus, hepatitis C virus or flaviviruses, with in particular yellow fever virus or Dengue virus.
More generally, the invention relates to the compounds of formulae and claims herein being useful as agents having biological activity or as diagnostic agents. Any of the uses mentioned with respect to the present invention may be restricted to a non-medical use, a non-therapeutic use, a non-diagnostic use, or exclusively an in vitro use, or a use related to cells remote from an animal.
DETAILED DESCRIPTION OF THE INVENTION
Definitions
In each of the following definitions, the number of carbon atoms represents the maximum number of carbon atoms generally optimally present in the substituent or linker; it is understood that where otherwise indicated in the present application, the number of carbon atoms represents the optimal maximum number of carbon atoms for that particular substituent or linker.
The term "alkyl" as used herein refers to C1-C18 normal, preferably primary, secondary, or tertiary hydrocarbon chains. Examples are methyl, ethyl, 1 -propyl, 2- propyl, 1-butyl, 2-methyl-l-propyl(i-Bu), 2-butyl (s-Bu) 2-methyl-2-propyl (t-Bu), 1- pentyl (n-pentyl), 2-pentyl, 3-pentyl, 2-methyl-2 -butyl, 3-methyl-2-butyl, 3-methyl-l- butyl, 2-methyl- 1-butyl, 1-hexyl, 2-hexyl, 3-hexyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 3-methyl-3-pentyl, 2-methyl-3-pentyl, 2,3-dimethyl-2-butyl, 3,3- dimethyl-2-butyl, M-pentyl, n-hexyl, M-heptyl, n-octyl, n-nonyl, «-decyl, n-undecyl, n- dodecyl, M-tridecyl, n-tetradecyl, w-pentadecyl, n-hexadecyl, rø-heptadecyl, w-octadecyl, n-nonadecyl and n-icosyl. The term "alkylene" as used herein refers to a saturated, branched or straight chain hydrocarbon radical of Cj-18 carbon atoms, and having two monovalent radical centers derived by the removal of two hydrogen atoms from the same or two different carbon atoms of a parent alkane. Typical alkylene radicals include, but are not limited to: methylene (-CH2-) 1,2-ethyl (-CH2CH2-), 1,3-propyl (-CH2CH2CH2-), 1,4-butyl (- CH2CH2CH2CH2-), and the like.
When reference is made to "alkyl can contain a heteroatom in or at the end of the alkyl chain, said heteroatom selected from O, S and N", than any carbon atom of the alkyl can be exchanged for a heteroatom selected from O, S and N when chemically feasible. Examples are CH3-CH2-O-; CH3-O-CH2- and CH3-CH2-CH2-NH-CH2-. The same counts for the term "alkylene" whereby the term "phosphonate-alkylene can contain a heteroatom in or at the end of the alkyl chain, said heteroatom selected from O, S and N" also includes phosphonalkyloxy such as phosphonylmethyl ether. As used herein, and unless stated otherwise, the term "phosphonalkyloxy" refers to a phosphonate coupled via an alkylgroup (such as defined herein after) to an oxygen atom which itself can be coupled to another molecule or group.
As used herein and unless otherwise stated, the term "cycloalkyl" means a monocyclic saturated hydrocarbon monovalent radical having from 3 to 10 carbon atoms, such as for instance cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl and the like, or a C7-10 polycyclic saturated hydrocarbon monovalent radical having from 7 to 10 carbon atoms such as, for instance, norbornyl, fenchyl, trimethyltricycloheptyl or adamantyl.
The terms "alkenyl" and "cycloalkenyl" as used herein is C2-C18 normal, preferably primary, secondary or tertiary and respectively C3-10 cyclic hydrocarbon with at least one site (usually 1 to 3, preferably 1) of unsaturation, i.e. a carbon-carbon, sp2 double bond. Examples include, but are not limited to: ethylene or vinyl (-CH=CH2), allyl (-CH2CH=CH2), cyclopentenyl (-C5H7), and 5-hexenyl (-CH2 CH2CH2CH2CH=CH2). The double bond may be in the cis or trans configuration. The terms "alkynyl" and "cycloalkynyl" as used herein refer respectively C2-C18 normal, preferably primary, secondary, tertiary or the C8-C13 cyclic hydrocarbon with at least one site (usually 1 to 3, preferably 1) of unsaturation, i.e. a carbon-carbon, sp triple bond. Examples include, but are not limited to: acetylenic (-C≡CH) and propargyl (- CH2C≡CH).
The term "aryl" as used herein means a aromatic hydrocarbon radical of 6-20 carbon atoms derived by the removal of hydrogen from a carbon atom of a parent aromatic ring system. Typical aryl groups include, but are not limited to 1 ring, or 2 or 3 rings fused together, radicals derived from benzene, naphthalene, anthracene, biphenyl, and the like.
" Arylalkyl" as used herein refers to an alkyl radical in which one of the hydrogen atoms bonded to a carbon atom, typically a terminal or sp3 carbon atom, is replaced with an aryl radical. Typical arylalkyl groups include, but are not limited to, benzyl, 2- phenylethan-1-yl, 2-phenylethen-l-yl, naphthyhnethyl, 2-naphthylethan-l-yl, 2- naphthylethen-1-yl, naphthobenzyl, 2-naphthophenylethan-l-yl and the like. The arylalkyl group comprises 6 to 20 carbon atoms, preferably 7 to 20 carbon atom, e.g. the alkyl moiety, including alkanyl, alkenyl or alkynyl groups, of the arylalkyl group is 1 to 6 carbon atoms and the aryl moiety is 5 to 14 carbon atoms, preferably 6 to 14 carbon atoms. The "arylalkyl" radical may itself be substituted such as but not limited to 4- chlorobenzyl, 4-fluorobenzyl, 2-fluorobenzyl, 3,4-dichlorobenzyl, 2,6-dichlorobenzyl, 3- methylbenzyl, 4-methylbenzyl, 4-ter-butylbenzyl, l-amino-2-phenylethyl and l-amino-2- [4-hydroxy-phenyl]ethyl. As used herein, and unless stated otherwise, the term "purine and pyrimidine heterocycles" include, but are not limited to, adenine, thymine, cytosine, uracyl, guanine and (2,6-)diaminopurine such as may be found in naturally-occurring nucleosides. The
term also includes analogs and derivatives thereof. An analog thereof is a heterocycle which mimics such naturally-occurring bases in such a way that its structure (the kinds of atoms present and their arrangement) is similar to the above-listed naturally-occurring heterocycles but is modified by either having additional functional properties with respect to the naturally-occurring bases or lacking certain functional properties of the naturally- occurring bases. Such analogues include, but are not limited to, those derived by replacement of a -CH- moiety by a nitrogen atom ("aza-analogs" e.g. 5-azapyrimidines such as 5-azacytosine) or vice-versa ("deaza-analogs" e.g. 7-deazapurines, such as 7- deaza-adenine or 7-deazaguanine) or both (e.g. 7-deaza, 8-azapurines). The purine and pyrimidine heterocycles can be unsubstituted or substituted and in the last instance can be refered to as a "derivative" of naturally-occurring heterocycles (bases), or analogs thereof. Such substituted derivatives are compounds wherein the heterocyclic ring is substituted with one or more conventional substituents independently selected from the group consisting of halogen; -NH2; -NH-alkyl; -N(alkyl)2; -OH; -O-alkyl (such as - OCH3); -O-aryl; -SH; -S-alkyl (such as -SCH3); -S-aryl; -CF3; -NO2; -COOH; -COO- alkyl; -S02alkyl; aryl; halogenoaryl; arylalkyl; or alkyl; wherein each of said alkyl can again be substituted with hydroxy, amino, halogen or -SH. Such purine or pyrimidine heterocycles, analogs and derivatives thereof are well known to those skilled in the art. Specific embodiments of purine and pyrimidine heterocycles B suitable for inclusion into the nucleoside analogs of the present invention include, but are not limited to, hypoxanthine, guanine, adenine, cytosine, inosine, thymine, uracil, xanthine, 8-aza derivatives of 2-aminopurine, 2,6-diaminopurine, 6-chloro-purine, 2,6-dichloro-purine, 2-amino-6-chloropurine, hypoxanthine, inosine and xanthine; 7-deaza-8-aza derivatives of adenine, guanine, 2-aminopurine, 2,6-diaminopurine, 6-chloro-purine, 2,6-dichloro- purine, 2-amino-6-chloropurine, hypoxanthine, inosine and xanthine; 1-deaza derivatives of 2-aminopurine, 2,6-diaminopurine, 6-chloro-purine, 2,6-dichloro-purine, 2-amino-6- chloropurine, hypoxanthine, inosine and xanthine; 7-deaza derivatives of 2-aminopurine, 2,6-diaminopurine, 6-chloro-purine, 2,6-dichloro-purine, 2-amino-6-chloropurine, hypoxanthine, inosine and xanthine; 3-deaza derivatives of 2-aminopurine, 2,6- diaminopurine, 6-chloro-purine, 2,6-dichloro-purine, 2-amino-6-chloropurine, hypoxanthine, inosine and xanthine; 6-azacytosine; 5-fluorocytosine; 5-chlorocytosine; 5-
iodocytosine; 5-bromocytosine; 5-methylcytosine; 5-bromovinyluracil; 5-fluorouracil; 5- chlorouracil; 5-iodouracil; 5-bromouracil; 5-trifluoromethyluracil; 5- methoxymethyluracil; 5-ethynyluracil and 5-propynyluracil. More in particular, B is a 9- purinyl residue selected from guanyl, 3-deazaguanyl, 1-deazaguanyl, 8-azaguanyl, 7- deazaguanyl, adenyl, 3-deazaadenyl, 1-dezazadenyl, 8-azaadenyl, 7-deazaadenyl, 2,6- diaminopurinyl, 2-aminopurinyl, 6-chloro-2-aminopurinyl and 6-thio-2-aminopurinyl.
In a particular embodiment, the purine heterocycle is according to formula (P-I),
wherein each of R20 and R21 are independently selected from hydrogen; halogen; -NH2; - N3; -OH; -O-alkyl (such as -OCH3); -SH; -S-alkyl (such as -SCH3); -CF3; -NO2; -COOH; -COO-alkyl; -S02alkyl; aryl; or alkyl; wherein each of said alkyl and aryl can again be substituted with hydroxy, amino, halogen or -SH;
and R22 is selected from hydrogen; halogen; -NH2; -OH; -O-alkyl (such as -OCH3); -SH; -S-alkyl (such as -SCH3); -N3; -NO2; -COOH; -COO-alkyl; -S02alkyl; aryl; or alkyl; wherein each of said alkyl and aryl can again be substituted with hydroxy, amino or -SH
(thereby including the isomers and salts thereof).
In a more particular embodiment, the purine heterocycle is according to formula (P-I), wherein
each of R20 and R21 are independently selected from hydrogen; F; Cl; Br; I; -N3; -NH2; - OH; -0-CH3; -0-C2H5; -0-CH2-CH2-CH3; -O-CH(CH3)2; -O-C(CH3)3; -SH; -S-CH3; -S-
C2H5; -S-CH2-CH2-CH3; -S-CH(CH3)2; -S-C(CH3)3; -CF3; -NO2; -COOH; -COO-CH3; -
COO-C2H5; -COO-CH(CH3)2; -COO-C(CH3)3; -SO2-CH3; -SO2-C2H5; -SO2-CH2-CH2- CH3; -SO2-CH(CH3)2; -SO2-C(CH3)3; -CH2F; -CHF2; -CH2Cl; -CHCl2; -CH2-OH; -CH2- CH2-OH; -CH3; -C2H5; -CH2-CH2-CH3; -CH(CH3)2; -C(CH3)3; n-butyl; isobutyl; n- pentyl; sec-pentyl; -(4-chloro)-phenyl; -(4-bromo)-phenyl and -(4-fluoro)-phenyl;
and R22 is selected from hydrogen; F; Cl; Br; I; -COOH; -COO-CH3; -COO-C2H5; -COO- CH(CH3)2; -COO-C(CH3)3; n-butyl; isobutyl; n-pentyl; sec-pentyl; -CH2-OH; -CH2-CH2- OH; -CH3; -C2H5; -CH2-CH2-CH3; n-butyl; isobutyl; n-pentyl; sec-pentyl; -CH(CH3)2 and -C(CH3)3.
In an even more particular embodiment, the purine heterocycle is according to formula (P-I), wherein
R20 is selected from hydrogen; F; Cl; Br; I; -N3; -NH2; -OH; -0-CH3; -0-C2H5; -0-CH2- CH2-CH3; -O-CH(CH3)2; -O-C(CH3)3; -SH; -S-CH3; -S-C2H5; -S-CH2-CH2-CH3; -S-
CH(CH3)2; -S-C(CH3)3; -CF3; -NO2; -COOH; -COO-CH3; -COO-C2H5; -COO-
CH(CH3)2; -COO-C(CH3)3; -SO2-CH3; -SO2-C2H5; -SO2-CH2-CH2-CH3; -SO2-
CH(CH3)2; -SO2-C(CH3)3; -CH2F; -CHF2; -CH2Cl; -CHCl2; -CH2-OH; -CH2-CH2-OH; -
CH3; -C2H5; -CH2-CH2-CH3; -CH(CH3)2; -C(CH3)3; n-butyl; isobutyl; n-pentyl; sec- pentyl; -(4-chloro)-phenyl; -(4-bromo)-phenyl and -(4-fluoro)-phenyl;
R21 is selected from hydrogen; F; Cl; Br; I; -0-CH3; -0-C2H5; -0-CH2-CH2-CH3; -O- CH(CH3)2; -O-C(CH3)3; -CH3; -C2H5; -CH2-CH2-CH3; -CH(CH3)2; -C(CH3)3; n-butyl; isobutyl; n-pentyl and sec-pentyl;
and R22 is selected from hydrogen; F; Cl; Br; I; -COOH; -COO-CH3; -COO-C2H5; -COO- CH(CH3)2; -COO-C(CH3)3; n-butyl; isobutyl; n-pentyl; sec-pentyl; -CH2-OH; -CH2-CH2- OH; -CH3; -C2H5; -CH2-CH2-CH3; n-butyl; isobutyl; n-pentyl; sec-pentyl; -CH(CH3)2 and -C(CH3)3.
As used herein with respect to a substituting group, and unless otherwise stated, the terms " arylalkyl ", " arylalkenyl " and " heterocyclic-substituted alkyl " refer to an aliphatic saturated or ethylenically unsaturated hydrocarbon monovalent group (preferably a C1-I8 alkyl or C2-18 alkenyl such as defined above) onto which an aryl or heterocyclic group (such as defined herein) is already bonded, and wherein the said aliphatic group and/or the said aryl or heterocyclic group may be optionally substituted with one or more substituents independently selected from the group consisting of halogen, amino, hydroxyl, sulfhydryl, Ci-7 alkyl, trifluoromethyl and nitro, such as but not limited to l-amino-2-[indol-2-yl]ethyl, styryl, pyridylmethyl (including all isomers thereof), pyridylethyl, 2-(2-pyridyl)isopropyl, oxazolylbutyl, 2-thienylmethyl, pyrrolylethyl, morpholinyl-ethyl, imidazol-1-yl-ethyl, benzodioxolylmethyl and 2- furylmethyl.
The term " acyl " as used herein, unless otherwise stated, refers to a carbonyl group directly attached to an alkyl, alkenyl, alkynyl, aryl, heterocyclic, arylalkyl, arylalkenyl, arylalkynyl, heterocyclic-alkyl, heterocyclic-alkenyl or heterocyclic-alkynyl group, such as for example alkanoyl (alkylcarbonyl), aroyl (arylcarbonyl), arylalkanoyl or alkylaroyl group, wherein the carbonyl group is coupled to another molecule. As an example, the term " acyloxyalkyl " refers to an acyl group coupled via an oxygen atom to an alkyl group, the latter being further coupled to another molecule or atom.
As an example, " alkylalkenylcarbonate " refers to a alkyl-OC(O)O-alkenyl group, thus a carbonate substituted at one side with an alkyl and on the other side with an alkenyl, one of the alkyl and alkenyl groups being further coupled to another molecule or atom. As used herein and unless otherwise stated, the terms " alkoxy ", " cyclo-alkoxy
", " aryloxy ", " arylalkyloxy ", " oxyheterocyclic ", " thioalkyl ", " thio cycloalkyl ", " arylthio ", " arylalkylthio " and " thioheterocyclic " refer to substituents wherein an alkyl group, respectively a cycloalkyl, aryl, arylalkyl or heterocyclic group (each of them such as defined herein), are attached to an oxygen atom or a sulfur atom through a single bond, such as but not limited to methoxy, ethoxy, propoxy, butoxy, thioethyl, thiomethyl, phenyloxy, benzyloxy, mercaptobenzyl and the like.
As used herein and unless otherwise stated, the term halogen means any atom selected from the group consisting of fluorine (F), chlorine (Cl), bromine (Br) and iodine
(I)-
Any substituent designation that is found in more than one site in a compound of this invention shall be independently selected.
Substituents optionally are designated with or without bonds. Regardless of bond indications, if a substituent is polyvalent (based on its position in the structure referred to), then any and all possible orientations of the substituent are intended.
Detailed description
The present invention relates to a series of novel nucleoside analogs which have been shown to possess antiviral activity, in particular against viruses of the family of the Picornaviridae. The invention therefore relates to the new nucleoside analogs, methods for their preparation, pharmaceutical compositions comprising them, the use of the nucleoside analogs for the preparation of a medicament and to the nucleoside analogs for use as a medicament, more in particular as antiviral medicament.
The compounds of the invention are employed for the treatment or prophylaxis of viral infections, more particularly Picornaviridae infections.
When using one or more compounds according to the formulae of the application as defined herein:
- the active ingredients of the compound(s) may be administered to the mammal (including a human) to be treated by any means well known in the art, i.e. orally, intranasally, subcutaneously, intramuscularly, intradermally, intravenously, intra- arterially, parenterally or by catheterization. the therapeutically effective amount of the preparation of the compound(s), especially for the treatment of viral infections in humans and other mammals, corresponds to an amount which ensures a plasma level of between lμg/ml and 100 mg/ml, optionally of 10 mg/ml. Depending upon the pathologic condition to be treated and the patient's
condition, the effective amount may be divided into several sub-units per day or may be administered at more than one day intervals.
The present invention further relates to a method for preventing or treating a viral infections in a subject or patient by administering to the patient in need thereof a therapeutically effective amount of the nucleoside analogs of the present invention. The therapeutically effective amount of the preparation of the compound(s), especially for the treatment of viral infections in humans and other mammals, preferably is Picornaviridae protein/enzyme inhibiting amount. More preferably, it is a Picornaviridae replication inhibiting amount or a Picornaviridae enzyme inhibiting amount of the nucleoside analogs of the formulae as defined herein. Depending upon the pathologic condition to be treated and the patient's condition, the effective amount may be divided into several sub- units per day or may be administered at more than one day intervals.
As is conventional in the art, the evaluation of a synergistic effect in a drug combination may be made by analyzing the quantification of the interactions between individual drugs, using the median effect principle described by Chou et al. in Adv. Enzyme Reg. (1984) 22:27. Briefly, this principle states that interactions (synergism, additivity, antagonism) between two drugs can be quantified using the combination index (hereinafter referred as CI) defined by the following equation:
EDfl EDl
Cl = ττ +
* ED;1 ED;2 wherein EDx is the dose of the first or respectively second drug used alone (Ia, 2a), or in combination with the second or respectively first drug (Ic, 2c), which is needed to produce a given effect. The said first and second drug have synergistic or additive or antagonistic effects depending upon CK 1, CI = 1, or CI > 1, respectively.
Synergistic activity of the pharmaceutical compositions or combined preparations of this invention against viral infection may also be readily determined by means of one or more tests such as, but not limited to, the isobologram method, as previously described by Elion et al. in J. Biol. Chem. (1954) 208:477-488 and by Baba et al. in Antimicrob.
Agents Chemother. (1984) 25:515-517, using EC50 for calculating the fractional inhibitory concentration (hereinafter referred as FIC). When the minimum FIC index corresponding to the FIC of combined compounds (e.g., FICx + FICy) is equal to 1.0, the combination is said to be additive; when it is between 1.0 and 0.5, the combination is defined as subsynergistic, and when it is lower than 0.5, the combination is defined as synergistic. When the minimum FIC index is between 1.0 and 2.0, the combination is defined as subantagonistic and, when it is higher than 2.0, the combination is defined as antagonistic. This principle may be applied to a combination of different antiviral drugs of the invention or to a combination of the antiviral drugs of the invention with other drugs that exhibit anti-Picornaviridae activity.
The invention thus relates to a pharmaceutical composition or combined preparation having synergistic effects against a viral infection and containing: Either: A)
(a) a combination of two or more of the nucleoside analogs of the present invention, and
(b) optionally one or more pharmaceutical excipients or pharmaceutically acceptable carriers, for simultaneous, separate or sequential use in the treatment or prevention of a viral infection or B)
(c) one or more anti-viral agents, and
(d) at least one of the nucleoside analogs of the present invention, and (e) optionally one or more pharmaceutical excipients or pharmaceutically acceptable carriers, for simultaneous, separate or sequential use in the treatment or prevention of a viral infection.
The pharmaceutical composition or combined preparation with synergistic activity against viral infection according to this invention may contain nucleoside analogs of the present invention, compounds according to the formulae of the application, over a broad
content range depending on the contemplated use and the expected effect of the preparation. Generally, the content of the nucleoside analogs of the present invention of the combined preparation is within the range of 0.1 to 99.9% by weight, preferably from 1 to 99% by weight, more preferably from 5 to 95% by weight.
hi a partiuclar embodiment, the nucleoside analogs of the invention can be used for the treatment or prevention of Aphthovirus (Foot-and-Mouth Disease Virus), Cardiovirus (Encephalomyocarditis virus + and Theilovirus), Enterovirus (Human Enterovirus A, B, C and D, Bovine Enterovirus, Porcine Enterovirus and Poliovirus), Erbovirus, Duck Hepatitis virus, Hepato virus (Avian Encephalomyelitis Virus, Hepatitis A virus +), Kobuvirus, Parechovirus, Rhinovirus or Teschovirus.
The invention also relates to the nucleoside analogs of the invention, according to the formulae of the application being used for inhibition of the proliferation of other viruses than Picornaviridae, particularly for the inhibition of other RNA- viruses, including ds and ss RNA viruses and thereby including negative strand and positive strand viruses.
The present invention further provides veterinary compositions comprising at least one active ingredient as above defined together with a veterinary carrier therefore. Veterinary carriers are materials useful for the purpose of administering the composition and may be solid, liquid or gaseous materials which are otherwise inert or acceptable in the veterinary art and are compatible with the active ingredient. These veterinary compositions may be administered orally, parenterally or by any other desired route.
More generally, the invention relates to the compounds according to the formulae of the application being useful as agents having biological activity (particularly antiviral activity) or as diagnostic agents. Any of the uses mentioned with respect to the present invention may be restricted to a non-medical use, a non-therapeutic use, a non-diagnostic use, or exclusively an in vitro use, or a use related to cells remote from an animal.
The compounds of the invention optionally are bonded covalently to an insoluble matrix and used for affinity chromatography (separations, depending on the nature of the groups
of the compounds, for example compounds with aryl are useful in hydrophobic affinity separations.
Those of skill in the art will also recognize that the compounds of the invention may exist in many different protonation states, depending on, among other things, the pH of their environment. While the structural formulae provided herein depict the compounds in only one of several possible protonation states, it will be understood that these structures are illustrative only, and that the invention is not limited to any particular protonation state, any and all protonated forms of the compounds are intended to fall within the scope of the invention.
The term "pharmaceutically acceptable salts" as used herein means the therapeutically active non-toxic salt forms which the compounds according to the formulae of the application are able to form. Therefore, the compounds of this invention optionally comprise salts of the compounds herein, especially pharmaceutically acceptable non- toxic salts containing, for example, Na+, Li+, K+, Ca+2 and Mg+2. Such salts may include those derived by combination of appropriate cations such as alkali and alkaline earth metal ions or ammonium and quaternary amino ions with an acid anion moiety, typically a carboxylic acid. The compounds of the invention may bear multiple positive or negative charges. The net charge of the compounds of the invention may be either positive or negative. Any associated counterions are typically dictated by the synthesis and/or isolation methods by which the compounds are obtained. Typical counterions include, but are not limited to ammonium, sodium, potassium, lithium, halides, acetate, trifluoroacetate, etc., and mixtures thereof. It will be understood that the identity of any associated counter ion is not a critical feature of the invention, and that the invention encompasses the compounds in association with any type of counter ion. Moreover, as the compounds can exist in a variety of different forms, the invention is intended to encompass not only forms of the compounds that are in association with counterions (e.g., dry salts), but also forms that are not in association with counterions (e.g., aqueous or organic solutions). Metal salts typically are prepared by reacting the metal hydroxide with a compound of this invention. Examples of metal salts which are prepared in this
way are salts containing Li+, Na+, and K+. A less soluble metal salt can be precipitated from the solution of a more soluble salt by addition of the suitable metal compound. In addition, salts may be formed from acid addition of certain organic and inorganic acids to basic centers, typically amines, or to acidic groups. Examples of such appropriate acids include, for instance, inorganic acids such as hydrohalic acids, e.g. hydrochloric or hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like; or organic acids such as, for example, acetic, propanoic, hydroxyacetic, 2-hydroxypropanoic, 2- oxopropanoic, lactic, pyruvic, oxalic (i.e. ethanedioic), malonic, succinic (i.e. butanedioic acid), maleic, fumaric, malic, tartaric, citric, methanesulfonic, ethanesulfonic, benzenesulfonic, p-toluenesulfonic, cyclohexanesulfamic, salicylic (i.e. 2- hydroxybenzoic), p-aminosalicylic and the like. Furthermore, this term also includes the solvates which the compounds according to the formulae of the application as well as their salts are able to form, such as for example hydrates, alcoholates and the like. Finally, it is to be understood that the compositions herein comprise compounds of the invention in their unionized, as well as zwitterionic form, and combinations with stoichiometric amounts of water as in hydrates.
Also included within the scope of this invention are the salts of the parental compounds with one or more amino acids, especially the naturally-occurring amino acids found as protein components. The amino acid typically is one bearing a side chain with a basic or acidic group, e.g., lysine, arginine or glutamic acid, or a neutral group such as glycine, serine, threonine, alanine, isoleucine, or leucine.
The compounds of the invention also include physiologically acceptable salts thereof. Examples of physiologically acceptable salts of the compounds of the invention include salts derived from an appropriate base, such as an alkali metal (for example, sodium), an alkaline earth (for example, magnesium), ammonium and NX4 + (wherein X is C1-C4 alkyl). Physiologically acceptable salts of an hydrogen atom or an amino group include salts of organic carboxylic acids such as acetic, benzoic, lactic, fumaric, tartaric, maleic, malonic, malic, isethionic, lactobionic and succinic acids; organic sulfonic acids, such as methanesulfonic, ethanesulfonic, benzenesulfonic and p-toluenesulfonic acids; and inorganic acids, such as hydrochloric, sulfuric, phosphoric and sulfamic acids. Physiologically acceptable salts of a compound containing a hydroxy group include the
anion of said compound in combination with a suitable cation such as Na+ and NX4 + (wherein X typically is independently selected from H or a C1-C4 alkyl group). However, salts of acids or bases which are not physiologically acceptable may also find use, for example, in the preparation or purification of a physiologically acceptable compound. All salts, whether or not derived form a physiologically acceptable acid or base, are within the scope of the present invention.
The nucleoside analogs of the present invention can have different isomeric forms and during the synthesis as provided herein normally one isomeric form is prepared (except for some isomeric impurities). All the atoms in the nucleoside analogs of the present invention can be in the R or S form. For some specific nucleoside analogs of the present invention, the isomeric configuration is given herein. hi a particular embodiment of the different aspects of the invention, the nucleoside analogs of the invention are according to one of the formulae A-IO to A-23 hereunder:
As used herein and unless otherwise stated, the term "enantiomer" means each individual optically active form of a compound of the invention, having an optical purity or enantiomeric excess (as determined by methods standard in the art) of at least 80% (i.e. at least 90% of one enantiomer and at most 10% of the other enantiomer), preferably at least 90% and more preferably at least 98%.
The term "isomers" as used herein means all possible isomeric forms, including tautomeric and sterochemical forms ("stereo-isomers") and including positional isomers, which the compounds according to the formulae of the application may possess, hi a particular embodiment, the term "isomers" excludes positional isomers. Typically, the structures shown herein exemplify only one tautomeric or resonance form of the compounds, but the corresponding alternative configurations are contemplated as well. Unless otherwise stated, the chemical designation of compounds denotes the mixture of all possible stereochemically isomeric forms, including stereoisomers and tautomers, said mixtures containing all diastereomers and enantiorners (since the compounds according to the formulae of the application may have at least one chiral center) of the basic molecular structure, as well as the stereochemically pure or enriched compounds. More particularly, stereogenic centers may have either the R- or S-configuration, and multiple bonds may have either cis- or trans-configuration. Pure isomeric forms of the said compounds are defined as isomers substantially free of other enantiomeric or diastereomeric forms of the same basic molecular structure, hi particular, the term "stereoisomerically pure" or "chirally pure" relates to compounds having a stereoisomers excess of at least about 80% (i.e. at least 90% of one isomer and at most 10% of the other possible isomers), preferably at least 90%, more preferably at least 94% and most preferably at least 97%. The terms "enantiomerically pure" and "diastereomerically pure" should be understood in a similar way, having regard to the enantiomeric excess, respectively the diastereomeric excess, of the mixture in question. Separation of stereoisomers is accomplished by standard methods known to those skilled in the art. One enantiomer of a compound of the invention can be separated substantially free of its opposing enantiomer by a method such as formation of diastereomers using optically active resolving agents ("Stereochemistry of Carbon Compounds," (1962) by E. L. Eliel, McGraw Hill; Lochmuller, C. H., (1975) J. Chromatogr., 113:(3) 283-302).
Separation of isomers in a mixture can be accomplished by any suitable method, including: (1) formation of ionic, diastereomeric salts with chiral compounds and separation by fractional crystallization or other methods, (2) formation of diastereomeric compounds with chiral derivatizing reagents, separation of the diastereomers, and conversion to the pure enantiomers, or (3) enantiomers can be separated directly under chiral conditions. Under method (1), diastereomeric salts can be formed by reaction of enantiomerically pure chiral bases such as brucine, quinine, ephedrine, strychnine, a- methyl-b-phenylethylamine (amphetamine), and the like with asymmetric compounds bearing acidic functionality, such as carboxylic acid and sulfonic acid. The diastereomeric salts may be induced to separate by fractional crystallization or ionic chromatography. For separation of the optical isomers of amino compounds, addition of chiral carboxylic or sulfonic acids, such as camphorsulfonic acid, tartaric acid, mandelic acid, or lactic acid can result in formation of the diastereomeric salts. Alternatively, by method (2), the substrate to be resolved may be reacted with one enantiomer of a chiral compound to form a diastereomeric pair (Eliel, E. and Wilen, S. (1994) Stereochemistry of Organic Compounds, John Wiley & Sons, Inc., p. 322). Diastereomeric compounds can be formed by reacting asymmetric compounds with enantiomerically pure chiral derivatizing reagents, such as menthyl derivatives, followed by separation of the diastereomers and hydrolysis to yield the free, enantiomerically enriched compounds of the invention. A method of determining optical purity involves making chiral esters, such as a menthyl ester or Mosher ester, a-methoxy-a-(trifluoromethyl)phenyl acetate (Jacob III. (1982) J. Org. Chem. 47:4165), of the racemic mixture, and analyzing the NMR spectrum for the presence of the two atropisomeric diastereomers. Stable diastereomers can be separated and isolated by normal- and reverse-phase chromatography following methods for separation of atropisomeric naphthyl-isoquinolines (Hoye, T., WO 96/15111). Under method (3), a racemic mixture of two asymmetric enantiomers is separated by chromatography using a chiral stationary phase. Suitable chiral stationary phases are, for example, polysaccharides, in particular cellulose or amylose derivatives. Commercially available polysaccharide based chiral stationary phases are ChiralCel™ CA, OA, OB5, OC5, OD, OF, OG, OJ and OK, and ChiralpakTM AD, AS, OP(+) and OT(+). Appropriate eluents or mobile phases for use in combination with said
polysaccharide chiral stationary phases are hexane and the like, modified with an alcohol such as ethanol, isopropanol and the like. ("Chiral Liquid Chromatography" (1989) W. J. Lough, Ed. Chapman and Hall, New York; Okamoto, (1990) "Optical resolution of dihydropyridine enantiomers by High-performance liquid chromatography using phenylcarbamates of polysaccharides as a chiral stationary phase", J. of Chromatogr. 513:375-378).
The terms cis and trans are used herein in accordance with Chemical Abstracts nomenclature and include reference to the position of the substituents on a ring moiety. The absolute stereochemical configuration of the compounds according to the formulae of the application may easily be determined by those skilled in the art while using well- known methods such as, for example, X-ray diffraction or NMR.
Tautomers are organic compounds that are interconvertible by a chemical reaction called tautomerization. As most commonly encountered, this reaction results in the formal migration of a hydrogen atom or proton, accompanied by a switch of a single bond and adjacent double bond. In solutions where tautomerization is possible, a chemical equilibrium of the tautomers will be reached. The exact ratio of the tautomers depends on everal factors, including temperature, solvent, and pH. For example, the compound 9-(l- benzyl)-l,9-dihydro-6H-purin-6-one is a tautomer of 9-(l-benzyl)-6-hydroxy-9Η-purine.
The compounds of the invention may be formulated with conventional carriers and excipients, which will be selected in accord with ordinary practice. Tablets will contain excipients, glidants, fillers, binders and the like. Aqueous formulations are prepared in sterile form, and when intended for delivery by other than oral administration generally will be isotonic. Formulations optionally contain excipients such as those set forth in the "Handbook of Pharmaceutical Excipients" (1986) and include ascorbic acid and other antioxidants, chelating agents such as EDTA, carbohydrates such as dextrin, hydroxyalkylcellulose, hydroxyalkylmethylcellulose, stearic acid and the like. Subsequently, the term "pharmaceutically acceptable carrier" as used herein means any material or substance with which the active ingredient is formulated in order to facilitate its application or dissemination to the locus to be treated, for instance by dissolving,
dispersing or diffusing the said composition, and/or to facilitate its storage, transport or handling without impairing its effectiveness. The pharmaceutically acceptable carrier may be a solid or a liquid or a gas which has been compressed to form a liquid, i.e. the compositions of this invention can suitably be used as concentrates, emulsions, solutions, granulates, dusts, sprays, aerosols, suspensions, ointments, creams, tablets, pellets or powders.
Suitable pharmaceutical carriers for use in the said pharmaceutical compositions and their formulation are well known to those skilled in the art, and there is no particular restriction to their selection within the present invention. They may also include additives such as wetting agents, dispersing agents, stickers, adhesives, emulsifying agents, solvents, coatings, antibacterial and antifungal agents (for example phenol, sorbic acid, chlorobutanol), isotonic agents (such as sugars or sodium chloride) and the like, provided the same are consistent with pharmaceutical practice, i.e. carriers and additives which do not create permanent damage to mammals. The pharmaceutical compositions of the present invention may be prepared in any known manner, for instance by homogeneously mixing, coating and/or grinding the active ingredients, in a one-step or multi-steps procedure, with the selected carrier material and, where appropriate, the other additives such as surface-active agents may also be prepared by inicronisation, for instance in view to obtain them in the form of microspheres usually having a diameter of about 1 to 10 gm, namely for the manufacture of microcapsules for controlled or sustained release of the active ingredients.
Suitable surface-active agents, also known as emulgent or emulsifier, to be used in the pharmaceutical compositions of the present invention are non-ionic, cationic and/or anionic materials having good emulsifying, dispersing and/or wetting properties. Suitable anionic surfactants include both water-soluble soaps and water-soluble synthetic surface- active agents. Suitable soaps are alkaline or alkaline-earth metal salts, unsubstituted or substituted ammonium salts of higher fatty acids (Ci0-C22), e.g. the sodium or potassium salts of oleic or stearic acid, or of natural fatty acid mixtures obtainable form coconut oil or tallow oil. Synthetic surfactants include sodium or calcium salts of polyacrylic acids; fatty sulphonates and sulphates; sulphonated benzimidazole derivatives and alkylarylsulphonates. Fatty sulphonates or sulphates are usually in the form of alkaline or
alkaline-earth metal salts, unsubstituted ammonium salts or ammonium salts substituted with an alkyl or acyl radical having from 8 to 22 carbon atoms, e.g. the sodium or calcium salt of lignosulphonic acid or dodecylsulphonic acid or a mixture of fatty alcohol sulphates obtained from natural fatty acids, alkaline or alkaline-earth metal salts of sulphuric or sulphonic acid esters (such as sodium lauryl sulphate) and sulphonic acids of fatty alcohol/ethylene oxide adducts. Suitable sulphonated benzimidazole derivatives preferably contain 8 to 22 carbon atoms. Examples of alkylarylsulphonates are the sodium, calcium or alcanolamine salts of dodecylbenzene sulphonic acid or dibutyl- naphtalenesulphonic acid or a naphtalene-sulphonic acid/formaldehyde condensation product. Also suitable are the corresponding phosphates, e.g. salts of phosphoric acid ester and an adduct of p-nonylphenol with ethylene and/or propylene oxide, or phospholipids. Suitable phospholipids for this purpose are the natural (originating from animal or plant cells) or synthetic phospholipids of the cephalin or lecithin type such as e.g. phosphatidylethanolamine, phosphatidylserine, phosphatidylglycerine, lysolecithin, cardiolipin, dioctanylphosphatidyl-choline, dipalmitoylphoshatidyl -choline and their mixtures.
Suitable non-ionic surfactants include polyethoxylated and polypropoxylated derivatives of alkylphenols, fatty alcohols, fatty acids, aliphatic amines or amides containing at least 12 carbon atoms in the molecule, alkylarenesulphonates and dialkylsulphosuccinates, such as polyglycol ether derivatives of aliphatic and cycloaliphatic alcohols, saturated and unsaturated fatty acids and alkylphenols, said derivatives preferably containing 3 to 10 glycol ether groups and 8 to 20 carbon atoms in the (aliphatic) hydrocarbon moiety and 6 to 18 carbon atoms in the alkyl moiety of the alkylphenol. Further suitable non- ionic surfactants are water-soluble adducts of polyethylene oxide with poylypropylene glycol, ethylenediaminopolypropylene glycol containing 1 to 10 carbon atoms in the alkyl chain, which adducts contain 20 to 250 ethyleneglycol ether groups and/or 10 to 100 propyleneglycol ether groups. Such compounds usually contain from 1 to 5 ethyleneglycol units per propyleneglycol unit. Representative examples of non-ionic surfactants are nonylphenol -polyethoxyethanol, castor oil polyglycolic ethers, polypropylene/polyethylene oxide adducts, tributylphenoxypolyethoxyethanol, polyethyleneglycol and octylphenoxypolyethoxyethanol. Fatty acid esters of polyethylene
sorbitan (such as polyoxyethylene sorbitan trioleate), glycerol, sorbitan, sucrose and pentaerythritol are also suitable non-ionic surfactants.
Suitable cationic surfactants include quaternary ammonium salts, particularly halides, having 4 hydrocarbon radicals optionally substituted with halo, phenyl, substituted phenyl or hydroxy; for instance quaternary ammonium salts containing as N-substituent at least one C8C22 alkyl radical (e.g. cetyl, lauryl, palmityl, myristyl, oleyl and the like) and, as further substituents, unsubstituted or halogenated lower alkyl, benzyl and/or hydroxy-lower alkyl radicals.
A more detailed description of surface-active agents suitable for this purpose may be found for instance in "McCutcheon's Detergents and Emulsifiers Annual" (MC Publishing Crop., Ridgewood, New Jersey, 1981), "Tensid-Taschenbucw1, 2 d ed. (Hanser Verlag, Vienna, 1981) and "Encyclopaedia of Surfactants, (Chemical Publishing Co., New York, 1981).
Compounds of the invention and their physiologically acceptable salts (hereafter collectively referred to as the active ingredients) may be administered by any route appropriate to the condition to be treated, suitable routes including oral, rectal, nasal, topical (including ocular, buccal and sublingual), vaginal and parenteral (including subcutaneous, intramuscular, intravenous, intradermal, intrathecal and epidural). The preferred route of administration may vary with for example the condition of the recipient.
While it is possible for the active ingredients to be administered alone it is preferable to present them as pharmaceutical formulations. The formulations, both for veterinary and for human use, of the present invention comprise at least one active ingredient, as above described, together with one or more pharmaceutically acceptable carriers therefore and optionally other therapeutic ingredients. The carrier(s) optimally are "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof. The formulations include those suitable for oral, rectal, nasal, topical (including buccal and sublingual), vaginal or parenteral (including subcutaneous, intramuscular, intravenous, intradermal, intrathecal and epidural) administration. The formulations may conveniently be presented in unit dosage form and
may be prepared by any of the methods well known in the art of pharmacy. Such methods include the step of bringing into association the active ingredient with the carrier which constitutes one or more accessory ingredients, hi general the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.
Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as solution or a suspension in an aqueous liquid or a non-aqueous liquid; or as an oil-in- water liquid emulsion or a water- in-oil liquid emulsion. The active ingredient may also be presented as a bolus, electuary or paste.
A tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free- flowing form such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, preservative, surface active or dispersing agent. Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent. The tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the active ingredient therein. For infections of the eye or other external tissues e.g. mouth and skin, the formulations are optionally applied as a topical ointment or cream containing the active ingredient(s) in an amount of, for example, 0.075 to 20% w/w (including active ingredient(s) in a range between 0.1% and 20% in increments of 0.1% w/w such as 0.6% w/w, 0.7% w/w, etc), preferably 0.2 to 15% w/w and most preferably 0.5 to 10% w/w. When formulated in an ointment, the active ingredients may be employed with either a paraffinic or a water-miscible ointment base. Alternatively, the active ingredients may be formulated in a cream with an oil-in-water cream base. If desired, the aqueous phase of the cream base may include, for example, at least 30% w/w of a polyhydric alcohol, i.e. an alcohol having two or more hydroxyl groups such as propylene glycol, butane 1,3-diol, mannitol, sorbitol, glycerol and polyethylene glycol (including PEG400) and mixtures thereof. The topical formulations may desirably
include a compound which enhances absorption or penetration of the active ingredient through the skin or other affected areas. Examples of such dermal penetration enhancers include dimethylsulfoxide and related analogs.
The oily phase of the emulsions of this invention may be constituted from known ingredients in a known manner. While the phase may comprise merely an emulsifier (otherwise known as an emulgent), it desirably comprises a mixture of at least one emulsifier with a fat or an oil or with both a fat and an oil. Optionally, a hydrophilic emulsifier is included together with a lipophilic emulsifier which acts as a stabilizer. It is also preferred to include both an oil and a fat. Together, the emulsifier(s) with or without stabilizer(s) make up the so-called emulsifying wax, and the wax together with the oil and fat make up the so-called emulsifying ointment base which forms the oily dispersed phase of the cream formulations.
The choice of suitable oils or fats for the formulation is based on achieving the desired cosmetic properties, since the solubility of the active compound in most oils likely to be used in pharmaceutical emulsion formulations is very low. Thus the cream should optionally be a non-greasy, non-staining and washable product with suitable consistency to avoid leakage from tubes or other containers. Straight or branched chain, mono- or dibasic alkyl esters such as di-isoadipate, isocetyl stearate, propylene glycol diester of coconut fatty acids, isopropyl myristate, decyl oleate, isopropyl palmitate, butyl stearate, 2-ethylhexyl palmitate or a blend of branched chain esters known as Crodamol CAP may be used, the last three being preferred esters. These may be used alone or in combination depending on the properties required. Alternatively, high melting point lipids such as white soft paraffin and/or liquid paraffin or other mineral oils can be used. Formulations suitable for topical administration to the eye also include eye drops wherein the active ingredient is dissolved or suspended in a suitable carrier, especially an aqueous solvent for the active ingredient. The active ingredient is optionally present in such formulations in a concentration of 0.5 to 20%, advantageously 0.5 to 10% particularly about 1.5% w/w. Formulations suitable for topical administration in the mouth include lozenges comprising the active ingredient in a flavored basis, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert basis such as gelatin
and glycerin, or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.
Formulations for rectal administration may be presented as a suppository with a suitable base comprising for example cocoa butter or a salicylate. Formulations suitable for nasal administration wherein the carrier is a solid include a coarse powder having a particle size for example in the range 20 to 500 microns (including particle sizes in a range between 20 and 500 microns in increments of 5 microns such as 30 microns, 35 microns, etc), which is administered in the manner in which snuff is taken, i.e. by rapid inhalation through the nasal passage from a container of the powder held close up to the nose. Suitable formulations wherein the carrier is a liquid, for administration as for example a nasal spray or as nasal drops, include aqueous or oily solutions of the active ingredient. Formulations suitable for aerosol administration may be prepared according to conventional methods and may be delivered with other therapeutic agents. Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations containing in addition to the active ingredient such carriers as are known in the art to be appropriate.
Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.
Preferred unit dosage formulations are those containing a daily dose or unit daily sub- dose, as herein above recited, or an appropriate fraction thereof, of an active ingredient. It should be understood that in addition to the ingredients particularly mentioned above the formulations of this invention may include other agents conventional in the art having
regard to the type of formulation in question, for example those suitable for oral administration may include flavoring agents.
Nucleoside analogs of the invention can be used to provide controlled release pharmaceutical formulations containing as active ingredient one or more compounds of the invention ("controlled release formulations") in which the release of the active ingredient can be controlled and regulated to allow less frequency dosing or to improve the pharmacokinetic or toxicity profile of a given invention compound. Controlled release formulations adapted for oral administration in which discrete units comprising one or more compounds of the invention can be prepared according to conventional methods.
Additional ingredients may be included in order to control the duration of action of the active ingredient in the composition. Control release compositions may thus be achieved by selecting appropriate polymer carriers such as for example polyesters, polyamino acids, polyvinyl pyrrolidone, ethylene-vinyl acetate copolymers, methylcellulose, carboxymethylcellulose, protamine sulfate and the like. The rate of drug release and duration of action may also be controlled by incorporating the active ingredient into particles, e.g. microcapsules, of a polymeric substance such as hydrogels, polylactic acid, hydroxymethylcellulose, polyethyl methacrylate and the other above-described polymers. Such methods include colloid drug delivery systems like liposomes, microspheres, microemulsions, nanoparticles, nanocapsules and so on. Depending on the route of administration, the pharmaceutical composition may require protective coatings. Pharmaceutical forms suitable for injectionable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation thereof. Typical carriers for this purpose therefore include biocompatible aqueous buffers, ethanol, glycerol, propylene glycol, polyethylene glycol and the like and mixtures thereof.
In view of the fact that, when several active ingredients are used in combination, they do not necessarily bring out their joint therapeutic effect directly at the same time in the mammal to be treated, the corresponding composition may also be in the form of a medical kit or package containing the two ingredients in separate but adjacent repositories or compartments, hi the latter context, each active ingredient may therefore
be formulated in a way suitable for an administration route different from that of the other ingredient, e.g. one of them may be in the form of an oral or parenteral formulation whereas the other is in the form of an ampoule for intravenous injection or an aerosol.
Prodrugs
Another embodiment of this invention relates to various precursor or " pro-drug " forms of the nucleoside analogs of the present invention. It may be desirable to formulate the nucleoside analogs of the present invention in the form of a chemical species which itself is not significantly biologically-active, but which when delivered to the animal or human will undergo a chemical reaction catalysed by the normal function of the body, inter alia, enzymes present in the stomach or in blood serum, said chemical reaction having the effect of releasing a nucleoside analog as defined herein. The term "pro-drug" thus relates to these species which are converted in vivo into the active pharmaceutical ingredient. The pro-drugs of the present invention can have any form suitable to the formulator, for example, esters are non-limiting common pro-drug forms. In the present case, however, the pro-drug may necessarily exist in a form wherein a covalent bond is cleaved by the action of an enzyme present at the target locus. For example, a C-C covalent bond may be selectively cleaved by one or more enzymes at said target locus and, therefore, a pro-drug in a form other than an easily hydrolysable precursor, inter alia an ester, an amide, and the like, may be used. The counterpart of the active pharmaceutical ingredient in the pro-drug can have different structures such as an amino acid or peptide structure, alkyl chains, sugar moieties and others as known in the art. For the purposes of the present invention the term "therapeutically suitable pro-drug" is defined herein as "a nucleoside analog modified in such a way as to be transformed in vivo to the therapeutically active form, whether by way of a single or by multiple biological transformations, when in contact with the tissues of the animal or human to which the pro-drug has been administered, and without undue toxicity, irritation, or allergic response, and achieving the intended therapeutic outcome ".
In a particular embodiment, the present invention relates to the phosphate or phosphonate prodrugs of the nucleoside analogs of the invention, thereby including but not limited to phosphate or phosphonate esters, amidates or esteramidates, wherein the phosphate or phosphonate can be mono- or disubstituted. Examples of such esters comprise alkyl esters, alkenyl esters, alkynyl esters, alkoxyalkyl esters, alkoxyalkenyl esters such as octyl, tetracosyl, hexadecyloxypropyl, octadecyloxyethyl, oleyloxypropyl, tetradecyloxypropyl, octadecyloxypropyl, oleyloxyethyl, l-O-octadecyl-2-O-benzyl- glyceryl and the like as described in the prior art (i.e. Keith K.A. et al. Antimicrobial agents and chemotherapy 2004, 1869-1871; Ciesla, S.L. et al Antiviral Research 2003, 59, 163-171 and are incorporated herein by reference), hi a particular embodiment the esters have at least 16-carbon atoms. Also conversion to the cyclic ester with a lower polarity or neutral hydrophobic cyclic diester are possible. Also the di- or tri-phosphate are included in the nucleoside analogs of the invention.
It should be understood that phosphate or phosphonate prodrugs are very well known in the art as for example described in U.S. Patent No. 6,225,460 and U.S. Patent No. 5,977,089, which are incorporated by reference herein. hi a particular embodiment, the phosphate or phosphonate prodrugs are esters or amidates of alkyl; alkenyl; alkynyl; cycloalkyl; cycloalkenyl; cycloalkynyl; aryl; arylalkyl; heterocyclic ring; heterocyclic ring-alkyl; acyloxyalkyl; acyloxyalkenyl; acyloxyalkynyl; acyloxyaryl; acyloxyarylalkyl; acyloxyarylalkenyl; acyloxyarylalkynyl; dialkylcarbonate; alkylarylcarbonate; alkylalkenylcarbonate; alkylalkynylcarbonate; alkenylarylcarbonate; alkynyl-arylcarbonate; alkenylalkynylcarbonate; dialkenylcarbonate; dialkynyl-carbonate; wherein said alkyl, alkenyl and alkynyl can contain a heteroatom in or at the end of the hydrocarbon chain, said heteroatom being selected from the group consisting of oxygen, sulfur and nitrogen; or the prodrugs are further selected from substituents known for phosphates or phosphonates described as anti-viral agents. hi yet another particular embodiment, the phoshate, respectively the phosphonate groups are according to the Formulae (P-2) or (P-3) respectively,
(P-2) (P-3) wherein
- each R30 and R31 are independently selected from the group consisting of hydrogen; (- PO3R32VPO3R33R34; alkyl; alkenyl; alkynyl; cycloalkyl; cycloalkenyl; cycloalkynyl; aryl; arylalkyl; heterocyclic ring; heterocyclic ring-alkyl; acyloxyalkyl; acyloxyalkenyl; acyloxyalkynyl; acyloxyaryl; acyloxyarylalkyl; acyloxyarylalkenyl; acyloxyarylalkynyl; dialkylcarbonate; alkylarylcarbonate; alkylalkenylcarbonate; alkylalkynylcarbonate; alkenylarylcarbonate; alkynyl-arylcarbonate; alkenylalkynylcarbonate; dialkenylcarbonate; dialkynyl-carbonate; wherein said alkyl, alkenyl and alkynyl can contain a heteroatom in or at the end of the hydrocarbon chain, said heteroatom being selected from the group consisting of oxygen, sulfur and nitrogen; and R30 and R31 are further selected from substituents known for phosphonates described as anti- viral agents;
- R32, R33 and R34 are each independently selected from the group consisting of hydrogen; alkyl; alkenyl; alkynyl; cycloalkyl; cycloalkenyl; cycloalkynyl; aryl; arylalkyl; heterocyclic ring; heterocyclic ring-alkyl; acyloxyalkyl; wherein said alkyl, alkenyl and alkynyl can contain a heteroatom in or at the end of the hydrocarbon chain, said heteroatom being selected from the group consisting of oxygen, sulfur and nitrogen; and R3 , R33 and R 4 are further selected from substituents known for phosphonates described as anti-viral agents;
- m is 0 or 1 ;
- q is 1, 2, 3, 4, 5 or 6.
It is understood that the prodrugs can also be in the form of amidates wherein in a particular embodiment the oxygen of each of OR30 and OR31 can be a nitrogen such as NHR30 and NHR31.
Method of preparation
The nucleoside analogs of the invention according to the formulae of the application can be prepared while using a series of chemical reactions known to those skilled in the art, altogether making up the process for preparing said compounds and exemplified further. The processes described further are only meant as examples and by no means are meant to limit the scope of the present invention.
The compound of this invention can be prepared by the following general methods:
Method A (see Example 3): The nucleoside analogs with a structure in analogy with the nucleoside analogs
11, 12, 17, 18, 19, 21, 22, 28, 30, 31, 51, and 52 can be prepared by reaction of 6- chloropurine or 2,6-dichloropurine or any other pyrimidine or purine heterocycle (or their aza or deaza analogs) with compounds of the formulae I to IX and XX and XXI (and analoguous structures), performed under Mitsunobu's conditions. The reaction may generally be carried out in tetrahydrofurane or 1,4-dioxane in the presence of triphenylphosphine and diethyl or diisopropyl azodicarboxylate at a temperature from room temperature (about 20 °C) to the boiling point of the solvent used. The compounds thus obtained can be separated from the reaction mixture by chromatography.
Furthermore, starting from the nucleoside analogs 51 or 52, the nucleoside analogs 35 and 36 can be prepared by the treatment of the benzoates 51 or 52 with a reducing agent such as lithium aluminium hydride or diisobutyl aluminium hydride in tetrahydrofurane at a temperature from -78 °C to 0 °C (Example 4).
Method B:
General Method B
The nucleoside analogs with a structure in analogy with the nucleoside analog 23 (Example 5) can be prepared from the amine of the formula X and analoguous structures like compounds 25, 27 and 57 can for example be prepared with the starting materials XXII, XXIII or XXIV:
by the following two step reaction:
1. Treatment with 5-amino-4,6-dichloropyrimidine can be performed in alcohol (e.g. ethanol, 1-propanol, 2-propanol , 1-butanol) in the presence of triethylamine at a temperature from 100 °C to 110 °C.
2. The next step, ring-closure can be carried out in trimethyl or triethyl orthoformate in the presence of acid such as concentrated hydrochloric acid, sulfuric acid or trifluoroacetic acid. Chromatography or crystallization from aqueous ethanol or aqueous methanol can be used for isolation of thus obtained compounds from the reaction mixture.
The nucleoside analogs with a structure in analogy with the nucleoside analogs 1, 14, 16, 24, 26, 32, 58, 59, 60, 62, 63, 64, 65 and 66 (Example 6) can be prepared from the amines of the formula XI- XXXIII (and analoguous structures) by the same procedure as described for 23 followed by hydrolysis which can be performed in the mixture of tetrahydrofurane or dioxane and diluted mineral acid (e.g. hydrochloric acid, sulfuric acid).
Intermediate amines for method B:
• The amines of the formulae XI- XIII (and analoguous structures) can be prepared from the unsaturated diols having the formulae XVI to XVIII
by the following method (reaction procedure (2)):
(reaction procedure 2, wherein Z1 is a methylene, an ethylene group, an oxygen atom).
The reaction procedure 2 can be effected by reacting XVI, XVII or XVIII with benzyl azidoformate in the presence of a small amount of an inert solvent such as toluene, dioxane at a temperature from around 68 °C to 110 °C. This is followed be hydrogenolysis of the obtained benzyloxycarbonylamine which can be performed in an organic solvent (e.g. methanol, ethanol) in the presence of palladium on carbon at room temperature.
• The unsaturated amine of the formula XIV can be obtained by multistep reaction procedure(l) (Example 7):
(1)
Commercially available 5-norbornen-2-yl acetate can be treated with ethyl azidoformate in toluene at 80 °C and then with silica gel. Unsaturated carbamate can be separated from thus obtained mixture by chromatography. Acetyl group can be removed with potasium carbonate in methanol or sodium methoxide in methanol. Conversion of the obtained exo- hydroxy to the endo-hydroxy derivative can be performed by oxidation with pyridinium dichromate followed by reduction thus obtained ketone with sodium borohydride. The free amine (XIV) can be obtained by deprotection with potassium hydroxide in boiling aqueous ethanol.
• The amine of the formula (XV) can be prepared from the unsaturated amine having the formula (XIV) by hydrogenation on palladium catalyst in an alcohol (e.g. methanol, ethanol)..
• The nucleoside analogs with a structure in analogy with the nucleoside analogs 2 and 20 (Example 8) can be prepared by the treatment of the compound 1 or 16 respectively, with methyl iodide in dimethylformamide.
• The nucleoside analogs with a structure in analogy with the nucleoside analog 7 (Example 10) can be prepared by the treatment of the compound 1 with benzyl bromide and sodium hydride in dimethylformamide.
• The nucleoside analogs with a structure in analogy with the nucleoside analog 6 (Examplel l) can be prepared by the treatment of the compound 1 with phenyl-
(methoxy-L-alaninyl)-phosphorochloridate in the presence of 1-methylimidazole in tetrahydrofurane.
• The nucleoside analogs with a structure in analogy with the nucleoside analogs 8 (Example 12) can be prepared by by the treatment of the compound 1 with thionyl chloride in hexamethylphosphortriamide. With the same procedure, for example compounds 67 and 68 can be prepared from their hydroxy-comprising analogs.
• The compounds as 69, 70, 71 and 72 and analogs thereof can be prepared by the treatment of their hydroxyl-comprising counterparts like compound 14 with
(diethylamino)sulfur trifluoride (DAST) in a mixture dichloromethane and pyridine at a temperature from 15 °C to 40 0C.
• Modifications like in compound 42 can be prepared by the treatment of the compound 31 with peracid (e.g. peracetic acid, m-chloroperbenzoic acid) in chlorinated solvent
(e.g. chloroform, dichloromethane). Also dihydroxy-substituents like in compound 37 can be introduced starting from compound 31 by the treatment with osmium tetroxide and 4-methylmorpholine-4-oxide in a mixture of water and methanol.
• Deaza-purine analogs like the compound below
can be prepared in analogy with the purine analogs. For examlpe, the compound above can be prepared by the treatment of the compound I with 4-chloro-7H-pyrrolo[2,3- cTjpyrimidine under conditions of the Mitsunobu reaction.
The purine base of the nucleoside analoges can be modified using the known methods as shown for compound I in the Scheme 1.
Scheme 1: Modification of a purine base of compounds of the invention.
All other nucleoside analogs not explicitely mentioned in this general description can be prepared by using the methods as described herein and further combined with the knowledge of a person skilled in the art. This counts for pyrimidines, their aza or deaza analogs or different substituents on the pyrimidine or purine heterocycles.
Examples
The following examples are provided for the purpose of illustrating the present invention and should in no way be interpreted as limiting the scope thereof.
Table 1: Structures of example nucleoside analogs of the invention and their respective codes.
EXAMPLE 1 : ANTIVIRAL SCREENING - ANTI-CBV ASSAY
Anti-Coxsackie virus assay: Ninety-six-well cell culture plates can be seeded with Vero cells in DMEM medium containing 10 fetal calf serum (FCS) so that cells reache confluency 24 -48 hr later. Medium can then be removed and serial 5-fold dilutions of the test compounds can be added in a total volume of 100 μl, after which the virus inoculum (100 μl) can be added to each well. The virus inoculum used results normally in a 90 - 100 % destruction of the cell monolayer after 5 days incubation at 37°C. Uninfected cells and cells receiving virus without compound can be included in each asay plate. After 5
days, the medium can be removed and 90 μl of DMEM-FCS and 10 μl of MTS/PMS solution (Promega) was added to each well. Following a 2 h incubation period at 37°C, the optical density of the wells can be read at 498 nm in a microplate reader. The 50% effective concentration (EC50) value can than be defined as the concentration of compound that protects 50% of the cell monolayer from virus-induced cytopathic effect.
Cytostatic activity assays: All assays are performed in 96-well microtiter plates. To each well are added 5 - 7.5 x 104 Vero cells and a given amount of the test compound. The cells are allowed to proliferate for 72 h at 37°C in a humidified CO2-controlled atmosphere. At the end of the incubation period the effect of the compounds on cell proliferation is measured using the MTS/PMS method (Promega). The CC50 (50% cytostatic concentration) was defined as the concentration of the compound that reduced the number of cells by 50%.
Many nucleoside analogs of the invention showed an EC50 of between 5 μM and 50 μM, while the CC50 was always higher than 200 μM. As an example, results of some nucleoside analogs in the anti-Coxsackie virus B3 (CBV) assay are shown in table 2.
Table 2: anti-CBV activity of some nucleoside analogs of the invention
EXAMPLE 2: MATERIALS AND GENERAL PREPARATION METHODS
For all reactions, analytical grade solvents were used. All moisture sensitive reactions were carried out in oven-dried glassware (135 °C) under a argon atmosphere. All standard equipment was used for the chemical preparation and analysis. For example, a Varian Unity 500 MHz spectrometer or a 200 MHz Varian Gemini apparatus can used for 1H NMR and 13C NMR. Exact mass measurements can be performed on a quadrupole time-of-flight mass spectrometer (Q-Tof-2, Micromass, Manchester, UK) equipped with a standard electrospray-ionization (ESI) interface; samples can be infused in i-PrOH/H2O 1:1 at 3 μL/min.
EXAMPLE 3: SYNTHESIS OF NUCLEOSIDE ANALOGS OF THE INVENTION SUCH AS 17, VIA MITSUNOBU REACTION (METHOD A)
To a mixture of bicyclo[2.2.1]heptan-2-ol (500 mg, 4.45 mmol), triphenylphosphine (1.52 g, 5.79 mmol) and 6-chloropurine (757 mg, 4.90 mmol) in THF (35 ml) was dropwise added solution of the diisopropyl azadicarboxylate (1.19 ml, 5.79 mmol) in THF (15 ml). The resulting mixture was stirred overnight (TLC control) and then heated to reflux for 2 hours. The reaction mixture was evaporated and the residue was chromatographed on silica gel column (200 g) in toluene - ethylacetate (6:1 → 4:1) and crystallized from water-methanol. It was obtained 430 mg (39%) of 9-[(lR*,2R*,4S*)- bicyclo[2.2.1]hept-2-yl]-6-chloro-9H-purine (~ example isomeric pure form of 17), m.p. = 104.2 - 104.8 0C. For Ci2H13ClN4 (248.7) calculated: 57.95% C, 5.27% H, 14.25% Cl,
22.53% N; found: 57.93% C, 5.32% H, 14.29% Cl, 22.34% N. 1H NMR (DMSO-(I6): 1.27 m, 1 H (H-5'exo); 1.28 m, 1 H (H-7'b); 1.40 dddd, 1 H, Jgem = 12.1, J(6'ex,5'exo) = 9.1, J(6'ex,5'en) = 4.1, J(6'ex,7'a) = 2.3 (H-6'exo); 1.54 m, 1 H (H-5'endo); 1.62 tt, 1 H, Jgem = J(6'en,5'en) = 12.2, J(6'en,5'ex) = J(6'en,l ') = 4.5 (H-6'endo); 1.71 dm, 1 H, Jgem = 10.3 (H-7'a); 2.00 ddd, 1 H, Jgem = 13.4, J(3'ex,2') = 8.5, J(3'ex,7b) = 2.3 (H-3exo); 2.07 m, 1 H (H-3'endo); 2.43 bt, 1 H, J(4',3'endo) = J(4',5'en) = 4.2 (H-4'); 2.55 bd, 1 H, J(l ',6'en) = 4.6 (H-I '); 4.56 ddd, 1 H, J(2',3'ex) = 8.4, J(2',3'en) = 4.5, J(2',7'b) = 0.9 (H-2'); 8.77 s, 1 H (H-2); 8.85 s, 1 H (H-8). 13C NMR (DMSO-(I6): 26.94 (C-6'); 27.95 (C-5'); 35.82 (C-7'); 35.93 (C-4'); 37.76 (C-3'); 42.16 (C-I '); 58.37 (C-2'); 131.43 (C-5); 145.62 (C-8); 149.11 (C-6); 151.45 (C-2); 152.11 (C-4).
According to the same procedure, there were obtained the following compounds:
• 9-[(lR*,2R*,4S*)-Bicyclo[2.2.1]hept-2-yl]-2,6-dichloro-9H-purine (~ example isomeric pure form of 18), m.p. = 163.3 - 164 °C. For Ci2H12Cl2N4 (283.2) calculated: 50.90% C, 4.27% H, 25.04% Cl, 19.79% N; found: 50.96% C, 4.18%
H, 24.94% Cl, 19.71% N. 1H NMR (DMSO-de): 1.28 m, 1 H (H-5'endo); 1.29 dm, 1 H, Jgem = 10.3 (H-7'a); 1.40 dddd, 1 H, Jgem = 12.1, J(6'en,5'endo) = 8.9, J(6'en,5'ex) = 4.2, J(6'en,7'b) = 2.3 (H-6'endo); 1.53 m, 1 H (H-5'exo); 1.62 tt, 1 H, Jgem = J(6'ex,5'ex) = 12.2, J(6'ex,5'en) = J(6'ex,l ') = 4.5 (H-6'exo); 1.69 dm, 1 H, Jgem = 10.4 (H-7'b); 2.00 m, 2 H (H-3'endo and H-3'exo); 2.42 m, 1 H (H-4');
2.57 dm, 1 H, J(l ',6'ex) = 4.6 (H-I '); 4.49 m, 1 H (H-2'); 8.89 s, 1 H (H-8). 13C NMR (DMSO-d6): 26.92 (C-6'); 27.89 (C-5'); 35.89 (C-7'); 35.92 (C-4'); 37.90 (C-3'); 41.95 (C-I '); 58.48 (C-2'); 131.05 (C-5); 146.56 (C-8); 149.65 and 150.82 (C-2 and C-6); 153.63 (C-4). • 6-Chloro-9-[(lS,2S,4S)-l,7,7-trimethylbicyclo[2.2.1]hept-2-yl]-9H-purine (~ example isomeric pure form of 19), m.p. = 132.3 - 134.5 0C. [α]D +25.2 (c 0.352, methanol). For C15Hi9ClN4 (290.8) calculated: 61.96% C, 6.59% H, 12.19% Cl, 19.27% N; found: 61.89% C, 6.70% H, 12.31% Cl, 19.07% N. 1H NMR (DMSO- d6): 0.65 s, 3 H (1 '-CH3); 0.85 s, 3 H and 0.99 s, 3 H (2 x 7'-CH3); 1.33 ddd, 1 H, Jgem = 12.3, J(5'en,6'en) = 9.3, J(5'en,6'ex) = 4.9 (H-5'endo); 1.45 ddd, 1 H, Jgem =
12.4, J(6'en,5'en) = 9.2, J(6'en,5'ex) = 3.6 (H-6'endo); 1.66 dt, 1 H, Jgem =
J(6'ex,5'ex) = 12.2, J(6'ex,5'en) = 4.9 (H-6'exo); 1.82 m, 1 H (H-5'exo); 1.95 t, 1 H, J(4',3'ex) = J(4',5'ex) = 4.2 (H-4'); 1.99 dd, 1 H, Jgem = 13.2, J(3'en,2') = 9.6 (H-3'endo); 2.77 dddd, 1 H, Jgem = 13.3, J(3'ex,2') = 6.9, J(3'ex,4') = 4.0, J(3'ex,5'ex) = 3.2 (H-3'exo); 4.70 dd, 1 H, J(2',3'en) = 9.5, J(2',3'ex) = 6.9 (H-2'); 8.79 s, 1 H (H-2); 9.00 s, 1 H (H-8). 13C NMR (DMSO-de): 12.06 (1 '-CH3); 19.82 and 21.13 (2 x 7'-CH3); 26.55 (C-5'); 34.31 (C-3'); 36.64 (C-6'); 44.59 (C-4'); 47.24 (C-7'); 50.66 (C-I '); 63.15 (C-2'); 131.18 (C-5); 146.77 (C-8); 149.28 (C-6); 151.41 (C-2); 153.48 (C-4). • 6-Chloro-9- {[(1 S,2S,5S)-6,6-dimethylbicyclo[3.1. l]hept-2-yl]methyl} -9H-purine (~ example isomeric pure form of 21), m.p. = 88.5 - 89.8 °C. [α]D -12.2 (c 0.779, methanol). For Ci5H19ClN4 (290.8) calculated: 61.96% C, 6.59% H, 12.19% Cl, 19.27% N; found: 61.91% C, 6.59% H, 12.29% Cl, 18.96% N. 1H NMR (DMSO- de): 0.74 s, 3 H and 1.12 s, 3 H (2 x 6'-CH3); 1.37 - 1.48 m, 3 H (H-3'a, H-3'b and H-7'a); 1.62 dt, 1 H, J(l ',7'b) = J(I ',5') = 5.4, J(I ',2') = 1.0 (H-I '); 1.70 m, 2 H (H-4'); 1.83 m, 1 H (H-5'); 2.06 dt, 1 H, Jgem = 10.2, J(7'b,l ') = J(7'b,5') = 5.8 (H-
7'b); 2.60 m, 1 H (H-2'); 4.13 m, 2 H (CH2N); 8.73 s, 1 H (H-8); 8.77 s, 1 H (H-2). 13C NMR (DMSO-d6): 18.89 (C-3'); 20.08 (6'-CH3); 23.06 (C-7'); 23.71 (C-4'); 26.57 (6'-CH3); 35.03 (C-2'); 39.10 (C-6'); 40.30 (C-5'); 42.55 (C-I '); 48.47 (CH2N); 130.89 (C-5); 148.00 (C-8); 149.19 (C-6); 151.71 (C-2); 152.37 (C-4). • 2,6-Dichloro-9-{[(lS,2S,5S)-6,6-dimethylbicyclo[3.1.1]hept-2-yl]methyl}-9H- purine (~ example isomeric pure form of 22), m.p. = 104.6 - 106.5 °C. [α]D -11.0 (c 0.504, methanol). For C15Hi8Cl2N4 (325.3) calculated: 55.39% C, 5.58% H, 21.80% Cl, 17.23% N; found: 55.39% C, 5.49% H, 22.09% Cl, 16.96% N. 1H NMR (DMSOd6): 0.76 s, 3 H and 1.14 s, 3 H (2 x 6'-CH3); 1.35 - 1.50 m, 3 H (H-3'a, H-3'b and H-7'a); 1.64 t, 1 H, J(I ',7 'b) = J(I ', 5') = 5.4 (H-I '); 1.71 m, 2 H (H-4');
1.84 m, 1 H (H-5'); 2.06 dt, 1 H, Jgem = 10.1, J(7'b,l ') = J(7'b,5') = 5.8 (H-7'b); 2.56 m, 1 H (H-2'); 4.08 m, 2 H (CH2N); 8.76 s, 1 H (H-8). 13C NMR (DMSO-d6): 18.87 (C-3'); 20.08 (6'-CH3); 23.04 (C-7'); 23.70 (C-4'); 26.57 (6'-CH3); 34.78 (C- 2'); 39.12 (C-6'); 40.30 (C-5'); 42.48 (C-I '); 48.68 (CH2N); 130.58 (C-5); 148.93 (C-8); 149.76 and 151.08 (C-2 and C-6); 153.87 (C-4).
• 6-Chloro-9-{[(lR,5S)-6,6-dimethylbicyclo[3.1.1]hept-2-en-2-yl]methyl}-9H-purine (~ example isomeric pure form of 28), m.p. = 83.3 - 84.8 °C. [α]D -33.0 (c 0.721, methanol). For C15H17ClN4 (288.8) calculated: 62.39% C, 5.93% H, 12.28% Cl, 19.40% N; found: 62.56% C, 6.06% H, 12.07% Cl, 19.22% N. 1H NMR (DMSO- d6): 0.51 s, 3 H (6'-CH3); 1.05 d, 1 H, Jgem = 8.6 (H-7'a); 1.13 s, 3 H (6'-CH3); 2.01 m, 1 H (H-5'); 2.07 dt, 1 H, J(l '-7'b) = J(l '-5') = 5.6, J(I '-3') = 1.6 (H-I'); 2.13 dm, 1 H, Jgem = 18.0 (H-4'a); 2.25 dm, 1 H, Jgem = 18.1 (H-4'b); 2.31 dt, 1 H, Jgem = 8.6, J(7'b,l ') = J(7'b,5') = 5.6 (H-7'b); 4.83 m, 2 H (CH2N); 5.48 m, 1 H (H-3'); 8.69 s, 1 H (H-8); 8.78 s, 1 H (H-2). 13C NMR (DMSO-d6): 20.83 and 25.93 (2 x 6'-CH3); 30.87 (C-7'); 31.11 (C-4'); 37.76 (C-6'); 40.09 (C-5'); 43.24 (C-I '); 48.20
(CH2N); 121.17 (C-3'); 130.86 (C-5); 142.52 (C-2'); 147.78 (C-8); 149.24 (C-6); 151.85 (C-2); 152.16 (C-4).
• 6-Chloro-9-[(lS,2R,4R)-3,3-dimethylbicyclo[2.2.1]hept-2-yl]-9H-purine (~ example isomeric pure form of 30), m.p. = 112.3 - 114 °C. [α]D +3.0 (c 0.231, methanol). For C14H17ClN4 (276.8) calculated: 60.76% C, 6.19% H, 12.81% Cl,
20.24% N; found: 60.48% C, 6.36% H, 12.57% Cl, 19.79% N. 1H NMR (DMSO- d6): 0.39 s, 3 H and 1.27 s, 3 H (2 x 3'-CH3); 1.40 - 1.48 m, 3 H (H-5 'ex, H-6'en and H-7'a); 1.73 m, 2 H (H-5 'en and H-6'ex); 1.92 dm, 1 H, J(4',5'ex) = 3.6 (H- 4'); 2.28 dm, 1 H, Jgem = 10.8 (H-7'b); 2.70 dm, 1 H, J(I ',6'ex) = 4.8 (H-I '); 4.15 d, 1 H, J(2',7'a) = 1.6 (H-2'); 8.78 s, 1 H (H-8); 8.78 s, 1 H (H-2). 13C NMR
(DMSO-Ci6): 23.37 (3'-CH3); 23.59 (C-5'); 26.14 (3'-CH3); 28.22 (C-6'); 37.09 (C- T); 42.68 (C-I '); 44.46 (C-3'); 48.03 (C-4'); 68.08 (C-2'); 131.57 (C-5); 145.68 (C-8); 149.22 (C-6); 151.82 (C-2); 152.86 (C-4).
• 9-[(lR*,2S*,4R*)-Bicyclo[2.2.1]hept-5-en-2-yl]-6-chloro-9H-purine (~ example isomeric pure form of 31), m.p. = 117.5 - 118.5 °C . For C12H11ClN4 (246.7) calculated: 58.42% C, 4.49% H, 14.37% Cl, 22.71% N; found: 58.44% C, 4.38% H, 14.34% Cl, 22.44% N. 1H NMR (DMSO-(I6): 1.56 dm, 1 H, Jgem = 9.2 (H-7a); 1.79 dm, 1 H, Jgem = 9.2 (H-7b); 1.88 ddd, 1 H, Jgem = 12.6, J(3en,2) = 8.3, J(3en,7a) = 2.6 (H-3endo); 2.18 dt, 1 H, Jgem = 12.6, J(3ex,2) = J(3ex,4) = 3.7 (H- 3exo); 3.05 m, 1 H (H-4); 3.21 m, 1 H (H-I); 4.46 ddd, 1 H, J(2,3en) = 8.3,
J(2,3ex) = 3.9, J(2,7a) = 1.6 (H-2); 6.26 dd, 1 H, J(6,5) = 5.7, J(6,l) = 3.2 (H-6);
6.37 dd, 1 H, J(5,6) = 5.7, J(5,4) = 2.9 (H-5); 8.78 s, 1 H (H-2'); 8.93 s, 1 H (H-8'). 13C NMR (DMSOd6): 32.14 (C-3); 41.28 (C-4); 46.23 (C-7); 47.55 (C-I); 55.82 (C-2); 131.51 (C-5'); 134.48 (C-6); 140.21 (C-5); 145.96 (C-8'); 149.14 (C-6'); 151.49 (C-2'); 152.60 (C-4'). • [(li?*,2i?*,4S*,6S*)-6-(6-Chloro-9H-purin-9-yl)bicyclo[2.2.1]hept-2-yl]methyl benzoate (~ example isomeric pure form of 51), m.p. 130.5 - 131.5 0C. For C20H19ClN4O2 (382,84) calculated: 62.74% C, 5.00% H, 9.26% Cl, 14.63% N; found: 62.77% C, 5.11% H, 9.20% Cl, 14,35% N. 1H NMR (CDCl3): 1.35 dddd, 1 H, Jgem = 12.7, J(3en,2) = 5.1, J(3en,4) = 4.2, J(3en,5en) = 3.0 (H-3endo); 1.64- 1.72 m, 3 H (H-7a, 7b, 3exo); 2,00 dm, IH Jgem = 13.7 (H-5endo); 2.21 ddd, IH,
Jgem = 13.8, J(5exo,6) = 8.5, j(5exo,7a) = 2.2, (H-5exo); 2.27 m, 1 H (H-2); 2.3 m, 1 H (H-4); 2.75 bs, 1 H (H-I); 4.16 dd, 1 H, Jgem = 11.1, J(OCH2b,2) = 6.0 (OCH2b); 4.26 dd, 1 H, Jgem = 11.1, J(OCH2a,2) = 9.4 (OCH2a); 4.68 ddd 1 H J(6,5exo) = 8.5, J(6,5en) = 4.0 (H-6); 7.44 m, 2 H (H-3"); 7.57 m, 1 H (H-4"); 8.04 m, 2 H (H-2"); 8.24 s, 1 H, (H-8'); 8.73 s, 1 H (H-2').13C NMR (CDCl3):
32.43 (C-3); 33.45 (C-7); 36.02 (C-4); 38.20 (C-5); 39.31 (C-2); 44.36 (C-I); 58.53 (C-6); 66.63 (CH2O); 128.38 (C-3"); 129.53 (C-2"); 129.91 (C-I "); 131.95 (C- 5'); 133.10 (C-4"); 142.60 (C-8'); 150.94 (C-6'); 151.64 (C-2'); 151,82 (C-4'); 166.48 (C=O). • [(IR *,2S*,4R *,55*)-5-(6-Chloro-9H-purin-9-yl)bicyclo[2.2.1 ]hept-2-yl]methyl benzoate (~ example isomeric pure form of 52), m.p. 160.5 - 162.5 °C. For C20Hi9ClN4O2 (382,84) calculated: 62.74% C, 5.00% H, 9.26% Cl, 14.63% N; found: 62.71% C, 4. 97% H, 9.28% Cl, 14.36% N. 1H NMR (CDCl3): 1.44 dt, 1 H, Jgem = 13.2, J(3en,2) = J(3en,4) = 4.9, (H-3endo); 1.69 dm, 1 H, Jgem = 11.0 (H-7a); 1.74 dm, 1 H, Jgem = 11.1 (H-7b); 1.81 ddd, 1 H, Jgem = 13.1, J(3ex,2)= 8.7, j(3exo,7a) = 2.2 (H-3exo); 2,00 dt, IH Jgem = 13.6, J(6en,5) = J(6en,l) = 4.6 (H- 6endo); 2.15 m, IH (H-2); 2.25 ddd, IH, Jgem = 13.6, J(6ex,5) = 8.5, J(6ex,7a) = 2,4, (H-6exo); 2.59 dm, 1 H, J(l,6en) = 4.3 (H-I); 2.71 dm, 1 H, J(4,3en) = 4.6 (H- 4); 4.17 dd, 1 H, Jgem = 11.1, J(OCH2b,2) = 9.0 (OCH2b); 4.22 dd, 1 H, Jgem = 11.1, J(OCH2a,2) = 6.3 (OCH2a); 4.68 ddd 1 H J(5,6exo) = 8.5, J(5,6en) = 4.6, J(5,7a) =
1.2 (H-5); 7.47 m, 2 H (H-3"); 7.59 m, 1 H (H-4"); 8.06 m, 2 H (H-2"); 8.24 s, 1
H, (H-8'); 8.76 s, 1 H (H-2').13C NMR (CDCl3): 31.59 (C-3); 33.48 (C-7); 38.49 (C-I); 39.10 (C-6); 39.91 (C-2); 42.35 (C-4); 57.87 (C-5); 67.29 (CH2O); 128.40 (C-3"); 129.53 (C-2"); 130.03 (C-I "); 131.89 (C-5'); 133.07 (C-4"); 142.60 (C- 8'); 150.98 (C-6'); 151.69 (C-2'); 151,79 (C-4'); 166.54 (C=O). • (IR *,2R *,3R *,6R *,7S*,9R *)-9-[(6-Chloro-9#-purin-9-yl)methyl]-4- oxatricyclo[4.2.1.03>7]nonan-2-ol (11), m.p. 245.5 - 247.5 °C. For C14Hi5ClN4O2 (306.76) calculated: 54.82% C, 4.93% H, 11.56% Cl, 18.26% N; found: 54.93% C, 4.98% H, 11.76% Cl, 18.19% N. 1H NMR: 1.64 m, 1 H (H-I); 1.80 m, 2 H (H-8); 1.84 td, 1 H, J(9,CH2) = 8.4, J(9,6) = 2.5 (H-9); 2.03 m, 1 H (H-6); 2.53 m, 1 H (H- 7); 3.11 m, 1 H (H-2); 3.45 d, 1 H, Jgem = 8.0 (H-5a); 3.55 dd, 1 H, Jgem = 8.0,
J(5b,6) = 3.9 (H-5b); 3.76 dd, 1 H, J(3,7) = 5.0, J(3,l) = 1.4 (H-3); 4.28 m, 2 H (9- CH2); 4.72 d, 1 H, J(OH,2) = 2.6 (OH); 8.79 s, 1 H (H-8'); 8.80 s, 1 H (H-2'). 13C NMR: 30.61 (C-8); 42.34 (C-6); 43.80 (C-I); 44.12 (C-7); 45.69 (C-9); 46.33 (9- CH2); 73.47 (C-5); 79.88 (C-2); 86.40 (C-3); 130.93 (C-5'); 147.86 (C-8'); 149.26 (C-6'); 151.80 (C-2'); 152.31 (C-4').
• (IR *,2R *,3R *,6R *,7S*,9R *)-9-[(2,6-Dichloro-9H-purin-9-yl)methyl]-4- oxatricyclo[4.2.1.03>7]nonan-2-ol (12), m.p. 260 - 262 0C. For Ci4Hi4Cl2N4O2 (341.20) calculated: 49.28% C, 4.14% H, 20.78% Cl, 16.42% N; found: 48.99% C, 4.12% H, 20.77% Cl, 16.20% N. • 6-chloro-9-[(li?*,2/?*,6i?*,7i?*,85*)-tricyclo[5.2.1.02'6]dec-8-yl]-9H-purine (55), m.p. = 104.3 - 106.5 °C. For Ci5H17ClN4 (288.8) calculated: 62.39% C, 5.93% H, 12.28% Cl, 19.40% N; found: 62.25% C, 5.86% H, 12.53% Cl, 19.17% N. 1H NMR (DMSO, 600.13 MHz): 0.93 - 1.01 m, 2 H (H-3'a and H-5'a); 1.17 - 1.26 m, 2 H (H-4'); 1.44 dm, 1 H, Jgem = 11.1 (H-10'a); 1.47 dm, 1 H, Jgem = 11.1 (H- 10'b); 1.65 m, 1 H (H-4'); 1.83 - 1.90 m, 2 H (H-3'b and H-5'b); 1.91 m, 1 H (H-
2'); 1.93 m, 1 H (H-9'endo); 2.02 m, 1 H (H-6'); 2.05 dt, 1 H, Jgem = 13.3, J(9'ex,8') = J(9'ex,l ') = 4.3 (H-9'exo); 2.15 d, 1 H, J(l ',9'ex) = 4.4 (H-I '); 2.33 s, 1 H (H-7'); 4.48 ddd, 1 H, J(8',9'en) = 8.4, J(8',9'ex) = 4.2, J(8',10'a) = 1.0 (H- 8'); 8.77 s, 1 H (H-2); 8.86 s, 1 H (H-8). 13C NMR (DMSO, 150.92 MHz): 27.46 (C-4'); 29.95 (C-IO'); 31.48 (C-3'); 31.87 (C-5'); 36.81 (C-9'); 40.21 (C-I ');
45.42 (C-6'); 46.40 (C-7'); 46.93 (C-2'); 57.90 (C-8'); 131.48 (C-5); 145.67 (C-8); 149.12 (C-6); 151.47 (C-2); 152.25 (C-4).
• 6-chloro-9-[(li?*,8i?*,95*)-tricyclo[6.2.1.02>7]undeca-2,4,6-trien-9-yl]-9H-purine (56), m.p. = 202.1 - 203.2 °C. For Ci6H13ClN4 x 1A H2O (301.3) calculated: 64.76% C, 4.42% H, 11.95% Cl, 18.88% N; found: 63.89% C, 4.21% H, 12.19%
Cl, 18.40% N. 1H NMR (DMSO, 499.84 MHz): 1.88 d, 1 H, Jgem = 9.7 (H-I l 'a); 1.99 ddd, 1 H, Jgem = 12.9, J(IO 'en, 9') = 8.4, J(10'en,l l 'a) = 2.5 (H-10'endo); 2.20 dt, 1 H, Jgem = 9.8, J(11 'b,l ') = J(11 'b,8') = 1.4 (H-11 'b); 2.52 dt, 1 H, Jgem = 12.9, J(10'ex,9') = J(10'ex,l ') = 4.0 (H-10'exo); 3.56 m, 1 H (H-I '); 3.73 bs, 1 H (H-8'); 4.53 ddd, 1 H, J(9',10'en) - 8.3, J(9',10'ex) = 4.2, J(9',l l 'a) = 1.0 (H-9');
7.12 - 7.17 m, 2 H (H-4' and H-5'); 7.28 m, 1 H (H-3'); 7.35 m, 1 H (H-6'); 8.80 s, 1 H (H-2); 9.03 s, 1 H (H-8). 13C NMR (DMSO, 125.70 MHz): 34.91 (C-IO'); 43.12 (C-I '); 46.90 (C-I l '); 49.36 (C-8'); 57.16 (C-9'); 121.31 (C-3'); 122.10 (C- 6'); 126.22 and 126.95 (C-4' and C-5'); 131.56 (C-5); 144.91 (C-7'); 146.07 (C- 8); 148.51 (C-2'); 149.23 (C-6); 151.63 (C-2); 152.52 (C-4).
• (IR *,2R *,3R *,6R *,7S*,9R *)-9-[(6-Chloro-9H-purin-9-yl)methyl]-4- oxatricyclo[4.2.1.03'7]nonan-2-ol (~ example isomeric pure form ofll), m.p. 245.5 - 247.5 °C. For C14H15ClN4O2 (306.76) calculated: 54.82% C, 4.93% H, 11.56% Cl, 18.26% N; found: 54.93% C, 4.98% H, 11.76% Cl, 18.19% N. • (Ii? *,2R *,3R *,6R *,7S*,9R *)-9-[(2,6-Dichloro-9H-purin-9-yl)methyl]-4- oxatricyclo[4.2.1.03'7]nonan-2-ol (~ example isomeric pure form ofl2), m.p. 260 - 262 °C. For Ci4H14Cl2N4O2 (341.20) calculated: 49.28% C, 4.14% H, 20.78% Cl, 16.42% N; found: 48.99% C, 4.12% H, 20.77% Cl, 16.20% N.
EXAMPLE 4: SYNTHESIS OF ISOMERIC PURE FORMS OF NUCLEOSIDE ANALOGS 35 AND 36 (METHOD A)
A solution of diisopropyl azodicarboxylate (2.85 ml, 14.7 mmol) in THF (20 ml) was slowly added to a solution of [(lΛ*,2Λ*,4JR*,6i?*)-6-hydroxybicyclo[2.2.1]hept-2- yl]methyl benzoate (2.41 g, 9.8 mmol), triphenylphosphine (5.14 g, 19.3 mmol) and 6-
chloropurine (2.27 g, 14.7 mmol) in THF (100 ml).The reaction mixture was stirred overnight and evaporated. Chromatography of the residue on silica gel (400 g) in toluene - ethyl acetate (1 : 1) followed by crystallization from ethanol afforded 2.03 g of white crystals. IM solution of DIBAL-H in dichloromethane (15.9 ml) was added dropwise to a solution of this product in dichloromethane (85 ml) at -78 0C under argon atmosphere. The reaction mixture was stirred for 45 min, excess of DIBAL-H was decomposed by addition of methanol and the solvent was evaporated. The residue was diluted with methanol and filtered with a Celite pad. Chromatography on silica gel (100 g) in ethyl acetate - toluene - acetone - ethanol (17 : 4 : 3 : 1) afforded 0.97 g (33%) of 35, m.p. 154-155 °C. For C13H15ClN4O (278.74) calculated: 56.02% C, 5.42% H, 12.72% Cl, 20.0% N; found: 55.89% C, 5.29% H, 12.44% Cl, 20.00% N. FAB MS m/z (%): 279/281 (100/37) [M+H], 154.9 (89). 1H NMR (CDCl3): 1.28 dt, 1 H, Jgem = 13.0, J(3exo,2) - J(3exo,4) = 4.9, (H-3exo); 1.58 dm, 1 H, Jgem = 10.9 (H-7a); 1.67 dm, 1 H, Jgem = 10.9 (H-7b); 1.71 ddd, 1 H, Jgem = 13.0, J(3endo,2)= 8.6, J(3endo,7b) = 2,4 (H-3endo); 1.82 t, 1 H, J(OH3CH2) = 4.8 (OH); 1.87 m, 1 H (H-2); 1,97 dt, IH Jgem - 13.5, J(6exo,5) = J(6exo,l) = 4.5 (H-6exo); 2.22 ddd, IH, Jgem = 13.5, J(6endo,5) = 8.5, J(6endo,7a) = 2.5, (H-6endo); 2.56 dm, 1 H, J(l,6ex) = 4.3 (H-I); 2.65 dm, 1 H, J(4,3ex) - 4.5 (H-4); 3.50 m, 2 H, (CH2O); 4.65 ddd 1 H, J(5,6endo) = 8.5, J(5,6exo) = 4.6, J(5,7a) = 1.4 (H-5); 8.25 s, 1 H, (H-8'); 8.76 s, 1 H (H-2'). 13C NMR (CDCl3): 31.45 (C-3); 33.36 (C-7); 38.04 (C-I); 39.33 (C-6); 42.29 (C-4); 43.35 (C-2); 57.98 (C-5); 65.99 (CH2O); 131.84 (C-5'); 142.67 (C-8'); 150.92 (C-6'); 151.66 (C-2'); 151.78 (C-4').
According to the same procedure, there was obtained [(lR*,2R*,4S*,6S*)-6-(6-Chloro- 9H-purin-9-yl)bicyclo[2.2.1]heptan-2-yl]methanol (36), yield 1.16 g (35%), m.p. 124-125 °C. For Ci3Hi5ClN4O (278.74) calculated: 56.02% C, 5.42% H, 12.72% Cl, 20.10% N; found: 56.00% C, 5.38% H, 12.52% Cl, 19.71% N. FAB MS m/z (%): 279/281 (78/33) [M+H], 154.9 (100). 1H NMR (CDCl3): 1.18 dddd, 1 H, Jgem = 12.6, J(3ex,2) = 5.1, J(3ex,4) = 4.1, J(3ex,5ex) = 2.9 (H-3exo); 1.54 ddd, 1 H, Jgem = 12.6, J(3endo,2) = 8.6, J(3endo,7b) = 2.3, (H-3endo); 1.56 dm, 1 H, Jgem = 11.0 (H-7b); 1.63 dm, 1 H, Jgem = 11.0 (H-7a); 1.94 m, IH (H-5exo); 1.99 m, 1 H (H-2); 2.12 bt, 1 H, J(OH5CH2) = 5.1 (OH); 2.19 ddd, IH, Jgem = 13.8, J(5endo,6) = 8.4, J(5endo,7a) = 2,3, (H-5endo); 2.56 tm,
1 H, J(4,3exo) = J(4,5exo) = 4.1 (H-4); 2.74 bs, 1 H (H-I); 3.49 ddd, 1 H, J(CH15H^) = 9.2, J(CHbH,OH) = 5.2 and 3.57 ddd, 1 H, J(CHaH,2) = 6.0, J(CH3H5OH) = 4.1, Jgem = 10.7 (CH2O); 4.64 ddd 1 H J(6,5endo) = 8.4, J(6,5exo) = 4.0, J(6,7a) = 1.4 (H-6); 8.25 s, 1 H, (H-8'); 8.75 s, 1 H (H-T). 13C NMR (CDCl3): 32.36 (C-3); 33.30 (C-7); 35.93 (C-4); 38.54 (C-5); 42.71 (C-2); 43.80 (C-I); 58.74 (C-6); 65.39 (CH2O); 131.87 (C-5'); 142.77 (C-8'); 150.88 (C-6'); 151.63 (C-2'); 151.76 (C-4').
EXAMPLE 5: SYNTHESIS OF ISOMERIC PURE 6-CHLORO-9-{[(lR,2S,5R)-6,6- DIMETHYL BICYCLO[3.1.1 ]HEPT-2-YL]METHYL} -9H-PURINE (23) (Method B)
A mixture of (-)-cis-myrtanylamine (460 mg, 3 mmol), 4,6-dichloropyrimidin-5-amine (984 mg, 6 mmol), and triethylamine (1.8 ml) in ethanol (9 ml) was heated in a pressure vessel at 105 °C for 6 days and, after cooling, was evaporated. The residue was chromatographed on a column of silica gel (200 g). Pyrimidine intermediate was eluted with toluene - ethylacetate (10:1 —> 6:1) and this intermediate (730 mg) was immediately used in the next step. Concentrated hydrochloric acid (1 ml) was added to a suspension of pyrimidine intermediate in triethyl orthoformate (80 ml) and the reaction mixture was vigorously stirred for 5 days at room temperature. Reaction mixture was evaporated and the residue was crystallized from water-methanol (95:5) to afford 575 mg (66%) of 6- chloro-9- {[(lR,2S,5R)-6,6-dimethylbicyclo[3.1. l]hept-2-yl]methyl}-9H-purine, m.p. = 121.3 - 122.6. [α]D -11.6 (c 0.368, methanol). For C15H19ClN4 (290.8) calculated: 61.96% C, 6.59% H, 12.19% Cl, 19.27% N; found: 61.91% C, 6.58% H, 11.89% Cl, 18.96% N. 1R NMR (DMSO, 600.13 MHz): 0.83 d, 1 H, Jgem = 9.6 (H-7'a); 1.15 s, 3 H and 1.18 s, 3 H (2 x 6'-CH3); 1.58 dddd, 1 H, Jgem = 14.9, J(3'a,4'b) = 10.7, J(3'a,2') = 6.4, J(3'a,4'a) = 5.5 (H-3'a); 1.66 ddd, 1 H, J(I ',7'b) = 6.4, J(I ',5') = 5.1, J(I ',T) = 2.1 (H-I '); 1.73 ddt, 1 H, Jgem = 14.9, J(3 'b,4'a) = J(3'b,2') = 10.5, J(3'b,4'b) = 2.7 (H-3'b); 1.79 dddd, 1 H, Jgem = 12.8, J(4'a,3'b) = 10.6, J(4'a,3'a) = 5.6, J(4'a,5') = 2.6 (H-4'a); 1.87 m, 1 H (H-5'); 1.91 m, 1 H (H-4'b); 2.27 ddt, 1 H, Jgem = 9.6, J(7'b,l ') = J(7'b,5') = 6.3, J(7'b,4'b) = 2.0 (H-7'b); 2.64 m, 1 H (H-2'); 4.27 m, 2 H (CH2N); 8.78 s, 1 H (H-8); 8.78 s, 1 H (H-2). 13C NMR (DMSO, 150.92 MHz): 18.69 (C-3'); 23.13 (6'-CH3); 25.58
(C-4'); 27.75 (6'-CH3); 32.52 (C-7'); 38.49 (C-6'); 40.75 (C-5'); 41.06 (C-2'); 42.93 (C- 1 '); 49.04 (CH2N); 130.86 (C-5); 147.91 (C-8); 149.22 (C-6); 151.72 (C-2); 152.35 (C-4).
According to the same procedure, there were obtained the following compounds: • 6-chloro-9-[(li? *,2S*,3S*,6S*,7R *)-4-oxatricyclo[4.2.1.03'7]non-2-yl]-9H-purine
(57), m.p. - 166 - 167 °C, For C13H13ClN4O (276.7) calculated: 56.42% C, 4.74% H, 12.81% Cl, 20.25% N; found: 56.21% C, 4.56% H, 13.08% Cl, 19.96% N. 1H NMR (DMSO, 600.13 MHz): 1.29 dt, 1 H, Jgem = 12.8, J(9'en,8'b) = J(9'en,6') = 2.3 (H-9'endo); 1.68 dm, 1 H, Jgem = 11.4 (H-8'a); 1.85 dm, 1 H, Jgem = 11.3 (H-8'b); 2.06 ddd, 1 H, Jgem = 12.8, J(9'ex,6') = 10.8, J(9'ex,l ') = 4.5 (H-
9'exo); 2.48 m, 1 H (H-6'); 2.60 m, 1 H (H-I '); 2.74 m, 1 H (FL-T); 3.75 d, 1 H, Jgem = 8.0 (H-5'a); 3.80 dd, 1 H, Jgem = 8.0, J(5'b,6') = 4.2 (H-5'b); 4.14 d, 1 H, J(2',8'a) = 2.1 (H-2'); 4.76 dd, 1 H, J(3',7') = 5.0, J(3',l ') - 1.4 (H-3'); 8.77 s, 1 H (H-2); 8.78 s, 1 H (H-8). 13C NMR (DMSO, 150.92 MHz): 35.13 (C-9'); 35.45 (C-8'); 37.16 (C-6'); 39.03 (C-I '); 45.78 (C-7'); 66.85 (C-2'); 74.51 (C-5'); 83.92
(C-3'); 131.30 (C-5); 145.79 (C-8); 149.23 (C-6); 151.57 (C-2); 152.30 (C-4). • 9-[(7-syn)-Bicyclo[2.2. l]hept-2-en-7-yl]-6-chloro-9H-purine (25), m.p. = 114.5 - 115.5 °C. For C12H11ClN4 (246.7) calculated: 58.42% C, 4.49% H, 14.37% Cl, 22.71% N; found: 58.50% C, 4.59% H, 14.63% Cl, 22.43% N. 1H NMR (DMSO, 600.13 MHz): 1.12 m, 2 H (H-5endo and H-6endo); 1.97 m, 2 H (H-5exo and H-
6exo); 3.60m, 2 H (H-I and H-4); 4.33 m, 1 H (H-7); 6.00 m, 2 H (H-2 and H-3); 8.49 s, 1 H (H-8'); 8.76 s, 1 H (H-2'). 13C NMR (DMSO, 150.92 MHz): 22.76, 2 C (C-5 and C-6); 44.81, 2 C (C-I and C-4); 70.73 (C-7); 131.07 (C-5'); 132.07, 2 C (C-2 and C-3); 147.70 (C-8'); 149.10 (C-6'); 151.55 (C-2'); 152.93 (C-4'). • 9-[(lR,4S)-Bicyclo[2.2.1]hept-7-yl]-6-chloro-9H-purine (27), m.p. = 95.5 - 96.7
0C. For C12Hi3ClN4 (248.7) calculated: 57.95% C, 5.27% H, 14.25% Cl, 22.53% N; found: 57.75% C, 5.20% H, 14.41% Cl, 22.33% N. 1H NMR (DMSO-d6): 1.32 m, 2 H (H-5'exo and H-6'exo); 1.42 m, 4 H (H-2'exo, H-3'exo, H-5'endo and H- 6'endo); 1.79 m, 2 H (H-2'endo and H-3'endo); 3.19 m, 2 H (H-I ' and H-4'); 4.25 bs, 1 H (H-7'); 8.73 s, 1 H (H-8); 8.76 s, 1 H (H-2). 13C NMR (DMSO-d6):
26.64, 2 C (C-5' and C-6'); 27.08, 2 C (C-2' and C-3'); 38.55, 2 C (C-I 'and C-
4'); 63.87 (C-7'); 131.17 (C-5'); 147.74 (C-8'); 149.21 (C-6'); 151.49 (C-2'); 152.71 (C-4').
EXAMPLE 6: Synthesis of (lR*,2R*,3R*,6R*,7S*,9S*)-2-(6-Chloro-9H-purin-9-yl)-4- oxatricyclo[4.2.1.03'7]nonane-9-methanol (1)
A mixture of bicyclo[2.2.1]hept-5-ene-2,3-diyldimethanol (6.17 g, 40 mmol), benzyl azidoformate (8.68 g, 49 mmol), and toluene (10 ml) was stirred at 68 °C (bath temperature). The bath was put off when a spontaneous exothermic reaction had occurred. After termination of the reaction, the mixture was applied on a silica gel column (300 g) and eluted with ethyl acetate. The fractions containing product were evaporated. Palladium(II) hydroxide on carbon (20% Pd, 500 mg) was added to a solution of the residue in methanol (200 ml) and the mixture was stirred under hydrogen atmosphere at room temperature for 7 h. The catalyst was filtered off with a Celite pad, washed with methanol and the filtrates were evaporated. The residue was mixed with ether and resulting crystalline compound (5.41 g) was filtered off. A solution of this compound , 4,6-dichloropyrimidin-5 -amine (7.89 g), and triethylamine (9.6 ml) in ethanol (100 ml) was heated in a pressure vessel at 100 °C for 6 days and, after cooling, was taken down. The product obtained by chromatography of the residue on a silica gel column (400 g) in ethyl acetate - acetone - ethanol - water (95 : 15 : 9 : 6) was suspended in triethyl orthoformate (450 ml). Cone, hydrochloric acid (10 ml) was added to this stirred mixture, the resulting solution was left aside at room temperature for 3 days and then evaporated. The residue was dissolved in tetrahydrofuran (125 ml). To the stirred solution, 0.5 M hydrochloric acid (125 ml) was added, the mixture was stirred at room temperature for 3 h and then neutralized with solid sodium hydrogencarbonate. The organic layer was separated and the aqueous layer was extracted with tetrahydrofuran (4 x 100 ml). The combined organic layers were evaporated. Crystallization of the residue from water gave 7.95 g mg (65%) of 1, m.p. 190.5 - 192 °C. For C14H15ClN4O2 (306.76)
calculated: 54.82% C, 4.93% H, 11.56% Cl, 18.26% N; found: 54.69% C, 4.94% H, 11.55% Cl, 18.08% N. 1H NMR (DMSO-de): 1.62 brtd, 1 H, J(9,l) ~ j(9,8a) = 1.0, J(9,6) = 2.6, J(9,CH2) = 7.9 (H-9); 1.72 dm, 1 H, Jgem = 11.7 (H-8a); 1.82 dq, 1 H, J(8b,l) ~ J(8b,2) ~ J(XbJ) = 1.4 (H-8b); 2.07 td, 1 H, J(6,5a) ~ J(6,7) = 4.0 (H-6); 2.58 m, 1 H (H- 1); 2.69 ddq, 1 H, J(7,l) ~ J(7,8a) ~ J(7,8b) = 1.2, J(7,3) = 5.0 (R-T); 3.39 dd, 2 H, J(CH25OH) = 5.3 (CH2OH); 3.75 d, 1 H, Jgem = 7.8 (H-5b); 3.78 dd, 1 H, J(5a,6) = 3.6 (H-5a); 4.12 brd, 1 H, J(2,l) ~ J(2,3) = 1.0, J(2,8b) = 1.6 (H-2); 4.12 t, 1 H (OH); 4.78 brd, 1 H, J(3,l) = 1.2, J(3,8b) = 1.0 (H-3); 8.77 s, 1 H and 8.78 s, 1 H (H-2', H-8'). 13C NMR (DMSO-d6): 32.05 (C-8); 41.10 (C-I); 41.35 (C-6); 45.24 (C-7); 50.67 (C-9); 62.75 (CH2O); 67.27 (C-2); 74.16 (C-5); 83.56 (C-3); 131.24 (C-5'); 145.76 (C-8'); 149.18 (C- 6'); 151.50 (C-2'); 152.28 (C-4').
According to the same procedure, there were obtained the following compounds:
• [(Ii? *,2R *,3R *,6R *,7S*, 10*5)-2-(6-Cloro-9H-purin-9-yl)-4- oxatricyclo[4.3.1.03l7]dec-10-yl]methanol (14), m.p. 183.5 - 184.5 0C. For
C15H17ClN4O2 (320.78) calculated: 56.16% C, 5.34% H, 11.05% Cl, 17.47% N; found: 56.88% C, 5.35% H, 11.03% Cl, 17.24% N. FAB MS, m/z (%): 323/321 (39/100) [M + H], 157/155 (35/73).
• {(IR *,2R *,3S*,6S*,7S*,9S*)-2-(6-Chloτo-9H-pυήn-9-yl)-4,8- dioxatricyclo[4.2.1.03'7]non-9-yl}methanol (32), m.p. 205.5 - 206.5 °C. For
C13Hi3ClN4O3 (308.73) calculated: 50.58% C, 4.24% H, 11.48% Cl, 18.15% N; found: 50.43% C, 4.29% H, 11.66% Cl, 18.01% N. FAB MS, m/z (%): 311/309 (37/100) [M + H]. 1H NMR (DMSO-(I6): 2.05 ddd, 1 H, J(9,6) = 2.0, J(9,CH2) = 7.3 and 8.8 (H-9); 2.16 dt, 1 H, J(6,7) = J(6,5a) = 4.5, J(6,9) = 2.0 (H-6); 3.33 m, 2 H (CH2O); 3.88 dd, 1 H, Jgem = 8.6, J(5a,6) = 4.2 (H-5a); 3.96 d, 1 H, Jgem = 8.5
(H-5b); 4.51 dd, 1 H, J(ZJ) = 4.8, J(3,2) = 1.5 (H-3); 4.59 m, 2 H (H-I and H-2); 4.86 t, 1 H, J(OH5CH2) = 5.3 (OH); 5.18 t, 1 H, J(7,3) = J(7,6) = 4.8 (R-T); 8.54 s, 1 H (H-8'); 8.80 s, 1 H (H-2'). 13C NMR (DMSO-d6): 41.06 (C-6); 50.92 (C-9); 61.66 (CH2O); 64.53 (C-2); 72.29 (C-5); 80.06 (C-I); 81.86 (C-7); 83.25 (C-3); 130.76 (C-5'); 145.24 (C-8'); 149.16 (C-6'); 151.69 (C-2'); 151.85 (C-4').
EXAMPLE 7: SYNTHESIS OF INTERMEDIATE AMINES SUCH AS THE FORMULA XIV FOR METHOD B AND OF COMPOUNDS SUCH AS 24
A solution of bicyclo[2.2.1]hept-5-en-2-yl acetate (mixture of isomers, 10.3 g, 67.7 mmol) and ethyl azidoformate (15.3 g, 133 mmol) in toluene (80 ml) was heated at 80 °C for 10 hours and evaporated. The residue was dissolved in ethyl acetate (80 ml) and silica gel (10 g) was added. After 12 hours of stirring, silica gel was filtered off and filtrate was evaporated. The products were separated by column chromatography on silica gel (400 g). Elution with toluene - ethyl acetate (8:1) afforded 8.3 g (51.2 %) of aziridine as an oil and 5.63 g (34.8 %) of carbamate as an oil. Carbamate (5.63 g, 23.5 mmol) was dissolved in methanol (200 ml) and K2CO3 was added (200 mg). The reaction mixture was vigorously stirred for 72 hours and then heated to reflux for 10 hours, K2CO3 was removed with DOWEX 50 (H+ cycle), the mixture was filtrated and evaporated. The residue was immediately used in next step. A mixture of pyridinium dichromate (13.5 g, 35.9 mmol), molecular sieves (3A, powder, 14 g) and dichloromethane (140 ml) was stirred at room temperature for 15 min. A solution of carbamate (from previous step) in dichloromethane (60 ml) was added to the mixture and reaction mixture was stirred for 12 hours, the insoluble portions were filtred and filtrate was evaporated. Residue was treated with ethylacetate (150 ml) and the mixture was filtrated throug a Celite pad and filtrates were taken down. Column chromatography of the residue on silica gel (300 g) with toluene - ethyl acetate (3:1) afforded 1.9 g of keto derivative. Ketocarbamate was dissolved in methanol (70 ml) and solution was immersed in an ice-bath, sodium borohydride (220 mg, 5.84 mmol) was added in small portions during 20 min and the reaction mixture was evaporated, co-distillled with methanol (50 ml) and the residue was partitionated between ethyl acetate (150 ml) and brine (70 ml). The aqeuos layer was extracted with ethyl acetate (2 x 150 ml) and combined organic layers were drid over anhydrous sodium sulfate and evaporated. The residue was chromatographed on silica gel (150 g) in ethylacetate - toluene (4:1) to afford 1.7 g of the alcohol. To a solution of alcohol (1.7 g, 8.62 mmol) in ethanol-water (20 ml, 1:1) potassium hydroxide (3.1 g, 55 mmol) was added and the reaction mixture was refluxed for 1O h in argon atmosphere.
Then second portion of potassium hydroxide (0.8 g, 14 mmol) was added and heating was continued for 4 h. The reaction mixture was neutralized with 6 M hydrochloric acid and solution was applied onto a Dowex 50 (H+ form, 100 ml). The column was eluted with methanol-water (1:1, 300 ml), water (300 ml), methanol (300 ml) and then with 3.5 M methanolic ammonia. Fractions containing the product were evaporated to yield 917 mg (85 %) of (li?*,25*,45*,7Λ*)-7-aminobicyclo[2.2.1]hept-5-en-2-ol (XIV, total yield from bicyclo[2.2.1]hept-5-en-2-yl acetate 10.8 %). A mixture of the residue (917 mg) and Pd(OH)2 (20% on charcoal , 300 mg) in methanol (50 ml) was stirred in atmosphere of hydrogen for 15 h. The catalyst was filtered off and washed with methanol and filtrate was evaporated. A mixture of the residue (841 mg, 6.6 mmol), 4,6-dichloropyrimidin-5- amine (1.63 g, 9.9 mmol), and triethylamine (2 ml) in ethanol (20 ml) was heated in a pressure vessel at 100 °C for 6 days and, after cooling, was taken down. The product obtained by chromatography of the residue on a silica gel column (100 g) in ethyl acetate - acetone - ethanol - water (95 : 15 : 9 : 6) was suspended in triethyl orthoformate (90 ml). Cone, hydrochloric acid (2 ml) was added to this stirred mixture, the resulting solution was left aside at room temperature for 3 days and then evaporated. The residue was dissolved in tetrahydrofuran (23 ml). To the stirred solution, 0.5 M hydrochloric acid (23 ml) was added, the mixture was stirred at room temperature for 3 h and then neutralized with solid sodium hydrogencarbonate. The organic layer was separated and the aqueous layer was extracted with tetrahydrofuran (4 x 20 ml). The combined organic layers were evaporated. Crystallization of the residue from water gave 1.12 g (6.2%) of 24, m.p. = 178.7 - 180. °C. For Ci2H13ClN4O (264.7) calculated: 54.45% C, 4.95% H, 13.39% Cl, 21.17% N; found: 54.32% C, 5.09% H, 13.40% Cl, 21.00% N. 1H NMR (DMSO-(I6): 1.01 dd, 1 H, Jgem = 12.8, J(3ex,2) = 3.8 (H-3exo); 1.28 m, 1 H (H-6endo); 1.34 m, 2 H (H-5exo, 5endo); 2.02 bddd, 1 H, Jgem = 12.8, J(6ex,5ex) = 9.0, J(6ex,5en) = 5.2 (H-6exo); 2.12 dddd, 1 H, Jgem = 12.9, J(3en,2) = 10.1, J(3en,4) = 4.9, J(3en,5en) = 2.6 (H-3endo); 3.11 tm, 1 H, J(4,3en) = J(4,5en) = 4.5 (H-4); 3.20 tm, 1 H, J(l,2) = J(1, 6en) = 4.2 (H-I); 4.28 m, 2 H (H-2, H-7); 4.93 d, 1 H, J(OH,2) = 4.2 (OH); 8.72 s, 1 H (H-8'); 8.75 s, 1 H (H-2'). 13C NMR (DMSO-(I6): 17.53 (C-6); 26.79 (C-5); 37.37 (C- 3); 39.82 (C-4); 45.23 (C-I); 61.94 (C-7); 67.78 (C-2); 131.17 (C-5'); 147.48 (C-8'); 149.22 (C-6'); 151.49 (C-2'); 152.60 (C-4'). For C12Hi3ClN4O (264.7) calculated:
54.45% C, 4.95% H, 13.39% Cl, 21.17% N; found: 54.32% C, 5.09% H, 13.40% Cl, 21.00% N.
According to the same procedure, exlcluding the hydrogenation step, there was obtained (lR*,2S*,4S*,7R*)-7-(6-Chloro-9H-purin-9-yl)bicyclo[2.2.1]hept-5-en-2-ol (16), m.p. = 202.6 - 203.5 °C (decomp.). For C12Hi1ClN4O (262.7) calculated: 54.87% C, 4.22% H, 13.05% Cl, 21.33% N; found: 54.56% C, 4.23% H, 12.96% Cl, 21.05% N. 1R NMR (DMSO-(I6): 0.90 dd, 1 H, Jgem = 12.1, J(3ex,2) = 3.0 (H-3exo); 2.27 ddd, 1 H, Jgem = 12.1, J(3en,2) = 7.9, J(3en,4) = 3.8 (H-3endo); 3.50 m, 1 H (H-4); 3.67 m, 1 H (H-I); 4.35 bs, 1 H (H-7); 4.55 m, 1 H (H-2); 4.81 d, 1 H, J(OH,2) = 4.6 (OH); 5.91 dd, 1 H, J(6,5) = 5.7, J(6,l) = 2.8 (H-6); 6.20 dd, 1 H, J(5,6) = 5.7, J(5,4) = 2.9 (H-5); 8.48 s, 1 H (H-8'); 8.75 s, 1 H (H-2'). 13C NMR (DMSO-d6): 35.05(C-3); 46.21 (C-4); 51.43 (C-I); 67.74 (C-2); 69.04 (C-7); 129.35 (C-6); 131.04 (C-5'); 133.98 (C-5); 147.56 (C-8'); 149.10 (C-6'); 151.54 (C-2'); 152.74 (C-4').
EXAMPLE 8: SYNTHESIS OF METHYL-ETHER COMPRISING NUCLEOSIDE ANALOGS OF THE INVENTION SUCH AS 2 AND 20
Sodium hydride (60% dispersion in mineral oil, 40 mg, 1 mmol) was added to a mixture of (lR*,2R*,3R*,6R*,7S*,9S*)-2-(6-chloro-9H-purin-9-yl)-4-oxatricyclo[4.2.1.03'7] nonane-9-methanol (1) (153 mg, 0.5 mmol) dimethylformamide (1.5 ml) and methyl iodide (1.5 ml). The mixture was stirred at 0 °C for 0.5 h then at room temperature for 2 h. and evaporated. Solution of the residue in ethyl acetate (15 ml) was washed with water
(2 x 5 ml), 10% aqueous sodium thiosulfate, dried over anhydrous sodium sulfate and evaporated. Crystallization of the residue from ethanol afforded 120 mg (75%) of 6- cloro-9-[(l^*,2i?*,3/?*,6i?*7S*,95'*)-9-(methoxvmethyl)-4-oxatricyclo[4.2.1.03'7]non-2- yl]-9H-purine (2), m.p. 147 - 148 °C. For C15H17ClN4O2 (320.78) calculated: 56.16% C,
5.34% H, 11.05% Cl, 17.47% N; found: 55.89% C, 5.41% H, 10.86% Cl, 17.20% N. 1H
NMR (DMSO-d6): 1.73 - 1.81 m, 2 H (H-8a, H-9); 1.86 dm, 1 H, Jgem = 11.9 (H-8b); 2.09 m, 1 H (H-6); 2.56 m, 1 H (H-I); 2.71 m, 1 H (H-7); 3.28 s, 3 H (CH3O); 3.30 - 3.38 m, 2 H (CH2O); 3.76 - 3.81 m, 2 H (2 x H-5); 4.14 d, 1 H, J(2,8b) = 1.8 (H-2); 4.80 brd,
1 H, J(3,7) = 5.0 (H-3); 8.77 s, 1 H (H-2'); 8.78 s, 1 H (H-8'). 13C NMR (DMSO-d6): 32.10 (C-8); 41.22 (C-I); 41.53 (C-6); 45.21 (C-7); 47.52 (C-9); 58.19 (CH3O); 67.09 (C- 2); 73.63 CH2O); 73.93 (C-5); 83.44 (C-3); 131.23 (C-5'); 145.73 (C-8'); 149.15 (C-4'); 151.45 (C-2'); 152.26 (C-6').
According to the same procedure, there was obtained <5-cΛ/oro-9-[(lR*,2S*,4R*,7R*)-2- methoxybicyclo[2.2.1]hept-7-yl]-9H-purine (20), m.p. = 104.2 - 104.8 °C. For C13Hi5ClN4O (264.7) calculated: 56.02% C, 5.42% H, 12.72% Cl, 20.10% N; found: 56.03% C, 5.37% H, 13.40% Cl, 19.82% N. 1H NMR (DMSO, 600.13 MHz): 1.11 dd, 1 H, Jgem = 13.1, J(3en,2) - 3.6 (H-3endo); 1.24 m, 1 H (H-6exo); 1.34 bddd, 1 H, Jgem = 12.9, J(5en,6en) = 9.5, J(5en,6ex) = 4.4 (H-5endo); 1.44 m, 1 H (H-5exo); 1.79 bddd, 1 H, Jgem = 12.9, J(6en,5en) = 9.5, J(6en,5ex) = 4.7 (H-6endo); 2.14 dddd, 1 H, Jgem = 13.1, J(3ex,2) - 10.0, J(3ex,4) - 4.7, J(3ex,5ex) = 3.0 (H-3exo); 3.15 bt, 1 H, J(4,3ex) = J(4,5ex) = 4.4 (H-4); 3.22 s, 3 H (OMe); 3.50 tm, 1 H, J(l,2) = J(l,6ex) = 4.1 (H-I); 3.93 ddt, 1 H, J(2,3ex) = 10.1, J(2,3en) = J(2,l) = 3.8, J(2,6ex) = 1.5 (H-2); 4.31 bs, 1 H (H- 7); 8.74 s, 1 H (H-8'); 8.77 s, 1 H (H-2'). 13C NMR (DMSO, 150.92 MHz): 17.46 (C-6); 26.67 (C-5); 35.08 (C-3); 39.20 (C-4); 42.05 (C-I); 56.45 (OMe); 61.84 (C-7); 77.74 (C- 2); 131.19 (C-5'); 147.43 (C-8'); 149.27 (C-6'); 151.55 (C-2'); 152.60 (C-4'). EXAMPLE 9: Synthesis of [(li?*,2£*,4i?*,7S*)-7-(6-chloro-9H-purin-9- yl)bicyclo[2.2. l]hept-5-en-2-yl]methanol (58) and analoguous compounds
A mixture of [(li?*,2i?*,4Λ*,75*)-7-aminobicyclo[2.2.1]hept-5-en-2-yl]methanol (780 mg, 5.60 mmol), 4,6-dichloropyrimidin-5 -amine (1.38 g, 8.42), and triethylamine (1.8 ml) in ethanol (9 ml) was heated in a pressure vessel at 105 0C for 6 days and, after cooling, was evaporated. The residue was chromatographed on a column of silica gel (200 g). Pyrimidine intermediate was eluted with ethylacetate → ethylacetate - toluene - acetone - ethanol (17:4:3:1) and this intermediate was immediately used in the next step. Concentrated hydrochloric acid (1.5 ml) was added to a suspension of pyrimidine intermediate in triethyl ortho formate (100 ml) and TΗF (20 ml) and the reaction mixture was vigorously stirred for 4 days at room temperature. Solution was evaporated and the residue was dissolved in mixture in a mixture of tetrahydrofuran (20 ml) and 0.5 M
hydrochloric acid (20 ml) and stirred at room temperature for 4 hours. After neutralization with solid sodium hydrogencarbonate, mixture was evaporated to a one fourth of original volume and absorbed on silica gel. This silica gel was placed on the top of the silica gel column (200 g). Chromatography with ethylacetate — » ethylacetate - toluene - acetone - ethanol (17:4:3:1) afforded product [(IR*, 2R* AR* J S*)-7-(6-ch\oτo- 9H-purin-9-yl)bicyclo[2.2.1]hept-5-en-2-yl]methanol (58) (900 mg, 58.1%). Compounds were crystallized from ethylacetate-hexanes. M.p. = 133.5 - 133.6 0C. For C13H13ClN4O (276.7) calculated: 56.42% C, 4.74% H, 12.81% Cl, 20.55% N; found: 56.79% C, 5.02% H, 13.05% Cl, 20.23% N. 1H NMR (DMSO, 499.84 MHz): 0.60 dd, 1 H, Jgem = 11.8, J(3en,2) = 4.7 (H-3endo); 2.06 ddd, 1 H, Jgem = 11.8, J(3ex,2) = 9.0, J(3ex,4) = 3.9 (H- 3exo); 2.49 m, 1 H (H-2); 3.02 ddd, 1 H, Jgem = 10.6, J(CH2,OH) = 5.5, J(CH2,2) = 9.6 (CH2Oa); 3.20 ddd, 1 H, Jgem = 10.6, J(CH2,OH) = 4.9, J(CH2,2) = 6.2 (CH2Ob); 3.55 m, 1 H (H-4); 3.70 m, 1 H (H-I); 4.42 bs, 1 H (H-7); 4.62 t, 1 H, J(OH5CH2) = 5.2 (OH); 5.90 dd, 1 H, J(6,5) = 5.7, J(6,l) = 2.8 (H-6); 6.10 bdd, 1 H, J(5,6) = 5.7, J(5,4) = 2.9 (H- 5); 8.48 s, 1 H (H-8'); 8.76 s, 1 H (H-2'). 13C NMR (DMSO, 125.70 MHz): 26.84 (C-3); 39.19 (C-2); 45.29 (C-4); 47.06 (C-I); 63.44 (CH2O); 71.18 (C-T); 129.66 (C-6); 131.07 (C-5'); 133.48 (C-5); 147.72 (C-8'); 149.11 (C-6'); 151.55 (C-2'); 152.90 (C-4').
According to the same procedure, there were obtained the following compounds: • [( IR *,2R *,4S*,7S*)-7-(6-Chloro-9H-purin-9-yl)bicyclo[2.2.1 ]hept-2-yl]methanol
(59), m.p. = 97.6 - 98.7 0C. For Ci3H15ClN4O (278.7) calculated: 56.02% C, 5.42% H, 12.72% Cl, 20.10% N; found: 55.99% C, 5.62% H, 12.84% Cl, 19.75% N. 1H NMR (DMSO, 600.13 MHz): 0.80 dd, 1 H, Jgem = 12.4, J(3en,2) = 5.4 (H- 3endo); 1.22 m, 1 H (H-6exo); 1.46 m, 1 H (H-5exo); 1.62 ddd, 1 H, Jgem = 13.2, J(6en,5en) = 9.2, J(6en,5ex) = 3.9 (H-6endo); 1.89 tdd, 1 H, Jgem = J(3ex,2) =
12.0, J(3ex,4) = 4.5, J(3ex,5ex) = 3.0 (H-3exo); 2.26 m, 1 H (H-2); 3.15 m, 1 H (H-4); 3.30 m, 1 H (H-I); 3.38 m, 1 H (CH2Oa); 3.48 ddd, 1 H, Jgem = 10.8, J(CH2,OH) = 4.6, J(CH2,2) = 6.5 (CH2Ob); 4.32 bs, 1 H (H-7); 4.59 dd, 1 H, J(OH5CH2) = 5.4 and 4.7 (OH); 8.73 s, 1 H (H-8'); 8.76 s, 1 H (H-2'). 13C NMR (DMSO, 150.92 MHz): 19.76 (C-6); 27.01 (C-5); 31.00 (C-3); 38.98 (C-4); 39.28
(C-2); 40.85 (C-I); 62.17 (CH2O); 64.39 (C-7); 131.19 (C-5'); 147.76 (C-8'); 149.24 (C-6'); 151.50 (C-2'); 152.70 (C-4').
• [(Ii? *,2S*,4R *,75*)-7-(6-Chloro-9H-purin-9-yl)bicyclo[2.2.1 ]hept-5-en-2- yl]methanol (60), m.p. = 184.5 - 186.3 °C. For C13H13ClN4O (276.7) calculated: 56.42% C, 4.74% H, 12.81% Cl, 20.55% N; found: 56.45% C, 4.71% H, 12.93%
Cl, 19.99% N. 1H NMR (DMSO, 499.84 MHz): 1.35 dd, 1 H, Jgem = 12.0, J(3en,2) = 9.2 (H-3endo); 1.53 ddd, 1 H, Jgem = 12.0, J(3ex,2) - 4.4, J(3ex,4) = 3.5 (H-3exo); 1.66 m, 1 H (H-2); 3.53 m, 1 H (H-I); 3.56 m, 1 H (H-4); 3.58 ddd, 1 H, Jgem = 10.8, J(CH25OH) = 5.3, J(CH2,2) = 8.3 (CH2Oa); 3.68 ddd, 1 H, Jgem = 10.8, J(CH25OH) = 4.9, J(CH2,2) = 5.7 (CH2Ob); 4.56 bs, 1 H (R-T); 4.82 t, 1 H,
J(OH5CH2) = 5.1 (OH); 5.99 bdd, 1 H, J(5,6) = 5.7, J(5,4) = 2.8 (R-S); 6.12 dd, 1 H, J(6,5) - 5.7, J(6,l) = 2.9 (H-6); 8.48 s, 1 H (H-8'); 8.75 s, 1 H (H-2'). 13C NMR (DMSO, 125.70 MHz): 21.78 (C-3); 40.76 (C-2); 44.96 (C-4); 46.78 (C-I); 64.09 (CH2O); 68.80 (C-7); 131.08 (C-5'); 132.78 (C-5); 133.67 (C-6); 147.81 (C-8'); 149.10 (C-6'); 151.55 (C-2'); 152.98 (C-4').
• (li?*,25*,45*,6i?*)-6-(6-Chloro-9H-purin-9-yl)bicyclo[2.2.1]heptan-2-ol26), m.p. = 154.9 - 156.1 °C(ethylacetate-hexanes). For C12H13ClN4O (264.7) calculated: 54.45% C, 4.95% H, 13.39% Cl, 21.17% N; found: 54.28% C, 4.89% H, 13.83% Cl, 20.92% N. 1H NMR (DMSO, 499.95 MHz): 1.28 m, 1 H (H-3exo); 1.65 m, 2 H (R-T); 1.68 ddd, 1 H, Jgem = 12.9, J(3en,2) = 7.0, J(3en,7) = 1.6 (H-
3endo); 1.87 ddd, 1 H, Jgem = 13.1, J(5en,6) = 8.5, J(5en,7) = 1.4 (H-5endo); 1.95 m, 1 H (H-5exo); 2.40 m, 2 H (H-I and H-4); 3.87 m, 1 H (H-2); 4.45 dd, 1 H, J(6,5en) = 8.4, J(6,5ex) = 4.8 (H-6); 4.84 d, 1 H, J(OH,2) = 3.8 (OH); 8.77 s, 1 H (H-2'); 8.85 s, 1 H (H-8'). 13C NMR (DMSO, 125.73 MHz): 32.42 (C-7); 34.96 (C-4); 37.00 (C-5); 40.51 (C-3); 50.25 (C-I); 54.67 (C-6); 71.00 (C-2); 131.45 (C-
5'); 145.69 (C-8'); 149.15 (C-6'); 151.45 (C-2'); 152.13 (C-4').
• (Ii? *,2S*,4R *,5S*)-5-(6-Chloro-9H-purin-9-yl)bicyclo[2.2.1 ]heptan-2-ol (62), m.p. = 202 - 203 °C (ethylacetate). For Ci2H13ClN4O (264.7) calculated: 54.45% C, 4.95% H, 13.39% Cl, 21.17% N; found: 57.75% C, 4.91% H, 13.19% Cl, 21.00% N. 1H NMR (DMSO, 600.13 MHz): 1.31 dddd, 1 H, Jgem = 13.3, J(3ex,4)
- 5.0, J(3ex,2) = 2.4, J(3ex,l) = 1.0 (H-3exo); 1.55 dm, 1 H, Jgem = 10.4 (H-7a);
1.65 dm, 1 H, Jgem = 10.5 (H-7b); 1.78 ddd, 1 H, Jgem = 13.3, J(3en,4) = 5.0, J(3en,2) = 6.8, J(3en,7a) = 2.4 (H-3endo); 1.83 ddd, 1 H, Jgem - 13.9, J(6en,5) = 8.4, J(6en,7b) = 2.2 (H-6endo); 2.02 dddd, 1 H, Jgem = 13.9, J(6ex,5) = 3.9, J(6ex,l) = 5.0, J(6ex,4) = 1.0 (H-3exo); 2.22 bd, 1 H, J(l,6ex) = 5.4 (H-I); 2.54 bd, 1 H, J(4,3ex) = 5.0 (H-4); 3.71 m, 1 H (H-2); 4.42 ddd, 1 H, J(5,6en) = 8.5,
J(5,6ex) = 3.9, J(5,7b) = 1.1 (H-5); 4.73 d, 1 H, J(OH,2) = 3.7 (OH); 8.75 s, 1 H (H-2'); 8.85 s, 1 H (US'). 13C NMR (DMSO, 150.92 MHz): 31.84 (C-7); 32.34 (C-6); 38.98 (C-3); 41.22 (C-4); 43.73 (C-I); 57.65 (C-5); 71.84 (C-2); 131.46 (C- 5'); 145.60 (C-8'); 149.11 (C-6'); 151.43 (C-2'); 152.22 (C-4'). • (l/?*,2i?*,45*,6i?*)-6-(6-Chloro-9H-purin-9-yl)bicyclo[2.2.1]heptan-2-ol (63), m.p.
- 156.2 - 157.2 °C (ether-hexanes). For C12H13ClN4O (264.7) calculated: 54.45% C, 4.95% H, 13.39% Cl, 21.17% N; found: 54.65% C, 5.15% H, 13.67% Cl, 20.87% N. 1H NMR (DMSO, 499.84 MHz): 0.88 dt, 1 H, Jgem = 12.6, J(3ex,2) = J(3ex,4) = 3.5 (H-3exo); 1.42 dm, 1 H, Jgem = 10.7 (H-7a); 1.85 dm, 1 H, Jgem = 10.7 (H-7b); 1.91 m, 1 H (H-3endo); 1.96 m, 1 H (H-5exo); 2.12 ddd, 1 H, Jgem =
12.8, J(5en,6) = 8.7, J(5en,7a) = 2.3 (H-5endo); 2.34 m, 1 H (H-4); 2.54 m, 1 H (H-I); 4.18 m, 1 H (H-2); 5.10 d, 1 H, J(OH,2) = 3.8 (OH); 5.30 bdd, 1 H, J(6,5en) = 8.8, J(6,5ex) = 4.5 (H-6); 8.78 s, 1 H (H-2'); 8.86 s, 1 H (H-8'). 13C NMR (DMSO, 125.70 MHz): 39.57 (C-5); 35.28 (C-7); 36.99 (C-4); 37.59 (C-3); 48.50 (C-I); 50.94 (C-6); 69.49 (C-2); 131.29 (C-5'); 146.04 (C-8'); 149.13 (C-
6'); 151.50 (C-2'); 152.17 (C-4').
• (l/?*,2/?*,4i?*,55*)-5-(6-Chloro-9H-purin-9-yl)bicyclo[2.2.1]heptan-2-ol (64), m.p. = 172.5 - 174 °C(ethylacetate). For C12H13ClN4O (264.7) calculated: 54.45% C, 4.95% H, 13.39% Cl, 21.17% N; found: 54.41% C, 4.78% H, 13.20% Cl, 21.05% N. 1H NMR (DMSO, 600.13 MHz): 0.95 dt, 1 H, Jgem = 13.1, J(3en,2) = J(3en,7b)
= 3.5 (H-3endo); 1.37 dm, 1 H, Jgem = 10.7 (H-7a); 1.71 dm, 1 H, Jgem = 10.7 (H- 7b); 1.91 dtt, 1 H, Jgem = 13.5, J(6ex,5) = J(6ex,l) = 4.2, J(6ex,2) =J(6ex,4) = 1.1 (H-6exo); 1.98 ddd, 1 H, Jgem = 13.1, J(3ex,2) = 10.1, J(3ex,4) = 5.2 (H-3exo); 2.33 m, 1 H (H-I); 2.44 bd, 1 H, J(4,3ex) = 5.1 (H-4); 2.63 ddd, 1 H, Jgem = 13.4, J(6en,5) = 8.6, J(6en,7a) = 2.4 (H-6endo); 4.09 m, 1 H (H-2); 4.58 ddd, 1 H,
J(5,6en) = 8.6, J(5,6ex) = 4.2, J(5,7a) = 1.2 (H-5); 4.83 d, 1 H, J(OH,2) = 4.0
(OH); 8.77 s, 1 H (H-2'); 8.87 s, 1 H (H-8'). 13C NMR (DMSO, 150.92 MHz): 28.93 (C-6); 34.58 (C-7); 37.44 (C-3); 42.14 (C-I); 42.92 (C-4); 58.28 (C-5); 69.39 (C-2); 131.45 (C-5'); 145.70 (C-8'); 149.14 (C-6'); 151.49 (C-2'); 152.15 (C-4'). • [(Ii? *,25*,35*,45*)-3-(6-Chloro-9H-purin-9-yl)bicyclo[2.2.1 ]hept-5-en-2- yl]methanol (65), m.p. = 158 - 159 °C. For C13H13ClN4O (276.7) calculated: 56.42% C, 4.74% H, 12.81% Cl, 20.25% N; found: 56.42% C, 4.76% H, 12.74% Cl, 19.96% N. 1H NMR: 1.63 dq, 1 H, J(Ib, 1) ~ J(7b, 3) ~ J(Ib, 4) ~ 1.7, Jgem = 9.2 (H-7b); 2.03 brdt, 1 H, J(7a, 1) ~ J(7a, 4) ~ 1.5 (H-7a); 2.79 dddd, 1 H, J(2, 1) = 3.2, J(2, 3) = 4.5, J(2, CHa) = 7.2, J(2, CHa) - 8.2 (H-2); 3.03 m, IH (H-I);
3.10 brdq, 1 H, J(4, 1) ~ 1.7, J(4, 5) = 3.2 (H-4); 3.33 ddd, 1 H, J(CHa, OH) = 4.9, Jgem = 10.5 (CHa); 3.44 ddd, 1 H, J(CHb, OH) = 5.5 (CHb); 4.01 dd, IH (H- 3); 4.65 t, 1 H (OH); 6.30 dd, 1 H, J(6, 1) = 2.7, J(6, 5) = 5.7 (H-6); 6.34 dd, 1 H (H-5); 8.78 s, 1 H and 8.96 s, 1 H (H-2', H-8'). 13C NMR: 43.35 (C-I); 47.09 (C- 7); 48.33 (C-2); 48.53 (C-4); 59.35 (C-5); 63.94 (OCH2); 131.47 (C-7'); 135.20
(C-6); 137.38 (C-5); 146.27 (C-8'); 149.16 (C-6'); 151.42 (C-2'); 152.46 (C-4). • [(IR *,2R *,3R *,45*)-3-(6-chloro-9H-purin-9-yl)bicyclo[2.2.1 ]hept-5-en-2- yl]methanol (66), m.p.= 156 - 157 °C. For C13H13ClN4O x 1A H2O (281.2) calculated: 55.52% C, 4.84% H, 12.61% Cl, 19.92% N; found: 55.50% C, 4.69% H, 12.42% Cl, 19.73% N. 1H NMR: 1.63 dq, 1 H, J(7b, 1) ~ J(7b, 3) ~ J(7b, 4) ~
1.7, Jgen, = 9.2 (H-7b); 2.03 brdt, 1 H, J(7a, 1) ~ J(7a, 4) ~ 1.5 (H-7a); 2.79 dddd, 1 H, J(2, 1) = 3.2, J(2, 3) = 4.5, J(2, CHa) = 7.2, J(2, CHa) = 8.2 (H-2); 3.03 m, IH (H-I); 3.10 brdq, 1 H, J(4, 1) ~ 1.7, J(4, 5) = 3.2 (H-4); 3.33 ddd, 1 H, J(CHa, OH) = 4.9, Jgem - 10.5 (CHa); 3.44 ddd, 1 H, J(CHb, OH) = 5.5 (CHb); 4.01 dd, IH (H-3); 4.65 t, 1 H (OH); 6.30 dd, 1 H, J(6, 1) = 2.7, J(6, 5) = 5.7 (H-6); 6.34 dd, 1 H (H-5); 8.78 s, 1 H and 8.96 s, 1 H (H-2', H-8'). 13C NMR: 43.35 (C-I); 47.09 (C-7); 48.33 (C-2); 48.53 (C-4); 59.35 (C-5); 63.94 (OCH2); 131.47 (C-7'); 135.20 (C-6); 137.38 (C-5); 146.27 (C-8'); 149.16 (C-6'); 151.42 (C-2'); 152.46 (C-4').
EXAMPLE 10: SYNTHESIS OF BENZYL-ETHER COMPRISING NUCLEOSIDE ANALOGS OF THE INVENTION SUCH AS 7
Sodium hydride (60% dispersion in mineral oil, 40 mg, 1 mmol) was added to a solution of (lR*,2R*,3R*,6R*,7S*,9S*)-2-(6-chloro-9H-purin-9-yl)-4-oxatricyclo[4.2.1.03'7] nonane-9-methanol (1) (153 mg, 0.5 mmol) and benzyl bromide (0.3 ml) in dimethylformamide (1.5 ml). ). The mixture was stirred at 0 °C for 0.5 h then at room temperature for 2 h. and evaporated. Solution of the residue in ethyl acetate (15 ml) was washed with water (2 x 5 ml), dried over anhydrous sodium sulfate and evaporated. Chromatography of the residue on silica gel (30 g) in ethyl acetate - toluene (3 : 1) followed by crystallization from ether gave 90 mg (45%) of 9- {(lR*,2R*,3R*,6R*,7S*,9S*)-9-[(benzyloxy)methyl]-4-oxatricyclo[4.2.1.03'7]non-2-yl}- 6-chloro-9H-purine (7), m.p. 113.5 - 116 °C. For C21Η2iClN4O2 (396.88) calculated: 63.55% C, 5.33% H, 8.93% Cl, 14.12% N; found: 63.63% C, 5.29% H, 8.72% Cl, 13.89% N. FAB MS, mlz (%): 396/397 (5/8) [M + H], 91(100), 57(31), 52(54). 1H NMR (DMSO-de): 1.76 dm, 1 H, Jgem = 11.7 (H-8a'); 1.81-1.87 m, 2 H (H-8b\ H-9'); 2.11 m, 1 H (H-6'); 2.61 m, 1 H (H-I '); 2.71 tq, 1 H, J(7,8a) = J(7,8b) = J(7,l) = 1.1, J(7,6) = J(7,3) = 4.7 (H-7'); 3.44 m, 2 H (CH2O); 3.79 m, 2 H (H-5'); 4.15 d, 1 H, J(2,8b) = 1.6 (H-2'); 4.51 m, 2 H (CH2O phenyl); 4.79 dd, 1 H, J(3,7) = 4.9, J(3,l) = 1.2, (H-3'); 7.25- 7.37 m, 5 H (phenyl); 8.78 s, 1 H (H-2); 8.79 s, 1 H (H-8). 13C NMR (DMSO-d6): 32.17 (C-8'); 41.31 (C-I '); 41.58 (C-6'); 45.28 (C-7'); 47.71 (C-9'); 67.12 (C-2'); 71.32 (CH2O); 72.20 (CH2O phenyl); 73.99 (C-5'); 83.54 (C-3'); 127.62 (C-4 phenyl); 127.73 (C-2 phenyl); 128.47 (C-3 phenyl); 131.28 (C-5); 138.63 (C-I phenyl); 145.83 (C-8); 149.19 (C-6); 151.52 (C-2); 152.31 (C-4).
EXAMPLE 11: SYNTHESIS OF PHOSPHATE COMPRISING NUCLEOSIDE ANALOGS OF THE INVENTION SUCH AS 6
N-methylimidazole (250 μl, 3 mmol) was added dropwise over 1 min to a stirred solution of phenyl-(methoxy-L-alaninyl)-phosphorochloridate (420 mg, 1.5 mmol) and
(lR*,2R*,3R*,6R*,7S*,9S*)-2-(6-chloro-9H-purin-9-yl)-4-oxatricyclo[4.2.1.03>7]nonane-
9-methanol (1) (153 mg, 0.5 mmol) in tetrahydrofurane (5 ml). The mixture was stirred under argon at room temperature overnight and then was evaporated. A solution of the residue in chloroform (10 ml) was washed with 1 M HCl (2 x 10 ml), saturated aqueous solution of sodium hydrogencarbonate (10 ml) and water (5 ml). The organic layer was dried over anhydrous sodium sulfate and the solvent was removed under reduced pressure. The residue was chromatographed on a silica gel column (40 g) in ethyl acetate - acetone - ethanol - water (100 : 15 : 6 : 4) to give 205 mg (75%) of (lR*,2R*,3R*,6R*,7S*,9S*)-2-(6-chloro-9H-purin-9-yl)-4-oxatricyclo[4.2.1.03'7]nonane- 9-methyl [phenyl methoxy-L-alaninyl] -phosphate (6) obtained as solid foams. For C24H27ClN5O6P (547.94) calculated: 52.61% C, 4.97% H, 6.47% Cl, 12.78% N, 5.65% P; found: 52.34% C, 5.08% H, 6.59% Cl, 12.52% N, 5.82% P. FAB MS, mlz (rel. %): 550/548 (17/ 43) [M + H], 214 (39), 200 (100). 1H NMR (DMSO-de): 1.23 m, 3H (CH3);1.75-1.93 m, 3 H (H-8a, H-8b, H-9); 2.16 m, 1 H (H-6); 2.51 brs, 2.54 brs, 2.56 brs and 2.60 brs, 1 H (H-I); 2.73 m, 1 H (H-7); 3.57 s, 3.58 s, 3.59 s and 3.59 s, 3 H (OCH3); 3.77 m, 2 H (H-5); 3.88 m, 1 H (CH); 4.00 m, 2 H (CH2O); 4.15 m, 1 H (H-2); 4.81 m, 1 H (H-3); 5.93-6.06 m, 1 H (NH); 7.09-7.22 m, 3 H (H-2 phenyl, H-4 phenyl); 7.30-7.36 m, 2 H (H-3 phenyl); 8.75 s, 8.76 s, 8.77 s and 8.78 s, 1 H (H-8'); 8.78 s and 8.79 s, 1 H (R-T). 13C NMR (DMSO-d6): 19.82, 19.88 and 19.94 (CH3); 32.05 (C-8); 40.92-41.13 m, 2 C (C-I, C-6); 45.35 (C-7); 48.10 m (C-9); 49.89 and 50.04 (CH); 52.05 (OCH3); 66.88-67.01 m, 2 C (C-2, CH2O); 73.83 (C-5); 83.44 (C-3); 120.43 m, 2 C (C-2 phenyl); 124.65 and 124.69 (C-4 phenyl); 129.74 and 129.78 2 C (C-3 phenyl); 131.26 (C-5'); 145.75 (C-8'); 149.24 (C-6'); 150.93 m (C-I phenyl); 151.56 (C-2'); 152.28 (C-4'); 173.85, 173.87, 173.97 and 174.00 (C-O).31P NMR (DMSO-d6): 3.99; 4.10; 4.39; 4.49.
EXAMPLE 12: SYNTHESIS OF NUCLEOSIDE ANALOGS OF THE INVENTION SUCH AS 8
Thionyl chloride (0.15 ml) was added dropwise to a solution of
(lR*,2R*,3R*,6R*,7S*,9S*)-2-(6-chloro-9H-purin-9-yl)-4-oxatricyclo[4.2.1.03'7]nonane- 9-methanol (1) (153 mg, 0.5 mmol) in hexamethylphosphortriamide (1 ml), the mixture was stirred at room temperature for 0.5 h and then at 80 °C for 2 h.The mixture was
poured into saturated aqueous sodium hydrogencarbonate (10 ml). The mixture was extracted with ethyl acetate (2 x 20 ml) and the combined extracts were washed with water (3 x 10 ml), dried over anhydrous sodium sulfate and evaporated. Crystallization from ether afforded 158 mg (97%) of 6-chloro-9-[(lR*,2R*,3R*,6R*,7S*,9S*)-9- (chloromethyl)- 4-oxatricyclo[4.2.1.03'7]non-2-yl]-9H-purine (~ example isomeric pure form of 8), m.p. 156.5 - 158 °C. For C14H14Cl2N4O (325.20) calculated: 51.71% C, 4.34% H, 21.80% Cl, 17.23% N; found: 51.70% C, 4.49% H, 21.59% Cl, 16.93% N. FAB MS, mlz (%): 327/325 (60/84) [M + H], 241(15), 57(100). 1H NMR (DMSO-(I6):
1.78 dm, 1 H, Jgem = 12.0 (H-8a'); 1 89 brt, 1 H, J(9,CH2) = 8.2 (H-9'); 1.93 dm, 1 H (H- 8b'); 2.21 m, 1 H (H-6'); 2.64 m, 1 H (H-I '); 2.76 tq, 1 H, J(7,8a) = J(7,8b) = J(7,l) =
1.3, J(7,6) = J(7,3) = 4.7 (H-7'); 3.72 d, 2 H, J(CH2,9) = 8.2 (CH2Cl); 3.79-3.83 m, 2 H (H-5'); 4.18 d, 1 H, J(2,8b) = 1.8 (H-2'); 4.81 dd, 1 H, J(3,7) = 5.0, J(3,l) = 1.0, (H-3');
8.79 s, 1 H (H-2); 8.80 s, 1 H (H-8). 13C NMR (DMSO-(I6): 31.92 (C-8'); 42.19 (C-I '); 43.48 (C-6'); 45.48 (C-7'); 46.91 (CH2Cl); 50.68 (C-9'); 66.85 (C-2'); 73.84 (C-5'); 83.32 (C-3'); 131.27 (C-5); 145.78 (C-8); 149.22 (C-6); 151.56 (C-2); 152.30 (C-4).
According to the same procedure, there were obtained the following compounds: • 6-Chloro-9-[(l£ *,2R *,3R *,6S*,7S*, 1 OS*)- 10-(chloromethyl)-4- oxatricyclo[4.3.1.03>7]dec-2-yl]-9H-purine (67), m.p. 192 - 193.5 °C. For C15H16Cl2N4O (339.23) calculated: 53.11% C, 4.75% H, 20.90% Cl, 16.52% N; found: 53.32 %C, 4.82 % H, 21.05 % Cl, 16.25 % N. FAB MS, m/z (%): 337/339 (59/100) [M + H], 157/155 (15/55) [6-chloropurine + H]. 1H NMR: 0.67 m, 1 H (H-9'a); 1.33 m, 1 H (H-9'b); 1.83 m, 1 H (H-8'a); 1.95 - 2.03 m, 3 H (H-6', 8'b and H-10'); 2.14 - 2.18 m, 2 H (H-I ' and H-7'); 3.58 d, 1 H, Jgem = 7.7 (H-5'a); 3.74 - 3.78 m, 2 H (CH3Cl and H-5'b); 3.88 dd, 1 H, Jgem = 10.9, J(CH5IO) = 7.3
(CHbCl); 4.53 dd, 1 H, J(2',1 ') = 4.1, J(2',9'b) = 1.5 (H-2'); 4.73 d, 1 H, J(3',7') = 5.2 (H-3'); 8.79 s, 1 H (H-2); 8.80 s, 1 H (H-8). 13C NMR: 11.19 (C-9'); 14.01 (C- 8'); 29.76 (C-I '); 35.15 (C-7'); 39.25 (C-6'); 44.16 (C-IO'); 47.44 (CH2Cl); 62.92 (C-2'); 74.86 (C-5'); 75.91 (C-3'); 131.01 (C-5); 146.30 (C-8); 149.47 (C-6); 151.72 (C-2); 152.19 (C-4).
. 6-Chloro-9-[( Ii? *,2R *,3S*,6S*,1S*,9R *)-9-(chloromethyl)-4,8- dioxatricyclo[4.2.1.03'7]non-2-yl]-9H-purine (68), m.p. 176 - 177 °C. For C13H12Cl2N4O2 (327.17) calculated: 47.72% C, 3.70% H, 21.67% Cl, 17.12% N; found: 47.67% C, 3.85% H, 21.85% Cl, 16.95% N. FAB MS, m/z (%): 329/327 (64/100) [M + H], 157/155 (5/15) [6-chloropurine + H]. 1H NMR: 2.34 dt, 1 H,
J(6',7') = J(6',5'a) = 4.7, J(6',9') = 2.0 (H-6'); 2.41 dt, 1 H, J(9',6') = 2.1, J(9',CH2) = 8.1 (H-9'); 3.61 d, 2 H, J(CH2,9') = 8.1 (CH2Cl); 3.92 dd, 1 H, Jgem = 8.8, J(5'a,6') = 4.4 (H-5'a); 4.01 d, 1 H, Jgem = 8.7 (H-5'b); 4.53 dd, 1 H, J(3',7') = 4.7, J(3',l ') = 1.4 (H-3'); 4.67 m, 2 H (H-I ' and H-2'); 5.25 t, 1 H, J(7',3') = J(7',6') = 4.7 (H-T); 8.55 s, 1 H (H-8); 8.80 s, 1 H (H-2). 13C NMR: 43.43 (C-6');
45.81 (CH2Cl); 50.80 (C-9'); 64.10 (C-2'); 71.96 (C-5'); 80.70 (C-I '); 82.17 (C- 7'); 83.07 (C-3'); 130.77 (C-5); 145.25 (C-8); 149.18 (C-6); 151.72 (C-2); 151.89 (C-4).
EXAMPLE 13: Synthesis of 6-Ch\oro-9-[(lR*,2R*,3R*,6S*,7S*,l0S*)-l0- (fluororomethyl)-4-oxatricyclo[4.3.1.03>7]dec-2-yl]-9H-purine (69)
(Diethylamino)sulfur trifluoride (DAST) (0.7 ml, 5 mmol) was added under argon to a stirred solution of chloropurine derivative 14 (321 mg, 1 mmol) and pyridine (1.3 ml) in tetrahydrofuran (12 ml). The mixture was refluxed for 4 h and then was poured under stirring into an aqueous saturated solution of potassium hydrogencarbonate (60 ml). The mixture was extracted with ethyl acetate (2 x 25 ml) and the collected extracts were washed with 10% aqueous solution of potassium hydrogencarbonate (20 ml), 5% hydrochloric acid (10ml), 10% aqueous potassium hydrogencarbonate (10 ml), dried over anhydrous sodium sulfate and evaporated. Chromatography of the residue on silica gel with ethyl acetate - toluene (22. : 3) and subsequent crystallization from methanol afforded 101 mg (31%) of fluoro derivative 69. For C15H16ClFN4O (322.77) calculated: 55.82% C, 5.00% H, 10.98% Cl, 5.89% F, 17.36% N; found: 55.76% C, 5.11% H, 11.14% Cl, 17.21% N. FAB MS, m/z (%): 325/323 (37/100) [M + H], 157/155 (5/15) [6- chloropurine + H]. 1H NMR: 0.69 m, 1 H (H-9'a); 1.36 m, 1 H (H-9'b); 1.80 m, 1 H (H- 8'a); 1.92 dt, 1 H, J(6',5'b) = J(6',7') = 3.9, J(6',3') = 1.8 (H-6'); 2.00 m, 1 H (H-8'b);
2.03 - 2.10 m, 2 H (H-I ' and H-IO'); 2.15 m, 1 H (H-7'); 3.58 d, 1 H, Jgem = 7.7 (H-5'a); 3.75 ddd, 1 H, Jgem = 7.7, J(5'b,6') = 3.9, J(5'b,F) = 0.8 (H-5'b); 4.44 dd, 1 H, J(2',l ') = 4.0, J(2',9'b) = 1.5 (H-2'); 4.48 - 4.65 m, 2 H (CH2F); 4.75 d, 1 H, J(3\7') = 5.2 (H-3'); 8.78 s, 1 H (H-2); 8.81 s, 1 H (H-8). 13C NMR: 11.82 (C-9'); 14.19 (C-8'); 28.53 d, J(1 ',F) = 5.0 (C-I '); 34.95 (C-7'); 36.09 d, J(6',F) = 7.4 (C-6'); 41.75 d, J(10',F) = 17.8 (C-IO'); 63.04 (C-2'); 74.81 (C-5'); 75.99 (C-3'); 84.50 d, J(CH2,F) = 166.9 (CH2F); 131.02 (C-5); 146.33 (C-8); 149.46 (C-6); 151.70 (C-2); 152.22 (C-4).
According to the same procedure, there were obtained the following compounds: • 6-Chloro-9-[(l/?*,2i?*,35r*,65*,7S*,9Λ*)-9-(fluoromethyl)-4,8- dioxatricyclo[4.2.1.03'7]non-2-yl]-9H-purine (70), m.p. 176 - 179 °C. For C13H12ClFN4O2 (310.72) calculated: 50.25% C, 3.89% H, 11.41% Cl, 6.11% F, 18.03% N; found: 1H NMR: 2.24 dt, 1 H, J(6',7') = J(6',5'a) = 4.6, J(6',9') = 2.1 (H-6'); 2.47 m, 1 H (H-9'); 3.90 ddd, 1 H, Jgem = 8.7, J(5'a,6') = 4.3, J(5'a,F) - 1.5 (H-5'a); 4.02 d, 1 H, Jgem = 8.7 (H-5'b); 4.32 dt, 1 H, Jgem =J(CH,9') = 9.3,
J(CH5F) = 47.7 (CH3F); 4.38 ddd, 1 H, Jgem = 9.1, J(CH,9') = 6.5, J(CH,F) = 46.8 (CHbF); 4.53 dd, 1 H, J(3',7') = 4.8, J(3',l ') = 1.5 (H-3'); 4.67 s, 1 H (H-2'); 4.70 m, 1 H (H-I '); 5.23 m, 1 H (H-7'); 8.55 s, 1 H (H-8); 8.79 s, 1 H (H-2). 13C NMR: 40.06 d, J(6',F) = 7.2 (C-6'); 48.06 d, J(9',F) = 19.1 (C-9'); 64.31 (C-2'); 71.85 (C-5'); .79.31 d, J(I ',F) = 4.8 (C-I '); 81.97 (C-7'); 82.87 d, J(CH2,F) = 167.8;
83.19 (C-3'); 130.79 (C-5); 145.30 (C-8); 149.16 (C-6); 151.71 (C-2); 151.91 (C- 4).
• 6-Chloro-9-[(15*,25*,4i? *,6R *)-6-fluorobicyclo[2.2.1 ]hept-2-yl]-9i/-purine (71), m.p. = 127.6 - 129 °C. For C12H12ClFN4 (266.7) calculated: 54.04% C, 4.54% H, 13.29% Cl, 7.12% F, 21.01% N; found: 53.92% C, 4.31% H, 20.85% N. 1H NMR
(DMSO, 499.95 MHz): 1.60 m, 1 H (H-5'exo); 1.62 m, 1 H (H-7'a); 1.84 m, 1 H (H-7'b); 1.86 m, 1 H (H-5'endo); 1.93 ddd, 1 H, Jgem = 13.0, J(3'en,2') = 8.3, J(3'en,7'a) = 2.2 (H-3'endo); 2.00 m, 1 H (H-3'exo); 2.52 m, 1 H (H-4'); 2.85 bd, 1 H, J(I ',F) = 8.8 (H-I '); 4.52 dd, 1 H, J(2',3'en) = 8.3, J(2',3'ex) = 5.0 (H-2'); 4.98 ddm, 1 H, J(6',F) = 54.5, J(6',5'en) = 6.4 (H-6'); 8.79 s, 1 H (H-2); 8.87 s, 1
H (H-8). 13C NMR (DMSO, 125.73 MHz): 32.90 (C-7'); 34.74 (C-4'); 36.54 (C-
3'); 38.45 d, J(5',F) = 19.7 (C-5'); 48.11 d, J(I ',F) = 21.9 (C-I '); 52.85 d, J(2',F) = 14.5 (C-2'); 93.71 d, J(6',F) = 181.6 (C-6'); 131.49 (C-5); 145.79 (C-8); 149.19 (C-6); 151.51 (C-2); 152.15 (C-4).
• 6-Chloro-9-[(li?*,25*,4i?*,55*)-5-fluorobicyclo[2.2.1]hept-2-yl]-9//-purine (72), m.p. = 110.9 - 112.4 °C. For C12H12ClFN4 (266.7) calculated: 54.04% C, 4.54%
H, 13.29% Cl, 7.12% F, 21.01% N; found: 53.91% C, 4.31% H, 20.71% N. 1H NMR (DMSO, 499.95 MHz): 1.60 m, 1 H (H-7'a); 1.64 ddt, 1 H, J(6'ex,F) = 39.1, Jgem = 14.4, J(6'ex,l ') = 5.1, J(6'ex,5') = JLr = 1.5 (H-6'exo); 1.72 dm, 1 H, Jgem = 11.0 (H-7'b); 1.88 ddm, 1 H, Jgem = 14.4, J(3'en,2') = 8.3 (H-3'endo); 1.99 ddd, 1 H, J(6'en,F) = 18.2, Jgem = 14.4, J(6'en,5') = 6.3, J(6'en,7'b) = 2.7 (H-
6'endo); 2.16 m, 1 H (H-3'exo); 2.58 m, 1 H (H-4'); 2.69 bd, 1 H, J(l ',6'ex) = 5.0 (H-I '); 4.47 ddm, 1 H, J(2',3'en) = 8.5, J(2',3'ex) = 3.8 (H-2'); 4.81 ddm, 1 H, J(5',F) = 56.0, J(5',6'en) = 6.3 (H-5'); 8.77 s, 1 H (H-2); 8.87 s, 1 H (H-8). 13C NMR (DMSO, 125.73 MHz): 29.96 d, J(3',F) = 11.5 (C-3'); 32.22 (C-7'); 36.94 d, J(6',F) = 20.7 (C-6'); 40.75 (C-I '); 41.74 d, J(4',F) = 20.7 (C-4'); 57.03 (C-2');
94.46 d, J(5',F) = 180.8 (C-5'); 131.50 (C-5); 145.68 (C-8); 149.17 (C-6); 151.46 (C-2); 152.26 (C-4).
EXAMPLE 14: Synthesis of 9-[(l/?*,2i?*,45*)-bicyclo[2.2.1]hept-2-yl]-9H-purine-6- thiol (38)
Mixture of chloropurine (17, 720 mg, 2.9 mmol), thiourea (300 mg, 3.7 mmol) was refluxed in ethanol (15 ml) for 2 hours, cooled to 4 °C in the refrigerator and the crystalline product was filtred off (520 mg, 72.8%). Second crop (110 mg, 15.4%) of the product was obtained after collumn chromatography on silica gel collumn (100 g) in ethylacetate. M.p. > 300 °C . For C12H14N4S (246.3) calculated: 58.51% C, 5.73% H, 22.74% N, 13.02% S; found: 58.15% C, 5.69% H, 22.47% N, 12.99% S. 1H NMR (DMSO, 600.13 MHz): 1.25 m, 2 H (H-5'endo and H-7'a); 1.36 dddd, 1 H, Jgem = 12.0, J(6'en,5'en) = 9.4, J(6'en,5'ex) = 3.8, J(6'en,7'b) = 2.3 (H-6'endo); 1.53 m, 1 H (H- 5'exo); 1.60 tt, 1 H, Jgem = J(6'ex,5'ex) = 12.2, J(6'ex,5'en) = J(6'ex,l ') = 4.4 (H-6'exo); 1.66 dm, 1 H, Jgem = 10.3 (H-7'b); 1.97 m, 2 H (H-3'endo and H-3'exo); 2.41 tm, 1 H,
J(4',3 'ex) = J(4',5'ex) = 4.2 (H-4'); 2.46 dm, 1 H, J(I ',6 'ex) = 4.5 (H-I '); 4.42 ddd, 1 H, J(2',3'en) = 8.4, J(2',3'ex) = 4.6, J(2',7'a) = 1.2 (H-2'); 8.19 s, 1 H (H-2); 8.44 s, 1 H (H-8); 13.71 bs, 1 H (SH). 13C NMR (DMSO, 150.92 MHz): 26.96 (C-6'); 27.94 (C-5'); 35.69 (C-7'); 35.89 (C-4'); 37.82 (C-3'); 42.46 (C-I '); 57.81 (C-2'); 135.53 (C-5); 140.99 (C-8); 144.25 (C-4); 144.84 (C-2); 176.02 (C-6).
EXAMPLE 15: Syntesis of 9-[(li?*,2i?*,4S*)-bicyclo[2.2.1]hept-2-yl]-6- (methylsulfanyl)-9H"-purine (39)
Mixture of purine (44, 270 mg, 1.1 mmol), K2CO3 (166 mg, 1.2 mmol) and iodomethane (0.2 ml, 3.2 mmol) was stirred at 0 °C for 4 hours in dimethylformamide (20 ml). Reaction mixture was evaporated, partitionated between ethylacetate (50 ml) and water (20 ml). Organic phase was washed with water (2 x 20 ml), saturated solution of sodium thiosulfate (2 x 25 ml), water (2 x 20 ml) and dried over anhydrous sodium sulfate and evaporated. The pure product (105 mg, 36.7%) was obtained after crystallization from water-methanol. M.p. = 92 - 93.5 0C. For C13H16N4S (246.3) calculated: 59.97% C, 6.19% H, 21.52% N, 12.32% S; found: 60.10% C, 6.21% H, 21.29% N, 12.23% S. 1H NMR (DMSO, 600.13 MHz): 1.26 m, 2 H (H-5'endo and H-7'a); 1.39 dddd, 1 H, Jgem = 12.1, J(6'en,5'en) = 9.0, J(6'en,5'ex) = 4.0, J(6'en,7'b) = 2.3 (H-6'endo); 1.49 m, 1 H (H-5'exo); 1.61 tt, 1 H, Jgem = J(6'ex,5'ex) = 12.1, J(6'ex,5'en) = J(6'ex,l ') - 5.0 (H- 6'exo); 1.71 dm, 1 H, Jgem = 10.3 (H-7'b); 1.97 ddd, 1 H, Jgem = 13.3, J(3'en,2') = 8.5, J(3'en,7'a) = 0.9 (H-3'endo); 2.05 m, 1 H (H-3'exo); 2.42 m, 1 H (H-4'); 2.49 m, 1 H (H- 1 '); 2.65 s, 3 H (SCH3); 4.52 ddd, 1 H, J(2',3'en) = 8.5, J(2',3'ex) = 4.4, J(2',7'a) = 0.9 (H-2'); 8.60 s, 1 H (H-8); 8.72 s, 1 H (H-2). 13C NMR (DMSO, 150.92 MHz): 11.36 (SCH3); 26.99 (C-6'); 27.97 (C-5'); 35.78 (C-7'); 35.91 (C-4'); 37.76 (C-3'); 42.32 (C- 1 '); 57.79 (C-2'); 131.32 (C-5); 142.59 (C-8); 148.38 (C-4); 151.41 (C-2); 159.90 (C-6).
EXAMPLE 16: Synthesis of 9-[(l/?*,2i?*,4S*)-bicyclo[2.2.1]hept-2-yl]-6- (methylsulfonyl)-9//-purine (45) S-methylthiopurine (39, 1.2 mmol) was dissolved in chloroform (20 ml). To this mixture was slowly added solution of m-chlorperbenzoic acid (1.46 g, 5.9 mmol, 65%) in
chloroform (25 ml). Reaction mixture was stirred for 2 days, diluted with ethylacetate (100 ml) and washed with saturated solution of sodium thiosulfate (70 ml), saturated solution OfNaHCO3 (2 x 70 ml) and dried over anhydrous sodium sulfate and evaporated. Residue was chromatographed on silica gel column (150 g) in toluene - ethylacetate (1 :1). It was obtained 140 mg (40.6%) of the product (crystallized from water-methanol). M.p. = 126.1 - 128.7 °C. For C13H16N4O2S x H2O (310.4) calculated: 50.31% C, 5.85% H, 18.05% N, 10.33% S; found: 50.25% C, 5.42% H, 17.71% N, 10.37% S. 1H NMR (DMSO, 600.13 MHz): 1.28 m, 2 H (H-5'endo and H-7'a); 1.41 dddd, 1 H, Jgem = 12.1, J(6'en,5'en) = 9.1, J(6'en,5'ex) = 4.2, J(6'en,7'b) = 2.3 (H-6'endo); 1.54 m, 1 H (H- 5'exo); 1.63 tt, 1 H, Jgem = J(6'ex,5'ex) = 12.1, J(6'ex,5'en) = J(6'ex,l ') = 4.5 (H-6'exo); 1.73 dm, 1 H, Jgem = 10.3 (H-7'b); 2.01 ddd, 1 H, Jgem = 13.3, J(3'en,2') = 8.4, J(3'en,7'a) = 2.3 (H-3'endo); 2.08 m, 1 H (H-3'exo); 2.44 bt, 1 H, J(4',3'ex) = J(4',5'ex) = 4.6 (H- 4'); 2.56 bd, 1 H, J(I ',6'ex) = 4.8 (H-I '); 3.87 s, 3 H (SO2CH3); 4.59 ddd, 1 H, J(2',3'en) - 8.4, J(2',3'ex) = 4.4, J(2',7'a) = 1.2 (H-2'); 8.78 s, 1 H (H-2); 8.85 s, 1 H (H-8). 13C NMR (DMSO, 150.92 MHz): 26.95 (C-6'); 27.95 (C-5'); 35.82 (C-V); 35.93 (C-4'); 37.77 (C-3'); 41.65 (SO2CH3); 42.19 (C-I '); 58.39 (C-2'); 123.16 (C-5); 145.56 (C-8); 150.95 (C-2); 153.38 (C-6); 154.91 (C-4).
EXAMPLE 17: Synthesis of 9-[(li?*,2i?*,45*)-bicyclo[2.2.1]hept-2-yl]-9H-purine (43)
Solution of 17 (250 mg, 1.01 mmol) in methanol (20 ml), triethylamine (0.3 ml) was stirred with Pd(OH)2 (20% on charcoal, 120 mg) in atmosphere of hydrogen for 2 days. The catalyst was filtered off and washed with methanol and filtrate was evaporated. Residue was patitionated between ethylacetate (30 ml) and water (10 ml). Organic phase was dried over anhydrous sodium sulfate and evaporated. Residue was crystallized from petrolether-ether to afford 116 mg (53.6%) of the saturated compound. M.p. = 86.2 - 87.6 °C. For C12H14N4 (214.3) calculated: 67.27% C, 6.59% H, 26.19% N; found: 67.40% C, 6.51% H, 25.98% N. 1H NMR (DMSO, 600.13 MHz): 1.27 m, 2 H (H-5'endo and H- 7'a); 1.41 dddd, 1 H, Jgem = 12.1, J(6'en,5'en) = 9.0, J(6'en,5'ex) = 4.0, J(6'en,7'b) = 2.3 (H-6'endo); 1.54 m, 1 H (H-5'exo); 1.62 tt, 1 H, Jgem = J(6'ex,5'ex) = 12.2, J(6'ex,5'en) = J(6'ex,l ') = 4.5 (H-6'exo); 1.73 dm, 1 H, Jgetn = 10.3 (H-7'b); 2.00 ddd, 1 H, Jgem =
13.3, J(3'en,2') = 8.5, J(3'en,7'a) = 2.4 (H-3'endo); 2.07 m, 1 H (H-3'exo); 2.43 bt, 1 H, J(4',3'ex) = J(4',5'ex) - 4.3 (H-4'); 2.52 bd, 1 H, J(I \6'ex) = 4.6 (H-I '); 4.57 ddd, 1 H, J(2',3'en) - 8.5, J(2\3'ex) = 4.5, J(2',7'a) = 1.4 (H-2'); 8.77 s, 1 H (H-8); 8.93 s, 1 H (H-2), 9.14 s, 1 H (H-6). 13C NMR (DMSO, 150.92 MHz): 27.01 (C-6'); 27.96 (C-5'); 35.85 (C-7'); 35.91 (C-4'); 37.76 (C-3'); 42.24 (C-I '); 57.57 (C-2'); 134.26 (C-5); 145.03 (C-8); 147.99 (C-6); 151.32 (C-4); 151.95 (C-2).
EXAMPLE 18: Synthesis of 9-[(li?*,2i?*,45*)-bicyclo[2.2.1]hept-2-yl]-6-iodo-9H- purine (44)
The compound 17 (400 mg, 1.61 mmol) was added portionswise into a stirred 57% aqueous HI (5 ml) at 0 0C and the resulting suspension was stirred at 0 °C for 2 h. Reaction mixture was poured onto water + ice (50 ml) and 35% aqueous NH3 (15 ml) was added. To this mixture, ethylacetate (150 ml) was added. Organic phase was washed with saturated aqueous Na2S2O3 (2 x 70 ml), and water (100 ml). The solvent was evaporated and the residue chromatographed on a silica gel column (150 g, toluene - ethyl acetate 6:1) to give the 6-iodopurine (390 mg, 71.2%) which was recrystallized from water-methanol. M.p. = 164.5 - 166 °C. For Ci2H13IN4 (340.2) calculated: 42.37% C, 3.85% H, 37.31% I, 16.47% N; found: 42.49% C, 3.77% H, 36.96% I, 16.17% N. 1H NMR (DMSO, 600.13 MHz): 1.27 m, 2 H (H-5'endo and H-7'a); 1.39 dddd, 1 H, Jgem = 12.1, J(6'en,5'en) = 9.1, J(6'en,5'ex) = 3.0, J(6'en,7'b) = 2.3 (H-6'endo); 1.54 m, 1 H (H-5'exo); 1.61 tt, 1 H, Jgem = J(6'ex,5'ex) = 12.1, J(6'ex,5'en) = J(6'ex,l ') = 4.5 (H- 6'exo); 1.71 dm, 1 H, Jgem = 10.3 (H-7'b); 1.98 ddd, 1 H, Jgem = 13.3, J(3 'en,2') = 8.5, J(3'en,7'a) = 2.3 (H-3'endo); 2.06 m, 1 H (H-3'exo); 2.42 bt, 1 H, J(4',3'ex) = J(4',5'ex) = 4.5 (H-4'); 2.54 bd, 1 H, J(l ',6'ex) = 4.7 (H-I '); 4.53 ddd, 1 H, J(2',3'en) = 8.5, J(2',3'ex) = 4.4, J(2',7'a) = 1.1 (H-2'); 8.61 s, 1 H (H-2); 8.81 s, 1 H (H-8). 13C NMR (DMSO, 150.92 MHz): 26.94 (C-6'); 27.95 (C-5'); 35.81 (C-7'); 35.91 (C-4'); 37.71 (C- 3'); 42.15 (C-I '); 58.24 (C-2'); 122.80 (C-6); 138.55 (C-5); 144.56 (C-8); 148.16 (C-4); 151.65 (C-2).
EXAMPLE 19: Synthesis of 6-azido-9-[(li?*,2Λ*,4S*)-bicyclo[2.2.1]hept-2-yl]-9H- purine (73)
Solution of 9-[(lR*,2R*,4S*)-bicyclo[2.2.1]hept-2-yl]-6-chloro-9Η-purine (1.29 g, 5.2 mmol), sodium azide (680 mg, 10.4 mmol) in dimethylformamide (40 ml) was heated with stirring under argon atmosphere for 2 hours, evaporated and partitionated between ethylacetate (150 ml) and water (80 ml). Organic phase was washed with brine (2 x 80 ml) and dried over anhydrous sodium sulfate and evaporated (1.24 g, 93%). The pure product (920 mg, 69.3%) was obtained after crystallization from water-methanol. M.p. = 181.0 - 183.3 0C (decomp.). For C12H13N7 (255.3) calculated: 56.46% C, 5.13% H,
38.41% N; found: 56.24% C, 5.18% H, 38.02% N. 1H NMR (DMSO, 499.84 MHz): 1.27
- 1.33 m, 1 H (H-5'endo and H-7'a); 1.45 m, 1 H (H-6'endo); 1.56 m, 1 H (H-5'exo); 1.65 tt, 1 H, Jgem = J(6'ex,5'ex) = 12.0, J(6'ex,5'en) = J(6'ex,l ') = 4.4 (H-6'exo); 1.71 dm, 1 H, Jgem = 10.3 (H-7'b); 2.08 m, 2 H (H-3'endo and H-3'exo); 2.46 m, 1 H (H-4'); 2.56 bd, 1 H, J(I ',6 'ex) = 4.3 (H-I '); 4.69 m, 1 H (H-2'); 8.80 s, 1 H (H-8); 10.08 s, 1 H (H-2). 13C NMR (DMSO, 125.70 MHz): 26.97 (C-6'); 27.98 (C-5'); 35.78 (C-7'); 36.00 (C-4'); 38.10 (C-3'); 42.61 (C-I '); 58.72 (C-2'); 120.33 (C-5); 135.58 (C-2); 142.32 (C- 8); 142.53 (C-4); 145.67 (C-6).
EXAMPLE 20: Synthesis of 9-[(lR*,2Λ*,45'*)-bicyclo[2.2.1]hept-2-yl]-9H-purin-6-amine (74)
Solution of the azidopurine 73 (1.14 g, 4.5 mmol) in methanol (20 ml) was stirred with Pd(OH)2 (20% on charcoal , 200 mg) in atmosphere of hydrogen for 1 day. The catalyst was filtered off and washed with methanol and filtrate was evaporated. Residue was crystallized from ethylacetate to afford 850 mg (82.4%) of the amino compound. M.p. = 212.6 - 214.5 °C (decomp.). For C12H15N5 (229.3) calculated: 62.86% C, 6.59% H, 30.54% N; found: 62.53% C, 6.56% H, 30.19% N. 1H NMR (DMSO, 499.84 MHz): 1.22
- 1.27 m, 2 H (H-5'endo and H-7'a); 1.37 m, 1 H (H-6'endo); 1.53 m, 1 H (H-5'exo); 1.59 tt, 1 H, Jgem = J(6'ex,5'ex) = 12.2, J(6'ex,5'en) = J(6'ex,l ') = 4.5 (H-6'exo); 1.70 dm, 1 H, Jgem = 10.2 (H-7'b); 1.93 ddd, 1 H, Jgem = 13.2, J(3'en,2') = 8.5, J(3'en,7'a) = 2.2 (H-3'endo); 2.01 m, 1 H (H-3'exo); 2.41 m, 1 H (H-4'); 2.43 bd, 1 H, J(I ',6 'ex) = 4.7
(H-I '); 4.41 ddd, 1 H, J(2',3'en) = 8.4, J(2',3'ex) = 4.6, J(2',7'a) = 1.1 (H-2'); 7.18 bs, 2 H (NH2); 8.12 s, 1 H (H-2); 8.26 s, 1 H (H-8). 13C NMR (DMSO, 125.70 MHz): 27.09 (C-6'); 28.03 (C-5'); 35.75 (C-7'); 35.89 (C-4'); 37.87 (C-3'); 42.47 (C-I '); 57.26 (C-2'); 119.32 (C-5); 138.80 (C-8); 149.74 (C-4); 152.44 (C-2); 156.18 (C-6).
EXAMPLE 21: Synthesis of 9-[(li?*,2i?*,45*)-bicyclo[2.2.1]hept-2-yl]-6-fluoro-9H- purine (75)
To a solution of 17 (205 mg, 0.82 mmol) in toluene (10 ml) was added AgF (750 mg, 5.9 mmol). Reaction mixture was refiuxed for 2 hours, inorganic salts were filltred off and filtrate was evaporated. Residue was dissolved in mixture ether-chloroform (25 ml, 9:1) and organic phase was washed with saturated EDTA (15 ml) and water (15 ml), dried over anhydrous sodium sulfate and evaporated. Residue was chromatographed on silica gel (20 g) in toluene-ethylacetate (6:1). It was obtained 136 mg (71.4%) of the flouro derivative. Compound was crystallized from water-methanol. M.p. = 96 - 97 °C. For C12Hi3FN4 (232.3) calculated: 62.06% C, 5.64% H, 8.18% F, 24.12% N; found: 62.07% C, 5.92% H, 8.26% F, 24.12% N. 1H NMR (DMSO, 499.84 MHz): 1.24 - 1.30 m, 2 H (H-5'endo and H-7'a); 1.41 m, 1 H (H-6'endo); 1.54 m, 1 H (H-5'exo); 1.62 tt, 1 H, Jgem = J(6'ex,5'ex) = 12.1, J(6'ex,5'en) = J(6'ex,l ') = 4.5 (H-6'exo); 1.72 dm, 1 H, Jgem = 10.3 (H-7'b); 2.00 ddd, 1 H, Jgem = 13.3, J(3'en,2') = 8.4, J(3'en,7'a) = 2.2 (H-3'endo); 2.07 m, 1 H (H-3'exo); 2.43 m, 1 H (H-4'); 2.55 bd, 1 H, J(l ',6'ex) = 4.6 (H-I'); 4.58 ddd, 1 H, J(2',3'en) = 8.4, J(2',3'ex) = 4.5, J(2',7'a) = 0.9 (H-2'); 8.67 d, 1 H, J(2,F) = 0.9 (H-2); 8.83 s, 1 H (H-8). 13C NMR (DMSO, 125.70 MHz): 26.97 (C-6'); 27.95 (C- 5'); 35.83 (C-7'); 35.95 (C-4'); 37.83 (C-3'); 42.23 (C-I '); 58.48 (C-2'); 119.84 d, J(5,F) = 29.1 (C-5); 145.35 d, J(8,F) = 2.7 (C-8); 151.15 d, J(2,F) = 14.2 (C-2); 155.92 d, J(4,F) = 11.8 (C-4); 158.94 d, J(6,F) = 255.4 (C-6).
EXAMPLE 22: Synthesis of 9-[(li?*,2Λ*,45*)-bicyclo[2.2.1]hept-2-yl]-6-(4- chlorophenyl)-9H-purine (76)
Toluene (12 ml) was added to an argon-purged flask containing 17 (300 mg, 1.21 mmol), K2CO3 (242 mg, 1.82 mmol), 4-chlorphenylboronic acid (283 mg, 1.8 mmol) and Pd(PPh3)4 (71 mg, 0.07 mmol) and the mixture was stirred under argon at 100 0C for 8 h. After cooling to ambient temperature the mixture was evaporated and the residue was chromatographed on a silica gel column (60 g, ethyl acetate-petrolether 1:7). It was obtained 220 mg (56%). Compound was crystallized from water-acetone. M.p. = 167 - 169 °C. For C18H17ClN4 (324.8) calculated: 66.56% C, 5.28% H, 10.92% Cl, 17.25% N; found: 66.61% C, 5.30% H, 11.20% Cl, 16.98% N. 1H NMR (DMSO, 499.84 MHz): 1.26 - 1.32 m, 2 H (H-5'endo and H-7'a); 1.43 m, 1 H (H-6'endo); 1.56 m, 1 H (H-5'exo); 1.64 tt, 1 H, Jgem = J(6'ex,5'ex) = 12.0, J(6'ex,5'en) = J(6'ex,l ') = 4.5 (H-6'exo); 1.75 dm, 1 H, Jgem = 10.3 (H-7'b); 2.02 ddd, 1 H, Jgem = 13.3, J(3'en,2') - 8.4, J(3'en,7'a) = 2.2 (H-3'endo); 2.10 m, 1 H (H-3'exo); 2.45 m, 1 H (H-4'); 2.55 bd, 1 H, J(l ',6'ex) = 4.9 (H-I '); 4.61 ddd, 1 H, J(2',3'en) = 8.4, J(2',3'ex) = 4.3, J(2\7'a) = 1.0 (H-2'); 7.67 m, 2 H (H-3"); 8.84 s, 1 H (H-8); 8.87 m, 2 H (H-2"); 8.98 s, 1 H (H-2). 13C NMR (DMSO, 125.70 MHz): 27.03 (C-6'); 28.02 (C-5'); 35.87 (C-7'); 35.96 (C-4'); 37.80 (C-3'); 42.26 (C-I '); 57.76 (C-2'); 129.07 (C-3"); 130.92 (C-5); 131.21 (C-2"); 134.52 (C-I "); 136.08 (C-4"); 144.81 (C-8); 151.27 (C-6); 151.76 (C-2); 152.77 (C-6).
EXAMPLE 23: Synthesis of 9-[(lΛ* 2Λ*,4S*)-bicyclo[2.2.1]hept-2-yl]-6- (trifluoromethyl)-9H-purine (77)
A mixture of the iodopurine derivative (44) (300 mg, 0.94 mmol), CF3SiMe3 (206 μl, 1.4 mmol), KF (82 mg, 1.4 mmol), CuI (304 mg, 1.6 mmol), DMF (1 ml) and NMP (1 ml) was stirred and heated at 60 0C for 40 h in an argon atmosphere. After cooling to room temperature the solvents were evaporated and the residue was chromatographed on a column of silica gel (170 g) in toluene - ethylacetate (20:1). It was obtained 215 mg (81%). Compound was crystallized from water-methanol. M.p. = 116.3 - 118 °C. For C13H13FN4 (282.3) calculated: 55.32% C, 4.64% H, 20.19% F, 19.85% N; found: 55.09% C, 4.53% H, 19.74% Cl, 19.60% N. 1H NMR (DMSO, 499.84 MHz): 1.26 - 1.32 m, 2 H (H-5'endo and H-7'a); 1.42 m, 1 H (H-6'endo); 1.56 m, 1 H (H-5'exo); 1.64 tt, 1 H, Jgem = J(6'ex,5'ex) = 12.1, J(6'ex,5'en) = J(6'ex,l ') = 4.5 (H-6'exo); 1.74 dm, 1 H, Jgem =
10.4 (H-7'b); 2.02 ddd, 1 H, Jgem = 13.3, J(3'en,2') = 8.5, J(3'en,7'a) = 2.3 (H-3'endo); 2.10 m, 1 H (H-3'exo); 2.44 m, 1 H (H-4'); 2.60 dm, 1 H, J(l ',6'ex) = 4.5 (H-I '); 4.63 ddd, 1 H, J(2',3'en) = 8.5, J(2',3'ex) = 4.4, J(2',7'a) = 1.1 (H-2'); 9.02 s, 1 H (H-8); 9.12 q, 1 H, J(2,F) = 0.6 (H-2). 13C NMR (DMSO, 125.70 MHz): 26.97 (C-6'); 27.98 (C-5'); 35.89 (C-7'); 35.96 (C-4'); 37.78 (C-3'); 42.07 (C-I '); 58.25 (C-2'); 121.19 q, J(C5F) = 275.5 (CF3); 130.20 (C-5); 142.65 q, J(6,F) = 35.8 (C-6); 147.97 (C-8); 151.35 (C-2); 154.16 (C-4).
EXAMPLE 24: Synthesis of 9-[(li?*,2i?*,45'*)-bicyclo[2.2.1]hept-2-yl]-6-methoxy-9H- purine (78)
To a solution of 17 (490 mg, 1.97 mmol) in methanol (10 ml) was added a solution of MeONa (prepared from 68 mg Na and 10 ml MeOH). Reaction mixture was stirred overnight, evaporated and residue was chromatographed on silca gel (40 g) in toluene - ethylacetate (2:1) to afford 365 mg (76%) of product. Compound was crystallized from pentane-ether. M.p. = 72 - 74.5 0C. For C13Hi6N4O (244.3) calculated: 63.91% C, 6.60% H, 22.93% N; found: 63.73% C, 6.59% H, 22.81% N. 1H NMR (DMSO, 499.84 MHz): 1.22 - 1.28 m, 2 H (H-5'endo and H-7'a); 1.39 m, 1 H (H-6'endo); 1.52 m, 1 H (H- 5'exo); 1.60 tt, 1 H, Jgem = J(6'ex,5'ex) = 12.1, J(6'ex,5'en) = J(6'ex,l ') = 4.5 (H-6'exo); 1.70 dm, 1 H, Jgem = 10.3 (H-7'b); 1.97 ddd, 1 H, Jgem = 13.2, J(3'en,2') = 8.4, J(3'en,7'a) = 2.1 (H-3'endo); 2.02 m, 1 H (H-3'exo); 2.41 m, 1 H (H-4'); 2.47 bd, 1 H, J(l ',6'ex) = 4.5 (H-I '); 4.08 s, 3 H (OCH3); 4.51 ddd, 1 H, J(2',3'en) = 8.3, J(2',3'ex) = 4.5, J(2',7'a) = 1.1 (H-2'); 8.51 s, 1 H (H-2); 8.52 s, 1 H (H-8). 13C NMR (DMSO, 125.70 MHz): 27.02 (C-6'); 27.97 (C-5'); 35.78 (C-7'); 35.91 (C-4'); 37.86 (C-3'); 42.38 (C-I '); 54.07 (OCH3); 57.81 (C-2'); 121.19 (C-5); 141.81 (C-8); 151.42 (C-2); 152.24 (C-4); 160.43 (C-6).
EXAMPLE 25: Synthesis of 9-[(li?*,2i?*,45*)-bicyclo[2.2.1]hept-2-yl]-6-methyl-9H- purine (79)
A solution of 17 (360 mg, 1.44 mmol) in THF (15 ml) was added to a mixture of methyltriphenylphosphonium iodide (1.14 g, 3.17 mmol) and n-butyllithium (1.6 M in tetrahydrofuran, 1.9 ml). Reation mixture was refluxed under argon for 5 hours. Sodium carbonate (500 mg) in water (15 ml) was added and refluxing continued an additional 8 h. The reaction mixture was diluted with ethylacetate (100 ml) and water (20 ml). Organic phase was washed with water (40 ml), dried over anhydrous sodium sulfate and evaporated. Residue was chromatographed on silica gel (150 g) in ethylacetate - toluene (4:1) → ethylacetate. It was obtained 249 mg (75.7%) as a solid foam. For C13H16N4 (228.3) calculated: 68.39% C, 7.06% H, 24.54% N; found: 68.34% C, 6.97% H, 24.35% N. 1H NMR (DMSO, 499.95 MHz): 1.23 - 1.29 m, 2 H (H-5'endo and H-7'a); 1.40 m, 1 H (H-6'endo); 1.53 m, 1 H (H-5'exo); 1.61 tt, 1 H, Jgem = J(6'ex,5'ex) = 12.1, J(6'ex,5'en) = J(6'ex,l ') = 4.5 (H-6'exo); 1.72 dm, 1 H, Jgem = 10.3 (H-7'b); 1.98 ddd, 1 H, Jgem = 13.3, J(3'en,2') = 8.4, J(3'en,7'a) = 2.2 (H-3'endo); 2.06 m, 1 H (H-3'exo); 2.42 m, 1 H (H-4'); 2.49 m, 1 H (H-I '); 2.70 s, 3 H (CH3); 4.53 ddd, 1 H, J(2',3'en) = 8.4, J(2',3'ex) = 4.4, J(2',7'a) - 1.1 (H-2'); 8.64 s, 1 H (H-8); 8.74 s, 1 H (H-2). 13C NMR (DMSO, 125.73 MHz): 19.19 (CH3); 27.00 (C-6'); 27.96 (C-5'); 35.81 (C-7'); 35.88 (C-4'); 37.73 (C-3'); 42.28 (C-I '); 57.62 (C-2'); 132.95 (C-5); 143.44 (C-8); 150.45 (C-4); 151.50 (C-2); 157.98 (C-6).
EXAMPLE 26: Synthesis of 9-[(li?*,2i.*,45*)-bicyclo[2.2.1]hept-2-yl]-6-chloro-2-nitro- 9H-purine (48)
Trifluoroaceticacid anhydride (0.37 ml, 2.58 mmol) was added dropwise to a solution of 1 (400 mg, 1.6 mmol) and tetrabutylammonium nitrate (790 mg, 2.6 mmol) in dry CH2Cl2 (5 ml) at 0 °C under a argon atmosphere. After stirring for 1 h the solution was poured into 75 ml of sat. aqueous NaHCO3-ice (1:1). The aqueous layer was extracted with 2 portions of 50 ml EtOAc-CHCl3 (3:1). The collected organic layers were washed with water (100 ml) and dried over anhydrous sodium sulfate and evaporated. Residue was chromatographed on silica gel (180 g) in toluene - ethylacetate (6:1) to afford 212 mg (45%) of product. Compound was crystallized from water-methanol. M.p. = 147 - 151 0C. For Ci2H12ClN5O2 (244.3) calculated: 49.07% C, 4.12% H, 12.07% Cl, 23.84%
N; found: 48.78% C, 4.03% H, 12.07% Cl, 23.62% N. 1H NMR (DMSO, 600.13 MHz): 1.31 m, 2 H (H-5'endo and H-7'a); 1.44 dddd, 1 H, Jgem = 12.2, J(6'en,5'en) = 9.1, J(6'en,5'ex) = 4.2, J(6'en,7'b) = 2.3 (H-6'endo); 1.55 m, 1 H (H-5'exo); 1.65 tt, 1 H, Jgem = J(6'ex,5'ex) = 12.2, J(6'ex,5'en) = J(6'ex,l ') = 4.6 (H-6'exo); 1.77 dm, 1 H, Jgem = 10.4 (H-7'b); 2.06 m, 2 H (H-3'endo and H-3'exo); 2.45 m, 1 H (H-4'); 2.65 dm, 1 H, J(I \6'ex) = 4.6 (H-I '); 4.60 m, 1 H (H-2'); 9.20 s, 1 H (H-8). 13C NMR (DMSO, 150.92 MHz): 26.96 (C-6'); 27.85 (C-5'); 35.96 (C-7'); 35.98 (C-4'); 38.03 (C-3'); 42.02 (C-I '); 59.03 (C-2'); 134.64 (C-5); 149.27 and 149.92 (C-2 and C-6); 149.92 (C-8); 152.37 (C-
4).
EXAMPLE 27: Synthesis of 9-[(lΛ*,2i?*,4S*)-bicyclo[2.2.1]hept-2-yl]-8-bromo-6- chloro-9H-purine (41)
Preparation of lithium salt: A stirred solution of diisopropylamine (0.24 ml, 2.6 mmol) in dry TΗF (5 ml) was cooled to -78 °C under argon. n-Butyllithium (1.6 M in hexanes, 1.1 ml, 2.6 mmol) was added dropwise and the mixture stirred for 0.5 hour. A solution of 17 (300 mg, 1.21 mmol) in TΗF (10 ml) was added slowly and the mixture stirred for 1.5 h at -78 0C. This lithiated intermediate was used for preparation of 8-substituted-6-chloropurines by quenching with the appropriate reagent.
A solution of dibromotetrachloroethane (790 mg, 2.4 mmol) in dry TΗF (8 ml) was added to the lithiated intermediate and the mixture was stirred for 2 hour at -78 °C. Saturated aqueous solution of NH4Cl (20 ml) was added. The mixture was allowed to warm to room temperature. Water (60 mL) was added to the mixture and the mixture was extracted with EtOAc (2 x 100 ml). The organic phase was dried over anhydrous sodium sulfate and evaporated. Residue was chromatographed on silica gel (150 g) in toluene - ethylacetate (24:1) to afford 286 mg (72.2%) of product. Compound was crystallized from water-methanol. M.p. = 152 - 154 °C. For C12H12BrClN4 (327.6) calculated: 43.99% C, 3.69% H, 23.39% Br, 10.82% Cl, 17.10% N; found: 43.80% C, 3.54% H, 16.77% N. 1H NMR (DMSO, 600.13 MHz): 1.28 m, 2 H (H-5'endo and H-7'a); 1.36 dddd, 1 H, Jgem = 11.8, J(6'en,5'en) = 8.9, J(6'en,5'ex) = 3.9, J(6'en,7'b) = 2.3 (H-
6'endo); 1.55 m, 1 H (H-5'exo); 1.62 tt, 1 H, Jgem = J(6'ex,5'ex) = 12.2, J(6'ex,5'en) = J(6'ex,l ') = 4.5 (H-6'exo); 1.89 ddd, 1 H, Jgem = 13.0, J(3'en,2') = 8.8, J(3'en,7'a) = 2.3 (H-3'endo); 2.19 dm, 1 H, Jgem = 10.0 (H-7'b); 2.47 bt, 1 H, J(4',3'ex) = J(4',5'ex) = 4.4 (H-4'); 2.46 bd, 1 H, J(l ',6'ex) = 4.6 (H-I '); 2.85 m, 1 H (H-3'exo); 4.50 ddd, 1 H, J(2',3'en) = 8.8, J(2',3'ex) = 4.7, J(2',7'a) = 1.3 (H-2'); 8.73 s, 1 H (H-2). 13C NMR (DMSO, 150.92 MHz): 27.49 (C-6'); 28.12 (C-5'); 35.59 (C-7'); 35.99 (C-4'); 36.86 (C- 3'); 42.60 (C-I '); 63.86 (C-2'); 131.59 (C-5); 137.40 (C-8); 147.95 (C-6); 150.98 (C-2); 152.96 (C-4).
EXAMPLE 28: Synthesis of 9-[(li?*,2i?*,4S*)-bicyclo[2.2.1]hept-2-yl]-6-chloro-8-iodo- 9H-purine (46)
A solution of iodine (615 mg, 2.4 mmol) in dry TΗF (10 ml) was added to the lithiated intermediate (see Example27) and the mixture was stirred for 2 hour at -78 0C. A saturated aqueous solution Of NH4Cl (20 ml) was added. The mixture was allowed to warm to room temperature. Water (60 ml) was added to the mixture and the mixture was extracted with Et2O (2 x 100 ml). The organic phase was washed with saturated aqueous Na2S2O3 (2 x 80 ml), dried over anhydrous sodium sulfate and evaporated. Residue was chromatographed on silica gel (150 g) in toluene - ethylacetate (24:1) to afford 194 mg (44%) of product. Compound was crystallized from water-methanol. M.p. = 183 - 184 °C. For C12H12ClIN4 (374.6) calculated: 38.47% C, 3.23% H, 33.88% I, 9.46% Cl, 14.96% N; found: 38.41% C, 3.12% H, 14.65% N. 1H NMR (DMSO, 600.13 MHz): 1.29 m, 2 H (H-5'endo and H-7'a); 1.39 dddd, 1 H, Jgem = 11.8, J(6'en,5'en) = 9.0, J(6'en,5'ex) = 3.9, J(6'en,7'b) = 2.3 (H-6'endo); 1.56 m, 1 H (H-5'exo); 1.62 tt, 1 H, Jgem = J(6'ex,5'ex) = 12.1, J(6'ex,5'en) = J(6'ex,l ') - 4.5 (H-6'exo); 1.89 ddd, 1 H, Jgem = 12.9, J(3'en,2') = 8.8, J(3'en,7'a) = 2.2 (H-3'endo); 2.24 dm, 1 H, Jgem = 9.9 (H-7'b); 2.49 m, 1 H (H-4'); 2.58 bd, 1 H, J(l ',6'ex) = 4.6 (H-I '); 2.96 m, 1 H (H-3'exo); 4.46 ddd, 1 H, J(2',3'en) = 8.8, J(2',3'ex) = 4.8, J(2',7'a) = 1.2 (H-2'); 8.66 s, 1 H (H-2). 13C NMR (DMSO, 150.92 MHz): 27.58 (C-6'); 28.09 (C-5'); 35.15 (C-7'); 36.11 (C-4'); 36.76 (C-3'); 43.19 (C-I '); 65.58 (C-2'); 116.67 (C-8); 133.84 (C-5); 147.68 (C-6); 150.57 (C-2); 152.60 (C-4).
EXAMPLE 29: Synthesis of ethyl 9-[(li?*,2i?*,4S*)-bicyclo[2.2.1]hept-2-yl]-6-chloro- 9H-purine-8-carboxylate (49)
Ethyl chloroformate (0.5 ml, 5.3 mmol) was added to the lithiated intermediate (see Example27) and the mixture was stirred for 1 hour at -78 0C and for 1 hour at -50 0C. A saturated aqueous solution of NH4Cl (20 ml) was added. The mixture was allowed to warm to room temperature. Water (60 ml) was added to the mixture and the mixture was extracted with EtOAc (100 ml). The organic phase was washed with water (50 ml), dried over anhydrous sodium sulfate and evaporated. Residue was chromatographed on silica gel (150 g) in toluene - ethylacetate (20:1) to afford 182 mg (43.9%) of product. Compound was crystallized from water-methanol. M.p. = 118 — 120 0C. For C15H17ClN4O x 1/4 H2O (325.3) calculated: 55.39% C, 5.42% H, 10.90% Cl, 17.22% N; found: 55.36% C, 5.34% H, 10.85% Cl, 10.85% N. 1H NMR (DMSO, 600.13 MHz): 1.24 m, 2 H (H-5'endo and H-7'a); 1.37 m, 1 H (H-6'endo); 1.39 t, 3 H, J(CH3,CH2) = 7.1 (CH3); 1.51 - 1.63 m, 2 H (H-5'exo and H-6'exo); 1.83 ddd, 1 H, Jgem = 12.9, J(3'en,2') = 8.9, J(3'en,7'a) = 2.2 (H-3'endo); 2.34 dm, 1 H, Jgem = 9.9 (H-7'b); 2.46 bt, 1 H, J(4',3'ex) = J(4',5'ex) = 4.0 (H-4'); 2.68 bd, 1 H, J(l ',6'ex) - 4.2 (H-I '); 2.87 m, 1 H (H-3'exo); 4.46 q, 2 H, J(CH25CH3) = 7.1 (CH2O); 5.07 bdd, 1 H, J(2',3'en) = 8.8, J(2',3'ex) = 4.9 (H-2'); 8.86 s, 1 H (H-2). 13C NMR (DMSO, 150.92 MHz): 14.14 (CH3); 27.69 (C-6'); 28.11 (C-5'); 36.08 (C-7'); 36.23 (C-4'); 36.78 (C-3'); 43.53 (C-I '); 62.81 (C-2'); 62.86 (CH2O); 130.12 (C-5); 145.36 (C-8); 151.99 (C-6); 152.53 (C-2); 152.62 (C-4); 159.05 (C=O).
EXAMPLE 30: Synthesis of {9-[(l/?*,2/?*,45*)-bicyclo[2.2.1]hept-2-yl]-6-chloro-9H- purin-8-yl} methanol (50)
Dimethylformamide (0.3 ml) was added to the lithiated intermediate (see Example 27 - synthesis of compound 41) and the mixture was stirred for 2 hour at -78 °C. A saturated aqueous solution of NH4Cl (20 ml) was added. The mixture was allowed to warm to room temperature. Water (60 ml) was added to the mixture and the mixture was extracted
with EtOAc (100 ml). The organic phase was dried over anhydrous sodium sulfate and evaporated. Residue was dissolved in methanol (20 ml) and NaBH4 (60 mg, 1.59 mmol) was added. Reaction mixture was stirred at 0 °C for 1 hour, evaporated and residue was partitionate between brine (30 ml) and ethylacetate (80 ml). Organic phase was washed with brine (20 ml), dried over anhydrous sodium sulfate and evaporated. Residue was chromatographed on silica gel (150 g) in toluene - ethylacetate (1:1) to afford 120 mg (36%) of product. Compound was crystallized from water-methanol. M.p. = 129 -131 °C. For C13H15ClN4O (278.7.3) calculated: 56.02% C, 5.42% H, 12.72% Cl, 20.10% N; found: 55.87% C, 5.13% H, 12.89% Cl, 19.90% N. 1H NMR (DMSO, 600.13 MHz): 1.24 m, 2 H (H-5'endo and H-7'a); 1.40 m, 1 H (H-6'endo); 1.56 m, 2 H (H-5'exo and H- 6'exo); 1.86 ddd, 1 H, Jgem = 12.7, J(3'en,2') = 8.9, J(3'en,7'a) = 2.2 (H-3'endo); 2.46 dm, 1 H, Jgem = 9.7 (H-7'b); 2.48 m, 1 H (H-4'); 2.56 m, 1 H (H-I '); 2.79 ddt, 1 H, Jgem = 12.8, J(3'ex,2') = J(3'ex,4') = 4.6, J(3'ex,5'ex) = 2.1 (H-3'exo); 4.63 bdd, 1 H, J(2',3'en) = 8.8, J(2',3'ex) = 5.0 (H-2'); 4.80 m, 2 H (CH2O); 5.88 t, 1 H, J(OH5CH2) = 5.9 (OH); 8.70 s, 1 H (H-2). 13C NMR (DMSO, 150.92 MHz): 27.97 and 28.04 (C-6' and C-5'); 35.83 (C-7'); 36.23 (C-4'); 36.83 (C-3'); 43.38 (C-I '); 57.46 (CH2OH); 60.81 (C-2'); 130.43 (C-5); 148.92 (C-6); 150.77 (C-2); 153.23 (C-4); 158.52 (C-8).
EXAMPLE 31: Synthesis of 6-chloro-9-[(li?*,2i?*,4S*,5S*,6S*)-3- oxatricyclo[3.2.1.02'4]oct-6-yl]-9H-purine (42)
To a solution 31 (250 mg, 1.01 mmol) in dichloromethane (45 ml) was added m- chloroperbenzoic acid (400 mg, 1.5 mmol, 65%) and the solution was stirred at r.t. overnight. Reaction mixture was washed with saturated aqueous Na2S2O3 (20 ml), saturated NaHCO3 (3 x 20 ml), dried over anhydrous sodium sulfate and evaporated. Residue was crystallized from water-methanol to afford 193 mg (72.7%) of the product. M.p. = 159 - 163 °C. For C12H11ClN4O (262.7) calculated: 54.87% C, 4.22% H, 13.50% Cl, 21.33% N; found: 54.63% C, 4.07% H, 13.79% Cl, 20.59% N. 1H NMR (DMSO, 600.13 MHz): 1.28 dm, 1 H, Jgem = 10.7 (H-7'a); 1.35 dm, 1 H, Jgem = 10.6 (H-7'b); 2.06 - 2.14 m, 2 H (H-5'endo and H-5'exo); 2.62 m, 1 H (H-4'); 2.89 m, 1 H (H-I '); 3.34 dd, 1 H, J(3',2') = 3.7, J(3',4') = 1.4 (H-3'); 3.38 dd, 1 H, J(2',3') = 3.8, J(2',l ') = 1.7 (H-
2'); 4.60 ddd, 1 H, J(6',5'en) = 8.0, J(6',5'ex) = 4.5, J(6',7'a) = 1.5 (H-6'); 8.79 s, 1 H (H-2); 8.88 s, 1 H (H-8). 13C NMR (DMSO, 150.92 MHz): 23.95 (C-7'); 33.84 (C-5'); 36.88 (C-4'); 42.68 (C-I '); 48.91 (C-2'); 50.83 (C-3'); 54.21 (C-6'); 131.38 (C-5); 145.96 (C-8); 149.18 (C-6); 151.53 (C-2); 152.20 (C-4).
EXAMPLE 32: Synthesis of (li?*,2i?*,35*,45*,55*)-5-(6-chloro-9H-purin-9- yl)bicyclo[2.2.1 ]heptane-2,3-diol (37)
Compound 31 (250 mg, 1.01 mmol) was dissolved in a mixture of water-methanol (15 ml, 1:1). Solution of NMMO (50% in water, 2 ml) and water solution of osmium tetroxide (50 μl, 100 mg/5 ml) was added and the reaction mixture was stirred at r.t. for 2 days. The reaction mixture was evaporated and the residue was chromatographed on silica gel column (100 g) in ethyl acetate - acetone - ethanol - water (100:15:6:4). It was obtained 224 mg (79%) of the product. Compound was crystallized from water. M.p. = 198 - 200 °C. For C12H13ClN4O2 x Vi H2O (289.7) calculated:49.57% C, 4.87% H, 12.24% Cl, 19.34% N; found: 49.82% C, 4.55% H, 12.51% Cl, 19.19% N. 1H NMR (DMSO, 600.13 MHz): 1.54 dm, 1 H, Jgem = 10.8 (H-7a); 1.80 dm, 1 H, Jgem = 10.8 (H- 7b); 1.89 ddd, 1 H, Jgem = 13.8, J(5en,6) = 8.5, J(5en,7b) - 2.2 (H-5endo); 1.99 m, 1 H (H-5exo); 2.19 dm, 1 H, J(4,5ex) = 4.7 (H-4); 2.40 bs, 1 H (H-I); 3.66 m, 1 H (H-3); 3.78 m, 1 H (H-2); 4.49 dd, 1 H, J(6,5en) = 8.5, J(6,5ex) = 4.3 (H-6); 4.80 d, 1 H, J(OH,2) = 6.1 (2-OH); 4.82 d, 1 H, J(OH-3) = 6.0 (3-OH); 8.76 s, 1 H (H-2'); 8.84 s, 1 H (H-8'). 13C NMR (DMSO, 150.92 MHz): 29.70 (C-7); 32.96 (C-5); 42.77 (C-4); 49.10 (C-I); 54.61 (C-6); 71.28 (C-2); 72.51 (C-3); 131.48 (C-5'); 145.67 (C-8'); 149.13 (C-6'); 151.45 (C-2'); 152.15 (C-4').
EXAMPLE 33: Synthesis of 7-[(li?*,2/?*,45*)-bicyclo[2.2.1]hept-2-yl]-4-chloro-7H- pyrrolo[2,3-rf]pyrimidine (80)
To a mixture of the bicyclo[2.2.1]heptan-2-ol (550 mg, 4.90 mmol), triphenylphosphine (1.2 g, 4.57 mmol) and 4-chloro-7H-pyrrolo[2,3-</]pyrimidine (300 mg, 1.95 mmol) in
TΗF (30 ml) was dropwise added solution of the diisopropyl azadicarboxylate (1.0 ml,
4.87 mmol) in THF (15 ml). The resulting mixture was stirred overnight (TLC control) and evaporated. The residue was chromatographed on silica gel column (200 g) in toluene - ethylacetate (15:1) to afford 419 mg (87% based on nucleobase). M.p. = 72 -73 °C. For C13H14ClN3 (247.7) calculated: 63.03% C, 5.70% H, 14.31% Cl, 16.96% N; found: 63.15% C, 5.55% H, 14.35% Cl, 16.71% N. 1H NMR (DMSO, 499.84 MHz): 1.20 - 1.28 m, 2 H (H-5'endo and H-7'a); 1.39 m, 1 H (H-6'endo); 1.48 - 1.61 m, 2 H (H- 5'exo and H-6'exo); 1.68 dm, 1 H, Jgem = 10.2 (H-7'b); 1.89 m, 1 H (H-3'exo); 1.97 ddd, 1 H, Jgem = 13.2, J(3'en,2') = 8.4, J(3'en,7'a) = 2.1 (H-3'endo); 2.35 bd, 1 H, J(I \6'ex) = 3.9 (H-I '); 2.40 m, 1 H (H-4'); 4.70 bdd, 1 H, J(2',3'en) = 8.2, J(2',3'ex) = 4.6 (H-2'); 6.61 d, 1 H, J(7,8) = 3.7 (H-7); 7.88 d, 1 H, J(8,7) = 3.7 (H-8); 8.61 s, 1 H (H-2). 13C NMR (DMSO, 125.70 MHz): 27.33 (C-6'); 27.92 (C-5'); 35.79 (C-4'); 36.00 (C-7'); 38.28 (C-3'); 42-59 (C-I '); 57.68 (C-2'); 98.46 (C-7); 117.24 (C-5); 128.79 (C-8); 150.21 (C-2); 152.64 and 150.70 (C-4 and C-6).
EXAMLE 34: Synthesis of (li?*,2i?*,3i?*,6i?*,75*,95*)-2-(2-amino-6-chloro-9H-purin- 9-yl)-4-oxatricyclo[4.2.1.03>7]nonane-9-methanol (9)
A solution of (li?*,2i?*,3Λ*,6i?*,75*,9S*)-2-amino-4-oxatricyclo[4.2.1.03'7]nonane-9- methanol (508 mg, 3 mmol), 4,6-dichloropyrimidine-2,5-diamine (537 mg, 3 mmol), and triethylamine (1.8 ml) in ethanol (18 ml) was heated in a pressure vessel at 100 °C for 7 days and, after cooling, was evaporated. Chromatography of the residue on a silica gel column (50 g) in ethyl acetate - acetone - ethanol - water (90 : 15 : 11 : 9) followed by crystallization from ethanol afforded 628 mg of a pyrimidinylamino derivative which was disolved in triethyl orthoformate (32 ml) and Cone, hydrochloric acid (1.5 ml). The resulting solution was left aside at room temperature for 3 days and then evaporated. The residue was dissolved in tetrahydrofuran (18 ml). To the stirred solution, 0.5 M hydrochloric acid (18 ml) was added, the mixture was stirred at room temperature for 3 h and then neutralized with solid sodium hydrogencarbonate. The organic layer was separated and the aqueous layer was extracted with tetrahydrofuran (4 x 16 ml). The combined organic layers were evaporated. The residue was crystallized from water. Yield 460 mg (52%). M.p. 238 - 241 °C. For C14H16ClN5O2 (321.77) calculated: 52.26% C,
5.01% H, 11.02% Cl, 21.77% N; found: 52.19% C, 5.10% H, 10.94% Cl, 21.50% N. FAB MS, mlz (rel. %): 324/322 (35/100) [M + H], 288 (37). 1H NMR: 1.52 brddd, 1 H, J(9,l) ~ J(9,8a) = 1.0, J(9,6) = 2.4, J(9,CHa) = 7.2, J(9,CHb) = 8.4 (H-9); 1.70 dm, 1 H, Jgem = 11.7 (H-8a); 1.79 dq, 1 H, J(8b,l) ~ J(8b,2) ~ J(8b,7) = 1.4 (H-8b); 2.04 td, 1 H, J(6,5a) ~ J(6,7) = 4.0 (H-6); 2.37 m, 1 H (H-I); 2.67 ddq, 1 H, J(7,l) ~ J(7,8a) ~ J(7,8b) = 1.2, J(7,3) = 5.0, J(7,6) = 4.0 (H-7); 3.35 ddd, 1 H, J(CH,5a) = 7.2, J(CH5OH) - 5.4 and 3.38 ddd, 1 H, J(CH,5a) = 8.4, J(CH5OH) 5.0, Jgem = 10.6 (CH2O); 3.72 d, 1 H, Jgem = 7.8 (H-5b); 3.76 dd, 1 H, J(5a,6) = 3.9 (H-5a); 3.88 brd, 1 H, J(2,8b) = 1.6 (H-2); 4.67 dd. 1 H, J(3,l) = 1.2 (H-3); 4.73 t, 1 H, J(OH5CH2) = 5.2 (OH); 6.94 brs, 2 H (NH2); 8.19 s, 1 H (H-8'). 13C NMR: 31.97 (C-8); 41.25 (C-I); 41.33 (C-6); 45.13 (C-7); 50.83 (C-9); 62.80 (CH2O); 66.23 (C-2); 74.09 (C-5); 83.74 (C-3); 123.50 (C-5'); 141.27 (C-8'); 149.61 (C-6'); 154.38 (C-4'); 159.85 (C-2').
EXAMPLE 35: Synthesis of 6-chloro-9-[(li?*,3Λ*,6i?*,7i?*,9i?*)-4- oxatricyclo[4.2.1.03J]non-9-yl]-9H-purine (5)
A mixture of amine (420 mg, 3 mmol), 4,6-dichloropyrimidin-5-amine (900 mg, 5.5 mmol), and triethylamine (1.8 ml) in ethanol (9 ml) was heated in a pressure vessel at 105 °C for 6 days and, after cooling, was evaporated. The residue was chromatographed on a column of silica gel (200 g). Pyrimidine intermediate was eluted with toluene - ethylacetate (5:1 → 1 :1) and this intermediate was immediately used in the next step. Concentrated hydrochloric acid (1 ml) was added to a suspension of pyrimidine intermediate in triethyl orthoformate (80 ml) and the reaction mixture was vigorously stirred for 5 days at room temperature. Solution was evaporated and the residue was crystallized from water-methanol (95:5) to afford product (540 mg, 65%). M.p. = 196 - 198 °C. For Ci3H13ClN4O (276.7) calculated: 56.42% C5 4.74% H5 12.81% Cl5 20.25% N; found: 56.31% C5 4.75% H5 12.72% Cl, 20.04% N. 1H NMR (DMSO, 600.13 MHz): 1.22 dd, 1 H, Jgem = 13.3, J(2'en,8'b) = 3.3 (H-2'endo); 1.50 dm, 1 H, Jgem = 11.2 (H- 8'a); 1.73 ddd, 1 H, Jgem = 13.3, J(2'ex,3') = 7.7, J(2'ex,l ') = 4.0 (H-2'exo); 1.96 dm, 1 H5 Jgem = 11.2 (H-8'b); 2.58 bd, 1 H5 J(l ',2'ex) = 3.9 (H-I '); 2.74 tq, 1 H, J(7',6') - J(7',3') = 4.8, J(7',8'a) = J(7',8'b) = J(7',l ') = 1.4 (H-7'); 3.04 bt, 1 H, J(6',7') =
J(6',5'b) = 5.2 (H-6'); 3.80 dd, 1 H, Jgem = 8.5, J(5'b,6') = 4.6 (H-5'b); 3.94 d, 1 H, Jgem = 8.5 (H-5'a); 4.33 m, 1 H (H-9'); 4.37 dd, 1 H, J(3',2'ex) - 7.7, J(3 ',7') = 4.9; 8.79 s, 1 H (H-2); 8.88 s, 1 H (H-8). 13C NMR (DMSO, 150.92 MHz): 35.18 (C-8'); 38.16 (C-2'); 39.50 (C-I '); 45.76 (C-7'); 46.70 (C-6'); 65.78 (C-9'); 71.58 (C-5'); 77.84 (C-3'); 131.49 (C-5); 145.72 (C-8); 149.17 (C-6); 151.57 (C-2); 152.22 (C-4).
EXAMPLE 36: SYNTHESIS OF ({[(li?*,3S*,6S*,7#*)-2-(5-METHYL-2,4-DIOXO-3,4- DIHYDROPYRIMIDIN- 1 (2H)-YL)-4-OXATRICYCLO[4.2.1.03'7]NON-9- YL]OXY}METΗYL)PΗOSPΗONIC ACID (3)
A mixture of (IR *,2R *,3S*,4S*)-3-(hydroxymethyl)bicyclo[2.2.1 ]hept-5-en-2-ol (4.22 g, 30 mmol), benzyl azidoformate (8.70 g, 37 mmol), and toluene (7 ml) was stirred at 85 °C (bath temperature) for 2.5 h. The mixture was applied onto a silica gel column (200 g) and eluted with ethyl acetate. The obtained product (4.58 g , 15.8 mmol) and diisopropyl (bromomethyl)phosphonate (7.77 g, 30 mmol) was disolved in dimethylformamide (50 ml). Sodium hydride (60% dispersion, 1.2 g, 30 mmol) was added to this stirred solution at 0 °C under argon. The mixture was stirred at 0 °C for 30 min and then at room teperature for 5h. The mixture was neutralized with acetic acid and evaporated. The residue was partitioned between ethyl acetate (400 ml) and water (100 ml). The organic phase was separated and washed with 10% aqueous sodium hydrogencarbonate (100 ml), dried over anhydrous sodium sulfate, and the solvent was evaporated. Palladium(II) hydroxide on carbon (20% Pd, 200 mg) was added to a solution of the residue (3.84 g, 8.5 mmol) in methanol (100 ml) and the mixture was stirred under hydrogen atmosphere at room temperature for 7 h. The catalyst was filtered off with a Celite pad, washed with methanol and the filtrates were evaporated. A solution of the residue (2.68 g, 8.4 mmol) and ethyl [(2£)-3-ethoxy-2-methylprop-2-enoyl]carbamate (1.69 g, 8.4 mmol) in 1,4-dioxane (80 ml) was heated at 100 °C for 2 h. Then 1 M sulfuric acid (10 ml) was added and the mixture was heated another 4 h. The solid was filtered off and the filtrates were evaporated. Chromatography on silica gel (250 g) with ethyl acetate - acetone - ethanol - water (100 : 15 : 6 : 4) afforded after crystallization from ether 1.98 g of diisopropyl ({[(l/?*,3S*,6S*,7Λ*)-2-(5-Methyl-2,4-dioxo-3,4-
dihydropyrimidin-l(2H)-yl)-4-oxatricyclo[4.2.1.03'7]non-9-yl]oxy}methyl)phosphonate. For C20H31N2O7P (442.46) calculated: 54.29% C, 7.06% H, 6.33% N, 7.00% P; found: 53.99% C, 7.18% H, 6.17% N, 6.86% P. FAB MS, mlz (%): 443 (27) [M + H], 401 (10), 359 (100). 1H NMR: 1.25 dd, 12 H, J(CH3,CH) = 6.1, J(CH3P) = 3.5 (CH3 isopropyl); 1.66 brd, 1 H, Jgem - 11.5 (H-8b); 1.78 d, 3 H, J(CH3,6) = 1.1 (CH3); 1.86 dm, 1 H (H- 8a); 2.28 m, 1 H (H-6); 2.56 brs, 1 H (H-I); 2.63 m, 1 H, (H-7); 3.46 brs, 1 H (H-9); 3.52 brs, 1 H (H-2); 3.73 - 3.82 m, 4 H (CH2P, 2 x H-5); 4.34 brd, 1 H, J(3,7) = 4.9 (H-3); 4.61 dh, 2 H, J(CH,P) = 7.7 (CH isopropyl); 7.46 q, 1 H (H-6'); 11.24 brs, 1 H (NH). 13C NMR: 23.89 d, J(CH3,P) = 4.4 (CH3 isopropyliden); 23.99 d, J(CH3,P) = 3.9 (CH3 isopropyliden); 31.59 (C-8); 42.65 (C-I); 44.00 (C-7); 46.83 (C-6); 62.61 d, J(CH2,P) = 166.0 (CH2P); 63.87 (C-2); 70.33 d, J(CH5P) = 6.4 (CH isopropyl); 70.36 d, J(CH5P) - 5.9 (CH isopropyl); 71.68 (C-5); 83.71 (C-3); 88.95 d, J(9,P) = 13.7 (C-9); 108.29 (C-5'); 138.13 (C-6'); 151.20 (C-2'); 163.87 (C-4'). A mixture of this protected phosphonate, dichloromethane (25 ml) and bromotrimethylsilane (2 ml) was stirred at room temperature overnight and evaporated. A solution of the residue in methanol (20 ml) and water (10 ml) was after 0.5 h evaporated. Crystallization of the residue from water afforded 1.03 g (9% overall yield) of comound 3. For C14Hi9N2O7PH2O (376.31) calculated: 44.68% C, 5.63% H, 7.44% N, 8.23% P; found: 44.64% C, 5.69% H, 7.29% N, 8.01% P.
EXAMPLE 37: SYNTHESIS OF 4-[(li?*,2Λ*,45*)-BICYCLO[2.2.1]HEPT-2- YLOXY]- 6-CHLOROPYRIMIDINE (81)
(l/?*,2Λ*,4S*)-bicyclo[2.2.1]heptan-2-ol (500 mg, 4.46 mmol) was dissolved in dimethylformamide (10 ml) under argon atmosphere. Sodium hydride (196 mg, 4.91 mmol, 60% dispersion in mineral oil) was carrefully added during 20 minutes at 0 0C. To this mixture was through septum added 4,6-dichloropyrimidine (731 mg, 4.91 mmol) and reaction mixture was stirred at 0 0C for 5 hours and then at r.t. overnight. Reaction mixture was partitionated between ethylacetate (130 ml) and water (80 ml). Organic phase was washed with water (4 x 100 ml), dried over anhydrous sodium sulfate and evaporated. Residue was chromatographed on silica gel (150 g) in toluene - ethylacetate
(30:1) to afford 259 mg (25.8 %) of product as an oil. For C11H13ClN2O (224.7) calculated: 58.80% C, 5.83% H, 15.78% Cl, 12.47% N; found: 59.10% C, 5.98% H, 15.88% Cl, 12.20% N. 1H NMR (DMSO, 499.84 MHz): 1.08 - 1.20 m, 3 H (H-5'endo, H-6'endo and H-7'a); 1.39 - 1.47 m, 2 H (H-3'exo and H-5'exo); 1.49 - 1.56 m, 2 H (H- 6'exo and H-7'b); 1.81 ddd, 1 H, Jgem = 13.4, J(3'en,2') = 7.0, J(3'en,7'a) = 2.5 (H- 3'endo); 2.28 m, 1 H (H-4'); 2.38 bd, 1 H, J(l \6'ex) = 4.6 (H-I '); 4.86 dm, 1 H, J(2',3'en) = 7.0 (H-2'); 7.10 d, 1 H, J(5,2) = 0.9 (H-5); 8.64 d, 1 H, J(2,5) = 0.9 (H-2). 13C NMR (DMSO, 125.70 MHz): 23.87 (C-6'); 27.88 (C-5'); 35.18 (C-7'); 35.18 (C-4'); 39.40 (C-3'); 40.98 (C-I '); 80.37 (C-2'); 108.05 (C-5); 158.66 (C-2); 160.11 (C-4); 169.62 (C-6).
EXAMPLE 38: SYNTHESIS OF 3-[(li?*,2i?*,4S*)-BICYCLO[2.2.1]HEPT-2-YL]-7- CHL0R0-3H-[ 1 ,2,3]TRIAZOLO[4,5-D]PYRIMIDINE (82)
A mixture of amine (420 mg, 3 mmol), 4,6-dichloropyrimidin-5 -amine (900 mg, 5.5 mmol), and triethylamine (1.8 ml) in ethanol (9 ml) was heated in a pressure vessel at 105 0C for 6 days and, after cooling, was evaporated. The residue was chromatographed on a column of silica gel (200 g). Pyrimidine intermediate was eluted with toluene - ethylacetate (5:1 → 2:1) and this intermediate was immediately used in the next step. The intermediate was dissolved in acetic acid (5 ml) and to this mixture was added solution of NaNO2 (200 mg) in water (10 ml) at 0 0C. Reaction mixture was stirred for 2 hours at 0 0C. White crystals were filtered off, wash with cold water amd ether. It was obtained 450 mg (48%). For CnHi2ClN5 (249.7) calculated: 52.91% C, 4.84% H, 14.20% Cl, 28.05% N; found: 52.65% C, 4.76% H, 14.41% Cl, 27.72% N.
EXAMPLE 39: SYNTHESiS OF (li?*,2i?*,35*,45*)-6-(chloromethyl)-3-(6-chloro-9H- purin-9-yl)bicyclo[2.2.1]hept-5-en-2-ol (83)
A solution of azido derivative (l/?*,2i?*,35*,45*)-3-Azido-6- (hydroxymethyl)bicyclo[2.2.1]hept-5-en-2-ol (1.45 g, 8 mmol) in tetrahydrofuran (15 ml) was added dropwise to a stirred 1.0 M solution of lithium aluminium hydride in
tetrahydrofuran (23 ml) at 0 °C under argon atmosphere. The mixture was stirred at 0 °C for 5 h, the excess of hydride was decomposed by slow addition of water. Then solid CO2 was added to adjusted pH of the mixture to ~8. The mixture was filtered with a Celite pad, the filter was washed with methanol (3 x 30 ml) and the combined filtrates were evaporated. The residue was dissolved in ethanol (10 ml), the insoluble portion was filtered off with a Celite pad and the filtrate was evaporated. A solution of amine, obtained in this way, 4,6-dichloropyrimidin-5-amine (1.15 g, 7 mmol), and triethylamine (2.1 ml) in ethanol (21 ml) was heated in a pressure vessel at 100 °C for 6 days and, after cooling, evaporated. The residue was chromatographed on a silica gel column (60 g) in ethyl acetate - acetone - ethanol - water (100 : 15 : 6 : 4) and crystallized from ethyl acetate. It was obtained 501 mg (22%) of (lR*,2R*,3S*,4S*)-3-[(5-Amino-6- chloropyrimidin-4-yl)amino]-6-(hydroxymethyl)bicyclo[2.2.1 ]hept-5-en-2-ol. Cone, hydrochloric acid (1.4 ml) was added to a stirred mixture of this compound (226 mg, 0.8 mmol) and triethyl ortho formate (14 ml), the resulting solution was stored at room temperature for 3 days and then evaporated. The residue was dissolved in tetrahydrofuran (5 ml). To the stirred solution, 0.5 M hydrochloric acid (5 ml) was added, the mixture was stirred at room temperature for 4 h and then neutralized with solid sodium hydrogencarbonate. The organic layer was separated and the aqueous layer was extracted with tetrahydrofuran (4 x 8 ml). The combined organic phases were dried over anhydrous sodium sulfate and evaporated. The residue was chromatographed on a silica gel column (20 g) in ethyl acetate - toluene and then crystallized from ethanol - ether. Yield 124 mg (50%). M.p. 176 - 177 °C. For Ci3H12Cl2N4O (311.17) calculated: 50.18% C, 3.89% H, 22.79% Cl, 18.01% N; found: 50.06% C, 3.75% H, 22.79% Cl, 17.86% N. FAB MS, mlz (%): 313/311 (71/100) [M + H], 157/155 (36/68) [6-chloropurine + H]. 1H NMR: 1.81 dm, 1 H, Jgem = 9.6 (H-7a); 2.39 dm, 1 H, Jgem = 9.7 (H-7b); 2.79 m, 1 H (H-I); 3.23 m, 1 H (H-4); 4.15 m, 1 H (H-2); 4.41 m, 2 H (CH2Cl); 4.59 dd, 1 H, J(3,2) = 6.2, J(3,7a) = 1.7 (H-3); 5.19 d, 1 H, J(OH,2) = 4.4 (2-OH); 6.33 m, 1 H (H-5); 8.66 s, 1 H (H-8'); 8.74 s, 1 H (H-2'). 13C NMR: 42.76 (CH2Cl); 44.78 (C-7); 46.29 (C-4); 50.89 (C-I); 57.53 (C- 3); 68.25 (C-2); 130.54 (C-5'); 135.67 (C-5); 146.51 (C-6); 146.77 (C-8'); 148.74 (C-6'); 151.41 (C-2'); 153.08 (C-4').
According to the same procedure, there were obtained the following compounds:
• (Ii? *,2i? *,3S*,4S*)-3-(6-Chloro-9H-purin-9-yl)-6- (hydroxymethyl)bicyclo[2.2.1]hept-5-en-2-ol (84), using trifluoroacetic acid instead of hydrochloric acid in the ring-closure step. Yield 250 mg (57%). M.p. 156.5 - 159 °C (decomp.). For Ci3Hi3ClN4O2 (292.73) calculated: 53.34% C,
4.48% H, 12.11% Cl, 19.14% N; found: 53.19% C, 4.42% H, 12.24% Cl, 18.98% N. FAB MS, mlz (%): 295/293 (33/100) [M + H], 157/155 (74/23) [6- chloropurine + H]. 1H NMR : 1.76 dp, 1 H, Jgem = 9.4, J(7a,2) = J(7a,3) = J(7a,l) = J(7a,4) = 1.6 (H-7a); 2.33 dm, 1 H, Jgem = 9.3 (H-7b); 2.70 bs, 1 H (H-I); 3.14 m, 1 H (H-4); 4.03 ddd, 1 H, Jgem = 14.8, J(CHa,OH) = 5.5, J(CHa,5) = 1.7
(CH3H-O); 4.04 m, 1 H (H-2); 4.10 ddd, 1 H, Jgem = 14.8, J(CHb,OH) = 5.5, J(CHb,5) = 1.9 (CHbH-O); 4.60 dd, 1 H, J(3,2) = 6.2, J(3,7a) - 1.6 (H-3); 4.82 t, 1 H, J(OH5CH2) = 5.5 (CH2OH); 5.08 d, 1 H, J(OH,2) = 4.5 (2-OH); 6.03 m, 1 H (H-5); 8.64 s, 1 H (H-8'); 8.74 s, 1 H (H-2'). 13C NMR: 44.16 (C-7); 45.89 (C-4); 49.87 (C-I); 57.90 (C-3); 59.29 (CH2O); 68.46 (C-2); 130.03 (C-5); 130.52 (C-
5'); 146.77 (C-8'); 148.68 (C-6'); 151.35 (C-2'); 151.82 (C-6); 153.10 (C-4').
• (Ii? *,2R *,3S*,4S*)-3-(6-Chloro-9H-purin-9-yl)-5-
(hydroxymethyl)bicyclo[2.2.1]hept-5-en-2-ol (85), using (li?*,2i?*,3S*,4S*)-3- Azido-5-(hydroxymethyl)bicyclo[2.2.1]hept-5-en-2-ol as starting comound and using trifluoroacetic acid instead of hydrochloric acid in the ring-closure step.
Yield 224 mg (51%). M.p. 179 - 181 °C (decomp.). For Ci3Hi3ClN4O2 (292.73) calculated: 53.34% C, 4.48% H, 12.11% Cl, 19.14% N; found: 53.01% C, 4.49% H, 12.26% Cl, 18.89% N. FAB MS, mlz (%): 295/293 (30/78) [M + H], 157/155 (37/100) [6-chloropurine + H]. 1H NMR: 1.76 dp, 1 H, Jgem = 9.4, J(7a,l) = J(7a,2) = J(7a,3) = J(7a,4) = 1.7 (H-7a); 2.32 dm, 1 H, Jgem = 9.3 (H-7b); 2.75 m,
1 H (H-I); 3.11 m, 1 H (H-4); 4.00 m, 1 H (H-2); 4.05 ddd, 1 H, J(CHaH,OH) = 5.1, J(CHaH,6) = 1.6 and 4.11 ddd, 1 H, J(CHbH,OH) = 5.6, J(CHbH,6) = 1.9, Jgem = 14.9 (CH2O); 4.57 dd, 1 H, J(3,2) = 6.2, J(3,7a) = 1.4 (H-3); 4.89 t, 1 H, J(OH,CH2) = 5.4 (CH2OH); 5.10 d, 1 H, J(OH,2) - 4.1 (2-OH); 5.89 m, 1 H (H- 6); 8.65 s, 1 H (H-8'); 8.75 s, 1 H (H-2'). 13C NMR: 44.14 (C-7); 46.34 (C-4);
49.24 (C-I); 57.02 (C-3); 58.99 (CH2O); 69.98 (C-2); 128.29 (C-6); 130.66 (C- 5'); 146.78 (C-8'); 148.78 (C-6'); 151.47 (C-2'); 153.21 (C-4'); 153.69 (C-5).
EXAMPLE 40: (li?*,4i?*,75*)-7-(6-Chloro-9H-purin-9-yl)bicyclo[2.2.1]hept-5-ene-2,2- dimethanol (86)
A mixture of amine (510 mg, 3 mmol), 4,6-dichloropyrimidin-5 -amine (984 mg, 6 mmol), and triethylamine (2.4 ml) in ethanol (18 ml) was heated in a pressure vessel at 105 °C for 6 days and, after cooling, it was evaporated. The residue was chromatographed on a column of silica gel (200 g) in ethyl acetate - acetone - ethanol - water (100:15:6:4) to afford 866 mg of pyrimidine intermediate as a foam. To a suspension of pirimidine intermediate in triethyl orthoformate (80 ml) concentrated hydrochloric acid (1.4 ml) was added and the reaction mixture was vigorously stirred for 3 days (suspension dissolved) at room temperature. The solution was evaporated and the residue was redissolved in a mixture of tetrahydrofuran (15 ml) and 0.5 M hydrochloric acid (15 ml) and stirred at room temperature for 4 h. After neutralization with solid sodium hydrogencarbonate, the mixture was evaporated to a fourth of the original volume and adsorbed on silica gel and this silica gel was placed on the top of a silica gel column (200 g). Elution with ethyl acetate - acetone - ethanol - water (100:15:6:4) gave 655 mg (79 %) of the chloropurine nucleoside. M.p. 193.5 - 195 0C (H2O). 1H NMR: 0.77 d, 1 H, Jgem = 12.3 (H-3endo); 1.80 dd, 1 H, J(3exo, 4) = 3.8 (H-3exo); 3.43 brdq, 1 H, J(I, 4) ~ J(I, 5) ~ J(I, 7) ~ 1.2, J(I, 6) = 2.8 (H-1); 3.12 dd, 1 H, J(CH5OH) = 5.2 and 3.28 dd, 1 H, J(CH5OH) = 4.9, Jgem = 10.4 (CH2O); 3.56 brt, 1 H, J(4, 1) ~ J(4, 6) ~ J(4, 7) ~ 0.7, J(4, 5) = 2.8 (H-4); 3.70 dd, 1 H, J(CH5OH) = 5.0 and 3.79 dd, 1 H, J(CH,OH) = 5.4, Jgem = 10.6 (CH2O); 4.49 t, 1 H (CH2OH); 4.78 t, 1 H (CH2OH); 4.80 m, 1 H (H-7); 6.02 brdd, 1 H , J(5, 7) = 1.0, J(5, 6) = 5.6 (H-5); 6.07 brdd, 1 H5 J(6, 7) = 1.0 (H-6); 8.47 s, 1 H and 8.70 s, 1 H (H-2\ H-8'). 13C NMR: 30.13 (C-3); 45.55 (C-4); 48.28 (C-2); 49.19 (C-I); 63.81 (CH2O); 64.82 (CH2O); 70.03 (C-7); 131.01 (C-5'); 132.53 (C-6); 132.58 (C-5); 147.81 (C-8'); 149.03 (C-6'); 151.49 (C-2'); 152.93 (C-4'). FAB MS, m/z (%): 309/307 (40/100) [M+H]. For C14Hi5ClN4O2 x 1/4 H2O (311.2) calculated: 54.02% C, 5.02% H, 11.39% Cl5 18.00% N; found: 54.07% C, 4.95% H, 11.32% Cl, 18.05% N.
Claims
1. A nucleoside analog having a structure according to the formula (A):
- B is selected from an unsubstituted or substituted pyrimidine or purine heterocycle or aza aza or deaza analogs thereof; whereby the purine heterocycle is not substituted with -CF3 in its 2-position;
- W is selected from (-CH2-),,, wherein n is selected from 0 (whereby B is directly bonded to carbon (I)) or 1 or W is -O-;
- X is not present (thereby forming a bond between carbon (2) and carbon (3)) or is selected from -CR6R6'- or -CR7R7'-C R8R8'-;
- Y is not present (thereby forming a bond between carbon (2) and carbon (I)) or is selected from -CR9R9'- or -CR10R10'-C R11R11 '-;
- Z is selected from -CR12R12'-; -CR13R13'-C R14R14'-; -CR15=CR15'-; -O-; and -S-;
- each of R1 and R4 is independently selected from hydrogen; alkyl; -OH; phosphate; phosphate-alkylene; phosphonate; or phosphonate-alkylene; wherein said alkyl or alkylene can be substituted with one or more -OH, aryl or halogen; and wherein said alkyl or alkylene can contain a heteroatom in or at the end of the alkyl chain, said heteroatom selected from O, S and N;
- each of R2 and R3 is independently selected from hydrogen; alkyl; -OH; phosphate; phosphate-alkylene; phosphonate; or phosphonate-alkylene; or when taken together with R 5 R , R or R7 forms a double bond or -O- (thereby forming an epoxy); wherein said alkyl or alkylene can be substituted with one or more -OH; aryl; arylalkyl (such as trityl); -OOC-aryl; or halogen; and wherein said alkyl can contain a heteroatom in or at the end of the alkyl chain, said heteroatom selected from O, S and N;
- or R2 or R3 when taken together with R6 or R6' is -CH2-CH2-CH2-; -CH2-CH2-CH2- CH2- or -CHR16=CHRI7-CHR18=CHR19-, wherein each of R16, R17, R18 and R19 is independently selected from hydrogen; F; Cl; Br or alkyl;
- R5 is hydrogen or when taken together with R9, R9 , R11 or R1 l forms a double bond;
- each of R6 and R6 is independently selected from hydrogen; alkyl; or -OH; or taken together with R9, R9', R10 or R10' is -CH2-O- or -O-CH2- thereby forming a 5- membered ring; or when taken together with one of R2 or R3 forms a double bond or -O- (thereby forming an epoxy); wherein said alkyl can be substituted with one or more -OH; aryl; or halogen;
- each of R7 and R7 is independently selected from hydrogen; alkyl; or -OH; or when taken together with one of R2 or R3 forms a double bond or -O- (thereby forming an epoxy); wherein said alkyl can be substituted with one or more -OH; aryl; or halogen; - each of R and R is independently selected from hydrogen; alkyl; or -OH; or taken together with R9, R9', R10 or R10> is -CH2-O- or -O-CH2- thereby forming a 5- membered ring; wherein said alkyl can be substituted with one or more -OH; aryl; or halogen;
- each of R9 and R9 is independently selected from hydrogen; alkyl; or -OH; or taken together with R6, R6', R8 or R8' is -CH2-O- or -0-CH2- thereby forming a 5-membered ring; or when taken together with R5 forms a double bond; wherein said alkyl can be substituted with one or more -OH; aryl; or halogen;
- each of R10 and R10 is independently selected from hydrogen; alkyl; or -OH; or taken together with R6, R6', R8 or R8' is -CH2-O- or -0-CH2- thereby forming a 5-membered ring;
- each of R11 and R11 is independently selected from hydrogen; alkyl; or -OH; or when taken together with R5 forms a double bond; wherein said alkyl can be substituted with one or more -OH; aryl; or halogen;
- each of R12, R12', R13, R13', R14 R14', R15, R15' is independently selected from hydrogen or alkyl; wherein said alkyl can be substituted with one or more -OH; aryl; or halogen; - the selections for the X, Y and R-groups like -CR7R7'-C R8R8'-; -CH2-O- or -CH2-
O- or -O-CH2- have to be placed in formula I from left to right; and isomers (in particular stereo-isomers or tautomers), solvates or pharmaceutically acceptable salts thereof or prodrugs thereof; provided that the nucleoside analog is not a 9-(6-substituted or 6,8-disubstituted or 2,6- disubstituted -9H-purin-9-yl)-5-oxa-tricyclo[4.2.1.03'7]nonane-3-methanol, more in particular is not the 6-amino-9Η-purin-9-yl; 6-(dimethylamino)-9H-purin-9-yl; 6- cyclopropylamino-9H-purin-9-yl; the 2,6-diamino-9H-purin-9-yl; the 6-amino-8-methyl-
9H-purin-9-yl; the 6-chloro-8-methyl-9H-purin-9-yl; the 6-chloro-9H-purin-9-yl or the
2-amino-6-chloro-9H-purin-9-yl derivative of 5-oxa-tricyclo[4.2.1.03'7]nonane-3- methanol.
2. The nucleoside analogs according to claim 1, wherein Y is -CR 9r R,9' - and X is - CR »6τ Rj6' - and thereby the nucleoside analogs are according to the formula (A-2),
- each of B, W, Z, R1, R4, R12, R12', R13, R13', R14 R14', R15 and R15' is according to formula (A); - each of R2 and R3 is independently selected from hydrogen; alkyl; -OH; phosphate; phosphate-alkylene; phosphonate; or phosphonate-alkylene; or when taken together with one of R6 or R6 forms a double bond or -O- (thereby forming an epoxy); wherein said alkyl or alkylene can be substituted with one or more -OH; aryl; -OOC-aryl; or halogen; and wherein said alkyl or alkylene can contain a heteroatom in or at the end of the alkyl chain, said heteroatom selected from O, S and N; - or R2 or R3 when taken together with R6 or R6' is -CH2-CH2-CH2-; -CH2-CH2-CH2- CH2- or -CHR16=CHR17-CHR18=CHR19-, wherein each of R16, R17, R18 and R19 is independently selected from hydrogen; F; Cl; Br or alkyl;
- R5 is hydrogen or when taken together with one of R9 or R9 forms a double bond; - each of R6 and R6 is independently selected from hydrogen; alkyl; or -OH; or taken together with one of R9 or R9 is -CH2-O- or -O-CH2- thereby forming a 5-membered ring; or when taken together with one of R2 or R3 forms a double bond or -O- (thereby forming an epoxy); wherein said alkyl can be substituted with one or more -OH; aryl; or halogen; - each of R9 and R9 is independently selected from hydrogen; alkyl; or -OH; or taken together with one of R6 or R6 is -CH2-O- or -0-CH2- thereby forming a 5-membered ring; or when taken together with R5 forms a double bond; wherein said alkyl can be substituted with one or more -OH; aryl; or halogen.
3. The nucleoside analogs according to claim 2, wherein
- B is according to formula (A);
- W is not present whereby B is directly bonded to carbon (1) or is -CH2- or W is -O- ;;
- Z is selected from -CR12R12'-;
- R1 is hydrogen; - R4 is selected from hydrogen or alkyl;
- each of R12 and R12 is independently selected from hydrogen or alkyl;
- each of R2 and R3 is independently selected from hydrogen; alkyl; -OH; phosphate; phosphate-alkylene; phosphonate; or phosphonate-alkylene; or R2 or R3 when taken together with R6 or R6' is -CH2-CH2-CH2-; -CH2-CH2-CH2-CH2- or -CHR16=CHR17- CHR18=CHR19-, wherein each of R16, R17, R18 and R19 is independently selected from hydrogen; F; Cl; Br or alkyl; or when taken together with one of R6 or R6 forms a double bond or -O— (thereby forming an epoxy); wherein said alkyl or alkylene can be substituted with one or more -OH; aryl; -OOC-aryl; or halogen; and wherein said alkyl or alkylene can contain a heteroatom in or at the end of the alkyl chain, said heteroatom selected from O, S and N;
- R5 is hydrogen or when taken together with one of R9 or R9 forms a double bond; - each of R6 and R6 is independently selected from hydrogen; alkyl; or -OH; or when taken together with one of R2 or R3 forms a double bond or -O- (thereby forming an epoxy); wherein said alkyl can be substituted with one or more -OH; aryl; or halogen;
- each of R9 and R is independently selected from hydrogen; alkyl; or -OH; or when taken together with R5 forms a double bond; wherein said alkyl can be substituted with one or more -OH; aryl; or halogen.
4. The nucleoside analogs according to claim 3, wherein
- Z is -CH2-; - each of R4, R2, R3, R5, R6, R6', R9 and R9' are hydrogen.
5. The nucleoside analogs according to claim 2, wherein R6 and R9 are taken together to form -0-CH2- or -CH2-O- and thereby the nucleoside analogs are according to the formula (A-3a) or (A-3b):
(A-3a) (A3-b)
wherein
- each of B, W, Z, R1, R4, R12, R12', R13, R13', R14, R14', R15 and R15' is according to formula (A);
- each of R2 and R is independently selected from hydrogen; alkyl; -OH; phosphate; phosphate-alkylene; phosphonate; or phosphonate-alkylene; or when taken together with one of R6 or R6 forms a double bond or -O- (thereby forming an epoxy); wherein said alkyl or alkylene can be substituted with one or more -OH; aryl; -OOC-aryl; or halogen; and wherein said alkyl or alkylene can contain a heteroatom in or at the end of the alkyl chain, said heteroatom selected from O, S and N; - R5 is hydrogen or when taken together with one of R9 or R9 forms a double bond;
- R6 is selected from hydrogen; alkyl; or -OH; or when taken together with one of R2 or R3 forms a double bond or -O- (thereby forming an epoxy); wherein said alkyl can be substituted with one or more -OH; aryl; or halogen;
- R9 is selected from hydrogen; alkyl; or -OH; or when taken together with R5 forms a double bond; wherein said alkyl can be substituted with one or more -OH; aryl; or halogen.
6. The nucleoside analogs according to claim 5, wherein
- Z is selected from -CH2-; -O-; or -CH2-CH2-;
- each of R1, R4, R5, R6 and R9 are hydrogen;
- each of R and R is independently selected from hydrogen; -OH; -OCH3; phosphonylmethylether; benzyloxymethyl; methoxymethyl and chloromethyl.
7. The nucleoside analogs according to claim 1, wherein Y is not present and thereby the nucleoside analogs are according to the formula (A-4),
wherein - each of B, W, X, Z, R1, R2, R3, R4, R7, R7', R12, R 12' R13, R13', R14 R14', R15 and R I5'
IS according to formula (A);
- R5 is hydrogen;
- each of R6 and R6 is independently selected from hydrogen; alkyl; or -OH; or when taken together with R2 or R3 forms a double bond or -O- (thereby forming an epoxy); wherein said alkyl can be substituted with one or more -OH; aryl; or halogen; - each of R8 and R8 is independently selected from hydrogen; alkyl; or -OH; wherein said alkyl can be substituted with one or more -OH; aryl; or halogen.
8. The nucleoside analogs according to claim 7, wherein - B and W are according to formula (A);
- X is -CH2-;
- Z is selected from -CH2-CH2-; or -CH2=CH2-;
- each of R1, R4 and R5 are hydrogen;
- each of R2 and R3 is independently selected from hydrogen; -OH; or -OCH3. phosphonylmethylether; benzyloxymethyl; methoxymethyl and chloromethyl.
9. The nucleoside analogs according to claim 1, wherein Y is -CR10R1^-CR11R1 v- and X is not present and thereby the nucleoside analogs are according to the formula (A-5),
wherein
- each of B, W, Z, R1, R4, R12, R12', R13, R13', R14 R14', R15 and R15' is according to formula (A);
- each of R2 and R3 is independently selected from hydrogen; alkyl; -OH; phosphate; phosphate-alkylene; phosphonate; or phosphonate-alkylene; wherein said alkyl or alkylene can be substituted with one or more -OH; aryl; -OOC-aryl; or halogen; and wherein said alkyl can contain a heteroatom in or at the end of the alkyl chain, said heteroatom selected from O, S and N;
- R is hydrogen or when taken together with R1 ' or R11 forms a double bond; - each of R10 and R10 is independently selected from hydrogen; alkyl; or -OH; - each of R11 and R11 is independently selected from hydrogen; alkyl; or -OH; or when taken together with R5 forms a double bond; wherein said alkyl can be substituted with one or more -OH; aryl; or halogen.
10. The nucleoside analogs according to claims 9, said nucleoside analogs having a structure according to formula (A-6),
- the dotted line represents a double bond which can be present or not present; - each of R2, R3, R12 and R12 is independently selected from hydrogen or alkyl (more in particular methyl).
11. The nucleoside analogs according to claim 1 selected from the list of compounds in table 1 (encoded from compound number 1 to 86).
12. The nucleoside analogs according to claim 1, selected from the list of:
- 9-[(lR*,2R*,4S*)-bicyclo[2.2.1]hept-2-yl]-6-chloro-9H-purine; - 9-[(lR*,2R*,4S*)-bicyclo[2.2.1]hept-2-yl]-2,6-dichloro-9H-purine; - 6-chloro-9-[(lS,2S,4S)-l,7,7-trimethylbicyclo[2.2.1]hept-2-yl]-9H-purine; - 6-chloro-9-{[(lS,2S,5S)-6,6-dimethylbicyclo[3.1.1]hept-2-yl]methyl}-9H-purine;
- 2,6-dichloro-9-{[(lS,2S,5S)-6,6-dimethylbicyclo[3.1.1]hept-2-yl]methyl}-9H-purine;
- 6-chloro-9- {[(lR,5S)-6,6-dimethylbicyclo[3.1.1 ]hept-2-en-2-yl]methyl} -9H-purine;
- 6-chloro-9-[(l S,2R,4R)-3,3-dimethylbicyclo[2.2. l]hept-2-yl]-9H-purine; - 9-[(lR*,2S*,4R*)-Bicyclo[2.2.1]hept-5-en-2-yl]-6-chloro-9H-purine; - [(IR *,2R *,45*,65*)-6-(6-chloro-9H-purin-9-yl)bicyclo[2.2.1 ]hept-2-yl]methyl benzoate; [(li?*,25*,4i?*,55*)-5-(6-chloro-9H-purin-9-yl)bicyclo[2.2.1]hept-2-yl]methyl benzoate;
(IR *,2R *,3R *,6R *,7S*,9R *)-9-[(6-chloro-9H-purin-9-yl)methyl]-4-oxatricyclo [4.2.1.03>7]nonan-2-ol; - (IR*,2R *,3R *,6R *,7S*,9R *)-9-[(2,6-dichloro-9H-purin-9-yl)methyl]-4-oxatricyclo [4.2.1.03J]nonan-2-ol;
- [(Ii? *,2R *,4S*,6,S*)-6-(6-chloro-9H-purin-9-yl)bicyclo[2.2.1 ]hept-2-yl]methanol;
- [(IR *,2S*,4R *,55*)-5-(6-chloro-9H-purin-9-yl)bicyclo[2.2.1 ]hept-2-yl]methanol;
- 6-chloro-9- {[(lR,2S,5R)-6,6-dimethylbicyclo[3.1. l]hept-2-yl]methyl}-9Η-purine; - (lR*,2R*,3R*,6R*,7S*,9S*)-2-(6-chloro-9H-purin-9-yl)-4-oxatricyclo[4.2.1.03'7] nonane-9-methanol;
- (lR*,2S*,4R*,7R*)-7-(6-chloro-9H-purin-9-yl)bicyclo[2.2.1 ]heptan-2-ol; - (lR*,2S*,4S*,7R*)-7-(6-chloro-9H-purin-9-yl)bicyclo[2.2.1]heρt-5-en-2-ol;
6-chloro-9-[(li?*,2i?*,3i?*,6/?*7S*,9S*)-9-(methoxymethyl)-4- oxatricyclo[4.2.1.03>7]non-2-yl]-9H-purine;
- 6-chloro-9-[(lR*,2S*,4R*,7R*)-2-methoxybicyclo[2.2.1]hept-7-yl]-9Η-purine;
- 9-{(lR*,2R*,3R*,6R*,7S*,9S*)-9-[(benzyloxy)methyl]-4-oxatricyclo[4.2.1.03'7]non-2- yl} -6-chloro-9H-purine;
(lR*,2R*,3R*,6R*,7S*,9S*)-2-(6-chloro-9Η-purin-9-yl)-4-oxatricyclo[4.2.1.03'7] nonane-9-methyl [phenyl methoxy-L-alaninyl]-phosphate;
- 6-chloro-9-[(lR*,2R*,3R*,6R*,7S*,9S*)-9-(chloromethyl)- 4-oxatricyclo[4.2.1.03'7] non-2-yl]-9H-purine;
- 6-chloro-9-[(li?*,2i?*,6Λ*,7i?*,85*)-tricyclo[5.2.1.02'6]dec-8-yl]-9H-purine;- 6-chloro- 9-[(IR *,SR *,95*)-tricyclo[6.2.1.02J]undeca-2,4,6-trien-9-yl]-9H-purine; - 6-chloro-9-[(l/?*,25*,35*,65*,7i?*)-4-oxatricyclo[4.2.1.03'7]non-2-yl]-9H-purine;
- 9-[(7-syn)-bicyclo[2.2. l]hept-2-en-7-yl]-6-chloro-9Η-purine;
- 9-[(lR,4S)-bicyclo[2.2.1]hept-7-yl]-6-chloro-9H-purine;
- [(l/?*,2/?*,3/?*,6i?*,75*,10*5)-2-(6-chloro-9H-purin-9-yl)-4-oxatricyclo[4.3.1.03'7]dec- 10-yl]methanol; -{(l/?*,2Λ*,35*,65*,75*,9S*)-2-(6-chloro-9H-purin-9-yl)-4,8- dioxatricyclo[4.2.1.03'7]non-9-yl}methanol; - [(Ii? *,2R *,AR *,7S*)-7-(6-chloro-9H-purin-9-yl)bicyclo[2.2.1 ]hept-5-en-2-yl]methanol; - [(l/?*,2i-*,45*,75*)-7-(6-chloro-9H-purin-9-yl)bicyclo[2.2.1]hept-2-yl]methanol; - [(li?*,25*,4i?*,7S*)-7-(6-chloro-9H-purin-9-yl)bicyclo[2.2.1]hept-5-en-2-yl]methanol; - (li?*,25*,45*,6i?*)-6-(6-chloro-9H-purin-9-yl)bicyclo[2.2.1]heptan-2-ol; - (IR *,2S*,4R *,55'*)-5-(6-chloro-9H-purin-9-yl)bicyclo[2.2.1 ]heptan-2-ol; - (li?*,2JR*,4S*,6i?*)-6-(6-chloro-9H-purin-9-yl)bicyclo[2.2.1]heptan-2-ol; - (li?*,2i?*,4i?*,55'*)-5-(6-chloro-9H-purin-9-yl)bicyclo[2.2.1]heptan-2-ol; - [(lΛ*,25*,35*,45*)-3-(6-chloro-9H-purin-9-yl)bicyclo[2.2.1]hept-5-en-2-yl]methanol;
- [(IR *,2R *,3i? *,45'*)-3-(6-chloro-9H-purin-9-yl)bicyclo[2.2.1 ]hept-5-en-2-yl]methanol; -6-chloro-9-[( Ii? *,2R *,3i? *,6S*,7S*, 1 OS*)- 10-(chloromethyl)-4- oxatricyclo[4.3.1.03'7]dec-2-yl]-9H-purine;
-6-chloro-9-[(li? *,2R *,3S*,6S*,7S*,9R *)-9-(chloromethyl)-4,8- dioxatricyclo[4.2.1.03'7]non-2-yl]-9H-purine;
-6-chloro-9-[( Ii? *,2i? *,3i? *,6S*,7S*, 1 OS*)- 10-(fluororomethyl)-4- oxatricyclo[4.3.1.03>7]dec-2-yl]-9H-purine;
-6-chloro-9-[(li? *,2i? *,3S*,6S*,7S*,9R *)-9-(fluoromethyl)-4,8- dioxatricyclo[4.2.1.03>7]non-2-yl]-9H-purine;
- 6-chloro-9-[(15*,2S*,4i?*,6i?*)-6-fluorobicyclo[2.2.1]hept-2-yl]-9//-purine;
- 6-chloro-9-[(li?*,25*,4i?*,55*)-5-fluorobicyclo[2.2.1]hept-2-yl]-9H-purine; - 9-[(li?*,2i?*,45*)-bicyclo[2.2.1]hept-2-yl]-9H-purine-6-thiol;
- 9-[(li?*,2i?*,45*)-bicyclo[2.2.1]hept-2-yl]-6-(methylsulfanyl)-9H-purine;
- 9-[(li?*,2i?*,45*)-bicyclo[2.2.1]hept-2-yl]-6-(methylsulfonyl)-9H-purine;
- 9-[(li?*,2i?*,4S*)-bicyclo[2.2.1]hept-2-yl]-9H-purine;
- 9-[(li?*,2i?*,45*)-bicyclo[2.2.1]hept-2-yl]-6-iodo-9H-purine; - 6-azido-9-[(li?*,2/?*,45*)-bicyclo[2.2.1]hept-2-yl]-9H-purine;
- 9-[(Ii? *,2R *,45*)-bicyclo[2.2.1 ]hept-2-yl]-9H-purin-6-amine;
- 9-[(li? *,2i? *,4S*)-bicyclo[2.2.1 ]hept-2-yl]-6-fluoro-9H-purine; - 9-[(li?*,2i?*,45*)-bicyclo[2.2.1]hept-2-yl]-6-(4-chlorophenyl)-9//-purine; - 9-[(li?*,2i?*,45*)-bicyclo[2.2.1]hept-2-yl]-6-(trifluoromethyl)-9H-purine; - 9-[(li? *,2i? *,4S*)-bicyclo[2.2.1 ]hept-2-yl]-6-methoxy-9H-purine;
- 9-[(li? *,2i? *,45*)-bicyclo[2.2. l]hept-2-yl]-6-methyl-9H-purine; - 9-[(l/?*,2i?*,45*)-bicyclo[2.2.1]hept-2-yl]-6-chloro-2-nitro-9H-purine; - 9-[(li?*,2i?*,45*)-bicyclo[2.2.1]hept-2-yl]-8-bromo-6-chloro-9H-purine;
- 9-[(IR *,2R *,4S*)-bicyclo[2.2.1 ]hept-2-yl]-6-chloro-8-iodo-9H-purine;
- ethyl 9-[(IR *,2R *,45'*)-bicyclo[2.2. l]hept-2-yl]-6-chloro-9H-purine-8-carboxylate; - {9-[(lR *,2R *,4S*)-bicyclo[2.2.1 ]hept-2-yl]-6-chloro-9H-purin-8-yl}methanol;
- 6-chloro-9-[(li?*,2i?*,45*,55*,6,S*)-3-oxatricyclo[3.2.1.02>4]oct-6-yl]-9H-purine; - (li?*,2/?*,35*,4S*,5.S*)-5-(6-chloro-9H-purin-9-yl)bicyclo[2.2.1]heptane-2,3-diol; - 7-[(li?*,2i?*,45*)-bicyclo[2.2.1]hept-2-yl]-4-chloro-7H-pyrrolo[2,3-flT|pyrimidine; -(l/?*,2/?*,3i?*,6/?*,75*,95*)-2-(2-amino-6-chloro-9H-purin-9-yl)-4- oxatricyclo[4.2.1.03'7]nonane-9-methanol;
- 6-chloro-9-[(li?*,3Λ*,6i?*,7i?*,9i?*)-4-oxatricyclo[4.2.1.03'7]non-9-yl]-9H-purine
- (lR*,2R*,3S*,4S*)-6-(chloromethyl)-3-(6-chloro-9Η-purin-9-yl)bicyclo[2.2.1]hept-5- en-2-ol;
- (li?*,2/?*,35*,45*)-3-(6-chloro-9H-purin-9-yl)-6-(hydroxymethyl)bicyclo[2.2.1]hept-5- en-2-ol;
- (lJR*,2i?*,35*,4<S*)-3-(6-chloro-9H-purin-9-yl)-5-(hydroxymethyl)bicyclo[2.2.1]hept-5- en-2-ol and
- (IR *,4R *,75'*)-7-(6-Chloro-9H-purin-9-yl)bicyclo[2.2.1 ]hept-5-ene-2,2-dimethanol.
13. The nucleoside analogs according to claims 1 to 12, wherein B is an unsubstituted purine heterocycle, its aza or deaza analogs or is a purine heterocycle, its aza or deaza analogs substituted with halogen; -NH2; -NH-alkyl; -N(alkyl)2; -OH; -O-alkyl (such as - OCH3); -SH; -S-alkyl (such as -SCH3); -N3; -CF3; -NO2; -COOH; -COO-alkyl; - S02alkyl; aryl or alkyl; wherein each of said alkyl and aryl can again be substituted with hydroxy, amino, halogen or -SH, whereby the purine heterocycle is not substituted with - CF3 in its 2-position.
14. The nucleoside analogs according to claim 1 to 13, wherein B is according to formula (P-I),
wherein each of R20 and R21 are independently selected from hydrogen; halogen; -NH2; - N3; -NH-alkyl; -N(alkyl)2;-OH; -O-alkyl (such as -OCH3); -SH; -S-alkyl (such as - SCH3); -CF3; -NO2; -COOH; -COO-alkyl; -S02alkyl; aryl; or alkyl; wherein each of said alkyl and aryl can again be substituted with hydroxy, amino, halogen or -SH;
and R22 is selected from hydrogen; halogen; -NH2; -NH-alkyl; -N(alkyl)2; -OH; -O-alkyl (such as -OCH3); -SH; -S-alkyl (such as -SCH3); -N3; -NO2; -COOH; -COO-alkyl; - S02alkyl; aryl; or alkyl; wherein each of said alkyl and aryl can again be substituted with hydroxy, amino or -SH.
15. The nucleoside analogs according to claim 14, wherein
each of R20 and R21 are independently selected from hydrogen; F; Cl; Br; I; -N3; -NH2; - NH-alkyl; -N(alkyl)2; -OH; -0-CH3; -0-C2H5; -0-CH2-CH2-CH3; -O-CH(CH3)2; -O- C(CH3)3; -SH; -S-CH3; -S-C2H5; -S-CH2-CH2-CH3; -S-CH(CH3)2; -S-C(CH3)3; -CF3; - NO2; -COOH; -COO-CH3; -COO-C2H5; -COO-CH(CH3)2; -COO-C(CH3)3; -SO2-CH3; - SO2-C2H5; -SO2-CH2-CH2-CH3; -SO2-CH(CH3)2; -SO2-C(CH3)3; -CH2F; -CHF2; -CH2Cl; -CHCl2; -CH2-OH; -CH2-CH2-OH; -CH3; -C2H5; -CH2-CH2-CH3; -CH(CH3)2; -C(CH3)3; n-butyl; isobutyl; n-pentyl; sec-pentyl; -(4-chloro)-phenyl; -(4-bromo)-phenyl and -(4- fluoro)-phenyl;
and R22 is selected from hydrogen; F; Cl; Br; I; -COOH; -COO-CH3; -COO-C2H5; -COO- CH(CH3)2; -COO-C(CH3)3; n-butyl; isobutyl; n-pentyl; sec-pentyl; -CH2-OH; -CH2-CH2- OH; -CH3; -C2H5; -CH2-CH2-CH3; n-butyl; isobutyl; n-pentyl; sec-pentyl; -CH(CH3)2 and -C(CH3)3.
16. The nucleoside analogs of general formulae (A-I), (A-2), (A3-a), (A3-b), (A-4), (A- 5) and (A-6);
(A-3a) (A3-b),
wherein
W, Z, X, R1, R2, R3, R4, R5, R6, R6>, R9, R9', R10, R10', R11, R11', R12 and R12' are defined as in claim 1 and wherein B is according to formula (P-I),
wherein each of R20 and R21 are independently selected from hydrogen; halogen; -NH2; NH-alkyl; -N(alkyl)2; -N3; -OH; -O-alkyl (such as -OCH3); -SH; -S-alkyl (such as - SCH3); -CF3; -NO2; -COOH; -COO-alkyl; -SO2alkyl; aryl; or alkyl; wherein each of said alkyl and aryl can again be substituted with hydroxy, amino, halogen or -SH;
and R22 is selected from hydrogen; halogen; -NH2; -OH; -O-alkyl (such as -OCH3); -SH; -S-alkyl (such as -SCH3); -N3; -NO2; -COOH; -COO-alkyl; -SO2alkyl; aryl; or alkyl; wherein each of said alkyl and aryl can again be substituted with hydroxy, amino or -SH.
17. The nucleoside analogs according to the claims 1 to 16 for use as a medicament.
18. The nucleoside analogs according to the claims 1 to 16 for use as a medicament for the prevention or treatment of a viral infection in an animal or human.
19. The nucleoside analogs according to claim 18, wherein the viral infection is caused by a RNA virus.
20. The nucleoside analogs according to claim 18, wherein the RNA virus is of the Picornaviridae.
21. The nucleoside analogs according to claims 1 to 16 for the treatment of a viral infection in an animal or mammal.
22. The use of a nucleoside analog according to claims 1 to 16 for the manufacture of a medicament.
23. The use of a nucleoside analog according to claim 22 wherein the medicament is for the prevention or treatment of a viral infection in an animal or mammal.
24. The use according to claim 23, wherein the viral infection is caused by a virus of the Picornaviridae.
25. A pharmaceutical composition comprising a nucleoside analog according to any of the claims 1 to 16 as an active ingredient in admixture with at least a pharmaceutically acceptable carrier.
26. A pharmaceutical composition according to claim 25, having antiviral activity.
27. A method of treatment or prevention of a viral infection in an animal or mammal, comprising administering to the animal or mammal in need of such treatment a therapeutically effective amount of a nucleoside analog according to any of the claims 1 to 16.
28. A method for the preparation of the nucleoside analogs according to any of the claims 1 to 16, said method comprising the steps of coupling a substituted or unsubstituted pyrimidine or purine heterocycle or aza or deaza analogs, preferably a substituted purine heterocycle or aza or deaza analogs, to compounds of the formula (A-7), in particular via the Mitsunobu-reaction:
wherein each of W, X, Y, Z, R1, R2, R3, R4, R5, R6, R6', R7, R7', R8, R8', R9, R9', R10, R10>, R11, R11 ', R12, R12', R13, R13', R14 R14', R15 and R15' is according to formula (A).
29. A method for the preparation of the nucleoside analogs according to any of the claims 1 to 16, said method comprising the steps of coupling a substituted or unsubstituted pyrimidine or purine heterocycle, preferably a substituted pyrimidine heterocycle, to compounds of the formula (A-8),
wherein each of W, X, Y, Z, R1, R2, R3, R4, R5, R6, R6', R7, R7', R8, R8', R9, R9', R10, R10', R11, R11 ', R12, R12>, R13, R13', R14 R14>, R15 and R15' is according to formula (A), said method comprising the steps of
- coupling a substituted 5-amino-pyrimidine, preferably a substituted 4-chloro-5-amino- pyrimidine, to the compounds of formula (A-8); and
- performing a ring-closure in acid trialkyl orthoformate reaction conditions.
30. A method for the preparation of the nucleoside analogs according to any of the claims 1 to 16, said method comprising the steps of
- coupling a unsubstituted or substituted purine heterocycle or aza or deaza analogs with unsubstituted or substituted bicycloalkanylalcohols, bicycloalkenylalcohols, tricycloalkanylalcohols, tricycloalkenylalcohols or hetero analogs thereof via the Mitsunobu reaction; or
- a substituted 5-amino-pyrimidine, preferably a substituted 4-chloro-5-amino- pyrimidine, thereof with unsubstituted or substituted bicycloalkanylamines, bicycloalkenylamines, tricycloalkanylamines, tricycloalkenylamines or hetero analogs thereof and subsequently performing a ring-closure in an acidic orthoformate; and - optionally transformation of these compounds obtained as outlined above.
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US92669207P | 2007-04-27 | 2007-04-27 | |
GB0708259A GB0708259D0 (en) | 2007-04-27 | 2007-04-27 | New anti-viral compounds |
GB0708259.7 | 2007-04-27 | ||
US60/926,692 | 2007-04-27 | ||
GB0708256A GB0708256D0 (en) | 2007-04-28 | 2007-04-28 | New anti-viral compounds |
GB0708256.3 | 2007-04-28 | ||
GB0708331.4 | 2007-04-30 | ||
GB0708331A GB0708331D0 (en) | 2007-04-30 | 2007-04-30 | New anti-viral nucleoside analogs |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008131501A2 true WO2008131501A2 (en) | 2008-11-06 |
WO2008131501A3 WO2008131501A3 (en) | 2009-04-23 |
Family
ID=39926142
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/BE2008/000032 WO2008131501A2 (en) | 2007-04-27 | 2008-04-28 | New anti-viral nucleoside analogs |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2008131501A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10189841B2 (en) | 2015-11-20 | 2019-01-29 | Forma Therapeutics, Inc. | Purinones as ubiquitin-specific protease 1 inhibitors |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996015111A1 (en) | 1994-11-15 | 1996-05-23 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
US5977089A (en) | 1996-07-26 | 1999-11-02 | Gilead Sciences, Inc. | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
US6225460B1 (en) | 1993-09-17 | 2001-05-01 | Gilead Sciences, Inc. | Nucleotide analogs |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1383767A1 (en) * | 2001-02-08 | 2004-01-28 | Memory Pharmaceutical Corporation | Trifluoromethylpurines as phosphodiesterase 4 inhibitors |
-
2008
- 2008-04-28 WO PCT/BE2008/000032 patent/WO2008131501A2/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6225460B1 (en) | 1993-09-17 | 2001-05-01 | Gilead Sciences, Inc. | Nucleotide analogs |
WO1996015111A1 (en) | 1994-11-15 | 1996-05-23 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
US5977089A (en) | 1996-07-26 | 1999-11-02 | Gilead Sciences, Inc. | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
Non-Patent Citations (16)
Title |
---|
"Chiral Liquid Chromatography", 1989, CHAPMAN AND HALL |
"Encyclopaedia of Surfactants", 1981, CHEMICAL PUBLISHING CO. |
"Handbook of Pharmaceutical Excipients", 1986 |
"McCutcheon's Detergents and Emulsifiers Annual", 1981, MC PUBLISHING CROP. |
"Tensid-Taschenbucw", 1981, HANSER VERLAG |
BABA ET AL., ANTIMICROB. AGENTS CHEMOTHER., vol. 25, 1984, pages 515 - 517 |
CHOU ET AL., ADV. ENZYME REG., vol. 22, 1984, pages 27 |
CIESLA, S.L. ET AL., ANTIVIRAL RESEARCH, vol. 59, 2003, pages 163 - 171 |
E. L. ELIEL: "Stereochemistry of Carbon Compounds", 1962, MCGRAW HILL |
ELIEL, E.; WILEN, S.: "Stereochemistry of Organic Compounds", 1994, JOHN WILEY & SONS, INC., pages: 322 |
ELION ET AL., J. BIOL. CHEM., vol. 208, 1954, pages 477 - 488 |
HREBABECKY H., COLLECTION OF CZECHOSLOVAK CHEMICAL COMMUNICATIONS, vol. 70, no. 1, 2005, pages 103 - 123 |
JACOB III., J. ORG. CHEM., vol. 47, 1982, pages 4165 |
KEITH K.A. ET AL., ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, pages 1869 - 1871 |
LOCHMULLER, C. H., J. CHROMATOGR., vol. 113, no. 3, 1975, pages 283 - 302 |
OKAMOTO: "Optical resolution of dihydropyridine enantiomers by High-performance liquid chromatography using phenylcarbamates of polysaccharides as a chiral stationary phase", J. OF CHROMATOGR., vol. 513, 1990, pages 375 - 378 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10189841B2 (en) | 2015-11-20 | 2019-01-29 | Forma Therapeutics, Inc. | Purinones as ubiquitin-specific protease 1 inhibitors |
US10399980B2 (en) | 2015-11-20 | 2019-09-03 | Forma Therapeutics, Inc. | Purinones as ubiquitin-specific protease 1 inhibitors |
US11161848B2 (en) | 2015-11-20 | 2021-11-02 | Forma Therapeutics, Inc. | Purinones as ubiquitin-specific protease 1 inhibitors |
Also Published As
Publication number | Publication date |
---|---|
WO2008131501A3 (en) | 2009-04-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10428027B2 (en) | Sulfinylphenyl or sulfonimidoylphenyl benzazepines | |
KR102536447B1 (en) | Cyclic Dinucleotide Compound | |
EP2430029B1 (en) | Thieno[2,3-b]pyridine derivatives as viral replication inhibitors | |
US10709709B2 (en) | Substituted carbonucleoside derivatives useful as anticancer agents | |
TWI510486B (en) | Inhibitors of e1 activating enzymes | |
JP5198055B2 (en) | Phosphonic acid nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for producing them | |
EP2769980A1 (en) | Pyrazoloquinoline derivative | |
CA2921314A1 (en) | Substituted nucleoside derivatives as prmt5 inhibitors | |
EP2094702B1 (en) | Viral inhibitors | |
US20090197910A1 (en) | Novel viral replication inhibitors | |
SG172921A1 (en) | Phosphoramidate derivatives of guanosine nucleoside compounds for treatment of viral infections | |
CA2574220A1 (en) | Imidazo[4,5-d]pyrimidines, their uses and methods of preparation | |
JP6912562B2 (en) | A pharmaceutical composition for the prevention and treatment of non-alcoholic steatohepatitis, liver fibrosis and cirrhosis containing an adenosine derivative. | |
WO2009015446A2 (en) | Triazole derivatives as viral replication inhibitors | |
WO2008131501A2 (en) | New anti-viral nucleoside analogs | |
EP2125807B1 (en) | Imidazo[1,2-a]pyrrolo[3,2-c]pyridine compounds useful as pestivirus inhibitors | |
WO2008131502A2 (en) | Antiviral compounds of the adamantane type | |
Peréz-Pérez et al. | Novel antiviral compounds | |
US5126347A (en) | Isomeric dideoxynuclesides | |
WO2014170368A1 (en) | Novel antiviral compounds | |
JP3561272B6 (en) | Antiretroviral enantiomeric nucleotide analogues | |
JP3561272B2 (en) | Antiretroviral enantiomeric nucleotide analogues |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08733484 Country of ref document: EP Kind code of ref document: A2 |